index,word,block,pos
1,nivolumab,"Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.",137
1,nivolumab,Infusions with nivolumab will start within 1 week of study start.,15
1,ipilimumab,Ipilimumab will either start with the second nivolumab infusion or at after tumor progression.,0
1,nivolumab,Ipilimumab will either start with the second nivolumab infusion or at after tumor progression.,45
1,nivolumab,Nivolumab is infused intravenously at 240 mg once every 2 weeks with or without ipilimumab for a maximum of 24 months.,0
1,ipilimumab,Nivolumab is infused intravenously at 240 mg once every 2 weeks with or without ipilimumab for a maximum of 24 months.,80
2,creatinine,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",264
2,bilirubin,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",331
2,glutamate,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",401
2,pyruvate,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",411
2,glutamate,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",449
2,oxaloacetate,"a new baseline scan is required 1.7 Measurable disease as per Response Assessment in Neuro-Oncology (RANO) criteria; Estimated survival of at least 3 months; signed informed consent form; Hgb > 9 gm; absolute neutrophil count (ANC) > 1500/μl; platelets > 100,000; Creatinine < 1.5 times the upper limit of laboratory normal value; Bilirubin < 2 times the upper limit of laboratory normal value; serum glutamate pyruvate transaminase (SGPT) or serum glutamate oxaloacetate transaminase (SGOT) < 3 times the upper limit of laboratory normal value;  EXCLUSION CRITERIA:  Exclusion Criteria:  Subjects with newly diagnosed GBM Pregnant women or nursing mothers cannot participate in the study.",459
2,creatinine,"Women of childbearing potential must practice medically approved contraceptive precautions; Abnormal hematological results at inclusion with: Neutrophils < 1,500/mm3; Blood-platelets < 100,000/mm3 Severe or chronic renal insufficiency (creatinine clearance ≤ 30 ml/min); Patient unable to follow procedures, visits, examinations described in the study; Any usual formal indication against imaging examinations (important claustrophobia, pacemaker);",236
3,gefitinib,"Patients on cytochrome P450 isoenzyme CYP3A4-inducing antiepileptic drugs (EIAE) are excluded due to ensuing interactions of these drugs with gefitinib metabolism, reducing systemic availability.",142
3,gefitinib,"After giving written informed consent, patients receive gefitinib 500 mg daily starting at least 5 days prior to re-operation, allowing a steady state condition.",56
4,plx3397,The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.,121
5,carbohydrates,A change of nutrition by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and therefore inhibit tumor growth.,34
5,fattyacids,A change of nutrition by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and therefore inhibit tumor growth.,81
5,temozolomide,"Standard treatment for glioblastoma includes resection, irradiation and temozolomide chemotherapy.",72
6,buparlisib,The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model.,123
6,carboplatin,The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model.,171
6,buparlisib,The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model.,186
6,lomustine,The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model.,243
6,ccnu,The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model.,254
6,buparlisib,Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.  ,47
6,carboplatin,Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.  ,78
6,buparlisib,Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.  ,177
6,lomustine,Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.  ,193
6,lomustine,Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.  ,210
6,buparlisib,A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine.,48
6,carboplatin,A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine.,64
6,lomustine,A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine.,79
6,carboplatin,A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine.,194
6,lomustine,A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine.,209
7,carbohydrates,Diet change by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and inhibit tumor growth.,24
7,fattyacids,Diet change by limiting carbohydrates and increasing the proportion of fatty acids and proteins can lead to ketogenic metabolism and might limit energy production in tumor cells and inhibit tumor growth.,71
8,ttac-0001,Primary - To evaluate the safety of TTAC-0001 in patients with recurrent glioblastoma.,36
8,ttac-0001,Secondary - To determine the efficacy of TTAC-0001 in patients with recurrent glioblastoma.,41
8,ttac-0001,Exploratory  To evaluate pharmacokinetic (PK) parameters of TTAC-0001 in patients with recurrent glioblastoma To evaluate pharmacodynamic (PD) parameters by clinical biomarker test  ,60
9,bev,VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases.,19
9,bev,BEV may stop the growth of tumor cells by blocking blood flow to the tumor.,0
9,cediranib,"Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.  VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM.",0
9,bibf-1120,"Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.  VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM.",172
10,ttac-0001,"This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with recurrent glioblastoma.",153
12,ttac-0001,"This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.",85
12,bevacizumab,"This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.",157
13,pt2385,"To estimate the efficacy of hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma.",77
13,pt2385,"To estimate the efficacy of hypoxia inducible factor (HIF)-2 alpha inhibitor PT2385 (PT2385) as measured by radiographic response rate (by Response Assessment in Neuro-Oncology, RANO, criteria) in patients with recurrent glioblastoma.",85
13,pt2385,To estimate the efficacy of PT2385 as measured by progression free and overall survival in patients with recurrent glioblastoma.,28
13,pt2385,To determine the safety of oral PT2385 in patients with recurrent glioblastoma.,32
13,pt2385,To describe the pharmacokinetic and pharmacodynamic properties of PT2385 in patients with recurrent glioblastoma.,66
13,pt2385,To explore genetic polymorphisms involved in the metabolism of PT2385.,63
13,pt2385,Patients receive HIF-2 alpha inhibitor PT2385 orally (PO) twice daily (BID) on days 1-28.,39
14,bevacizumab,Subjects with recurrent glioblastoma who are candidates for bevacizumab treatment according to standard of care will be eligible for this study.,60
14,[18f]fmiso,[18F]FMISO to image the brain and evaluate for hypoxia pre and post therapy..,0
15,cediranib,The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma.,50
15,lomustine,Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents.,0
15,cediranib,Cediranib is a new drug that has not yet been approved for this disease.,0
15,lomustine,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",35
15,cediranib,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",50
15,cediranib,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",61
15,lomustine,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",80
15,cediranib,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",160
15,lomustine,"This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo (""inactive substance"") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.",228
16,panm,The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.,79
16,temozolomide,The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.,138
17,glucose,Increased glucose metabolism is characteristic for solid tumors.,10
17,glucose,"Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.",9
17,atp,"Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.",52
17,oxygen,"Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells.",116
17,glucose,"In preclinical models, restricting glucose availability using a ketogenic diet, calorie-restriction or transient fasting inhibits tumor growth.  ",35
18,cot,All patients will receive 3 mCi of Cotara® for biodistribution and radiation dosimetry purposes.,35
19,temozolomide,"In patient diagnosed with recurrence/progression glioblastoma (recGB) following prior therapy with surgery, radiation therapy and temozolomide, cytotoxic salvage therapies resulted in a best overall response rate of 5 to 10%, 6-month PFS rates of 9% to 21%, and a median OS of 25 to 30 weeks.",130
19,bevacizumab,Bevacizumab treatment has been registered by FDA based on objective tumor response rates and PFS results obtained in uncontrolled phase II trials.,0
19,axitinib,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",0
19,tyrosine,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",42
19,lomustine,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",168
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,92
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,104
19,lomustine,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,118
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,140
19,axitinib,There was also a reduction of TIM3 expression and an increased cytokine production in the patients treated with axitinib.,112
19,axitinib,"Upon progression during axitinib treatment patients displayed an increased immune suppression with an increased number of Treg, an increased PD-1 expression on CD4+ and CD8+ T cells, and a reduced T cell functionality.  ",24
19,axitinib,In preclinical mouse models we demonstrated that axitinib reduces the immune suppressive microenvironment through reduction of the suppressive capacity of monocytic MDSCs (both in intra-cranial as well as subcutaneous tumors).,49
19,axitinib,"When we combined axitinib with active immunotherapy in the form of CTLA4 blockade not only a supplementary reduction of the suppressive capacity of these monocytic MDSCs was found, but also a reduction of the intratumoral granulocytic MDSCs and an increased antigen-presenting function of intratumoral DCs (manuscript accepted for publication in High-grade gliomas of the central nervous system (CNS) are characterized by profound tumor related neo-angiogenesis, and intracranial perilesional edema.",17
19,temozolomide,"In patient diagnosed with recurrence/progression glioblastoma (recGB) following prior therapy with surgery, radiation therapy and temozolomide, cytotoxic salvage therapies resulted in a best overall response rate of 5 to 10%, 6-month PFS rates of 9% to 21%, and a median OS of 25 to 30 weeks.",130
19,bevacizumab,Bevacizumab treatment has been registered by FDA based on objective tumor response rates and PFS results obtained in uncontrolled phase II trials.,0
19,axitinib,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",0
19,tyrosine,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",42
19,lomustine,"Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16).",168
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,92
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,104
19,lomustine,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,118
19,axitinib,Immunocytochemical profiling of the peripheral blood of recurrent GBM patients treated with axitinib or axitinib plus lomustine showed that axitinib treatment increases the number of naive CD8+ T cells and central memory CD4+ and CD8+ T cells.,140
19,axitinib,There was also a reduction of TIM3 expression and an increased cytokine production in the patients treated with axitinib.,112
19,axitinib,"Upon progression during axitinib treatment patients displayed an increased immune suppression with an increased number of Treg, an increased PD-1 expression on CD4+ and CD8+ T cells, and a reduced T cell functionality.  ",24
19,axitinib,In preclinical mouse models we demonstrated that axitinib reduces the immune suppressive microenvironment through reduction of the suppressive capacity of monocytic MDSCs (both in intra-cranial as well as subcutaneous tumors).,49
19,axitinib,"When we combined axitinib with active immunotherapy in the form of CTLA4 blockade not only a supplementary reduction of the suppressive capacity of these monocytic MDSCs was found, but also a reduction of the intratumoral granulocytic MDSCs and an increased antigen-presenting function of intratumoral DCs (manuscript accepted for publication in American Journal of Cancer Research).",17
19,axitinib,"The rational for combining avelumab with for the treatment of recGB is based on the potential of axitinib to normalize the glioblastoma associated neo-vasculature, counteracting the immunosuppressive role of VEGF in the tumor microenvironment and controlling intracranial edema.",97
19,axitinib,"In addition, axitinib may reduce the inflammatory edema related to the anti-tumor effect mediated by PD-L1 inhibition with avelumab.  ",13
19,corticosteroids,High dose corticosteroids however are known to be immunosuppressive and are likely to counteract the therapeutic effect of anti-PD-L1 antibody therapy.,10
19,axitinib,Axitinib has the capacity to control recGBM associated edema of the brain.,0
19,axitinib,Out of the 32 patients who were treated with corticosteroids at baseline in the AxiG trial (EudraCT 2011-000900-16) 17 could lower and 5 could stop their steroids during treatment with axitinib.,185
19,steroids,PFS was identical for patient with or without need for steroids at baseline in the AxiG trial but OS was numerically superior for patients not in need for steroids at baseline.,55
19,steroids,PFS was identical for patient with or without need for steroids at baseline in the AxiG trial but OS was numerically superior for patients not in need for steroids at baseline.,155
20,bevacizumab,This study does not add any additional treatment to patients with malignant glioma who are already scheduled to receive bevacizumab monotherapy.,120
20,bevacizumab, Day 1-The participant will have the following procedures done before they can receive bevacizumab:  ,87
20,bevacizumab,:The participant will have the following procedures done after they receive bevacizumab:  ,76
20,bevacizumab,An assessment of the participant's tumor by Vascular MRI (Magnetic Resonance Imaging) and FMISO-PET scans before the participant have received bevacizumab Blood pregnancy test for women of childbearing potential.,143
20,bevacizumab,: The participant will have the following procedures done after they receive bevacizumab:  ,77
20,bevacizumab,An assessment of the participant's tumor by Vascular MRI (Magnetic Resonance Imaging) and FMISO-PET scans after the participant has received bevacizumab Blood pregnancy test for women of childbearing potential.,141
20,fmiso, FMISO-PET Scans:  ,1
20,fmiso, FMISO for PET scan and a contrast dye for the MRI scan Drawing blood to assess the radioactivity of FMISO The PET scan will take approximately 60-75 minutes.,1
20,fmiso, FMISO for PET scan and a contrast dye for the MRI scan Drawing blood to assess the radioactivity of FMISO The PET scan will take approximately 60-75 minutes.,101
20,fmiso,The participant will receive one injection of FMISO.,46
21,tr,"TRC105 binding to CD105 leads to inhibition of EC proliferation, neovascularization, and induces cell death via apoptosis.",0
21,trc105,To obtain information regarding the safety of TRC105 in patients with recurrent GBM.,46
21,trc105,To evaluate the health-related quality of life (HRQL) in patients while on treatment with TRC105.,90
21,trc105,To examine the effect of TRC105 on vascular permeability as measured by percent change from baseline in the forward contrast transfer rate (Ktrans) of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).,25
21,trc105,"To examine the effect of TRC105 on vascular perfusion as measured by percent change from baseline in cerebral blood volume (CBV), cerebral blood flow (CBF), and mean transit time (MTT) of dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI).",25
21,trc105,To examine the effect of TRC105 on water diffusion as measured by percent change from baseline in apparent diffusion coefficient (ADC) and fractional anisotropy (FA) of diffusion magnetic resonance imaging (MRI).,25
21,trc105,To examine the effect of TRC105 on tumor metabolism as measured by percent change from baseline in fludeoxyglucose F18 injection (FDG) uptake of positron emission tomography (PET) scan.,25
21,fludeoxyglucosef1,To examine the effect of TRC105 on tumor metabolism as measured by percent change from baseline in fludeoxyglucose F18 injection (FDG) uptake of positron emission tomography (PET) scan.,99
21,fdg,To examine the effect of TRC105 on tumor metabolism as measured by percent change from baseline in fludeoxyglucose F18 injection (FDG) uptake of positron emission tomography (PET) scan.,130
21,trc105,Patients will then receive TRC105 as a single agent (weekly dose of 10 mg/kg IV).,27
21,trc105,"Patients who are clinically and neurologically stable, and who have radiographic stable or responding disease at the end of each cycle will continue treatment with TRC105.",164
22,mmf,The goal of the Phase 0 component is to determine if MMF achieves active concentrations in brain tumors.,53
22,mmf,Eight participants in Phase 0 will receive MMF for one week before undergoing an already planned biopsy or re-resection (surgical removal) of glioblastoma (GBM).,43
22,mmf,The goal of the Phase 1 component is to find the dose of MMF that works best without causing severe side effects (the maximum tolerated dose) when combined with radiation.,57
23,temozolomide,This is a phase II study of the combination of Avastin and temozolomide for patients with recurrent glioblastoma multiforme.,59
23,temozolomide,Avastin is administered intravenously at a dose of 10 mg/kg on days 1 and 15 every 28 days and temozolomide is administered at a dose of 100 mg/m2 on days 1-5 and 15-19 every 28 days (one cycle).,95
24,bevacizumab,"To date, no clinical data are available on the interaction of concomitant tumor treating fields with radiation therapy either with or without bevacizumab.",142
24,bevacizumab,The addition of bevacizumab to this regimen has both therapeutic and improved-toxicity implications.,16
26,temozolomide,"In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the Induction phase beginning at the conclusion of radiation.",109
26,bevacizumab,"Patients with recurrent glioblastoma will not receive treatment other than the investigative treatment, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab.",145
26,bevacizumab,"Patients with recurrent glioblastoma will not receive treatment other than the investigative treatment, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab.",215
28,nu-0129,To assess the safety of intravenous NU-0129 in patients with recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS).,36
28,nu-0129,To demonstrate intratumoral penetration of NU-0129.,43
28,nu-0129,To assess the feasibility of giving NU-0129 as a standard treatment for recurrent GBM or GS.  TERTIARY OBJECTIVES:,36
28,nu-0129,To analyze tumor tissue for Bcl2L12 expression levels after NU-0129 administration.,60
28,nu-0129,Patients receive NU-0129 intravenously (IV) over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.,17
29,bevacizumab,There will be no change in your treatment with bevacizumab and daily temozolomide based on the results of any procedures or tests carried out as a part of the study.,47
29,temozolomide,There will be no change in your treatment with bevacizumab and daily temozolomide based on the results of any procedures or tests carried out as a part of the study.,69
29,creatinine,Before each set of scans the participant will have the following tests and procedures:  Routine blood tests to check the participant's overall health Creatinine clearance blood test to check for proper kidney function Blood pregnancy test for women of childbearing potential  ,150
29,tmz,"After the participant have been taking oral TMZ for 7-13 days, the participant will have:  - An assessment of their tumor by DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans and PET (Positron Emission Tomography) scan  MRI-PET Scan Procedure:  ",44
29,[11c]temozolomide,[11C] temozolomide for PET scan and a contrast dye for the MRI scan Drawing blood to assess the radioactivity of [11C] temozolomide,0
29,[11c]temozolomide,[11C] temozolomide for PET scan and a contrast dye for the MRI scan Drawing blood to assess the radioactivity of [11C] temozolomide,113
29,[11c]temozolomide,[11C] temozolomide PET Scans (TMZ PET Scan): The PET scan will take approximately 90 minutes.,0
29,tmz,[11C] temozolomide PET Scans (TMZ PET Scan): The PET scan will take approximately 90 minutes.,30
29,[11c]temozolomide,The participant will receive one injection of [11C] temozolomide.,46
29,bevacizumab,The MR-PET scan(s) will be performed again on Day 1 after initiation of bevacizumab (or Day 15 after initiation of temozolomide) and Day 30 after initiation of bevacizumab (on Day 45 after initiation of temozolomide).,72
29,temozolomide,The MR-PET scan(s) will be performed again on Day 1 after initiation of bevacizumab (or Day 15 after initiation of temozolomide) and Day 30 after initiation of bevacizumab (on Day 45 after initiation of temozolomide).,115
29,bevacizumab,The MR-PET scan(s) will be performed again on Day 1 after initiation of bevacizumab (or Day 15 after initiation of temozolomide) and Day 30 after initiation of bevacizumab (on Day 45 after initiation of temozolomide).,160
29,temozolomide,The MR-PET scan(s) will be performed again on Day 1 after initiation of bevacizumab (or Day 15 after initiation of temozolomide) and Day 30 after initiation of bevacizumab (on Day 45 after initiation of temozolomide).,203
29,[11c]temozolomide,[11C] temozolomide,0
29,[11c]temozolomide,"Blood samples will be drawn 2.5, 5, 10, 20, 40, 60, 75, and 90 minutes after the [11C] temozolomide injection.",81
30,ipilimumab,To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO),40
30,nivolumab,To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO),55
30,nivolumab," SECONDARY OBJECTIVES:  I. Estimate the overall survival distribution, median survival, and one-year survival rate of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab.",205
30,ipilimumab,"Estimate the progression-free survival distribution and median progression-free survival of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab.",164
30,nivolumab,"Estimate the progression-free survival distribution and median progression-free survival of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab.",179
30,nivolumab,"Determine the adverse event profile of patients with hypermutated, recurrent glioblastoma who are treated with ipilimumab and nivolumab.",126
30,nivolumab,Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1.,17
30,ipilimumab,Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1.,66
30,nivolumab,Patients then receive nivolumab IV over 30 minutes on day 1.,22
31,regorafenib,The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.,73
31,bevacizumab,The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab.,169
31,regorafenib,Regorafenib is FDA approved administered as monotherapy during the study.,0
33,azd1775,To determine the maximum tolerated doses (MTD) of AZD1775 (adavosertib) in combination with the current standard of care (radiotherapy/temozolomide for concomitant therapy and temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.,50
33,ada,To determine the maximum tolerated doses (MTD) of AZD1775 (adavosertib) in combination with the current standard of care (radiotherapy/temozolomide for concomitant therapy and temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.,59
33,temozolomide,To determine the maximum tolerated doses (MTD) of AZD1775 (adavosertib) in combination with the current standard of care (radiotherapy/temozolomide for concomitant therapy and temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.,135
33,temozolomide,To determine the maximum tolerated doses (MTD) of AZD1775 (adavosertib) in combination with the current standard of care (radiotherapy/temozolomide for concomitant therapy and temozolomide for adjuvant therapy) for treating patients with newly diagnosed glioblastoma.,176
33,azd1775,To define the MTD of AZD1775 (adavosertib) in combination with 6 weeks of daily (Monday-Friday,21
33,adavosertib,To define the MTD of AZD1775 (adavosertib) in combination with 6 weeks of daily (Monday-Friday,30
33,temozolomide,[M-F]) radiotherapy (RT) and concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly diagnosed glioblastoma.,41
33,tmz,[M-F]) radiotherapy (RT) and concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly diagnosed glioblastoma.,55
33,azd1775,To define the MTD of AZD1775 (adavosertib) in combination with adjuvant TMZ administered at 150 mg/m^2/day-200 mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ.,21
33,ada,To define the MTD of AZD1775 (adavosertib) in combination with adjuvant TMZ administered at 150 mg/m^2/day-200 mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ.,30
33,tmz,To define the MTD of AZD1775 (adavosertib) in combination with adjuvant TMZ administered at 150 mg/m^2/day-200 mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ.,72
33,tmz,To define the MTD of AZD1775 (adavosertib) in combination with adjuvant TMZ administered at 150 mg/m^2/day-200 mg/m^2/day for 5 days every 28 days in patients with glioblastoma after concurrent RT/TMZ.,197
33,azd1775,To characterize the safety profile of AZD1775 (adavosertib) in combination with RT and concomitant TMZ (Arm 1) and AZD1775 (adavosertib) with adjuvant TMZ (Arm 2) in patients with newly diagnosed glioblastoma.,38
33,tmz,To characterize the safety profile of AZD1775 (adavosertib) in combination with RT and concomitant TMZ (Arm 1) and AZD1775 (adavosertib) with adjuvant TMZ (Arm 2) in patients with newly diagnosed glioblastoma.,99
33,azd1775,To characterize the safety profile of AZD1775 (adavosertib) in combination with RT and concomitant TMZ (Arm 1) and AZD1775 (adavosertib) with adjuvant TMZ (Arm 2) in patients with newly diagnosed glioblastoma.,115
33,tmz,To characterize the safety profile of AZD1775 (adavosertib) in combination with RT and concomitant TMZ (Arm 1) and AZD1775 (adavosertib) with adjuvant TMZ (Arm 2) in patients with newly diagnosed glioblastoma.,151
33,azd1775,To assess the pharmacokinetic (PK) profile of AZD1775 (adavosertib) in combination with upfront radiation/TMZ and adjuvant TMZ in patients with newly diagnosed glioblastoma.,46
33,tmz,To assess the pharmacokinetic (PK) profile of AZD1775 (adavosertib) in combination with upfront radiation/TMZ and adjuvant TMZ in patients with newly diagnosed glioblastoma.,106
33,tmz,To assess the pharmacokinetic (PK) profile of AZD1775 (adavosertib) in combination with upfront radiation/TMZ and adjuvant TMZ in patients with newly diagnosed glioblastoma.,123
33,azd1775,To determine the intratumoral concentration of AZD1775 (adavosertib) achieved in patients treated with the putative MTD.,47
33,adavosertib,To determine the intratumoral concentration of AZD1775 (adavosertib) achieved in patients treated with the putative MTD.,56
33,azd1775,To characterize the time course of AZD1775 (adavosertib) in extracellular fluid within brain tumors following a single oral dose of drug by microdialysis.,35
33,azd1775,"To characterize the pharmacodynamic effects of AZD1775 on tumor through immunohistochemistry (IHC) analysis of pRb (S807/811), proliferation (e.g. Ki-67), pCDC2, Wee1, and apoptosis (e.g. cleaved caspase 3) on resected tumors exposed to drug.",47
33,azd1775,"To characterize MGMT methylation and P53 pathway status, also P-gp and wee1 expression levels in patients with newly diagnosed glioblastoma treated with standard therapy in combination with AZD1775 (adavosertib).",190
33,adavosertib,"To characterize MGMT methylation and P53 pathway status, also P-gp and wee1 expression levels in patients with newly diagnosed glioblastoma treated with standard therapy in combination with AZD1775 (adavosertib).",199
33,azd1775,"To explore and analyze adaptive resistance mechanisms to AZD1775 using proteogenomics, and connect this data to spatially resolved drug distribution through targeted, imaging-based quantification of drug efficacy and tumor response.",57
33,adavosertib,This is a dose-escalation study of adavosertib.,35
33,adavosertib,"Patients receive adavosertib orally (PO) on days 1, 3, and 5 or days 1-5 weekly and temozolomide PO once daily (QD) for 6 weeks.",17
33,temozolomide,"Patients receive adavosertib orally (PO) on days 1, 3, and 5 or days 1-5 weekly and temozolomide PO once daily (QD) for 6 weeks.",84
33,temozolomide,"Beginning in week 10, patients receive temozolomide PO QD on days 1-5.",39
33,adavosertib,"Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5.",17
33,temozolomide,"Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5.",74
34,ate,Patients receive systemic treatment with atezolizumab IV over 30-60 minutes on day 1.,41
35,tesevatinib,"This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.",63
36,bevacizumab,"Although overall the effects on prolonging survival in bevacizumab-treated patients is modest at best, it is still unclear whether there is not a more substantial positive effect in a subset of patients, potentially identifiable by imaging markers.",55
39,sulfasalazine,The investigators have shown in experimental studies that the drug sulfasalazine enhances the number of cancer cells that dies as result of radiation therapy and thereby improves survival in combination with SRS in animals with glioblastoma.,67
39,sulfasalazine,Sulfasalazine inhibits the production of an antioxidant that normally protects the tumor against radiation.,0
40,temozolomide,"The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts.",79
40,tmz,"The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts.",93
40,o6-methylguanine,"The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts.",119
40,tmz,"The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts.",185
40,o6-guanine,"The primary mechanism of resistance to current standard chemotherapeutic agent Temozolomide (TMZ) is overexpression of O6-methylguanine-DNA-methyl transferase (MGMT), which repairs the TMZ-induced DNA lesion by removing the o6-guanine adducts.",224
40,tmz,"Thus, a means to down modulate MGMT activity would enhance the therapeutic effect of TMZ.",85
40,temozolomide,"This is a Phase II clinical trial of the tumor-targeted SGT-53 nanocomplex in combination with chemotherapeutic agent, temozolomide which is the standard of care for Glioblastoma Multiforme (GBM) brain tumors.",119
40,temozolomide,We propose to test the combination of SGT-53 and standard temozolomide to determine efficacy and safety in patients with confirmed glioblastoma who have proven tumor recurrence or progression.,58
41,amg386,To determine the efficacy of AMG 386 in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6),29
41,amg386,To determine the maximum tolerated dose of AMG 386 in combination with bevacizumab given at 10mg/kg every 2 weeks in participants with recurrent glioblastoma.,43
41,amg386,To determine the efficacy of AMG 386 plus bevacizumab in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).,29
41,bevacizumab,To determine the efficacy of AMG 386 plus bevacizumab in participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).,42
41,amg386, To evaluate expression of factors associated with tumor angiogenesis using a multiples cytokine assay among participants undergoing therapy with AMG 386 with response to therapy and development of resistance.,146
41,amg386,This is an open-label Phase I/II study of AMG 386 monotherapy and AMG 386 in combination with bevacizumab.,42
41,amg386,This is an open-label Phase I/II study of AMG 386 monotherapy and AMG 386 in combination with bevacizumab.,66
41,amg386,Cohort A will assess recurrent GBM participants who receive AMG 386 monotherapy at 30 g/kg every week.,60
41,amg386,Cohort B will assess recurrent GBM participants who receive weekly AMG 386 plus bi-weekly bevacizumab (10mg/kg).,67
41,bevacizumab,Cohort B will assess recurrent GBM participants who receive weekly AMG 386 plus bi-weekly bevacizumab (10mg/kg).,90
41,amg386,Cohort B will start with a Phase I component to determine the MTD of AMG 386 that is safe when used in combination with bevacizumab.,69
41,amg386,"AMG 386 is administered intravenously, and, when used in combination with intravenous bevacizumab, will be administered first.",0
42,cediranibmaleate,"I. To compare the antitumor activity of cediranib maleate (cediranib)/olaparib versus reference bevacizumab monotherapy, as measured by progression-free survival at 6 months (PF6), in patients with recurrent glioblastoma (GBM).",40
42,cediranib,"I. To compare the antitumor activity of cediranib maleate (cediranib)/olaparib versus reference bevacizumab monotherapy, as measured by progression-free survival at 6 months (PF6), in patients with recurrent glioblastoma (GBM).",59
42,olaparib,"I. To compare the antitumor activity of cediranib maleate (cediranib)/olaparib versus reference bevacizumab monotherapy, as measured by progression-free survival at 6 months (PF6), in patients with recurrent glioblastoma (GBM).",70
42,bevacizumab,"I. To compare the antitumor activity of cediranib maleate (cediranib)/olaparib versus reference bevacizumab monotherapy, as measured by progression-free survival at 6 months (PF6), in patients with recurrent glioblastoma (GBM).",96
42,cediranib,"I. To compare overall survival (OS), progression free survival (PFS) and objective response (ORR) in patients with recurrent GBM treated with cediranib/olaparib versus bevacizumab.",142
42,olaparib,"I. To compare overall survival (OS), progression free survival (PFS) and objective response (ORR) in patients with recurrent GBM treated with cediranib/olaparib versus bevacizumab.",152
42,bevacizumab,"I. To compare overall survival (OS), progression free survival (PFS) and objective response (ORR) in patients with recurrent GBM treated with cediranib/olaparib versus bevacizumab.",168
42,olaparib,To assess the safety of the combination of olaparib and cediranib in patients with recurrent GBM.,43
42,cediranib,To assess the safety of the combination of olaparib and cediranib in patients with recurrent GBM.,56
42,cediranib,"To evaluate the association of blood based biomarkers involved with angiogenesis using the Biomarker Review Committee-approved Plasma Angiome Panel (bFGF, Ang-1, Ang-2, Tie-2, SDF1-alpha, Collagen IV, PlGF, sVEGFR1, sVEGFR2, VEGF, Il-1beta, Il-6, Il-8, TNF-alpha, CAIX) with the clinical activity of cediranib/olaparib.",300
42,olaparib,"To evaluate the association of blood based biomarkers involved with angiogenesis using the Biomarker Review Committee-approved Plasma Angiome Panel (bFGF, Ang-1, Ang-2, Tie-2, SDF1-alpha, Collagen IV, PlGF, sVEGFR1, sVEGFR2, VEGF, Il-1beta, Il-6, Il-8, TNF-alpha, CAIX) with the clinical activity of cediranib/olaparib.",310
42,cediranib,To evaluate the association of tissue biomarkers involved with deoxyribonucleic acid (DNA) repair using the Biomarker Review Committee-approved BROCA panel with the clinical activity of cediranib/olaparib.,186
42,olaparib,To evaluate the association of tissue biomarkers involved with deoxyribonucleic acid (DNA) repair using the Biomarker Review Committee-approved BROCA panel with the clinical activity of cediranib/olaparib.,196
42,cediranib,To identify genomic alteration by whole exome sequencing in GBM tumor specimens that correlate with the clinical activity of cediranib/olaparib.,125
42,ol,To identify genomic alteration by whole exome sequencing in GBM tumor specimens that correlate with the clinical activity of cediranib/olaparib.,135
42,cediranib,"To evaluate the association of magnetic resonance imaging (MRI) imaging parameters (tumor perfusion and oxygenation, brain tumor cellularity) with the biological response of cediranib/olaparib.  ",174
42,olaparib,"To evaluate the association of magnetic resonance imaging (MRI) imaging parameters (tumor perfusion and oxygenation, brain tumor cellularity) with the biological response of cediranib/olaparib.  ",184
42,formalin,"To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Experimental Therapeutics Clinical Trials Network (ETCTN) Biorepository at Nationwide Children's Hospital.",8
42,olaparib,Patients receive olaparib orally (PO) twice daily (BID) and cediranib maleate PO once daily (QD) on days 1-28.,17
42,cediranibmaleate,Patients receive olaparib orally (PO) twice daily (BID) and cediranib maleate PO once daily (QD) on days 1-28.,60
42,bevacizumab,ARM B: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks.,24
43,cu,This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.,18
43,tmz,This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.,41
43,cu,Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months.,23
43,tmz,Patients will take DSF-Cu daily during their routine standard of care with TMZ therapy for approximately 6 months.,75
43,cu,Patients will be followed up 2 years after the last dose of DSF-Cu.,64
45,aprepitant,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",127
45,auranofin,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",139
45,captopril,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",150
45,celecoxib,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",161
45,disulfiram,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",172
45,itraconazole,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",184
45,minocycline,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",198
45,ritonavir,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",211
45,sertraline,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",225
45,temozolomide,"A proof-of-concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs (aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, ritonavir and sertraline) combined with metronomic temozolomide (CUSP9v3 treatment protocol) for recurrent glioblastoma.",262
45,cusp9v3,A total of 10 patients will be treated with the CUSP9v3 treatment protocol.,48
47,bevacizumab,The purpose of this study is to compare the effects of a vaccine with bevacizumab versus bevacizumab alone on a patient's brain tumor.,70
47,bevacizumab,The purpose of this study is to compare the effects of a vaccine with bevacizumab versus bevacizumab alone on a patient's brain tumor.,89
47,bevacizumab,Bevacizumab has been approved by the Food and Drug administration for treating brain tumors that grow back.,0
47,bevacizumab,"In this study, patients will either get HSPPC-96 vaccine at the same time as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or bevacizumab alone.",77
47,bevacizumab,"In this study, patients will either get HSPPC-96 vaccine at the same time as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or bevacizumab alone.",119
47,bevacizumab,"In this study, patients will either get HSPPC-96 vaccine at the same time as bevacizumab, HSPPC vaccine first and then bevacizumab if the tumor comes back, or bevacizumab alone.",159
47,bevacizumab,The use of HSPPC-96 and bevacizumab is investigational.,24
47,bevacizumab,"The primary objective of the study is to determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent glioblastoma multiforme.  ",128
47,bevacizumab,"The primary objective of the study is to determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent glioblastoma multiforme.  ",212
47,bevacizumab,"The secondary objectives are:  to evaluate the safety and tolerability of HSPPC-96 with bevacizumab to evaluate the progression free survival of HSPPC-96 with bevacizumab, given concomitantly or at the point of progression.",88
47,bevacizumab,"The secondary objectives are:  to evaluate the safety and tolerability of HSPPC-96 with bevacizumab to evaluate the progression free survival of HSPPC-96 with bevacizumab, given concomitantly or at the point of progression.",159
48,temozolomide,Each treatment cycle lasts 4 weeks (28 days) during which time they will be taking temozolomide orally once a day for the first three weeks.,83
48,temozolomide,Participants may continue taking temozolomide until their tumor grows or if they experience unacceptable side effects.,33
49,vb-111,"The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.",82
49,bevacizumab,"The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.",94
49,bevacizumab/5-aminolevulinicacid,"The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.",109
53,nitrosoureas,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",58
53,carboplatin,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",72
53,bevacizumab,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",85
53,etoposide,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",98
53,irinotecan,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",109
53,imatinib,"At present a number of chemotherapeutic agents, including nitrosoureas, carboplatin, bevacizumab, etoposide, irinotecan, and imatinib, have been used as salvage therapy either alone or in combination.",125
53,nitrosoureas,"Currently, only nitrosoureas (lomustine and carmustine), including Gliadel® Wafer (carmustine) as adjunct to surgery, are approved for use in previously treated GBM.",16
53,lomustine,"Currently, only nitrosoureas (lomustine and carmustine), including Gliadel® Wafer (carmustine) as adjunct to surgery, are approved for use in previously treated GBM.",30
53,carmustine,"Currently, only nitrosoureas (lomustine and carmustine), including Gliadel® Wafer (carmustine) as adjunct to surgery, are approved for use in previously treated GBM.",44
53,carmustine,"Currently, only nitrosoureas (lomustine and carmustine), including Gliadel® Wafer (carmustine) as adjunct to surgery, are approved for use in previously treated GBM.",83
55,bal101553,This is the first study of prolonged intravenous infusion of BAL101553.,61
55,bal101553,"BAL101553 will be administered as an intravenous infusion over 48 hours, to adults with advanced or recurrent solid tumors or recurrent glioblastoma who have failed standard therapy, or for whom no effective standard therapy is available.  ",0
55,bal101553,The primary goal of the study is to find the highest dose of BAL101553 that can safely be given to humans and to assess what side effects occur.,61
55,platinum,"Once the highest, well tolerated dose is identified, 20 new patients with platinum-resistant/refractory ovarian cancer and 20 new patients with recurrent glioblastoma will be treated at that dose (this part is called ""dose expansion"") to further assess the tolerability and potential anticancer activity of oral BAL101553.",74
55,bal101553,"Once the highest, well tolerated dose is identified, 20 new patients with platinum-resistant/refractory ovarian cancer and 20 new patients with recurrent glioblastoma will be treated at that dose (this part is called ""dose expansion"") to further assess the tolerability and potential anticancer activity of oral BAL101553.",312
56,bevacizumab,"The treatment of recurrent glioblastoma after a standard first-line treatment is not clearly codified, however, many results in the literature show the benefit of bevacizumab (anti- angiogenic therapy) and it is often proposed in this indication .",163
57,temozolomide,"Despite surgery and first-line standard of care which consist of radiotherapy with concomitant and adjuvant temozolomide, all patients with glioblastoma (GB) will experience relapse.",108
57,bevacizumab,"At the time of recurrence, therapeutic options include surgery or reirradiation in selected cases, while in other cases, bevacizumab, approved by Food and Drug Administration (FDA) but not European Medicines Agency (EMA), is the preferred option worldwide.",121
57,bevacizumab,Primary and acquired resistance to bevacizumab has been explored without definitive finding.,35
57,bevacizumab,Biomarkers able to predict response to antiangiogenic agents and particularly to bevacizumab are an unmet medical need.,81
57,bevacizumab,We have showed that a low Matrix metallopeptidase 9 (MMP9) or a high Matrix metallopeptidase 2 (MMP2) baseline plasma levels were associated with a high response rate and a prolonged Progression-free survival (PFS) and overall survival (OS) in recurrent GB patients treated with bevacizumab but not with cytotoxic chemotherapy.,279
57,bevacizumab,We also observed that MMP9 plasma level decreased during bevacizumab treatment and tend to increase at progression.,57
57,bevacizumab,"Finally, in a retrospective analysis performed in the Avaglio trial (a randomized phase III trial that tested bevacizumab versus placebo in addition to standard of care in patients with newly diagnosed glioblastoma), a low plasma level of MMP9 at baseline predicted consistently PFS and OS gain associated to bevacizumab.",110
57,bevacizumab,"Finally, in a retrospective analysis performed in the Avaglio trial (a randomized phase III trial that tested bevacizumab versus placebo in addition to standard of care in patients with newly diagnosed glioblastoma), a low plasma level of MMP9 at baseline predicted consistently PFS and OS gain associated to bevacizumab.",309
57,bevacizumab,Our results strongly support a role for MMP9 in the primary or acquired resistance to bevacizumab.,86
57,gs5745,"Therefore, we hypothesize that the Monoclonal Antibody GS5745 may overcome resistance to bevacizumab through a specific inhibition of MMP9.",55
57,bevacizumab,"Therefore, we hypothesize that the Monoclonal Antibody GS5745 may overcome resistance to bevacizumab through a specific inhibition of MMP9.",89
57,gs5745,"While a preclinical program is initiated in our lab, the proposed phase I study is the first step to analyze the tolerance, determine the recommended dose of the combination and explore the impact of GS5745 on MMP9 plasma levels and multimodal imaging in patients with recurrent glioblastoma.",200
57,gs5745,Determine the safety profile and tolerability of GS5745 given in combination with a fixed dose of bevacizumab in patients with recurrent GB in terms of Dose-Limiting Toxicities.,49
57,bevacizumab,Determine the safety profile and tolerability of GS5745 given in combination with a fixed dose of bevacizumab in patients with recurrent GB in terms of Dose-Limiting Toxicities.,98
57,gs5745," Multicenter, open label, dose-finding study of GS5745 in combination with bevacizumab administered at a fixed dose; both drugs will be administered once every two weeks for a total treatment duration of a maximum of 12 months.",48
58,bevacizumab,"Bevacizumab, the first angiogenesis inhibitor approved against cancer by FDA based on improved survival of advanced colon cancer patient, has recently been studied in the GBM.",0
58,vorinostat,"The present study aims to determine the potential of vorinostat, an HDAC inhibitor plus bevacizumab, versus bevacizumab alone, in an attempt to increase the anti-angiogenic effects of VEGF by blocking the evasive resistance by combination with vorinostat and to also not only provide the potential of the independent effects of both agents but also the potential for synergy.",53
58,vorinostat,"The present study aims to determine the potential of vorinostat, an HDAC inhibitor plus bevacizumab, versus bevacizumab alone, in an attempt to increase the anti-angiogenic effects of VEGF by blocking the evasive resistance by combination with vorinostat and to also not only provide the potential of the independent effects of both agents but also the potential for synergy.",244
58,vorinostat,Objectives  To determine the maximum tolerated dose (MTD) of vorinostat plus bevacizumab in adult patients with malignant glioma.,61
58,vorinostat,To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as determined by progression free survival (PFS) using an adaptive randomization phase II trial design.,29
58,bevacizumab,To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as determined by progression free survival (PFS) using an adaptive randomization phase II trial design.,45
58,bevacizumab,To determine the efficacy of vorinostat plus bevacizumab versus bevacizumab alone in patients with recurrent WHO grade IV glioma (glioblastoma and gliosarcoma) as determined by progression free survival (PFS) using an adaptive randomization phase II trial design.,64
58,bevacizumab,No prior treatment with bevacizumab or Vorinostat  Design  ,24
58,vorinostat,No prior treatment with bevacizumab or Vorinostat  Design  ,39
58,vorinostat,The phase I component will assess the MTD of Vorinostat in combination with Bevacizumab.,45
58,bevacizumab,The phase II component of the trial compares Bevacizumab to Vorinostat+ Bevacizumab in patients with recurrent GBM.,45
58,vorinostat,The phase II component of the trial compares Bevacizumab to Vorinostat+ Bevacizumab in patients with recurrent GBM.,60
58,bevacizumab,The phase II component of the trial compares Bevacizumab to Vorinostat+ Bevacizumab in patients with recurrent GBM.,72
59,bevacizumab,Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.,46
61,dnx-2401,Eligible subjects will receive a single intratumoral injection of DNX-2401 into a recurrent glioblastoma or gliosarcoma brain tumor using the Alcyone MEMS Cannula (AMC™) System (cannula).,66
61,dnx-2401,"After receiving DNX-2401, subjects will return to the clinic for study visits at regular intervals for safety monitoring, MRI scans and other assessments for up to 18 months.",16
62,sl-701,The purpose of this study is to determine the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiform (GBM).,69
63,ct-322,RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor.,11
63,irinotecan,"Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.",36
63,ct-322,Giving CT-322 together with irinotecan may kill more tumor cells.,7
63,irinotecan,Giving CT-322 together with irinotecan may kill more tumor cells.,28
63,ct-322,"This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.",79
63,irinotecan,"This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.",127
64,sorafenib,"Sorafenib will be administered at a set dose of 400 mg (2 x 200 mg tablets) twice daily, without food (at least 1 hour before or 2 hours after eating).",0
64,temozolomide,Temozolomide will be administered at a set dose of 50 mg/m2 once daily without food (at least 1 hour before or 2 hours after eating).,0
65,temozolomide,One strategy is re-exposure to temozolomide in a higher dose.,31
65,temozolomide,"In study arm A patients receive temozolomide for one week, followed by a week without temozolomide.",32
65,temozolomide,"In study arm A patients receive temozolomide for one week, followed by a week without temozolomide.",86
65,temozolomide,"In study arm B patients receive temozolomide for three weeks, followed by a week without temozolomide.",32
65,temozolomide,"In study arm B patients receive temozolomide for three weeks, followed by a week without temozolomide.",89
66,imatinibmesylate,"Both studies were phase II, open-label, multicenter, single-arm studies that evaluated the efficacy of imatinib mesylate plus hydroxyurea in subjects with progressive glioblastoma multiforme.",103
66,hydroxyurea,"Both studies were phase II, open-label, multicenter, single-arm studies that evaluated the efficacy of imatinib mesylate plus hydroxyurea in subjects with progressive glioblastoma multiforme.",126
66,imatinib,The studies were identical in design with two exceptions: Patients in study CSTI571H2201 received a dose of imatinib 600 mg once daily and were not allowed concomitant use of enzyme-inducing anticonvulsant drugs (EIACDs); patients in study CSTI571H2202 received a dose of imatinib 500 mg twice daily and were allowed concomitant use of EIACDs.,108
66,imatinib,The studies were identical in design with two exceptions: Patients in study CSTI571H2201 received a dose of imatinib 600 mg once daily and were not allowed concomitant use of enzyme-inducing anticonvulsant drugs (EIACDs); patients in study CSTI571H2202 received a dose of imatinib 500 mg twice daily and were allowed concomitant use of EIACDs.,272
67,temozolomide,"In newly diagnosed GBM, the concurrent use of radiation and temozolomide is standard of care.",60
68,irinotecan,To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma.,56
68,temozolomide,To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma.,92
68,irinotecan,To assess the preliminary response rate and progression free survival of nanaliposomal irinotecan with continuous low-dose temozolomide in patients with recurrent glioblastoma.,87
68,temozolomide,To assess the preliminary response rate and progression free survival of nanaliposomal irinotecan with continuous low-dose temozolomide in patients with recurrent glioblastoma.,123
68,irinotecan,To evaluate the safety of nanoliposomal irinotecan with continuous low-dose temozolomide.,40
68,temozolomide,To evaluate the safety of nanoliposomal irinotecan with continuous low-dose temozolomide.,76
69,vorinostat,"The Study Drugs:  Vorinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die.",18
69,erlotinib,Erlotinib is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival.,0
69,temozolomide,Temozolomide is designed to kill cancer cells by damaging DNA (the genetic material of cells).,0
69,vorinostat,"If you are in Group 1, you will take vorinostat, erlotinib, and temozolomide.",37
69,erlotinib,"If you are in Group 1, you will take vorinostat, erlotinib, and temozolomide.",49
69,temozolomide,"If you are in Group 1, you will take vorinostat, erlotinib, and temozolomide.",64
69,vorinostat,"If you are in Group 2, you will take vorinostat and erlotinib.",37
69,erlotinib,"If you are in Group 2, you will take vorinostat and erlotinib.",52
69,erlotinib,"In addition, no matter which group or dose level you are assigned to, if you are on enzyme inducing anti-seizure drug, you will take a higher dose of erlotinib.  ",150
69,vorinostat,"If you are in Group 1:  On Days 1-7 and 15-21 of every cycle, you will take vorinostat by mouth 2 times a day.",76
69,vorinostat,You should take vorinostat with food.,16
69,erlotinib,"On Days 1-21 of every cycle, you will take erlotinib by mouth 1 time a day.",43
69,erlotinib,You should take erlotinib in the morning 1 hour before or 2 hours after food with 1 cup (about 8 oz.) of water.,16
69,temozolomide,"On Days 1-7 and 15-21of every cycle, you will take the temozolomide by mouth 1 time a day.",55
69,temozolomide,"You should swallow the temozolomide capsules whole, one right after the other, without chewing them.",23
69,temozolomide,"If you vomit while taking temozolomide, you cannot take more capsules before the next scheduled dose.",26
69,vorinostat,"If you are in Group 2:  On Days 1-14 of every cycle, you will take vorinostat by mouth 2 times a day.",67
69,vorinostat,You should take vorinostat with food.,16
69,erlotinib,"On Days 1-21 of every cycle, you will take erlotinib by mouth 1 time a day.",43
69,erlotinib,You should take erlotinib in the morning 1 hour before or 2 hours after food with 1 cup (about 8 oz.) of water.,16
69,erlotinib,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",0
69,temozolomide,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",90
69,vorinostat,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",139
69,vorinostat,"The Study Drugs:  Vorinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die.",18
69,erlotinib,Erlotinib is designed to block the activity of a protein found on the surface of many tumor cells that may control tumor growth and survival.,0
69,temozolomide,Temozolomide is designed to kill cancer cells by damaging DNA (the genetic material of cells).,0
69,vorinostat,"If you are in Group 1, you will take vorinostat and erlotinib.",37
69,erlotinib,"If you are in Group 1, you will take vorinostat and erlotinib.",52
69,vorinostat,"If you are in Group 2, you will take vorinostat, erlotinib, and temozolomide.  ",37
69,erlotinib,"If you are in Group 2, you will take vorinostat, erlotinib, and temozolomide.  ",49
69,temozolomide,"If you are in Group 2, you will take vorinostat, erlotinib, and temozolomide.  ",64
69,vorinostat,This subset group of the study is done to learn the effects of vorinostat on tumor tissue and blood cells.,63
69,vorinostat,"If you are in Group A, you will receive vorinostat alone.",40
69,erlotinib,"If you are in Group B, you will receive erlotinib alone.",40
69,vorinostat,"If you are in Group C, you will receive both vorinostat and erlotinib.",45
69,erlotinib,"If you are in Group C, you will receive both vorinostat and erlotinib.",60
69,erlotinib,"In addition, no matter which group you are assigned to, if you are on enzyme inducing anti-seizure drug, you will take the higher dose of erlotinib.",138
69,vorinostat,"If you are in Group 1:  On Days 1-14 of every cycle, you will take vorinostat by mouth 2 times a day.",67
69,vorinostat,You should take vorinostat with food.,16
69,erlotinib,"On Days 1-21 of every cycle, you will take erlotinib by mouth 1 time a day.",43
69,erlotinib,You should take erlotinib in the morning 1 hour before or 2 hours after food with 1 cup (about 8 oz.) of water.,16
69,vorinostat,"If you are in Group 2:  On Days 1-7 and 15-21 of every cycle, you will take vorinostat by mouth 2 times a day .You should take vorinostat with food.",76
69,vorinostat,"If you are in Group 2:  On Days 1-7 and 15-21 of every cycle, you will take vorinostat by mouth 2 times a day .You should take vorinostat with food.",127
69,erlotinib,"On Days 1-21 of every cycle, you will take erlotinib by mouth 1 time a day .",43
69,erlotinib,You should take erlotinib in the morning 1 hour before or 2 hours after food with 1 cup (about 8 oz.) of water.,16
69,temozolomide,"On Days 1-7 and 15-21 of every cycle, you will take the temozolomide by mouth 1 time a day.",56
69,temozolomide,"You should swallow the temozolomide capsules whole, one right after the other, without chewing them.",23
69,temozolomide,"If you vomit while taking temozolomide, you cannot take more capsules before the next scheduled dose.",26
69,vorinostat,"If you are in Group A, you will take vorinostat by mouth 2 times a day.",37
69,erlotinib,"If you are in Group B, you will take erlotinib by mouth 1 time a day.",37
69,vorinostat,"If you are in Group C, you will take vorinostat by mouth 2 time a day and erlotinib by mouth 1 time a day.",37
69,erlotinib,"If you are in Group C, you will take vorinostat by mouth 2 time a day and erlotinib by mouth 1 time a day.",74
69,vorinostat,"In addition to the above tests, blood (about 1 teaspoon each time) will be drawn 1 time before and 3 times after the first dose of vorinostat, and during surgery.",131
69,vorinostat,"After the surgery, part of the leftover tumor tissue from the surgery will be used to measure the drug levels and the effects of vorinostat on the tumor and be used for biomarker tests.",129
69,erlotinib,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",0
69,temozolomide,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",90
69,vorinostat,"Erlotinib is FDA approved drug for treatment of some types of non-small cell lung cancer, temozolomide for some types of brain cancer, and vorinostat for some types of lymphoma.",139
70,carboplatin,"This is a Phase 1/2, open-label, prospective, multi-center, single-arm study to establish the safety and feasibility of blood-brain-barrier disruption (BBBD) combined with intravenous carboplatin for the treatment of rGBM using the Exablate Neuro Model 4000 Type 2 system.",184
70,carboplatin,Adult glioblastoma subjects that are planned for carboplatin chemotherapy will be considered for study enrollment.,49
70,carboplatin,Eligible subjects will undergo up to 6 cycles of Exablate BBBD procedures in conjunction with carboplatin chemotherapy.,94
71,carboplatin,"This is a Phase 1/2, open-label, prospective, multi-center, single-arm study to establish the safety and feasibility of blood-brain-barrier disruption (BBBD) combined with intravenous carboplatin for the treatment of rGBM using the Exablate Neuro Model 4000 Type 2 system with microbubble resonators.",184
71,carboplatin,Adult glioblastoma subjects that are planned for carboplatin chemotherapy will be considered for study enrollment.,49
71,carboplatin,Eligible subjects will undergo up to 6 cycles of Exablate BBBD procedures in conjunction with carboplatin chemotherapy.,94
72,ribo,Preliminary evaluation of efficacy and determination of the ribociclib safety profile in patients with brain tumors will be studied.,60
72,ribociclib,All patients will be treated with ribociclib (600 mg/day) for 8-21 days before surgical resection of the recurrent tumor.,34
72,ribociclib,We will determine whether molecular markers associated with changes induced by ribociclib treatment in tumors (matching initial vs. recurrent tumors) correlate with progression-free survival.,79
72,ribociclib,"An extra 10 mL of blood will be collected during a routine clinical procedure prior to initiation of ribociclib treatment (i.e., baseline blood sample), separated into plasma and buffy coat fractions, and frozen for pharmacokinetic (PK) analysis.",101
73,fludeoxyglucose,PRIMARY OBJECTIVES:  I. Define the test - retest variance of tumor fludeoxyglucose (FDG) uptake using double baseline 18F-FDG PET imaging (18 to 54 hours apart) in patients with EGFR activated recurrent glioblastoma.,67
73,fdg,PRIMARY OBJECTIVES:  I. Define the test - retest variance of tumor fludeoxyglucose (FDG) uptake using double baseline 18F-FDG PET imaging (18 to 54 hours apart) in patients with EGFR activated recurrent glioblastoma.,84
73,18f-fdg,PRIMARY OBJECTIVES:  I. Define the test - retest variance of tumor fludeoxyglucose (FDG) uptake using double baseline 18F-FDG PET imaging (18 to 54 hours apart) in patients with EGFR activated recurrent glioblastoma.,118
73,osimertinib,"After defining #1, evaluate whether osimertinib can create a statistically significant decrease in glucose utilization as determined using early, post dosing (24-72 hour) FDG-PET imaging in patients with EGFR activated recurrent glioblastoma.",36
73,glucose,"After defining #1, evaluate whether osimertinib can create a statistically significant decrease in glucose utilization as determined using early, post dosing (24-72 hour) FDG-PET imaging in patients with EGFR activated recurrent glioblastoma.",99
73,fdg,"After defining #1, evaluate whether osimertinib can create a statistically significant decrease in glucose utilization as determined using early, post dosing (24-72 hour) FDG-PET imaging in patients with EGFR activated recurrent glioblastoma.",171
73,osimertinib, SECONDARY OBJECTIVES:  I. Safety and tolerability of osimertinib in this patient population.,54
73,osimertinib,"Determine clinical effect of osimertinib in this patient population, as determined by 6 months progression-free survival.",29
73,osimertinib,"Correlated clinical effect of osimertinib with FDG-PET results in this patient population, to define by receiver operating characteristic (ROC) analysis a clinically meaningful decrease in glucose utilization, which correlates with the clinical effect.",30
73,fdg,"Correlated clinical effect of osimertinib with FDG-PET results in this patient population, to define by receiver operating characteristic (ROC) analysis a clinically meaningful decrease in glucose utilization, which correlates with the clinical effect.",47
73,glucose,"Correlated clinical effect of osimertinib with FDG-PET results in this patient population, to define by receiver operating characteristic (ROC) analysis a clinically meaningful decrease in glucose utilization, which correlates with the clinical effect.",189
73,fludeoxyglucosef-18,"Within days -28 to -4, patients receive fludeoxyglucose F-18 intravenously (IV) and after 60 minutes undergo PET scan over 15 minutes.",40
73,fludeoxyglucose,"After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan.",45
73,f-18,"After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan.",61
73,osimertinib,"Patients then receive osimertinib orally (PO) once daily (QD) on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan.",22
73,fludeoxyglucose,"Patients then receive osimertinib orally (PO) once daily (QD) on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan.",118
73,f-18,"Patients then receive osimertinib orally (PO) once daily (QD) on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan.",134
73,osimertinib,Patients then receive osimertinib PO QD on days 1-28.,22
74,panzem/2-methoxyestradiol,"This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)",132
74,2me2,"This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)",160
75,ab154,AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat).,0
75,ab122,AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat).,46
75,ab154,The purpose of cohort B is to provide an additional safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment.,73
75,ab122,The purpose of cohort B is to provide an additional safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment.,81
75,ab154,The purpose of cohort B is to provide an additional safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment.,178
75,ab122,The purpose of cohort B is to provide an additional safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment.,186
75,ab154,"A total of 10 patients will be allocated to each one of the following groups in a blinded fashion, approximately two weeks before surgery:  B1 (N=10): AB154 single agent (10 mg/kg) + placebo B2 (N=10): AB122 single agent (240 mg) + placebo B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg) B4 (N=10): Two placebo infusions  ",151
75,ab122,"A total of 10 patients will be allocated to each one of the following groups in a blinded fashion, approximately two weeks before surgery:  B1 (N=10): AB154 single agent (10 mg/kg) + placebo B2 (N=10): AB122 single agent (240 mg) + placebo B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg) B4 (N=10): Two placebo infusions  ",202
75,ab154,"A total of 10 patients will be allocated to each one of the following groups in a blinded fashion, approximately two weeks before surgery:  B1 (N=10): AB154 single agent (10 mg/kg) + placebo B2 (N=10): AB122 single agent (240 mg) + placebo B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg) B4 (N=10): Two placebo infusions  ",251
75,ab122,"A total of 10 patients will be allocated to each one of the following groups in a blinded fashion, approximately two weeks before surgery:  B1 (N=10): AB154 single agent (10 mg/kg) + placebo B2 (N=10): AB122 single agent (240 mg) + placebo B3 (N=10): AB154 (10 mg/kg) +AB122 (240 mg) B4 (N=10): Two placebo infusions  ",269
75,ab154,"Following surgery, all patients (N=40) will initiate treatment with the combination of AB154 and AB122.",87
75,ab122,"Following surgery, all patients (N=40) will initiate treatment with the combination of AB154 and AB122.",97
76,inc280,"The aim of the phase Ib part was to estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy of INC280 single agent and in combination with buparlisib (BKM120), and to further assess the safety of the combination.",132
76,buparlisib,"The aim of the phase Ib part was to estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy of INC280 single agent and in combination with buparlisib (BKM120), and to further assess the safety of the combination.",143
76,inc280,"The aim of the phase Ib part was to estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy of INC280 single agent and in combination with buparlisib (BKM120), and to further assess the safety of the combination.",220
76,buparlisib,"The aim of the phase Ib part was to estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy of INC280 single agent and in combination with buparlisib (BKM120), and to further assess the safety of the combination.",264
76,bkm120,"The aim of the phase Ib part was to estimate the MTD and/or to identify the recommended phase II dose (RP2D) for the combination of INC280 and buparlisib, followed by the phase II part to assess the clinical efficacy of INC280 single agent and in combination with buparlisib (BKM120), and to further assess the safety of the combination.",276
76,inc280," RP2D was not declared due to a lack of efficacy of the combination in the phase Ib stage, and phase II was continued with INC280 monotherapy only.",123
77,temozolomide,"In this phase II study, adult patients with histologically confirmed GBM in recurrence after surgery or biopsy, standard radiotherapy and chemotherapy with temozolomide were eligible.",156
77,ortataxel,Patients included were treated with ortataxel 75 mg/m² i.v.,36
77,ortataxel,The primary objective of the study was to evaluate the efficacy of ortataxel in terms of progression free survival at six months after the enrolment (PFS-6).,67
78,bosutinib,Participants will receive daily doses of bosutinib orally for 7-9 days prior to surgery.,41
78,bosutinib,"On the day of the scheduled surgery (either craniotomy or surgical resection as planned by the treating doctor), participants will take the bosutinib within 6-12 hours of the surgery.",140
78,bosutinib,"During the surgery, tissue samples of the tumor will be collected to test the levels of bosutinib in the brain.",88
78,bosutinib,Daily dosing of bosutinib will resume after a recovery period of 10 days.,16
78,bosutinib,Arm B: Participants will receive daily doses of bosutinib.,48
78,bosutinib,There are no breaks from taking bosutinib between treatment cycles.,32
78,bosutinib,"Participants may continue to receive daily bosutinib until their disease worsens, they experience unmanageable side-effects, or they decide to stop treatment.",43
79,nivolumab,"Nivolumab (OpdivoTM, BMS), a human IgG-4 mAb that blocks the Programmed cell death protein 1 (PD-1, CD279) has demonstrated anti-tumor activity in patients with various solid- and hematological neoplasms.",0
79,nivolumab,"Nivolumab has been registered by EMA and/or FDA for the treatment of patients with advanced melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and Hodgkin lymphoma.",0
79,nivolumab,"In a phase I dose escalation clinical trial, receptor blockade of PD-1 by nivolumab on circulating lymphocytes was maximal at a dose of 0,3",74
79,nivolumab,In patients with advanced melanoma nivolumab had a comparable tumor response rate at a dose range of 0.1 to 10 mg/kg q2wks.,35
79,nivolumab,"Nivolumab was further developed at a dose of 3 mg/kg q2wks and improved the overall survival of patients with advanced melanoma, NSCL, RCC and HNSCC.  ",0
79,ipilimumab,Combined treatment with ipilimumab (3 mg/kg q3wks x4) plus nivolumab (1 mg/kg q3 wks x4 followed by 3 mg/kg q2 wks) further increases the tumor response rate and progression-free survival of patients with advanced melanoma and has been registered by EMA and FDA; this combination therapy is associated with a higher incidence of immune related adverse events.,24
79,nivolumab,Combined treatment with ipilimumab (3 mg/kg q3wks x4) plus nivolumab (1 mg/kg q3 wks x4 followed by 3 mg/kg q2 wks) further increases the tumor response rate and progression-free survival of patients with advanced melanoma and has been registered by EMA and FDA; this combination therapy is associated with a higher incidence of immune related adverse events.,59
79,nivolumab,Nivolumab and ipilimumab have distinct immunological mechanisms that can be revealed by analyzing TCR usage in blood lymphocytes.,0
79,nivolumab, Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (CHECKMATE-143) were presented at the 2015 and 2016 ASCO,36
79,nivolumab,[15] All nivolumab related AEs were grade 1 or 2.,9
79,nivolumab,Eight (80%) nivolumab plus ipilimumab treated patients experienced grade 3/4 AEs.,12
79,ipilimumab,Eight (80%) nivolumab plus ipilimumab treated patients experienced grade 3/4 AEs.,27
79,nivolumab,"Drug-related AEs leading to discontinuation occurred only in nivolumab plus ipilimumab patients (n = 5; 50%), including colitis, cholecystitis, diabetic ketoacidosis, confusion, and increased lipase.",61
79,nivolumab,"Based on these experiences, the sponsor (BMS) decided to further investigate nivolumab as a mono-therapy in patients with recurrent- and newly diagnosed glioblastoma (CA209-143; CA209-498 and CA209-548).",77
79,nivolumab,Antitumor activity of nivolumab has recently been established in children with recurrent glioblastoma that is characterized by biallelic mismatch repair deficiency.,22
80,azixa,The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma,74
81,dasatinib,To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma,21
81,lomustine,To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma,36
82,abema,The FDA (the U.S. Food and Drug Administration) has not approved abemaciclib as a treatment for any disease.,65
82,abemaciclib,"In laboratory studies, Abemaciclib was able to enter the brain, stop CDK 4 and CDK 6 from making cells, and slow growth of mice Glioblastoma.",23
82,abemaciclib,"In the surgical participants, the investigators are looking to see if Abemaciclib reached the brain tumor.",70
85,gc1118,"This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.",33
85,gc1118, GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles.,1
86,poly-adpribose,Tumors that are deficient in the homologous recombination DNA damage repair pathway are highly sensitive to blockade of the repair of single strand DNA breaks via poly-ADP ribose polymerase (PARP) inhibition.,163
86,niraparib,"This is a study of niraparib, a PARP inhibitor, in combination with tumor-treating fields for recurrent glioblastoma.",19
87,o6methylguanine,Patients harbouring tumours with functional O6 methylguanine DNA methyltransferase (MGMT) DNA repair enzyme efficiently repair the DNA damage inflicted by Temozolomide and gain limited benefit from this chemotherapy.,44
87,temozolomide,Patients harbouring tumours with functional O6 methylguanine DNA methyltransferase (MGMT) DNA repair enzyme efficiently repair the DNA damage inflicted by Temozolomide and gain limited benefit from this chemotherapy.,155
87,bortezomib,"Bortezomib depletes the MGMT enzyme, restoring the tumour´s susceptibility to Temozolomide, if the chemotherapy is administered in the precise schedule when the MGMT enzyme is depleted.",0
87,temozolomide,"Bortezomib depletes the MGMT enzyme, restoring the tumour´s susceptibility to Temozolomide, if the chemotherapy is administered in the precise schedule when the MGMT enzyme is depleted.",78
87,bortezomib,"Additionally, Bortezomib inhibits the growth of tumour cells by blocking autophagy flux.",14
87,temozolomide,Temozolomide causes genotoxic stress in cancer cells that in turn respond by inducing protective processes such as autophagy.,0
87,temozolomide,"If both autophagy and MGMT DNA repair enzyme are blocked a priori, the efficacy of Temozolomide will be enhanced.",83
87,bortezomib,"Thus, pre-treating the tumour with Bortezomib prior to administration of Temozolomide leads to DNA repair enzyme depletion and blockade of autophagy-induced survival signals.",35
87,temozolomide,"Thus, pre-treating the tumour with Bortezomib prior to administration of Temozolomide leads to DNA repair enzyme depletion and blockade of autophagy-induced survival signals.",73
87,bortezomib,Hypothesis: Pretreatment with Bortezomib administered prior to Temozolomide will sensitize recurrent GBM with unmethylated MGMT promoter to standard TMZ in palliative setting.,30
87,temozolomide,Hypothesis: Pretreatment with Bortezomib administered prior to Temozolomide will sensitize recurrent GBM with unmethylated MGMT promoter to standard TMZ in palliative setting.,63
87,tmz,Hypothesis: Pretreatment with Bortezomib administered prior to Temozolomide will sensitize recurrent GBM with unmethylated MGMT promoter to standard TMZ in palliative setting.,149
87,bortezomib,Assessment of safety and tolerability of Bortezomib administered with Temozolomide.,41
87,temozolomide,Assessment of safety and tolerability of Bortezomib administered with Temozolomide.,70
87,tmz,"Determining the optimal dose of TMZ, when administered as combination therapy",32
87,bortezomib,Estimate the progression free survival (PFS) and overall survival (OS) of patients with recurrent or progressed glioblastoma after pre-treatment with Bortezomib prior to combination with Temozolomide.,150
87,temozolomide,Estimate the progression free survival (PFS) and overall survival (OS) of patients with recurrent or progressed glioblastoma after pre-treatment with Bortezomib prior to combination with Temozolomide.,187
88,azd2171,I. Determine the proportion of patients with recurrent glioblastoma multiforme (GM) who are alive and progression free 6 months after starting AZD2171 therapy.,143
88,azd2171, SECONDARY OBJECTIVES:  I. Assess the biological effect of AZD2171 by using the following MRI techniques: dynamic contrast-enhanced imaging; arterial spin-labeling imaging; perfusion-weighted imaging; and diffusion- tensor imaging at serial time points.,59
88,azd2171,"Correlate treatment outcomes with pre-AZD2171 tumor specimens with respect to microvascular density, basement membrane and pericyte coverage, and angiopoietin-1 and -2 expression to determine whether these immunohistochemical analyses can be predictive of the response to AZD2171.",38
88,azd2171,"Correlate treatment outcomes with pre-AZD2171 tumor specimens with respect to microvascular density, basement membrane and pericyte coverage, and angiopoietin-1 and -2 expression to determine whether these immunohistochemical analyses can be predictive of the response to AZD2171.",272
88,azd2171,V. Determine the overall survival of patients with recurrent GM treated with AZD2171.,77
88,azd2171,Determine the radiographic response rate in patients with recurrent GM treated with AZD2171.  VII.,84
88,azd2171,Determine the safety of AZD2171 in this patient population.,24
88,azd2171,Patients receive oral AZD2171 once daily on days 1-28.,22
89,acalabrutinib,"A Phase 1b/2, multicenter, open-label study was designed to evaluate the efficacy and safety of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed after one or two prior systemic treatment regimens.",96
90,bevacizumab,Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to receive bevacizumab with the addition of Tumor Treating Fields Therapy.,65
90,bevacizumab,Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to receive bevacizumab with the addition of Tumor Treating Fields Therapy.,97
91,pazopanibhydrochloride,"PRIMARY OBJECTIVES:  I. Determine the therapeutic efficacy of pazopanib hydrochloride, as measured by 6-month progression-free survival (PFS), in patients with recurrent glioblastoma.",62
91,pazopanibhydrochloride,Patients receive oral pazopanib hydrochloride daily on days 1-28.,22
92,bevacizumab,I. To establish an improvement in overall survival in recurrent glioblastoma (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.,102
92,bevacizumab,I. To establish an improvement in overall survival in recurrent glioblastoma (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone.,166
94,cci-779,"OBJECTIVES:  I. Determine the efficacy of CCI-779, in terms of the percentage of patients who are progression-free at 6 months, time to progression, and time to death, in patients with recurrent glioblastoma multiforme.",42
94,cci-779,Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks.,17
95,nivolumab,The effect of Nivolumab in oncologic diseases is to modulate the immune system in order to generate and/or restore a durable anti-tumor response leading to clearance of tumor.,14
95,nivolumab,Clinical data generated with Nivolumab monotherapy in a variety of settings support the hypothesis that blockade of the PD-1 pathway results in rejection of tumor by the host immune system.,29
95,nivolumab,The precise mechanisms by which Nivolumab exerts its anti-tumor activity are still under investigation.,32
95,nivolumab,In the surgical group (Arm A) of this study NGS will be repeated after one dose of Nivolumab.,83
95,nivolumab,This information will be used in combination with the clinical observations for each patient receiving the combination of Nivolumab and Bevacizumab and the aim is that these results could be useful towards finding prognostic and/or predictive biomarkers in GBM.  ,122
95,bevacizumab,This information will be used in combination with the clinical observations for each patient receiving the combination of Nivolumab and Bevacizumab and the aim is that these results could be useful towards finding prognostic and/or predictive biomarkers in GBM.  ,136
96,lit,"Characterize the safety profile of LITT followed by treatment with lomustine chemotherapy in the recurrent disease setting, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.",35
96,lomustine,"Characterize the safety profile of LITT followed by treatment with lomustine chemotherapy in the recurrent disease setting, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.",67
96,steroid," V. Assess the long-term steroid requirements following LITT, compared to historical controls.",25
96,litt,"Determine the radiographic evolution of LITT-treated glioblastoma over time, using conventional magnetic resonance imaging (MRI) (T1 pre and post-contrast images, T2-weighted images [T2WI], fluid attenuating inversion recovery [FLAIR] images) and advanced brain tumor imaging (ABTI)",40
96,lomustine,Patients undergo LITT at baseline and receive lomustine orally (PO) on day 1.,46
96,lomustine,Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.,15
97,amino-acids,"The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors.",42
97,l-[methyl-11c]-methionine,"The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors.",55
97,met,"The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors.",82
97,o-(2-(1)-fluoroethyl)-l-tyrosine,"The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors.",90
97,fet,"The higher sensitivity and specificity of amino-acids (L-[methyl-11C]-methionine, MET and O-(2-(1)-Fluoroethyl)-L-tyrosine, FET) positron emission tomography (AA-PET) in the diagnosis of gliomas in comparison to computed tomography (CT) and magnetic resonance imaging (MRI) was demonstrated in many studies and is the rationale for using them in target volume delineation of these tumors.",124
98,erlotinib,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,45
98,temozolomide,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,58
98,carmustine,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,74
98,erlotinib,Arm I: Patients receive oral erlotinib* once daily on day 1-28.,29
98,erlotinib,*Patients treated with enzyme inducing anti-epileptic drugs (EIAEDs) receive a higher dose of erlotinib than patients not receiving any anti-epileptic drugs or EIAEDs.,94
98,temozolomide,Patients who have not received prior temozolomide are assigned to receive temozolomide.,37
98,temozolomide,Patients who have not received prior temozolomide are assigned to receive temozolomide.,74
98,temozolomide,Patients who have received prior temozolomide are assigned to receive carmustine.,33
98,carmustine,Patients who have received prior temozolomide are assigned to receive carmustine.,70
98,temozolomide,Patients receive oral temozolomide* once daily on days 1-5.,22
98,carmustine,Patients receive carmustine IV once daily on days 1-3.,17
98,temozolomide,NOTE: *Chemotherapy-naïve patients receive a higher dose of temozolomide than patients who have received prior adjuvant chemotherapy.  ,60
99,at-101,To estimate the overall survival rate associated with AT-101 in treating adult patients with recurrent glioblastoma multiforme.,54
99,r-(-)-gossypol/06-methylguanine,Patients receive oral R-(-)-gossypol once daily on days 1-21.,22
100,erlotinib,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,45
100,temozolomide,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,58
100,carmustine,Primary  Compare the therapeutic activity of erlotinib vs temozolomide or carmustine in patients with recurrent glioblastoma multiforme.,74
100,erlotinib,Arm I: Patients receive oral erlotinib* once daily on day 1-28.,29
100,erlotinib,*Patients treated with enzyme inducing anti-epileptic drugs (EIAEDs) receive a higher dose of erlotinib than patients not receiving any anti-epileptic drugs or EIAEDs.,94
100,temozolomide,Patients who have not received prior temozolomide are assigned to receive temozolomide.,37
100,temozolomide,Patients who have not received prior temozolomide are assigned to receive temozolomide.,74
100,temozolomide,Patients who have received prior temozolomide are assigned to receive carmustine.,33
100,carmustine,Patients who have received prior temozolomide are assigned to receive carmustine.,70
100,temozolomide,Patients receive oral temozolomide* once daily on days 1-5.,22
100,carmustine,Patients receive carmustine IV once daily on days 1-3.,17
100,temozolomide,NOTE: *Chemotherapy-naïve patients receive a higher dose of temozolomide than patients who have received prior adjuvant chemotherapy.  ,60
102,gdc-0449,Arm I: Patients receive oral Hedgehog antagonist GDC-0449 once daily for 7 days before surgery.,49
102,gdc-0449,"Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28.",97
103,fluzoparil,The main purpose of this study was to evaluate the efficacy and safety of fluzoparil combined with temozolomide in patients with recurrent glioblastoma.,74
103,temozolomide,The main purpose of this study was to evaluate the efficacy and safety of fluzoparil combined with temozolomide in patients with recurrent glioblastoma.,99
104,nivolumab,"Anti-PD-1 antibodies such as nivolumab show a strong potential to treat many types of cancers including glioblastoma, the most common and most lethal brain cancer.",29
104,nivolumab,"This study will examine a means of further focusing immune response on glioblastoma by combining stereotactic ""gamma knife"" radiosurgery with nivolumab.",142
104,nivolumab,"Additionally, a study from investigators at Johns Hopkins indicates that histone deacetylase (HDAC) inhibitors may boost the anti-cancer efficacy of PD-1 antibodies like nivolumab.",170
104,valproate,"Valproate, a class I HDAC inhibitor, will be used concurrently with nivolumab with the goal of enhancing the effects of both the nivolumab and the radiotherapy.",0
104,nivolumab,"Valproate, a class I HDAC inhibitor, will be used concurrently with nivolumab with the goal of enhancing the effects of both the nivolumab and the radiotherapy.",68
104,nivolumab,"Valproate, a class I HDAC inhibitor, will be used concurrently with nivolumab with the goal of enhancing the effects of both the nivolumab and the radiotherapy.",129
105,imiquimod,"This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma (GBM) in adults.",161
106,e7050,The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7050 and E7080 (lenvatinib) in combination in participants with unresectable advanced or metastatic solid tumors.,84
106,e7080,The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7050 and E7080 (lenvatinib) in combination in participants with unresectable advanced or metastatic solid tumors.,94
106,lenvatinib,The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7050 and E7080 (lenvatinib) in combination in participants with unresectable advanced or metastatic solid tumors.,101
106,e7050,"In the subsequent Phase 1b expansion cohort and Phase 2 cohorts, additional participants with recurrent glioblastoma or unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will be enrolled to confirm the MTD (expansion cohort) and to further explore the clinical activity of E7050 and lenvatinib.",322
106,lenvatinib,"In the subsequent Phase 1b expansion cohort and Phase 2 cohorts, additional participants with recurrent glioblastoma or unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will be enrolled to confirm the MTD (expansion cohort) and to further explore the clinical activity of E7050 and lenvatinib.",332
107,npc-08,The purpose of this study is to evaluate whether NPC-08 is safety and efficacy in the treatment of newly-diagnosed malignant glioma and recurrent glioblastoma multiforme.,49
108,incmga00012,"Subjects in this arm receive a single priming dose of both INCMGA00012 and INCAGN01876 prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions).",59
108,incagn01876,"Subjects in this arm receive a single priming dose of both INCMGA00012 and INCAGN01876 prior to stereotactic radiosurgery (SRS), then undergo SRS (8 Gy x 3 fractions).",75
108,incmga00012,"Following SRS, INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.",15
108,incagn01876,"Following SRS, INCMGA00012 (IV every 4 weeks) and INCAGN01876 (IV every 2 weeks) are resumed and continued until disease progression, unacceptable toxicity, or for 2 years, whichever occurs first.",50
109,sch900105,The Study Drug:  SCH 900105 is designed to block the activity of one of the tumor-causing proteins responsible for the development and uncontrolled growth of tumor cells and the formation of new blood vessels.,17
109,sch900105,You will need to take SCH 900105 for 14 days before surgery.,22
109,sch900105,"If you are found to be eligible to take part in this study, you will be assigned to a dose level of SCH 900105 based on when you joined this study.",100
109,sch900105,"Up to 3 dose levels (Dose Levels 0, 1, and 2) of SCH 900105 will be tested before surgery.",49
109,sch900105,This will continue until the highest tolerable dose of SCH 900105 is found.  ,55
109,sch900105,"No matter what dose level you are assigned before surgery, all participants will receive Dose Level 1 of SCH 900105 after surgery.",105
109,sch,"If you are assigned to Dose Levels 0 or 2, you will receive SCH 900105 by vein over about 1 hour on Days 1, 8, and 15 of Cycle 1.",60
109,sch900105,"If you are assigned to Dose Level 1, you will receive SCH 900105 by vein over about 1 hour on Days 1 and 15 of Cycle 1.  ",54
109,sch900105,You will not receive SCH 900105 for about 2 weeks after surgery.,21
109,sch900105,"After 2 weeks, you will receive SCH 900105 by vein on Days 1 and 15 of each cycle (Cycles 2 and beyond).",32
109,sch900105,"At 45 and 60 days after the last dose of SCH 900105, blood will be drawn 1 time.",41
109,sch900105,You may continue receiving SCH 900105 for as long as you are benefitting.,27
109,sch900105,SCH 900105 is not FDA approved or commercially available.,0
109,sch900105,"At this time, SCH 900105 is only being used in research.",14
110,mafodotin,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",58
110,abt-414,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",69
110,temozolomide,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",107
110,tmz,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",121
110,steroid,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",277
110,lomustine,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",325
110,tmz,"The study objectives were to assess whether depatuxizumab mafodotin (ABT-414) alone or in combination with temozolomide (TMZ) improved overall survival (OS), progression-free survival (PFS), tumor response, quality of life, neurological deterioration-free survival (NDFS), and steroid use compared to standard treatment with lomustine single agent or TMZ re-challenge in adult subjects ≥ 18 years of age with centrally-confirmed recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma.",351
110,mafodotin,"The safety, pharmacokinetics, and efficacy of depatuxizumab mafodotin in children <18 years of age was evaluated in a pediatric substudy.",60
110,mafodotin,The EMEA-001732-PIP02-15 pediatric investigation plan was withdrawn on 07 July 2019 due to the discontinuation of the depatuxizumab mafodotin research program.,132
111,epothilone,Assess the therapeutic activity of epothilone ZK-219477 in patients with recurrent glioblastoma.,35
111,zk-219477,Assess the therapeutic activity of epothilone ZK-219477 in patients with recurrent glioblastoma.,46
111,epothilone,Patients receive epothilone ZK-219477 IV over 3 hours on day 1.,17
111,zk-219477,Patients receive epothilone ZK-219477 IV over 3 hours on day 1.,28
113,bortezomib,"This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme.",115
113,temozolomide,"This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme.",182
114,cediranib,To determine the safety profile of cediranib (cediranib maleate) in combination with cilengitide in patients with recurrent glioblastoma (Part A).,35
114,cediranibmaleate,To determine the safety profile of cediranib (cediranib maleate) in combination with cilengitide in patients with recurrent glioblastoma (Part A).,46
114,cediranib,To estimate the proportion of radiographic responses in recurrent glioblastoma patients with measurable disease treated with cediranib and cilengitide.,125
114,cilengitide,To estimate the proportion of radiographic responses in recurrent glioblastoma patients with measurable disease treated with cediranib and cilengitide.,139
114,cediranibmaleate,This is a dose-escalation study of cediranib maleate.,35
114,cediranibmaleate,"Once the safe dose of cediranib maleate is determined, additional patients are enrolled in the dose-expansion portion of the study (part B).",22
114,cediranibmaleate,"Part A (dose finding): Patients receive cediranib maleate orally (PO) once daily on days 1-28 and cilengitide intravenously (IV) over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25.",40
114,cilengitide,"Part A (dose finding): Patients receive cediranib maleate orally (PO) once daily on days 1-28 and cilengitide intravenously (IV) over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25.",98
114,cediranibmaleate,"Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A.  After completion of study therapy, patients are followed up every 2 months.",32
114,cilengitide,"Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A.  After completion of study therapy, patients are followed up every 2 months.",107
116,sunitinib,"Study design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM.  ",82
116,lomustine,"Study design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM.  ",99
116,ccnu,"Study design: Multicenter, phase II/III, randomized clinical trial with high-dose sunitinib versus lomustine (CCNU) in patients with recurrent GBM.  ",110
116,sunitinib,"Hypothesis: Sunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine.",12
116,lomustine,"Hypothesis: Sunitinib, when given in a high-dose, intermittent schedule, may exhibit improved efficacy in patients with recurrent GBM with an acceptable toxicity profile, compared to lomustine.",183
116,sunitinib," Primary objective:  - To determine the effect of high-dose sunitinib versus lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria.",60
116,lomustine," Primary objective:  - To determine the effect of high-dose sunitinib versus lomustine on six-month progression-free survival (PFS6) in patients with recurrent GBM, using the RANO criteria.",77
116,sunitinib," Secondary objectives:  To determine the effect of high-dose sunitinib on overall survival (OS 9, OS 12) in patients with recurrent GBM.",61
116,steroid,To assess patient-oriented criteria: steroid use and health-related quality of life (reported by patients and caregivers/relatives).,37
116,sunitinib,To explore if MGMT promoter methylation status modulates the response to sunitinib.,73
116,sunitinib,"Treatment: After randomization, 100 patients will be divided equally over two treatment groups and will receive:  Group 1 (experimental arm): Sunitinib, 300 mg administered orally in a weekly schedule.",142
116,lomustine,"Group 2 (control arm): Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.",23
117,vorinostat,"To determine the clinical efficacy of vorinostat (SAHA) and bortezomib, in terms of progression-free survival (PFS) at 6 months, in patients with progressive, recurrent glioblastoma multiforme.",38
117,saha,"To determine the clinical efficacy of vorinostat (SAHA) and bortezomib, in terms of progression-free survival (PFS) at 6 months, in patients with progressive, recurrent glioblastoma multiforme.",50
117,bortezomib,"To determine the clinical efficacy of vorinostat (SAHA) and bortezomib, in terms of progression-free survival (PFS) at 6 months, in patients with progressive, recurrent glioblastoma multiforme.",60
117,vorinostat,"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11.",22
117,saha,"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11.",34
117,bortezomib,"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11.",68
117,saha,Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery.,22
117,bortezomib,Patients also receive bortezomib IV on the day of surgery.,22
117,saha,"After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor.",32
117,saha,"Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.  ",58
117,bortezomib,"Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.  ",67
118,vorinostat,"PRIMARY OBJECTIVES:  I. Determine the efficacy of vorinostat (SAHA), in terms of 6-month progression-free survival, in patients with progressive or recurrent glioblastoma multiforme.",50
118,saha,"PRIMARY OBJECTIVES:  I. Determine the efficacy of vorinostat (SAHA), in terms of 6-month progression-free survival, in patients with progressive or recurrent glioblastoma multiforme.",62
118,vorinostat, STRATUM 1: Patients receive oral vorinostat (SAHA) twice daily for 2 weeks.,34
118,saha, STRATUM 1: Patients receive oral vorinostat (SAHA) twice daily for 2 weeks.,46
118,saha,"(not undergoing surgery)  STRATUM 2: Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses.",94
118,saha,"Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks.",64
119,poly-iclc,"All patients will receive the same dose of vaccine, Poly-ICLC and bevacizumab.",52
119,bevacizumab,"All patients will receive the same dose of vaccine, Poly-ICLC and bevacizumab.",66
119,bevacizumab,"During the first block, patients will receive bevacizumab every 2 weeks for 2 doses.",46
119,poly-iclc,"During block 2, patients will receive vaccine + Poly-ICLC + bevacizumab on weeks 1, 3, 5 and 7.",48
119,bevacizumab,"During block 2, patients will receive vaccine + Poly-ICLC + bevacizumab on weeks 1, 3, 5 and 7.",60
119,poly-iclc,"During block 3, therapy consists of vaccine + Poly-ICLC monthly and bevacizumab every 2 weeks for 10 months.",46
119,bevacizumab,"During block 3, therapy consists of vaccine + Poly-ICLC monthly and bevacizumab every 2 weeks for 10 months.",68
120,erlotinibhydrochloride,Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28.,22
120,sorafenibtosylate,Patients receive oral erlotinib hydrochloride once daily and oral sorafenib tosylate twice daily on days 1-28.,66
120,erlotinibhydrochloride,Samples are analyzed by reversed-phase isocratic high-performance liquid chromatography with electrospray ionization mass spectrometry to determine the concentration of erlotinib hydrochloride and sorafenib tosylate and its known metabolites.,169
120,sorafenibtosylate,Samples are analyzed by reversed-phase isocratic high-performance liquid chromatography with electrospray ionization mass spectrometry to determine the concentration of erlotinib hydrochloride and sorafenib tosylate and its known metabolites.,197
121,temozolomide,OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and carboplatin in patients with recurrent glioblastoma multiforme.,61
121,carboplatin,OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and carboplatin in patients with recurrent glioblastoma multiforme.,78
121,nitrosourea,Patients are stratified according to prior nitrosourea-based chemotherapy (yes vs no).,43
121,carboplatin,Patients receive carboplatin IV over 30 minutes on day 1 and oral temozolomide once daily on days 1-5.,17
121,temozolomide,Patients receive carboplatin IV over 30 minutes on day 1 and oral temozolomide once daily on days 1-5.,66
121,temozolomide,Patients with a persistent response may continue to receive temozolomide only for an additional 6 courses.,60
121,carboplatin,Cohorts of 3-6 patients receive escalating doses of carboplatin and temozolomide until the maximum tolerated dose (MTD) is determined.,52
121,temozolomide,Cohorts of 3-6 patients receive escalating doses of carboplatin and temozolomide until the maximum tolerated dose (MTD) is determined.,68
121,carboplatin,"Once the MTD is determined, additional patients are accrued to receive carboplatin and temozolomide at the recommended phase II dose.",71
121,temozolomide,"Once the MTD is determined, additional patients are accrued to receive carboplatin and temozolomide at the recommended phase II dose.",87
122,imatinibmesylate,"This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme.",40
123,temozolomide,Primary objectives: To determine the proportion of patients with progression- free survival after 6 months of intensive dose temozolomide treatment alone or in combination with thalidomide in patients with recurrent glioblastoma multiforme after standard therapy.,125
123,thalidomide,Primary objectives: To determine the proportion of patients with progression- free survival after 6 months of intensive dose temozolomide treatment alone or in combination with thalidomide in patients with recurrent glioblastoma multiforme after standard therapy.,177
123,temozolomide,To assess the safety of intensive dose temozolomide treatment alone or in combination with thalidomide.,39
123,thalidomide,To assess the safety of intensive dose temozolomide treatment alone or in combination with thalidomide.,91
124,temozolomide,OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and carboplatin in patients with recurrent glioblastoma multiforme.,61
124,carboplatin,OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of temozolomide and carboplatin in patients with recurrent glioblastoma multiforme.,78
124,carmustine,"Patients are stratified according to age (under 50 vs 50 and over), ECOG performance status (0 vs 1-2), and prior therapy with carmustine or lomustine (yes vs no).",127
124,lomustine,"Patients are stratified according to age (under 50 vs 50 and over), ECOG performance status (0 vs 1-2), and prior therapy with carmustine or lomustine (yes vs no).",141
124,carboplatin,Patients receive carboplatin IV over 30 minutes on day 1 and oral temozolomide on days 1-5.,17
124,temozolomide,Patients receive carboplatin IV over 30 minutes on day 1 and oral temozolomide on days 1-5.,66
124,temozolomide,Patients with stable or responsive disease may receive 6 additional courses of temozolomide.,79
124,carboplatin,Cohorts of 1-6 patients receive escalating doses of carboplatin and temozolomide until the maximum tolerated dose (MTD) is determined.,52
124,temozolomide,Cohorts of 1-6 patients receive escalating doses of carboplatin and temozolomide until the maximum tolerated dose (MTD) is determined.,68
125,glufosfamide,"OBJECTIVES: I. Determine the activity of glufosfamide, in terms of objective response rate and/or progression-free survival at 6 months, in patients with recurrent glioblastoma multiforme.",41
125,glufosfamide,Patients receive glufosfamide IV over 60 minutes on day 1.,17
126,capecitabine,Primary Objective: To achieve a 20-fold MDSC reduction in the concentration of circulating MDSCs after treatment with low dose capecitabine.,127
126,capecitabine, To determine the concentration of circulating MDSCs in patients with recurrent glioblastoma after treatment with low dose capecitabine To determine the concentration of tissue MDSCs and T-regulatory cells in resected glioblastoma after treatment with low dose capecitabine To determine the safety and toxicity of continuous low dose capecitabine with and without standard dose bevacizumab.,123
126,capecitabine, To determine the concentration of circulating MDSCs in patients with recurrent glioblastoma after treatment with low dose capecitabine To determine the concentration of tissue MDSCs and T-regulatory cells in resected glioblastoma after treatment with low dose capecitabine To determine the safety and toxicity of continuous low dose capecitabine with and without standard dose bevacizumab.,261
126,capecitabine, To determine the concentration of circulating MDSCs in patients with recurrent glioblastoma after treatment with low dose capecitabine To determine the concentration of tissue MDSCs and T-regulatory cells in resected glioblastoma after treatment with low dose capecitabine To determine the safety and toxicity of continuous low dose capecitabine with and without standard dose bevacizumab.,334
126,bevacizumab, To determine the concentration of circulating MDSCs in patients with recurrent glioblastoma after treatment with low dose capecitabine To determine the concentration of tissue MDSCs and T-regulatory cells in resected glioblastoma after treatment with low dose capecitabine To determine the safety and toxicity of continuous low dose capecitabine with and without standard dose bevacizumab.,378
127,o6-benzylguanine,Define the activity of Gliadel® wafers in combination with a 5-day infusion of O6-benzylguanine in patients with recurrent glioblastoma multiforme.,79
127,o6-benzylguanine,Define the toxicity of Gliadel® wafers in combination with 5-day infusion of O6-benzylguanine in patients with recurrent glioblastoma multiforme.,77
127,o6-benzylguanine,"Within 6 hours after completion of surgery, patients receive a 1 hour high dose infusion of O6-benzylguanine followed by a lower dose continuous infusion for 5 days.",92
128,bevacizumab,"This randomized, non-comparative study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with recurrent glioblastoma.",89
128,fotemustine,"mg/kg intravenously every 2 weeks or fotemustine 75 mg/m2 on days 1, 8 and 15, followed by, after a 5 weeks interval, 100 mg/m2 intravenously every 3 weeks.",37
128,fotemustine,Treatment with fotemustine serves as a calibration arm and no formal efficacy comparison will be made between the two treatment arms.,15
129,carmustine,Determine the maximum tolerated dose of intratumoral carmustine in ethanol (DTI-015) in patients with unresectable recurrent glioblastoma multiforme.,53
129,ethanol,Determine the maximum tolerated dose of intratumoral carmustine in ethanol (DTI-015) in patients with unresectable recurrent glioblastoma multiforme.,67
129,dti-015,Determine the maximum tolerated dose of intratumoral carmustine in ethanol (DTI-015) in patients with unresectable recurrent glioblastoma multiforme.,76
129,carmustine,Estimate peripheral blood carmustine levels in these patients treated with this regimen.,26
129,carmustine,Patients receive carmustine in ethanol (DTI-015) intratumorally over 5 minutes during stereotactic biopsy or open craniotomy.,17
129,ethanol,Patients receive carmustine in ethanol (DTI-015) intratumorally over 5 minutes during stereotactic biopsy or open craniotomy.,31
129,dti-015,Patients receive carmustine in ethanol (DTI-015) intratumorally over 5 minutes during stereotactic biopsy or open craniotomy.,40
129,dti-015,Cohorts of 3-6 patients receive escalating doses of DTI-015 until the maximum tolerated dose (MTD) is determined.,52
129,dti-015,Additional patients then receive treatment with DTI-015 at the recommended phase II dose.,48
130,bevacizumab,"This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure.",119
130,temozolomide,"This is a Phase II, national, multicenter, open-label, non-comparative study to investigate the efficacy and safety of bevacizumab and temozolomide in patients with recurrent glioblastoma multiforme (GBM) after a first treatment failure.",135
130,bevacizumab,"Patients will receive bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent withdrawal, or unacceptable toxicity.",22
131,bevacizumab," Bevacizumab: Bevacizumab (also known as ""Avastin"") is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.",1
131,bevacizumab," Bevacizumab: Bevacizumab (also known as ""Avastin"") is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.",14
131,bevacizumab,The FDA (the U.S. Food and Drug Administration) has approved bevacizumab as a treatment option for this disease.,61
131,bevacizumab,"If the participant has already been receiving bevacizumab, the participant will continue to receive this along with pembrolizumab and re-irradiation.",46
131,bevacizumab,This study will also test the safety and tolerability of this combination (pembrolizumab + re-irradiation) when given alone or with bevacizumab,132
132,okn-007,"This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM).",109
132,temozolomide,"This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM).",131
132,tmz,"This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM).",144
132,okn-007,"Patients with unequivocal recurrence (first or greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.",142
133,18f-fluorodeoxyglucose,"In this pilot study, the study evaluators will evaluate the ability of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG PET) and the computed tomography (CT) perfusion scanner, individually and combined, to predict the effectiveness of anti-angiogenic treatment.",111
133,fdg,"In this pilot study, the study evaluators will evaluate the ability of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG PET) and the computed tomography (CT) perfusion scanner, individually and combined, to predict the effectiveness of anti-angiogenic treatment.",135
134,bevacizumab,The NovoTTF-100A treatment and Bevacizumab will be administered on an outpatient basis; NovoTTF-100A treatment will be initiated in the outpatient clinic.,31
134,bevacizumab,To determine the efficacy of the combination of bevacizumab and NovoTTF-100A in bevacizumab-naive patients with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).,48
134,bevacizumab,To determine the efficacy of the combination of bevacizumab and NovoTTF-100A in bevacizumab-naive patients with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6).,80
134,bevacizumab,To assess safety and tolerability of the combination of bevacizumab and Novo-TTF-100A in this patient population.,56
134,bevacizumab,Patients receive bevacizumab intravenously (IV) on days 1 and 15.,17
134,novottf-100a,Patients also undergo electric field therapy with NovoTTF-100A for at least 18 hours daily.,50
135,sativex,Patients will receive Sativex and dose-intense Temozolomide in an open-label phase.,22
135,temozolomide,Patients will receive Sativex and dose-intense Temozolomide in an open-label phase.,47
135,sativex,Patients who enrol in the randomisation phase patients will receive either Sativex or placebo.,75
135,temozolomide,"The safety of Sativex compared to placebo will be assessed by pharmacokinetic analysis of Temozolomide and its metabolites, clinical laboratory tests, adverse events and vital signs.",90
136,ly3214996,Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor.,34
138,bevacizumab,"OBJECTIVES:  Primary  Identify the clinical efficacy of bevacizumab and sorafenib, as measured by 6-month progression-free survival, in patients with recurrent glioblastoma multiforme.  ",56
138,sorafenib,"OBJECTIVES:  Primary  Identify the clinical efficacy of bevacizumab and sorafenib, as measured by 6-month progression-free survival, in patients with recurrent glioblastoma multiforme.  ",72
138,sorafenib,Patients receive oral sorafenib once daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1.,22
138,bevacizumab,Patients receive oral sorafenib once daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1.,60
139,sativex,Patients will receive Sativex and dose-intense Temozolomide in an open-label phase.,22
139,temozolomide,Patients will receive Sativex and dose-intense Temozolomide in an open-label phase.,47
139,sativex,Patients who enrol in the randomisation phase patients will receive either Sativex or placebo.,75
139,temozolomide,"The safety of Sativex compared to placebo will be assessed by pharmacokinetic analysis of Temozolomide and its metabolites, clinical laboratory tests, adverse events and vital signs.",90
141,fluorinef18,PRIMARY OBJECTIVES:  I. Determine whether the fluorine F 18 DASA-23 ([18F]DASA 23),46
141,dasa-23,PRIMARY OBJECTIVES:  I. Determine whether the fluorine F 18 DASA-23 ([18F]DASA 23),60
141,[18f]dasa23,PRIMARY OBJECTIVES:  I. Determine whether the fluorine F 18 DASA-23 ([18F]DASA 23),69
141,[18f]dasa-23," SECONDARY OBJECTIVES:  I. Determine the sensitivity, specificity, and accuracy of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.",83
141,[18f]dasa-23,"Determine whether the [18F]DASA-23 PET scan signal change from pre therapy to one week after initiation of therapy can predict progression free survival (PFS) and overall survival (OS), in suspected recurrent glioblastoma.",22
141,[18f]dasa-23, GROUP I: Healthy volunteers receive [18F]DASA-23 intravenously (IV) and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.,37
141,[18f]dasa-23,Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.,40
141,[18f]dasa-23, GROUP III: Subjects with glioblastoma will receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.,52
142,dox,"This is an open-label, Phase 1, dose exploration and preliminary immunogenicity study of single agent EGFR(V)-EDV-Dox in subjects with recurrent glioblastoma (GBM).",114
142,dox,"Eligible subjects enrolled in the study will receive EGFR(V)-EDV-Dox administered weekly for 7 weeks via IV 20 minute infusion, followed by radiological evaluation at week 8 (1 Cycle).",65
142,dox,"Subjects may continue to receive subsequent cycles of EGFR(V)-EDV-Dox unless the subject becomes intolerant to investigational product (IP), withdraw consent or the individual is no longer receiving clinical benefit (factors taken in to consideration will be disease progression radiologically or clinically, and clinical benefits to quality of life).",66
143,patupilone,"Prior to and after re-operation patients with recurrent glioblastoma receive the investigational drug Patupilone, a tubulin-inhibitor.",102
143,patupilone,"Patupilone is already used in clinical trials of other tumor entities such as ovarian cancer, breast and lung cancer.",0
144,dacomitinib,"This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.",96
145,xl765,The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection.,67
145,sar245409,The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection.,74
145,xl147,The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection.,103
145,sar245408,The purpose of this study is to measure what effect the study drug XL765 (SAR245409) or the study drug XL147 (SAR245408) has on tumor tissue in subjects with recurrent glioblastoma (GB) who are candidates for surgical resection.,110
145,xl765,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",0
145,sar245409,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",7
145,xl147,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",22
145,sar245408,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",29
145,xl147,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",96
145,sar245408,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",103
145,xl765,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",161
145,sar245409,"XL765 (SAR245409) and XL147 (SAR245408), the two investigational agents examined in this study, XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K) and XL765 (SAR245409) is a dual PI3K and mTOR inhibitor.",168
147,vandetanib,Vandetanib will be given to participants in tablet form.,0
147,sirolimus,Sirolimus will also be given to participants in tablet form.,0
147,bactm,"Participants will also be given Bactrim, one double-strength table three times each week (Monday, Wednesday, Friday) to help prevent participants from getting a type of pneumonia called pneumocystis pneumonia.",32
148,ro5323441,"This open-label, multicenter study will evaluate the safety and efficacy of RO5323441 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma.",76
148,ro5323441,"In the dose-finding part, patients will receive intravenous escalating doses of RO5323441 in combination with 10 mg/kg",80
148,ro5323441,"In the efficacy-finding part, patients will be randomized to receive the established dose (from the dose-finding part) of RO5323441 plus Avastin or Avastin alone.",122
148,ro5323441,Patients in the dose-finding part may continue treatment with RO5323441 and Avastin on the study until evidence of progressive disease or unacceptable adverse events happen.,62
150,onartuzumab,"This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma.",119
150,bevacizumab,"This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma.",151
150,bevacizumab,"This randomized, double-blind, placebo-controlled, multicenter phase II study will evaluate the safety and efficacy of onartuzumab in combination with bevacizumab as compared to bevacizumab alone in participants with recurrent glioblastoma.",178
150,bevacizumab,"Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab.",67
150,onuzumab,"Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab.",97
150,bevacizumab,"Participants will be randomized 1:1 to receive either placebo plus bevacizumab every 3 weeks, or onartuzumab plus bevacizumab.",114
151,tipifarnib,"Determine the maximum tolerated dose (MTD) of tipifarnib, erlotinib hydrochloride, or temsirolimus in combination with a fixed dose of sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma who are not taking enzyme-inducing antiepileptic drugs.",46
151,erlotinibhydrochloride,"Determine the maximum tolerated dose (MTD) of tipifarnib, erlotinib hydrochloride, or temsirolimus in combination with a fixed dose of sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma who are not taking enzyme-inducing antiepileptic drugs.",58
151,temsirolimus,"Determine the maximum tolerated dose (MTD) of tipifarnib, erlotinib hydrochloride, or temsirolimus in combination with a fixed dose of sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma who are not taking enzyme-inducing antiepileptic drugs.",86
151,sorafenib,"Determine the maximum tolerated dose (MTD) of tipifarnib, erlotinib hydrochloride, or temsirolimus in combination with a fixed dose of sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma who are not taking enzyme-inducing antiepileptic drugs.",135
151,tipifarnib,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",63
151,sorafenib,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",74
151,erlotinibhydrochloride,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",85
151,sorafenib,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",109
151,temsirolimus,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",124
151,sorafenib,"Characterize the safety profile of the doublet combinations of tipifarnib-sorafenib, erlotinib hydrochloride-sorafenib, and temsirolimus-sorafenib in patients with recurrent glioblastoma multiforme or gliosarcoma.",137
151,tipifarnib,"This is a multicenter, phase I, dose-escalation study of tipifarnib, erlotinib hydrochloride, and temsirolimus followed by a phase II open-label study.",57
151,erlotinibhydrochloride,"This is a multicenter, phase I, dose-escalation study of tipifarnib, erlotinib hydrochloride, and temsirolimus followed by a phase II open-label study.",69
151,temsirolimus,"This is a multicenter, phase I, dose-escalation study of tipifarnib, erlotinib hydrochloride, and temsirolimus followed by a phase II open-label study.",98
151,sorafenib, GROUP 1: Patients receive oral sorafenib twice daily and oral erlotinib hydrochloride once daily on days 1-28.,32
151,erlotinibhydrochloride, GROUP 1: Patients receive oral sorafenib twice daily and oral erlotinib hydrochloride once daily on days 1-28.,63
151,sorafenib, GROUP 2: Patients receive sorafenib as in group 1.,27
151,temsirolimus,"Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.",22
151,sorafenib, GROUP 3: Patients receive sorafenib as in group 1.,27
151,tipifarnib,Patients also receive oral tipifarnib twice daily on days 1-21.  ,27
151,erlotinibhydrochloride,"In each treatment group, cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride (group 1), temsirolimus (group 2), or tipifarnib (group 3) sequentially until the maximum tolerated dose (MTD) is determined for each group.",77
151,temsirolimus,"In each treatment group, cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride (group 1), temsirolimus (group 2), or tipifarnib (group 3) sequentially until the maximum tolerated dose (MTD) is determined for each group.",112
151,tipifarnib,"In each treatment group, cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride (group 1), temsirolimus (group 2), or tipifarnib (group 3) sequentially until the maximum tolerated dose (MTD) is determined for each group.",139
151,sorafenib,"Patients receive sorafenib as in phase I. Patients also receive erlotinib hydrochloride, temsirolimus, or tipifarnib as in phase I at the MTD determined in phase",17
151,erlotinibhydrochloride,"Patients receive sorafenib as in phase I. Patients also receive erlotinib hydrochloride, temsirolimus, or tipifarnib as in phase I at the MTD determined in phase",64
151,temsirolimus,"Patients receive sorafenib as in phase I. Patients also receive erlotinib hydrochloride, temsirolimus, or tipifarnib as in phase I at the MTD determined in phase",89
151,tipifarnib,"Patients receive sorafenib as in phase I. Patients also receive erlotinib hydrochloride, temsirolimus, or tipifarnib as in phase I at the MTD determined in phase",106
151,tyrosine,"Protein kinase B (AKT), S6 ribosomal protein, and Receptor-linked tyrosine kinases (Erk).",66
152,macitentan,"This is an open-label, single arm, Phase 1 study to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide in adult patients with recurrent glioblastoma or gliosarcoma.",90
152,temozolomide,"This is an open-label, single arm, Phase 1 study to assess the safety and tolerability of macitentan in combination with dose-dense temozolomide in adult patients with recurrent glioblastoma or gliosarcoma.",132
152,macitentan,A Phase 1 Dose Escalation Period with a traditional 3+3 design will determine the maximum tolerated dose of macitentan in combination with dose-dense temozolomide.,108
152,temozolomide,A Phase 1 Dose Escalation Period with a traditional 3+3 design will determine the maximum tolerated dose of macitentan in combination with dose-dense temozolomide.,150
152,macitentan,A Phase 1b Period will expand the safety and tolerability data of two doses of macitentan and dose-dense temozolomide selected from the Dose Escalation Period and explore efficacy.,79
152,temozolomide,A Phase 1b Period will expand the safety and tolerability data of two doses of macitentan and dose-dense temozolomide selected from the Dose Escalation Period and explore efficacy.,105
152,macitentan,An Ancillary Study will further evaluate the effects of macitentan on biomarkers in brain tumor tissue.,56
153,fenretinide,"PRIMARY OBJECTIVES:  I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma multiforme undergoing surgical resection II.",73
153,fenretinide,"PRIMARY OBJECTIVES:  I. Compare the efficacy of neoadjuvant and adjuvant fenretinide vs adjuvant fenretinide alone, in terms of 6-month progression-free survival, in patients with recurrent glioblastoma multiforme undergoing surgical resection II.",97
153,fenretinide,Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.,34
153,fenretinide,"Beginning two weeks after surgery, all patients receive adjuvant oral fenretinide twice daily on weeks 1 and 4.",70
154,crm,Three cohorts of 3-6 patients receive escalating doses of Tf-CRM107 until the maximum tolerated dose (MTD) is determined.,61
154,crm107,Two cohorts of 3-6 patients receive escalating doses of Tf-CRM107 until the MTD is determined.,59
156,bevacizumab,"The rationale to add Bevacizumab as a systemic treatment is to target radio-resistant and highly tumorigenic cancer stem cells as well as to benefit from its radioprotective effects, i.e. reducing risk of radiation necrosis.",21
156,bevacizumab,"Lastly, using Bevacizumab as a systemic therapy will enable the comparison of the results to the historic control arm, the EBRT arm of RTOG 1205.",14
161,mn-166,"This is a multi-center open-label, dose escalation study to evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) and Temozolomide combination treatment in patients with newly diagnosed or recurrent glioblastomas.",110
161,ibudilast,"This is a multi-center open-label, dose escalation study to evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) and Temozolomide combination treatment in patients with newly diagnosed or recurrent glioblastomas.",118
161,temozolomide,"This is a multi-center open-label, dose escalation study to evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) and Temozolomide combination treatment in patients with newly diagnosed or recurrent glioblastomas.",133
161,mn-166,"Part 1 will evaluate the safety and tolerability of MN-166 (ibudilast) when given in combination with TMZ, and determine the dose of MN-166 (ibudilast) to be used in Part 2 of the study.",52
161,ibudilast,"Part 1 will evaluate the safety and tolerability of MN-166 (ibudilast) when given in combination with TMZ, and determine the dose of MN-166 (ibudilast) to be used in Part 2 of the study.",60
161,tmz,"Part 1 will evaluate the safety and tolerability of MN-166 (ibudilast) when given in combination with TMZ, and determine the dose of MN-166 (ibudilast) to be used in Part 2 of the study.",102
161,mn-166,"Part 1 will evaluate the safety and tolerability of MN-166 (ibudilast) when given in combination with TMZ, and determine the dose of MN-166 (ibudilast) to be used in Part 2 of the study.",133
161,ibudilast,"Part 1 will evaluate the safety and tolerability of MN-166 (ibudilast) when given in combination with TMZ, and determine the dose of MN-166 (ibudilast) to be used in Part 2 of the study.",141
161,mn-166,Part 2 will evaluate the efficacy of MN-166 (ibudilast) and temozolomide combination treatment as measured by the proportion of subjects who are progression-free at 6 months.,37
161,ibudilast,Part 2 will evaluate the efficacy of MN-166 (ibudilast) and temozolomide combination treatment as measured by the proportion of subjects who are progression-free at 6 months.,45
161,temozolomide,Part 2 will evaluate the efficacy of MN-166 (ibudilast) and temozolomide combination treatment as measured by the proportion of subjects who are progression-free at 6 months.,60
162,selinexor,"For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 dose (RP2D), preliminary efficacy, and safety of selinexor in combination with SoC therapy for newly diagnosed glioblastoma multiforme (GBM) (nGBM) or recurrent GBM (rGBM).",153
162,o6-methylguanine,"The study will independently evaluate 3 different combination regimens in 3 treatment arms in participants with nGBM O6-methylguanine-DNA-methyltransferase [MGMT] promotor unmethylated [uMGMT] disease in Arm A, MGMT methylated [mMGMT]) in Arm B, and participants with rGBM regardless of MGMT status in Arm C.",117
162,selinexor,The second phase of the study will compare selinexor+SoC treatments versus SoC treatment alone in the three treatment Arms.,43
163,temozolomide,The combination therapy of temozolomide and radiation has been established as the standard therapy for the initial treatment of glioblastoma.,27
163,temozolomide,There is no efficient and standard care at the time of recurrence or progression following temozolomide administration.,91
163,nitrosoureas,"Recently, many clinicians have reassessed the efficacy of second-line chemotherapeutic agents such as nitrosoureas for the treatment of recurrent/refractory glioblastoma.",102
163,ccnu,"We modify the PCV chemotherapy in the dose and administration schedule of CCNU and procarbazine to reduce the side effect, especially hematologic problems.",74
163,procarbazine,"We modify the PCV chemotherapy in the dose and administration schedule of CCNU and procarbazine to reduce the side effect, especially hematologic problems.",83
163,ccnu,The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU and procarbazine is increased.,12
163,ccnu,The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU and procarbazine is increased.,64
163,procarbazine,The dose of CCNU is reduced to 75mg/m2 and the interval between CCNU and procarbazine is increased.,73
163,vincristine,"Moreover, vincristine is excluded because BBB permeability of vincristine is very poor and the risk of neurotoxicity is high.",10
163,vincristine,"Moreover, vincristine is excluded because BBB permeability of vincristine is very poor and the risk of neurotoxicity is high.",62
164,temozolomide,"Specifically, the addition of TTFields to maintenance temozolomide (TMZ) therapy for newly diagnosed GBM patients, who had completed initial concurrent radio-chemotherapy, resulted in significantly prolonged median progression-free survival (PFS = 6.7 vs. 4.0 months, p<0.001) and median overall survival (OS = 20.9 vs. 16.0 months, p<0.001) compared to maintenance TMZ therapy alone (ef-14 trial) (4).",54
164,tmz,"Specifically, the addition of TTFields to maintenance temozolomide (TMZ) therapy for newly diagnosed GBM patients, who had completed initial concurrent radio-chemotherapy, resulted in significantly prolonged median progression-free survival (PFS = 6.7 vs. 4.0 months, p<0.001) and median overall survival (OS = 20.9 vs. 16.0 months, p<0.001) compared to maintenance TMZ therapy alone (ef-14 trial) (4).",68
164,tmz,"Specifically, the addition of TTFields to maintenance temozolomide (TMZ) therapy for newly diagnosed GBM patients, who had completed initial concurrent radio-chemotherapy, resulted in significantly prolonged median progression-free survival (PFS = 6.7 vs. 4.0 months, p<0.001) and median overall survival (OS = 20.9 vs. 16.0 months, p<0.001) compared to maintenance TMZ therapy alone (ef-14 trial) (4).",366
164,steroid,"The secondary endpoints were OS, PFS, PFS rate at six months (PFS6), objective response rate (ORR) based on the iRANO criteria (14), quality of life (QoL), Karnofsky performance score (KPS), and steroid dose.20 patients were screened, 2 declined, and 3 had KPS < 70.",195
164,bevacizumab,9 patients received adjuvant bevacizumab monotherapy and 2 temozolomide rechallenge.,29
164,temozolomide,9 patients received adjuvant bevacizumab monotherapy and 2 temozolomide rechallenge.,59
164,lomustine,"The expected OS12 in the control arm is set to 40% based on the EORTC 26101 trial, in which patients with first recurrence of GBM were treated with lomustine monotherapy or lomustine/bevacizumab combination therapy.",148
164,lomustine,"The expected OS12 in the control arm is set to 40% based on the EORTC 26101 trial, in which patients with first recurrence of GBM were treated with lomustine monotherapy or lomustine/bevacizumab combination therapy.",173
164,bevacizumab,"The expected OS12 in the control arm is set to 40% based on the EORTC 26101 trial, in which patients with first recurrence of GBM were treated with lomustine monotherapy or lomustine/bevacizumab combination therapy.",183
164,corticosteroids,"Skin rash may be treated with topical corticosteroids, more frequent electrode replacement and short pauses in TTFields therapy, if needed.",38
165,polyiclc,Patients also receive ATL-DC intradermally (ID) with poly ICLC intramuscularly (IM) every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.,53
166,novottf-100a,"Although the number of patients in the pilot trials is small, The FDA has determined that the data gathered so far warrant testing of NovoTTF-100A treatment as a possible therapy for patients with recurrent GBM.",134
166,temozolomide,"Patients with GBM whose disease has recurred or progressed despite standard treatment (Surgery, radiation therapy, Temozolomide treatment) and meet all of the requirements for participation in the study will be randomly assigned to one of two groups:",115
167,nivolumab,To evaluate the safety and tolerability of the combination treatment of autologous dendritic cells pulsed with tumor lysate antigen vaccine (DCVax-L) and nivolumab.,154
167,nivolumab,To compare overall survival (OS) from the date of surgery in a pooled evaluation of group 1 subjects receiving DCVax-L and group 2 subjects receiving DCVax-L and nivolumab to recent historical standards.,162
167,dcvax,Evaluation of the safety of the DCVax-L + nivolumab combination regimen.,32
167,nivolumab,Evaluation of the safety of the DCVax-L + nivolumab combination regimen.,42
167,nivolumab,Explore effect of nivolumab on TIL proliferation (CD8+/Ki-67+ staining).,18
167,nivolumab,"Explore whether oligoclonal T cell populations within tumor tissue are similarly expanded in peripheral blood after nivolumab, the magnitude of which correlates with clinical responses.",116
167,nivolumab,Explore if a mesenchymal gene expression signature present in the initial archived tumor sample correlates with T lymphocytic response in tumor after nivolumab.,150
167,nivolumab,"Patients receive dendritic cell-autologous lung tumor vaccine as in Group I, and nivolumab intravenously (IV) over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.  ",81
168,bevacizumab,The Study Drugs:  Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels.,18
168,lomustine," Lomustine is designed to damage the DNA (genetic material of cells) of tumor cells, which may cause the tumor cells to die.",1
168,bevacizumab,"If you are in Group 1, you will receive a higher dose of bevacizumab.",57
168,lomustine,"If you are in Group 2, you will receive lomustine and a lower dose of bevacizumab  ",40
168,bevacizumab,"If you are in Group 2, you will receive lomustine and a lower dose of bevacizumab  ",70
168,bevacizumab,"If you are in Group 1:  On Days 1, 15, and 29 of every cycle, you will receive bevacizumab by vein over 90 minutes.",79
168,bevacizumab,"If you are in Group 2:  On Days 1 and 22 of every cycle, you will receive bevacizumab by vein over 90 minutes.",74
168,lomustine,"On Day 3 of every cycle, you will take lomustine by mouth 1 time a day.",39
168,lomustine,You should take lomustine at bedtime 1 hour before or 2 hours after your last meal of the day with 1 cup (about 8 ounces) of water.,16
168,lomustine,You may stay on study treatment of lomustine and/or bevacizumab for up to 1 1/2 years.,35
168,bevacizumab,You may stay on study treatment of lomustine and/or bevacizumab for up to 1 1/2 years.,52
168,bevacizumab,"After that, you may continue taking bevacizumab for as long as the study doctor thinks it is in your best interest.",36
168,bevacizumab,Bevacizumab and lomustine are FDA approved drugs and commercially available for the treatment of brain tumors.,0
168,lomustine,Bevacizumab and lomustine are FDA approved drugs and commercially available for the treatment of brain tumors.,16
169,rad001,"This was a multicenter, open label, randomized study of RAD001 dosed daily in patients with recurrent GBM.",56
169,rad001,"Group 1 was designed to study the biological effects of RAD001 in patients scheduled to undergo salvage surgical resection, and Group 2 was to enroll patients who were not scheduled for surgery.",56
169,rad001,"Patients in Group 1 were randomly assigned to one of three pre-surgery treatment groups (0, 5 or 10 mg/day RAD001 for 7 days).",107
169,rad001,All patients in Group 2 were to receive a fixed daily dose of 10 mg/day oral RAD001.,77
170,carboplatin,This study will evaluate the safety of temporary disruption of the BBB during carboplatin chemotherapy delivery in patients with recurrent glioblastoma.,78
171,irinotecan,Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle.,0
171,bevacizumab,Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle.,15
171,vorinostat,Vorinostat is given orally on days 1-7 and 15-21 of each cycle.  ,0
171,vorinostat,"Vorinostat (provided in 100mg capsules) begins at a dose of 200mg/day, escalating to 300mg/day and then to a maximum of 400mg/day.",0
171,vorinostat,Vorinostat will be taken prior to irinotecan and bevacizumab on days 1 and 15.,0
171,irinotecan,Vorinostat will be taken prior to irinotecan and bevacizumab on days 1 and 15.,34
171,bevacizumab,Vorinostat will be taken prior to irinotecan and bevacizumab on days 1 and 15.,49
171,compazine,"Patients will be treated prophylactically with compazine 30 minutes prior to vorinostat which, in turn, should be taken 30 minutes prior to a meal whenever possible.",47
171,vorinostat,"Patients will be treated prophylactically with compazine 30 minutes prior to vorinostat which, in turn, should be taken 30 minutes prior to a meal whenever possible.",77
171,irinotecan, Irinotecan is given at a dose of 125mg/m².,1
171,bevacizumab,Bevacizumab is given at a dose of 10mg/kg.,0
171,vorinostat,"If DLT is not achieved in any cohort of up to a dose level of 400mg/day of vorinostat, further dose escalations will not be made.",75
172,pam,"Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus fractionated radiotherapy (recurrent cases).",177
172,pam,"Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus fractionated radiotherapy (recurrent cases).",274
172,ol,"Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus fractionated radiotherapy (recurrent cases).",340
173,panobinostat,"After screening and enrollment on the study, subjects will receive 20mg panobinostat 3 times a week for one week prior to surgery.",72
173,panobinostat,"Within 2-6 weeks of resection, subjects will resume panobinostat at 20mg panobinostat 3 times per week.",52
173,panobinostat,"Within 2-6 weeks of resection, subjects will resume panobinostat at 20mg panobinostat 3 times per week.",73
173,panobinostat,"Patients may continue treatment with oral panobinostat until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.",42
174,memantine,The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma.,65
174,memantine,"Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors.",0
174,glutamate,"Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors.",48
174,memantine,The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine.,115
174,memantine,Memantine will be taken by mouth twice a day.,0
175,vorinostat,"If you are in Group 1, you will take vorinostat and isotretinoin.",37
175,isotretinoin,"If you are in Group 1, you will take vorinostat and isotretinoin.",52
175,isotretinoin,"If you are in Group 2, you will take isotretinoin and temozolomide.",37
175,temozolomide,"If you are in Group 2, you will take isotretinoin and temozolomide.",54
175,vorinostat,"If you are in Group 3, you will take vorinostat, isotretinoin and temozolomide.",37
175,isotretinoin,"If you are in Group 3, you will take vorinostat, isotretinoin and temozolomide.",49
175,temozolomide,"If you are in Group 3, you will take vorinostat, isotretinoin and temozolomide.",66
175,vorinostat,You will take vorinostat by mouth once a day during Days 1-7 and Days 15-21 of each cycle.,14
175,vorinostat,"You should take vorinostat by mouth in the morning, at about the same time each day.",16
175,vorinostat,Vorinostat capsules should be swallowed whole and should not be opened.,0
175,vorinostat,"If a capsule is damaged or broken, spills of powder from vorinostat capsules should be cleaned up carefully.",57
175,alcohol,"If the spill is on a surface, the area must be washed at least 3 times with rubbing alcohol, followed by water.",84
175,vorinostat,Vorinostat capsules should be stored at room temperature (59°-86°F [15°-30°C]) in a dry area.,0
175,vorinostat,"You should take vorinostat with food, but not a high fat meal.",16
175,isotretinoin,You will also take isotretinoin by mouth 2 times a day on Days 1-21 of each cycle.,19
175,temozolomide,You will take temozolomide by mouth once a day on Days 1-7 and Days 15-21 of each cycle.,14
175,temozolomide,"You should take temozolomide by mouth at bedtime, at about the same time each day.",16
175,temozolomide,"You should swallow the temozolomide capsules whole, one right after the other, without chewing them.",23
175,vorinostat,"If you vomit while taking vorinostat, isotretinoin and/or temozolomide, you should not ""make up"" the dose.",26
175,isotretinoin,"If you vomit while taking vorinostat, isotretinoin and/or temozolomide, you should not ""make up"" the dose.",38
175,temozolomide,"If you vomit while taking vorinostat, isotretinoin and/or temozolomide, you should not ""make up"" the dose.",58
175,isotretinoin,"Isotretinoin, temozolomide, and vorinostat are FDA approved drugs and commercially available.",0
175,temozolomide,"Isotretinoin, temozolomide, and vorinostat are FDA approved drugs and commercially available.",14
175,vorinostat,"Isotretinoin, temozolomide, and vorinostat are FDA approved drugs and commercially available.",32
176,paclitaxel,"During the tumor resection, an initial low dose of paclitaxel will be given following sonication.",51
176,paclitaxel,"About two weeks after surgery, patients will undergo sonication and albumin-bound paclitaxel administration with MRI to quantify extent of blood brain barrier opening.",82
176,paclitaxel,Sonication and administration of albumin-bound paclitaxel will continue every 3 weeks until disease progression.,47
177,niraparib,"After enrollment, patients were given niraparib 300mg/day (body weight ≥77Kg and baseline platelet count ≥150,000/µL) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/µL), combined with radiotherapy (total dose 55Gy), follow-up Time 1 year.",38
178,zk219477,"ZK 219477 is a fully synthetic analogue of Epothilone B, a naturally occurring cytotoxic substance.",0
178,epothiloneb,"ZK 219477 is a fully synthetic analogue of Epothilone B, a naturally occurring cytotoxic substance.",43
178,zk219477,"ZK 219477 inhibits microtubule depolymerization, causing cell cycle blockage in G2/M phase and induction to apoptosis.",0
178,taxanes,"This mechanism of action is similar to that of taxanes (paclitaxel and docetaxel), but epothilones retain activity against multi-drug resistance (MDR) tumours.",47
178,paclitaxel,"This mechanism of action is similar to that of taxanes (paclitaxel and docetaxel), but epothilones retain activity against multi-drug resistance (MDR) tumours.",56
178,docetaxel,"This mechanism of action is similar to that of taxanes (paclitaxel and docetaxel), but epothilones retain activity against multi-drug resistance (MDR) tumours.",71
178,epothilones,"This mechanism of action is similar to that of taxanes (paclitaxel and docetaxel), but epothilones retain activity against multi-drug resistance (MDR) tumours.",87
178,zk219477,"ZK 219477 demonstrated both in vitro and in vivo considerable anti-tumour activity against a wide range of malignancies, and it is now about to enter phase II studies in a number of selected indications.",0
178,zk219477,In pre-clinical model ZK 219477 has demonstrated anti-tumorigenic activity for gliomas tumours both in vitro and in vivo.  ,22
178,zk219477,"ZK 219477 has the ability to cross the blood-brain barrier, a fundamental characteristic for a potential GBM chemotherapy.",0
178,zk219477,"In a preclinical PK study, similar concentrations of ZK 219477 were detected in plasma (1.2 μg/ml) and brain (0.9 μg/g) after 10 min after i.v.",53
178,zk219477,"ZK 219477 produced strong antiproliferative activity in the human glioma cell line U373 inoculated subcutaneous in nude mice (2 mg/kg and 9 mg/kg) as well as paclitaxel (8 mg/kg), but on the contrary of paclitaxel, only ZK 219477 demonstrated antitumour activity against U373 implanted in nude mice (9 mg/kg): 8 complete response out 9 treated mice.",0
178,paclitaxel,"ZK 219477 produced strong antiproliferative activity in the human glioma cell line U373 inoculated subcutaneous in nude mice (2 mg/kg and 9 mg/kg) as well as paclitaxel (8 mg/kg), but on the contrary of paclitaxel, only ZK 219477 demonstrated antitumour activity against U373 implanted in nude mice (9 mg/kg): 8 complete response out 9 treated mice.",158
178,paclitaxel,"ZK 219477 produced strong antiproliferative activity in the human glioma cell line U373 inoculated subcutaneous in nude mice (2 mg/kg and 9 mg/kg) as well as paclitaxel (8 mg/kg), but on the contrary of paclitaxel, only ZK 219477 demonstrated antitumour activity against U373 implanted in nude mice (9 mg/kg): 8 complete response out 9 treated mice.",203
178,zk219477,"ZK 219477 produced strong antiproliferative activity in the human glioma cell line U373 inoculated subcutaneous in nude mice (2 mg/kg and 9 mg/kg) as well as paclitaxel (8 mg/kg), but on the contrary of paclitaxel, only ZK 219477 demonstrated antitumour activity against U373 implanted in nude mice (9 mg/kg): 8 complete response out 9 treated mice.",220
178,zk219477,"Of interest for GBM indication, ZK 219477 is not metabolized by liver cytochrome P450, which is induced by phenytoin and other anti-convulsion drug, commonly used in post-surgery GBM patients.",32
178,phenytoin,"Of interest for GBM indication, ZK 219477 is not metabolized by liver cytochrome P450, which is induced by phenytoin and other anti-convulsion drug, commonly used in post-surgery GBM patients.",107
178,zk219477,"The purpose of this single arm phase II study is to evaluate safety and efficacy of ZK 219477 in the treatment of pre-treated, recurrent GBM patients.",84
178,zk219477,"Aim of the study: The purpose of this single arm phase II study is to evaluate safety and efficacy of ZK 219477 in the treatment of pre-treated, recurrent GBM patients.",102
178,zk219477,Study medication: ZK 219477 epothilone B analog.,18
178,epothiloneb,Study medication: ZK 219477 epothilone B analog.,28
178,temozolomide,"Study Population: 15 recurrent glioblastoma patients previously treated by surgery, conventional radiotherapy and chemotherapy with temozolomide (TMZ.",132
178,tmz,"Study Population: 15 recurrent glioblastoma patients previously treated by surgery, conventional radiotherapy and chemotherapy with temozolomide (TMZ.",146
178,gadolinium,"Histologically proven (at diagnosis) GBM Age between 18 and 70 years KPS ≥ 70 Life expectancy of at least 3 months Presence of at least one bi-dimensionally measurable lesion on gadolinium (Gd)-enhanced MRI, indicating progressive or recurrent disease at least 8 weeks after standard external-beam radiotherapy Recurrence or progression after treatment with radiotherapy and temozolomide.",178
178,gd,"Histologically proven (at diagnosis) GBM Age between 18 and 70 years KPS ≥ 70 Life expectancy of at least 3 months Presence of at least one bi-dimensionally measurable lesion on gadolinium (Gd)-enhanced MRI, indicating progressive or recurrent disease at least 8 weeks after standard external-beam radiotherapy Recurrence or progression after treatment with radiotherapy and temozolomide.",190
178,temozolomide,"Histologically proven (at diagnosis) GBM Age between 18 and 70 years KPS ≥ 70 Life expectancy of at least 3 months Presence of at least one bi-dimensionally measurable lesion on gadolinium (Gd)-enhanced MRI, indicating progressive or recurrent disease at least 8 weeks after standard external-beam radiotherapy Recurrence or progression after treatment with radiotherapy and temozolomide.",375
178,bilirubin,"Also patients with residual disease after surgery for recurrent GBM will be included Adequate bone marrow reserve (leukocytes ≥ 3,500/ml, ANC ≥ 1,500/ml, platelets ≥100,000/ ml); normal baseline liver (serum bilirubin ≤ 20",208
178,creatinine,"/mol/ L), renal (serum creatinine <150 /mol/L) and cardiac function Absence of infectious disease, debilitating chronic diseases, and known psychiatric disorders Corticosteroid dose stable for at least 1 week Adequate recovery from previous surgery, radiation and chemotherapy Negative pregnancy test at enrolment in females of child-bearing potential Agreement to use highly effective contraception methods in adults of reproductive potential Fully informed written consent  Exclusion Criteria:  ",23
178,zk219477,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",182
178,epothilones,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",501
178,taxanes,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",542
178,paclitaxel,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",556
178,docetaxel,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",568
178,vincaalkaloids,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",583
178,vincristine,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",604
178,vinblastine,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",617
178,vinorelbine,"Pregnant women Patients who have had chemotherapy or radiotherapy within 4 weeks History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZK219477 Uncontrolled inter current illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure,unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements HIV-infection Any prior treatment with epothilones, other tubulin-targetting as taxanes (e.g. paclitaxel, docetaxel) and vinca alkaloids (e.g.vincristine, vinblastine, vinorelbine)",630
178,zk219477,ZK 219477 will be administered as an i.v.,0
179,tpi287,"If you are in Part I, you will be assigned to receive 1 of 4 dose levels of TPI 287 based on when you join this study.",76
179,bevacizumab,All participants will receive bevacizumab at the same dose level for the entire study.,30
179,bevacizumab,"If you are in Group 1, you will receive bevacizumab.",40
179,bevacizumab,"If you are in Group 2, you will receive bevacizumab and TPI 287.",40
179,tpi,"If you are in Group 2, you will receive bevacizumab and TPI 287.",56
179,bevacizumab,"If the disease gets worse at any time during the treatment with bevacizumab alone, you may enroll in the Crossover Group to receive TPI 287 and bevacizumab.",64
179,tpi287,"If the disease gets worse at any time during the treatment with bevacizumab alone, you may enroll in the Crossover Group to receive TPI 287 and bevacizumab.",132
179,bevacizumab,"If the disease gets worse at any time during the treatment with bevacizumab alone, you may enroll in the Crossover Group to receive TPI 287 and bevacizumab.",144
179,tpi287,"If you are taking TPI 287, you will be given standard drugs such as Benadryl® (diphenhydramine) and cimetidine to help decrease the risk of side effects.",18
179,benadryl®,"If you are taking TPI 287, you will be given standard drugs such as Benadryl® (diphenhydramine) and cimetidine to help decrease the risk of side effects.",68
179,diphenhydramine,"If you are taking TPI 287, you will be given standard drugs such as Benadryl® (diphenhydramine) and cimetidine to help decrease the risk of side effects.",79
179,cimetidine,"If you are taking TPI 287, you will be given standard drugs such as Benadryl® (diphenhydramine) and cimetidine to help decrease the risk of side effects.",100
179,tpi287,"On Days 1 and 22 of every cycle, you will receive TPI 287 by vein over 1 hour.",50
179,bevacizumab,"On Days 1, 15, and 29 of every cycle, you will receive bevacizumab by vein over 30-90 minutes.",55
179,bevacizumab,"If you are in Group 1:  ° On Days 1,15, and 29 of every cycle, you will receive bevacizumab by vein over 30-90 minutes.",80
179,tpi,"If you are in Group 2 or the Crossover Group:  On Days 1 and 22 of every cycle, you will receive TPI 287 by vein over 1 hour.",97
179,bevacizumab,"On Days 1, 15, and 29 of every cycle, you will receive bevacizumab by vein over 30-90 minutes.",55
179,tpi287,TPI 287 is not FDA approved or commercially available.,0
179,bevacizumab,"Bevacizumab is FDA approved and commercially available for the treatment of brain tumors, including glioblastoma.",0
179,tpi287,The combination of TPI 287 and bevacizumab in glioblastoma is investigational.,19
179,bevacizumab,The combination of TPI 287 and bevacizumab in glioblastoma is investigational.,31
184,cilengitide, Cilengitide will be given as an intravenous (IV) infusion (into a vein) 2 times a week during each 4-week cycle.,1
184,bevacizumab, Bevacizumab will be given on as an IV infusion over 90 minutes on Days 1 and 15 of each cycle.,1
184,bevacizumab,"If the study doctor thinks it is in your best interest and depending on how you react to bevacizumab, the length of the infusion time may be decreased.",89
184,cilengitide,"On the days you are scheduled to receive both cilengitide and bevacizumab, you will receive cilengitide after the bevacizumab infusion.",46
184,bevacizumab,"On the days you are scheduled to receive both cilengitide and bevacizumab, you will receive cilengitide after the bevacizumab infusion.",62
184,cilengitide,"On the days you are scheduled to receive both cilengitide and bevacizumab, you will receive cilengitide after the bevacizumab infusion.",92
184,bevacizumab,"On the days you are scheduled to receive both cilengitide and bevacizumab, you will receive cilengitide after the bevacizumab infusion.",114
184,bevacizumab,Bevacizumab is FDA approved and commercially available for the treatment of recurrent glioblastoma.,0
184,cilengitide,Cilengitide is not FDA approved or commercially available.,0
184,cilengitide,"At this time, the combination of cilengitide and bevacizumab is being used for research purposes only.",33
184,bevacizumab,"At this time, the combination of cilengitide and bevacizumab is being used for research purposes only.",49
185,ly2157299,"The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer",58
185,ly2157299,"The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer",80
185,lomustine,"The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer",95
185,lomustine,"The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer",116
187,temozolomide,Only patients with recurrence after Temozolomide and VEGF-directed therapy with Bevacizumab will be considered for the study.,36
187,bevacizumab,Only patients with recurrence after Temozolomide and VEGF-directed therapy with Bevacizumab will be considered for the study.,80
187,temsirolimus,"Patients will receive temsirolimus 25 mg IV over 30-60 minutes on days 1, 8, 15 and 22 and bevacizumab 10 mg/kg IV over 30-90 minutes on day 8 and 22.",22
187,bevacizumab,"Patients will receive temsirolimus 25 mg IV over 30-60 minutes on days 1, 8, 15 and 22 and bevacizumab 10 mg/kg IV over 30-90 minutes on day 8 and 22.",91
188,dasatinib,"To determine the therapeutic efficacy of dasatinib in all patients (i.e., stages 1B and 2 combined) with recurrent/progressive glioblastoma (GBM) as measured by 6-month progression-free survival.",41
188,dasatinib,To determine the therapeutic efficacy of dasatinib for stage 1B patients with recurrent/progressive GBM as measured by a hybrid endpoint of 6-month progression-free survival OR objective response of (complete response [CR] or partial response [PR]) rate.,41
188,dasatinib,To determine the toxicity of dasatinib in the treatment of patients with GBM.,29
188,dasatinib,Patients receive dasatinib orally (PO) twice daily (BID) on days 1-28.,17
189,lb100,"LB100, a water soluble small molecule novel protein phosphatase 2A (PP2A) inhibitor, was commercially developed through a CRADA based on our previous intramural research.",0
189,lb100,"Preclinical studies indicate LB100 has in vitro and in vivo activity as a single agent as well as potentiating the effect of cytotoxic agents including temozolomide, docetaxel, doxorubicin, and ionizing radiation.",29
189,temozolomide,"Preclinical studies indicate LB100 has in vitro and in vivo activity as a single agent as well as potentiating the effect of cytotoxic agents including temozolomide, docetaxel, doxorubicin, and ionizing radiation.",152
189,docetaxel,"Preclinical studies indicate LB100 has in vitro and in vivo activity as a single agent as well as potentiating the effect of cytotoxic agents including temozolomide, docetaxel, doxorubicin, and ionizing radiation.",166
189,doxorubicin,"Preclinical studies indicate LB100 has in vitro and in vivo activity as a single agent as well as potentiating the effect of cytotoxic agents including temozolomide, docetaxel, doxorubicin, and ionizing radiation.",177
189,lb100,"LB100 is active in combination with temozolomide or doxorubicin against xenografts of glioblastoma, neuroblastoma, pheochromocytoma, breast cancer, fibrosarcoma, and melanoma.",0
189,temozolomide,"LB100 is active in combination with temozolomide or doxorubicin against xenografts of glioblastoma, neuroblastoma, pheochromocytoma, breast cancer, fibrosarcoma, and melanoma.",36
189,doxorubicin,"LB100 is active in combination with temozolomide or doxorubicin against xenografts of glioblastoma, neuroblastoma, pheochromocytoma, breast cancer, fibrosarcoma, and melanoma.",52
189,lb100,"Although it is a polar compound, rodent studies suggest LB100 has activity in the brain.",56
189,lb100,"Whether LB100 can across the human blood brain barrier (BBB), and at what concentration relative to the plasma level is not known.",8
189,lb100,Our ongoing in vitro studies indicate that LB100 has distinct mechanisms of action at different drug concentrations (e.g. nM versus uM); 2) There are other brain tumors lacking effective medical therapies but without a BBB.,43
189,lb100,Objective:  -To determine the pharmacokinetic (PK) properties of LB100 in glioma tumor tissues.,65
189,lb100,"This is a two stage Phase II, open label, single institution study to determine the PK and PD profile of LB100.",105
189,lb100,PK and PD effect of LB100 treated tissues will only be evaluated with pathologic confirmation of recurrent tumor.,20
189,phospho,PD effect is defined as statistically significant elevation of phospho-proteins in treated tumor tissues compared to untreated glioma specimens.,63
190,temsirolimus, To establish a maximum tolerable dose of temsirolimus in combination with sorafenib in patients with recurrent glioblastoma not receiving enzyme-inducing anticonvulsants (EIACs).,42
190,sorafenib, To establish a maximum tolerable dose of temsirolimus in combination with sorafenib in patients with recurrent glioblastoma not receiving enzyme-inducing anticonvulsants (EIACs).,75
190,temsirolimus,To assess the efficacy of temsirolimus and sorafenib in the treatment of recurrent glioblastoma in non-EIAC patients as measured by progression-free survival status at six months (PFS6).,26
190,sorafenib,To assess the efficacy of temsirolimus and sorafenib in the treatment of recurrent glioblastoma in non-EIAC patients as measured by progression-free survival status at six months (PFS6).,43
190,temsirolimus,To define the safety profile of temsirolimus and sorafenib in non-EIAC patients.,32
190,sorafenib,To define the safety profile of temsirolimus and sorafenib in non-EIAC patients.,49
190,temsirolimus,I. To assess the safety and toxicities of temsirolimus and sorafenib in the above-noted patient populations.,42
190,sorafenib,I. To assess the safety and toxicities of temsirolimus and sorafenib in the above-noted patient populations.,59
190,sorafenib,"Patients receive sorafenib orally (PO) twice daily (BID) on days 1-28 and temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22.",17
190,temsirolimus,"Patients receive sorafenib orally (PO) twice daily (BID) on days 1-28 and temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22.",74
190,temsirolimus,Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined.,52
190,sorafenib, Group 1 (Arm B): Patients receive sorafenib and temsirolimus as in phase I at the MTD.,35
190,temsirolimus, Group 1 (Arm B): Patients receive sorafenib and temsirolimus as in phase I at the MTD.,49
190,sorafenib,Patients receive sorafenib PO BID on days 1-8 (15 doses) and temsirolimus IV at the MTD on day 1.,17
190,temsirolimus,Patients receive sorafenib PO BID on days 1-8 (15 doses) and temsirolimus IV at the MTD on day 1.,61
190,sorafenib,"After recovering from surgery, patients receive sorafenib and temsirolimus as in phase I at the MTD.",48
190,temsirolimus,"After recovering from surgery, patients receive sorafenib and temsirolimus as in phase I at the MTD.",62
190,sorafenib, Group 3 (Arm D): Patient receive sorafenib and temsirolimus as in phase I at the MTD.,34
190,temsirolimus, Group 3 (Arm D): Patient receive sorafenib and temsirolimus as in phase I at the MTD.,48
191,trc102,"To estimate the efficacy of TRC102 (methoxyamine) and temozolomide, as measured by response rate, in bevacizumab naïve glioblastoma.",28
191,methoxyamine,"To estimate the efficacy of TRC102 (methoxyamine) and temozolomide, as measured by response rate, in bevacizumab naïve glioblastoma.",36
191,temozolomide,"To estimate the efficacy of TRC102 (methoxyamine) and temozolomide, as measured by response rate, in bevacizumab naïve glioblastoma.",54
191,bevacizumab,"To estimate the efficacy of TRC102 (methoxyamine) and temozolomide, as measured by response rate, in bevacizumab naïve glioblastoma.",101
191,trc102,"To estimate the efficacy of TRC102 and temozolomide, as measured by response rate, in bevacizumab refractory glioblastoma.",28
191,temozolomide,"To estimate the efficacy of TRC102 and temozolomide, as measured by response rate, in bevacizumab refractory glioblastoma.",39
191,bevacizumab,"To estimate the efficacy of TRC102 and temozolomide, as measured by response rate, in bevacizumab refractory glioblastoma.",86
191,trc102, I. Evaluate the toxicities of oral TRC102 and temozolomide in this patient population.,36
191,temozolomide, I. Evaluate the toxicities of oral TRC102 and temozolomide in this patient population.,47
191,trc102,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival, progression-free survival at 6 months and overall survival, in bevacizumab naïve glioblastoma.",25
191,temozolomide,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival, progression-free survival at 6 months and overall survival, in bevacizumab naïve glioblastoma.",36
191,bevacizumab,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival, progression-free survival at 6 months and overall survival, in bevacizumab naïve glioblastoma.",155
191,trc102,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival in bevacizumab refractory glioblastoma.",25
191,temozolomide,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival in bevacizumab refractory glioblastoma.",36
191,bevacizumab,"Estimate the efficacy of TRC102 and temozolomide, as measured by progression-free survival in bevacizumab refractory glioblastoma.",94
191,n-methylpurine, TERTIARY OBJECTIVES:  I. Assess the tissue correlates of N-methylpurine-deoxyribonucleic acid (DNA) glycosylase,58
191,o-6-methylguanine,"(MPG), topoisomerase II-alpha (topo II a), and O-6-methylguanine-DNA methyltransferase (MGMT) status, with response, progression-free survival (PFS), and overall survival.",47
191,methoxyamine,Patients receive methoxyamine orally (PO) once daily (QD) and temozolomide PO QD on days 1-5.,17
191,temozolomide,Patients receive methoxyamine orally (PO) once daily (QD) and temozolomide PO QD on days 1-5.,62
192,bkm120, Secondary Objectives  Evaluate effects of BKM120 on tumor cell proliferation and tumor cell death Investigate the safety profile of BKM120 in this population Investigate pharmacokinetics of BKM120 in this population  ,43
192,bkm120, Secondary Objectives  Evaluate effects of BKM120 on tumor cell proliferation and tumor cell death Investigate the safety profile of BKM120 in this population Investigate pharmacokinetics of BKM120 in this population  ,133
192,bkm120, Secondary Objectives  Evaluate effects of BKM120 on tumor cell proliferation and tumor cell death Investigate the safety profile of BKM120 in this population Investigate pharmacokinetics of BKM120 in this population  ,191
192,fdg,Exploratory Objectives  Correlate FDG-PET and FLT-PET with pharmacodynamic effects and 6-month progressive-free survival (PFS6) Determine the effects of BKM120 on primary GBM cell lines derived from participants and correlate with participant benefit from BKM120 treatment  ,34
192,bk20,Exploratory Objectives  Correlate FDG-PET and FLT-PET with pharmacodynamic effects and 6-month progressive-free survival (PFS6) Determine the effects of BKM120 on primary GBM cell lines derived from participants and correlate with participant benefit from BKM120 treatment  ,153
192,bkm120,"Secondary Objectives  Investigate the radiographic response, progression free survival, overall survival Investigate the safety profile efficacy of BKM120 in this population  ",148
192,bkm120,"Exploratory Objectives  Correlate benefit from BKM120 treatment with molecular genotype of tumor (using immunohistochemistry, mutation analysis and RNA expression profiling), and whole blood proteomics Correlate benefit from BKM120 treatment with circulating angiogenic biomarkers Utilize advance MRI (perfusion, permeability, diffusion imaging) to determine the effects of BKM120 on tumor vasculature and to correlate with benefit from BKM120 treatment  STATISTICAL DESIGN:  ",47
192,bkm120,"Exploratory Objectives  Correlate benefit from BKM120 treatment with molecular genotype of tumor (using immunohistochemistry, mutation analysis and RNA expression profiling), and whole blood proteomics Correlate benefit from BKM120 treatment with circulating angiogenic biomarkers Utilize advance MRI (perfusion, permeability, diffusion imaging) to determine the effects of BKM120 on tumor vasculature and to correlate with benefit from BKM120 treatment  STATISTICAL DESIGN:  ",225
192,bkm120,"Exploratory Objectives  Correlate benefit from BKM120 treatment with molecular genotype of tumor (using immunohistochemistry, mutation analysis and RNA expression profiling), and whole blood proteomics Correlate benefit from BKM120 treatment with circulating angiogenic biomarkers Utilize advance MRI (perfusion, permeability, diffusion imaging) to determine the effects of BKM120 on tumor vasculature and to correlate with benefit from BKM120 treatment  STATISTICAL DESIGN:  ",374
192,bkm120,"Exploratory Objectives  Correlate benefit from BKM120 treatment with molecular genotype of tumor (using immunohistochemistry, mutation analysis and RNA expression profiling), and whole blood proteomics Correlate benefit from BKM120 treatment with circulating angiogenic biomarkers Utilize advance MRI (perfusion, permeability, diffusion imaging) to determine the effects of BKM120 on tumor vasculature and to correlate with benefit from BKM120 treatment  STATISTICAL DESIGN:  ",437
193,pf-00299804,There are no breaks from taking PF-00299804 between treatment cycles.,32
193,pf-00299804,Participants will take PF-00299804 once a day for a total of 7 to 9 days before surgery.,23
193,pf-00299804,They will then stop taking PF-00299804 until they have recovered from surgery.,27
193,pf-00299804,"Once they have recovered from surgery, they will continue to take PF-00299804 once a day until their disease worsens, they experience side effects or they decide to stop study treatment.",66
193,pf-00299804,There are no breaks from taking PF-00299804 between treatment cycles.,32
193,pf-00299804,"Participants will take PF-00299804 orally once a day until their disease worsens, they experience any side effect, or if they decide to stop study treatment.",23
194,tmz,Phase I trial: TMZ will be administered in a fixed schedule as follows:  TMZ  50 mg/m2/day divided in three daily doses (approx.,15
194,tmz,Phase I trial: TMZ will be administered in a fixed schedule as follows:  TMZ  50 mg/m2/day divided in three daily doses (approx.,73
194,cpt-11,"100 mg/m2 in a morning single dose on days 8 and 22  CPT-11 starting dose:  .100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ.(Level 1).One cycle = 28 days.",53
194,tmz,"100 mg/m2 in a morning single dose on days 8 and 22  CPT-11 starting dose:  .100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ.(Level 1).One cycle = 28 days.",137
194,cpt-11,"CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .",0
195,bgb324,PRIMARY OBJECTIVES:  I. Evaluate the penetration of AXL inhibitor BGB324 (BGB324) across the blood brain barrier measured by pharmacokinetics/drug concentration of 1.0 uM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma patients.,66
195,bgb324,PRIMARY OBJECTIVES:  I. Evaluate the penetration of AXL inhibitor BGB324 (BGB324) across the blood brain barrier measured by pharmacokinetics/drug concentration of 1.0 uM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma patients.,74
195,bgb324,Determine the BGB324 concentration in tissue resected from a contrast non-enhancing region of the tumor.,14
195,bgb324,Characterize the steady state pharmacokinetics of BGB324 in patients with recurrent glioblastoma.,50
195,bgb324,Estimate safety and tolerability of BGB324 for recurrent glioblastoma.,36
195,bgb324,"Participants receive AXL inhibitor BGB324 orally (PO) once daily (QD) on days 1-5, then undergo surgery 3-6 hours after last dose.",35
195,bgb324,"Within 45 days, participants receive AXL inhibitor BGB324 PO QD on days 1-21.",51
195,bgb324," GROUP B: Participants undergo surgery, then within 45 days receive AXL inhibitor BGB324 PO QD on days 1-21.",82
196,sap,To evaluate the penetration of sapanisertib (MLN0128 [TAK-228]) across the blood brain barrier and achieve a concentration of 70 nM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma (GBM) patients.,31
196,mln0128,To evaluate the penetration of sapanisertib (MLN0128 [TAK-228]) across the blood brain barrier and achieve a concentration of 70 nM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma (GBM) patients.,45
196,tak-228,To evaluate the penetration of sapanisertib (MLN0128 [TAK-228]) across the blood brain barrier and achieve a concentration of 70 nM in tissue resected from a contrast enhancing region of the tumor in 60% of recurrent glioblastoma (GBM) patients.,54
196,mln0128,To determine the ability of MLN0128 (TAK-228) to inhibit TOR complex (TORC)1/2 in the enhancing components of the tumor as determined by modulation of RPS6 phosphorylated Ser-235 (pS235) in reverse phase protein array (RPPA) assays.,28
196,tak-228,To determine the ability of MLN0128 (TAK-228) to inhibit TOR complex (TORC)1/2 in the enhancing components of the tumor as determined by modulation of RPS6 phosphorylated Ser-235 (pS235) in reverse phase protein array (RPPA) assays.,37
196,ser-235,To determine the ability of MLN0128 (TAK-228) to inhibit TOR complex (TORC)1/2 in the enhancing components of the tumor as determined by modulation of RPS6 phosphorylated Ser-235 (pS235) in reverse phase protein array (RPPA) assays.,171
196,ps235,To determine the ability of MLN0128 (TAK-228) to inhibit TOR complex (TORC)1/2 in the enhancing components of the tumor as determined by modulation of RPS6 phosphorylated Ser-235 (pS235) in reverse phase protein array (RPPA) assays.,180
196,mln0128,To evaluate the penetration of MLN0128 (TAK-228) across the blood brain barrier by determining its concentration in tissue resected from a non-contrast enhancing region of the tumor.,31
196,tak-228,To evaluate the penetration of MLN0128 (TAK-228) across the blood brain barrier by determining its concentration in tissue resected from a non-contrast enhancing region of the tumor.,40
196,mln0128,To assess the plasma pharmacokinetics of MLN0128 (TAK-228) in patients with recurrent GBM.,41
196,tak-228,To assess the plasma pharmacokinetics of MLN0128 (TAK-228) in patients with recurrent GBM.,50
196,mln0128,To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 in the non-enhancing components of the tumor as determined by modulation of RPS6 pS235 in RPPA assays.,28
196,tak-228,To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 in the non-enhancing components of the tumor as determined by modulation of RPS6 pS235 in RPPA assays.,37
196,mln0128,"To assess the ability of MLN0128 (TAK-228) to inhibit TORC1/2 by evaluating pharmacodynamics (PD) markers by immunohistochemistry such as pS235, pS236, phosphorylated 4E-binding protein (p4EBP), phosphorylated-mechanistic target of rapamycin (serine/threonine kinase) (pmTOR), and AKTpSer473.",25
196,tak-228,"To assess the ability of MLN0128 (TAK-228) to inhibit TORC1/2 by evaluating pharmacodynamics (PD) markers by immunohistochemistry such as pS235, pS236, phosphorylated 4E-binding protein (p4EBP), phosphorylated-mechanistic target of rapamycin (serine/threonine kinase) (pmTOR), and AKTpSer473.",34
196,serine,"To assess the ability of MLN0128 (TAK-228) to inhibit TORC1/2 by evaluating pharmacodynamics (PD) markers by immunohistochemistry such as pS235, pS236, phosphorylated 4E-binding protein (p4EBP), phosphorylated-mechanistic target of rapamycin (serine/threonine kinase) (pmTOR), and AKTpSer473.",243
196,threonine,"To assess the ability of MLN0128 (TAK-228) to inhibit TORC1/2 by evaluating pharmacodynamics (PD) markers by immunohistochemistry such as pS235, pS236, phosphorylated 4E-binding protein (p4EBP), phosphorylated-mechanistic target of rapamycin (serine/threonine kinase) (pmTOR), and AKTpSer473.",250
196,mln0128,To evaluate the safety profile of MLN0128 (TAK-228) in pre-operative patients with recurrent GBM.  VI.,34
196,tak-228,To evaluate the safety profile of MLN0128 (TAK-228) in pre-operative patients with recurrent GBM.  VI.,43
196,mln0128,I. To perform mass spectrometry imaging (MSI) to qualitatively assess the ability of MLN0128 (TAK-228) to penetrate the blood brain barrier and enter tumor tissue in enhancing and non-enhancing regions of the tumor.,85
196,tak-228,I. To perform mass spectrometry imaging (MSI) to qualitatively assess the ability of MLN0128 (TAK-228) to penetrate the blood brain barrier and enter tumor tissue in enhancing and non-enhancing regions of the tumor.,94
196,mln0128,To determine ex-vivo sensitivity of tumor neurosphere cultures (patient derived cell lines [PDCL]) established from surgical specimens to MLN0128 (TAK-228).,138
196,tak-228,To determine ex-vivo sensitivity of tumor neurosphere cultures (patient derived cell lines [PDCL]) established from surgical specimens to MLN0128 (TAK-228).,147
196,mln0128,To explore the potential association of tumor genotype with progression-free survival among patients treated with MLN0128 (TAK-228).,114
196,tak-228,To explore the potential association of tumor genotype with progression-free survival among patients treated with MLN0128 (TAK-228).,123
196,mln0128,To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 as determined by modulation of additional TORC1/2 markers in RPPA assays.,28
196,tak-228,To determine the ability of MLN0128 (TAK-228) to inhibit TORC1/2 as determined by modulation of additional TORC1/2 markers in RPPA assays.,37
196,sap,Patients receive sapanisertib orally (PO) once daily (QD) for 7-9 days (including 2-4 hours before surgery).,17
196,sap,"If patients do not demonstrate adequate sapanisertib tumor tissue concentrations, patients are enrolled in Cohort B.  ",40
196,sap,Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0.,17
197,ketone,Compliance is assessed by review of the daily food diary and the urine and serum ketone levels.,81
197,glucose,Determine patient compliance in monitoring of blood glucose and urine levels of ketosis.,52
197,ketone,"Determine the frequency of achieving ketosis, as measured by urine ketones checked daily and serum BHB checked every two weeks.",67
197,sugar-124,To correlate levels of ketosis and blood sugar with treatment outcome.,41
198,clr1404,The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.,104
199,bevacizumab,Subjects who have evidence of bevacizumab-refractory GBM will be eligible to participate in this research study.,30
199,bevacizumab,"Subjects will undergo 12 months of planned continuous treatment with TTFields followed by pulsed bevacizumab treatment when there is evidence of further progression per RANO, with the option of extending treatment up to a total of 24 months in patients who have not progressed and/or have adequate performance status at the 12 month mark.",97
199,bevacizumab,Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off.,7
199,bevacizumab,"If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle.",66
199,bevacizumab,"If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death.",53
199,bevacizumab,"If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle or until progression is noted again per RANO, whichever is later, at which time pulsed bevacizumab will be restarted as outlined above.",70
199,ran,"If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle or until progression is noted again per RANO, whichever is later, at which time pulsed bevacizumab will be restarted as outlined above.",166
199,bevacizumab,"If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle or until progression is noted again per RANO, whichever is later, at which time pulsed bevacizumab will be restarted as outlined above.",213
199,bevacizumab,"In addition, the following will be performed: Bevacizumab will be given at 10mg/",46
200,maprotiline,The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.,75
200,temozolomide,The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.,132
200,tamoxifen,The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.,149
200,temozolomide,Temozolomide is approved to treat glioblastoma and the investigator wants to understand what doses are safe to use.,0
200,tamoxifen,Tamoxifen has been used for many years to treat breast cancer and there have also been studies combining it with temozolomide for the treatment of brain tumors that have shown the combination to be safe.,0
200,temozolomide,Tamoxifen has been used for many years to treat breast cancer and there have also been studies combining it with temozolomide for the treatment of brain tumors that have shown the combination to be safe.,113
200,maprotiline,"In this study, the investigator will be adding maprotiline to temozolomide and tamoxifen, determining the highest possible dose that is safe, making sure there are no significant drug interactions and studying the safety of this combination.",47
200,temozolomide,"In this study, the investigator will be adding maprotiline to temozolomide and tamoxifen, determining the highest possible dose that is safe, making sure there are no significant drug interactions and studying the safety of this combination.",62
200,tamoxifen,"In this study, the investigator will be adding maprotiline to temozolomide and tamoxifen, determining the highest possible dose that is safe, making sure there are no significant drug interactions and studying the safety of this combination.",79
203,lenalidomide,Lenalidomide is designed to change the body's immune system.,0
203,irinotecan," Irinotecan is designed to stop cancer cells from dividing by causing ""breaks"" in the tumor cell DNA (the genetic material of cells), which may cause the cancer cells to die.",1
203,lenalidomide,"For this phase, you will be enrolled in a group of at least 3 participants to begin receiving lenalidomide and irinotecan.",94
203,irinotecan,"For this phase, you will be enrolled in a group of at least 3 participants to begin receiving lenalidomide and irinotecan.",111
203,lenalidomide,You will take lenalidomide by mouth (capsules) every morning on Days 1-21 of each 28 day cycle.,14
203,lenalidomide,Swallow lenalidomide capsules whole with water at the same time each day.,8
203,lenalidomide,"In addition, you will also receive 1 additional dose of lenalidomide by mouth before the beginning of Cycle 1 (on Day 0 of Cycle 1).",56
203,lenalidomide,"If you miss a dose of lenalidomide, take it as soon as you remember on the same day.",22
203,lenalidomide,"If you take too much lenalidomide or overdose, call your study doctor or health care provider or poison control center right away.",21
203,irinotecan,You will receive irinotecan by vein over 90 minutes once every 2 weeks (on Days 1 and 15).,17
203,lenalidomide,"For this phase, you will take lenalidomide by mouth (capsules) every morning on Days 1-21.",30
203,lenalidomide,Swallow lenalidomide capsules whole with water at the same time each day.,8
203,lenalidomide,"If you miss a dose of lenalidomide, take it as soon as you remember on the same day.",22
203,lenalidomide,"If you take too much lenalidomide or overdose, call your study doctor or health care provider or poison control center right away.",21
203,irinotecan,You will receive irinotecan by vein over 90 minutes once every 2 weeks on Days 1 and 15.,17
203,lenalidomide,"For the subset, you will take lenalidomide (in the same manner as mentioned above), before surgery, for 3 days in a row with the last dose to be taken on the day of surgery.",30
203,lenalidomide,"Also, leftover tumor tissue (removed during your surgery) will be collected and used for testing to learn the effect of lenalidomide on your tumor tissue.",120
203,lenalidomide,"For all women who are able to have children: You will have a pregnancy test performed by your doctor within 10 - 14 days and 24 hours prior to starting lenalidomide therapy, even if you have not had any menses due to treatment of your disease or had as little as one menstrual period in the past 24 months.",152
203,lenalidomide,"If you have regular or no menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 28 days while taking lenalidomide, when you stop taking lenalidomide, then 28 days after you have stopped taking lenalidomide.",140
203,lenalidomide,"If you have regular or no menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 28 days while taking lenalidomide, when you stop taking lenalidomide, then 28 days after you have stopped taking lenalidomide.",175
203,lenalidomide,"If you have regular or no menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 28 days while taking lenalidomide, when you stop taking lenalidomide, then 28 days after you have stopped taking lenalidomide.",232
203,lenalidomide,"If you have irregular menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 14 days while taking lenalidomide, again when you have been taken off of lenalidomide therapy, and then 14 days and 28 days after you have stopped taking lenalidomide.  ",136
203,lenalidomide,"If you have irregular menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 14 days while taking lenalidomide, again when you have been taken off of lenalidomide therapy, and then 14 days and 28 days after you have stopped taking lenalidomide.  ",188
203,lenalidomide,"If you have irregular menstrual cycles, you will have pregnancy tests every week for the first 28 days, then every 14 days while taking lenalidomide, again when you have been taken off of lenalidomide therapy, and then 14 days and 28 days after you have stopped taking lenalidomide.  ",269
203,lenalidomide,Lenalidomide and irinotecan are FDA approved and commercially available for the treatment of some cancers.,0
203,irinotecan,Lenalidomide and irinotecan are FDA approved and commercially available for the treatment of some cancers.,17
204,vo,The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab.,55
204,lomustine,The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab.,68
204,bevacizumab,The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab.,94
206,mln0128,To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with advanced solid tumors including recurrent glioblastoma (GBM).,94
206,ink128,To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with advanced solid tumors including recurrent glioblastoma (GBM).,121
206,bevacizumab,To determine the maximum tolerated dose and recommended phase 2 dose (MTD/RP2D) of daily oral MLN0128 (TORC1/2 inhibitor INK128) when administered with bevacizumab in patients with advanced solid tumors including recurrent glioblastoma (GBM).,152
206,mln0128,To evaluate the overall safety and tolerability of the combination of MLN0128 and bevacizumab.,70
206,bevacizumab,To evaluate the overall safety and tolerability of the combination of MLN0128 and bevacizumab.,82
206,mln0128,"To assess the preliminary anti-tumor activity of the combination of MLN0128 and bevacizumab, as determined by response rate (RR), progression-free survival (PFS) and overall survival (OS).",68
206,bevacizumab,"To assess the preliminary anti-tumor activity of the combination of MLN0128 and bevacizumab, as determined by response rate (RR), progression-free survival (PFS) and overall survival (OS).",80
206,mln0128,"To assess tolerability throughout study therapy with MLN0128 and bevacizumab, including beyond the MTD interval with the following measures of cumulative treatment-related toxicities: frequency of toxicities leading to missed doses or delays; percentage of cycles given or not within 7 days of their scheduled times; percentage of actual planned dosage administration; percentage of patients that discontinue study drugs due to treatment related toxicity.",53
206,bevacizumab,"To assess tolerability throughout study therapy with MLN0128 and bevacizumab, including beyond the MTD interval with the following measures of cumulative treatment-related toxicities: frequency of toxicities leading to missed doses or delays; percentage of cycles given or not within 7 days of their scheduled times; percentage of actual planned dosage administration; percentage of patients that discontinue study drugs due to treatment related toxicity.",65
206,mln0128,To assess cerebrospinal fluid (CSF) penetration of MLN0128 in combination with bevacizumab in patients with recurrent GBM by evaluating the plasma and CSF concentrations of MLN0128 in the absence and presence of bevacizumab.,51
206,bevacizumab,To assess cerebrospinal fluid (CSF) penetration of MLN0128 in combination with bevacizumab in patients with recurrent GBM by evaluating the plasma and CSF concentrations of MLN0128 in the absence and presence of bevacizumab.,79
206,mln0128,To assess cerebrospinal fluid (CSF) penetration of MLN0128 in combination with bevacizumab in patients with recurrent GBM by evaluating the plasma and CSF concentrations of MLN0128 in the absence and presence of bevacizumab.,173
206,bevacizumab,To assess cerebrospinal fluid (CSF) penetration of MLN0128 in combination with bevacizumab in patients with recurrent GBM by evaluating the plasma and CSF concentrations of MLN0128 in the absence and presence of bevacizumab.,212
206,rapamycin,"To perform archival tumor analysis for markers of dysregulated cell signaling that may predict response to mechanistic target of rapamycin (mTOR) inhibitor therapy such as epidermal growth factor receptor (EGFR) (expression by immunohistochemistry [IHC] and amplification by fluorescent in situ hybridization [FISH]), phosphatase and tensin homolog (PTEN) (expression by IHC and deletion by FISH), phosphorylated (p)-protein kinase B (AKT), p-ribosomal protein S6 kinase (S6K), p-eukaryotic translation initiation factor 4E binding protein 1 (4EBP), p-mTOR and p-mitogen-activated protein kinase 1 (Erk) in patients with recurrent GBM.",129
206,mln0128,"[p70S6K], rS6) from tumor biopsies obtained at baseline and after treatment with MLN0128 from endometrial and ovarian cancer patients enrolled in stage 2.",81
206,mln0128,"To analyze circulating plasma levels of angiogenic growth factors before, during and after treatment with MLN0128 and bevacizumab V.",106
206,bevacizumab,"To analyze circulating plasma levels of angiogenic growth factors before, during and after treatment with MLN0128 and bevacizumab V.",118
206,"phosphatidylinositol-4,5-bisphosphate","To perform genetic mutation analysis and proteomic analysis of tissue from biopsies of endometrial and ovarian cancer patients including analysis of Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1) and PTEN.",254
206,mln0128,This is a dose-escalation study of MLN0128.  ,35
206,mln0128,Patients receive TORC1/2 inhibitor MLN0128 orally (PO) once daily (QD) and bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.,35
206,bevacizumab,Patients receive TORC1/2 inhibitor MLN0128 orally (PO) once daily (QD) and bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15.,75
208,tg6002,"All patients within a given cohort will be treated with the same dose schedule of TG6002, administered as 3 weekly IV infusions at Days 1, 8, and 15.",82
208,tg6002/5-fc,"Following the 1st and 2nd infusion of TG6002 on Day 1 and 8, patients will be given oral 5-FC for 3 days starting on Day 5 and 12 and ending on Day 7 and 14, respectively.",38
208,tg6002/5-fc,"Following the 3rd infusion of TG6002 on Day 15, patients will be given oral 5-FC for 21 days starting on Day 19 and ending on Day 39 (end of treatment).",30
208,tg,The maximum tolerated dose (MTD) is defined as the highest TG6002 dose level at which at most 1 Dose-Limiting Toxicity (DLT) is observed in 6 patients exposed to that dose level..,59
208,tg6002/5-fc,The DLT period is defined as the interval between the first TG6002 IV infusion (Day 1) and the 8th day of the 21-day 5-FC treatment occurring on Day 26.,60
208,tg6002/5-fc,The initiation of the next higher dose cohort will be determined following an analysis by the DSMB of the safety results from one cycle of TG6002 treatment in combination with 5-FC.  ,139
209,abemaciclib,Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations,55
209,bevacizumab,Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations,116
210,sunitinib,"Participants will take the study drug, sunitinib, for 7 days prior to their surgery.",39
210,sunitinib,"Fourteen days after the participants surgery (Day 22), they will restart sunitinib treatment.",73
211,nbi-3001,Cohorts of 6 patients receive escalating doses of NBI-3001 until the maximum tolerated dose is determined.,50
212,tmz,"Glioblastoma (GBM), the most frequent malignant primary brain tumor, has yet been incurable despite recent progress on its standard of care using TMZ as the main trunk of initial therapy in the newly diagnosed setting.",146
212,bevacizumab," Bevacizumab, a humanized monoclonal antibody against cardinal angiogenic factor vascular endothelial growth factor (VEGF), has recently shown efficacy for recurrent GBM, and has been approved in Japan, thereby being a standard care for recurrent GBM.",1
212,bevacizumab,"Since there is no effective drugs or regimens developed at bevacizumab failure, insertion of another active drug prior to bevacizumab induction would enhance survival time for patients with recurrent GBM.",59
212,bevacizumab,"Since there is no effective drugs or regimens developed at bevacizumab failure, insertion of another active drug prior to bevacizumab induction would enhance survival time for patients with recurrent GBM.",122
212,tmz,"Among them rechallenge with alternating dosing of TMZ have shown certain efficacy with acceptable toxicities for patients with TMZ-pretreated recurrent GBM, thus being a good candidate for the regimen used prior to bevacizumab at recurrence.",50
212,tmz,"Among them rechallenge with alternating dosing of TMZ have shown certain efficacy with acceptable toxicities for patients with TMZ-pretreated recurrent GBM, thus being a good candidate for the regimen used prior to bevacizumab at recurrence.",127
212,bevacizumab,"Among them rechallenge with alternating dosing of TMZ have shown certain efficacy with acceptable toxicities for patients with TMZ-pretreated recurrent GBM, thus being a good candidate for the regimen used prior to bevacizumab at recurrence.",215
212,tmz,The present proposal of sequential administration of dose dense TMZ (7/14d) followed by bevacizumab wishes to define a new standard of care for recurrent disease and hopes to identify the subgroups of patients with progressive or recurrent glioblastoma that respond particularly well to dose-dense temozolomide regimens.,64
212,bevacizumab,The present proposal of sequential administration of dose dense TMZ (7/14d) followed by bevacizumab wishes to define a new standard of care for recurrent disease and hopes to identify the subgroups of patients with progressive or recurrent glioblastoma that respond particularly well to dose-dense temozolomide regimens.,88
212,temozolomide,The present proposal of sequential administration of dose dense TMZ (7/14d) followed by bevacizumab wishes to define a new standard of care for recurrent disease and hopes to identify the subgroups of patients with progressive or recurrent glioblastoma that respond particularly well to dose-dense temozolomide regimens.,298
213,cilengitide,"This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).",104
213,emd121974,"This study will investigate clinical activity, safety, and tolerability of the anti-angiogenic compound cilengitide (EMD 121974) in the treatment of first recurrence of glioblastoma multiforme (GBM).",117
214,birabresib,A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure.,24
214,mk-8628,A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure.,36
214,otx015,A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure.,64
215,temozolomide,"Patients with GBM whose disease has recurred or progressed despite standard treatment (Surgery, radiation therapy, Temozolomide treatment) and meet all of the requirements for participation in the study will be included.",115
215,bpc,"Before receiving TTFields treatment, the patient can receive surgery again, and TTFields+BPC chemotherapy can be used after surgery; TTFields+BPC chemotherapy can also be used directly without surgery.  ",89
215,bpc,"Before receiving TTFields treatment, the patient can receive surgery again, and TTFields+BPC chemotherapy can be used after surgery; TTFields+BPC chemotherapy can also be used directly without surgery.  ",142
216,berubicin,Berubicin is one of the first anthracyclines that crosses the blood brain barrier and overcomes drug resistance (i.e. it is not a substrate for multi-drug resistant/breast cancer resistant transporters).,0
216,anthracyclines,Berubicin is one of the first anthracyclines that crosses the blood brain barrier and overcomes drug resistance (i.e. it is not a substrate for multi-drug resistant/breast cancer resistant transporters).,30
216,berubicin,A Phase 1 clinical trial of berubicin in patients with primary CNS malignancies demonstrated a durable response (one subject alive 13+ years) as well as stable disease in heavily pretreated patients.,28
216,berubicin,"Therefore, this phase 2 study is designed to further evaluate Berubicin's activity in patients with rGBM after treatment with standard of care.",62
217,methyl-guanine,The attempt to obtain the Methyl-guanine methyl-transferase (MGMT) gene promoter methylation and IDH1 and IDH2 mutation from primary tumor are made during the study whenever not defined before entering to the study.,26
217,methyl,The attempt to obtain the Methyl-guanine methyl-transferase (MGMT) gene promoter methylation and IDH1 and IDH2 mutation from primary tumor are made during the study whenever not defined before entering to the study.,41
218,tr05,To establish a maximum tolerated dose (MTD) of TRC105 (anti-endoglin monoclonal antibody TRC105) combined with bevacizumab in this patient population.,47
218,tr,To establish a maximum tolerated dose (MTD) of TRC105 (anti-endoglin monoclonal antibody TRC105) combined with bevacizumab in this patient population.,89
218,bevacizumab,To establish a maximum tolerated dose (MTD) of TRC105 (anti-endoglin monoclonal antibody TRC105) combined with bevacizumab in this patient population.,111
218,trc105,To assess the safety and adverse events of TRC105 in combination with bevacizumab in this patient population.,43
218,bevacizumab,To assess the safety and adverse events of TRC105 in combination with bevacizumab in this patient population.,70
218,trc105,To determine the efficacy of TRC105 in combination with bevacizumab in recurrent glioblastoma as measured by progression-free survival and compare it with the efficacy of bevacizumab alone in this patient population.,29
218,bevacizumab,To determine the efficacy of TRC105 in combination with bevacizumab in recurrent glioblastoma as measured by progression-free survival and compare it with the efficacy of bevacizumab alone in this patient population.,56
218,bevacizumab,To determine the efficacy of TRC105 in combination with bevacizumab in recurrent glioblastoma as measured by progression-free survival and compare it with the efficacy of bevacizumab alone in this patient population.,171
218,bevacizumab,"To assess the proportion of patients, who are progression free at 6 months, treated with TRC105 in combination with bevacizumab as compared to bevacizumab alone.",116
218,bevacizumab,"To assess the proportion of patients, who are progression free at 6 months, treated with TRC105 in combination with bevacizumab as compared to bevacizumab alone.",143
218,trc105,To assess the overall survival of patients treated with TRC105 in combination with bevacizumab compared to bevacizumab alone.,56
218,bevacizumab,To assess the overall survival of patients treated with TRC105 in combination with bevacizumab compared to bevacizumab alone.,83
218,bevacizumab,To assess the overall survival of patients treated with TRC105 in combination with bevacizumab compared to bevacizumab alone.,107
218,trc105,To evaluate the pharmacokinetics of TRC105.,36
218,bevacizumab,To assess the utility of dynamic contrast enhanced (DCE) MRI as a predictor of response to bevacizumab with or without TRC105.,91
218,tr,To assess the utility of dynamic contrast enhanced (DCE) MRI as a predictor of response to bevacizumab with or without TRC105.,119
218,bevacizumab,Phase I (closed to accrual 1/14/14): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses.,54
218,tr,Phase I (closed to accrual 1/14/14): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses.,151
218,bevacizumab,Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody,17
218,bevacizumab,Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.,17
219,axitinib,"Patients randomized to the Axitinib treatment-arm will be treated with Axitinib until progression (they can be treated after progression in the Axitinib plus lomustine arm), unacceptable treatment related toxicity, or patients refusal to continue study treatment.",27
219,axitinib,"Patients randomized to the Axitinib treatment-arm will be treated with Axitinib until progression (they can be treated after progression in the Axitinib plus lomustine arm), unacceptable treatment related toxicity, or patients refusal to continue study treatment.",71
219,axitinib,"Patients randomized to the Axitinib treatment-arm will be treated with Axitinib until progression (they can be treated after progression in the Axitinib plus lomustine arm), unacceptable treatment related toxicity, or patients refusal to continue study treatment.",144
219,lomustine,"Patients randomized to the Axitinib treatment-arm will be treated with Axitinib until progression (they can be treated after progression in the Axitinib plus lomustine arm), unacceptable treatment related toxicity, or patients refusal to continue study treatment.",158
219,axitinib,"Patients randomized to the Axitinib plus Lomustine-arm will receive treatment until progression, unacceptable treatment related toxicity, or patients refusal to continue study treatment.",27
219,lomustine,"Patients randomized to the Axitinib plus Lomustine-arm will receive treatment until progression, unacceptable treatment related toxicity, or patients refusal to continue study treatment.",41
220,temozolomide,The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.,75
220,semustine,The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.,100
222,usl311,"This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2).",109
222,lomustine,"This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2).",147
222,usl311,"The study is designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of USL311 alone and in combination with lomustine.",105
222,lomustine,"The study is designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of USL311 alone and in combination with lomustine.",142
223,can008,"This is a multi-center, randomized, controlled clinical trial to evaluate the efficacy and safety of CAN008 administered once-weekly with re-radiation therapy (rRT) in patients with an initial relapse of GBM.",101
223,can008,The subjects will be randomized into the treatment group (CAN008 + rRT) or the control group (rRT).,58
223,tmz,"The subjects must have received standard care, including combination of radiotherapy and TMZ after surgical resection, and must be candidates for re-radiation therapy (rRT).",89
224,bevacizumab,"Recently, bevacizumab was approved for recurrent GBM patients who fail bevacizumab indicate a short survival, on the order of 10 weeks, an approximate PFS 3 and 6 months of 0%.",10
224,bevacizumab,"Recently, bevacizumab was approved for recurrent GBM patients who fail bevacizumab indicate a short survival, on the order of 10 weeks, an approximate PFS 3 and 6 months of 0%.",71
224,pazopanib,"Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor (VEGFR), Platelet-derived growth factor receptors (PDGFR), and c-Kit, and was recently Food and Drug Administration (FDA) approved for advanced renal cell carcinoma.",0
224,topotecan,Topotecan is an orally bioavailable topoisomerase I and Hypoxia-inducible factor 1 (HIF-1) alpha inhibitor with reasonably high central nervous system (CNS)/cerebrospinal fluid (CSF) penetration Recent pre-clinical reports have begun to argue for the clinical testing of metronomic chemotherapy administration in various cancers.,0
224,pazopanib,"The theory of improved activity of Pazopanib + Topotecan administered metronomically is based on targeting tumor vasculature (both existing capillary endothelial cells and circulating bone marrow derived endothelial cell precursors), immune modulation, as well as tumor cell HIF-1 alpha inhibition, and the induction of Deoxyribonucleic acid (DNA) damage.",35
224,topotecan,"The theory of improved activity of Pazopanib + Topotecan administered metronomically is based on targeting tumor vasculature (both existing capillary endothelial cells and circulating bone marrow derived endothelial cell precursors), immune modulation, as well as tumor cell HIF-1 alpha inhibition, and the induction of Deoxyribonucleic acid (DNA) damage.",47
224,pazopanib,Further support for the combination comes from recent data tying drug-induced VEGF inhibition to the induction of HIF-1 alpha activity in GBM suggesting possible synergy between Pazopanib and Topotecan The combination of Topotecan and Pazopanib has been directly demonstrated as active in  animal models  ,178
224,topotecan,Further support for the combination comes from recent data tying drug-induced VEGF inhibition to the induction of HIF-1 alpha activity in GBM suggesting possible synergy between Pazopanib and Topotecan The combination of Topotecan and Pazopanib has been directly demonstrated as active in  animal models  ,192
224,topotecan,Further support for the combination comes from recent data tying drug-induced VEGF inhibition to the induction of HIF-1 alpha activity in GBM suggesting possible synergy between Pazopanib and Topotecan The combination of Topotecan and Pazopanib has been directly demonstrated as active in  animal models  ,221
224,pazopanib,Further support for the combination comes from recent data tying drug-induced VEGF inhibition to the induction of HIF-1 alpha activity in GBM suggesting possible synergy between Pazopanib and Topotecan The combination of Topotecan and Pazopanib has been directly demonstrated as active in  animal models  ,235
224,bevacizumab,Objectives  6 month progression free survival rate for recurrent glioblastoma (rGBM) patients with no prior bevacizumab exposure treated with pazopanib and topotecan (Group A).,108
224,pazopanib,Objectives  6 month progression free survival rate for recurrent glioblastoma (rGBM) patients with no prior bevacizumab exposure treated with pazopanib and topotecan (Group A).,142
224,topotecan,Objectives  6 month progression free survival rate for recurrent glioblastoma (rGBM) patients with no prior bevacizumab exposure treated with pazopanib and topotecan (Group A).,156
224,bevacizumab,3 month progression free survival rate for rGBM patients with prior bevacizumab exposure treated with pazopanib and topotecan (Group B).,68
224,pazopanib,3 month progression free survival rate for rGBM patients with prior bevacizumab exposure treated with pazopanib and topotecan (Group B).,102
224,topotecan,3 month progression free survival rate for rGBM patients with prior bevacizumab exposure treated with pazopanib and topotecan (Group B).,116
224,temozolomide,"Patient must have failed prior chemoradiation with temozolomide and any other therapies except Bevacizumab (BEV) (group A), or must have failed primary chemoradiation and a BEVincorporating treatment (group B).",51
224,bevacizumab,"Patient must have failed prior chemoradiation with temozolomide and any other therapies except Bevacizumab (BEV) (group A), or must have failed primary chemoradiation and a BEVincorporating treatment (group B).",95
224,bev,"Patient must have failed prior chemoradiation with temozolomide and any other therapies except Bevacizumab (BEV) (group A), or must have failed primary chemoradiation and a BEVincorporating treatment (group B).",108
224,be,"Patient must have failed prior chemoradiation with temozolomide and any other therapies except Bevacizumab (BEV) (group A), or must have failed primary chemoradiation and a BEVincorporating treatment (group B).",173
224,pazopanib,No known hypersensitivity to pazopanib or topotecan or to their excipients.,29
224,topotecan,No known hypersensitivity to pazopanib or topotecan or to their excipients.,42
224,dexamethasone,No total daily dose of dexamethasone greater than 16 mg/day.,23
224,topotecan,"No prior therapy with topotecan, pazopanib, or related drugs such as tyrosine kinase inhibitors, VEGF inhibitors (except bevacizumab).",22
224,pazopanib,"No prior therapy with topotecan, pazopanib, or related drugs such as tyrosine kinase inhibitors, VEGF inhibitors (except bevacizumab).",33
224,tyrosine,"No prior therapy with topotecan, pazopanib, or related drugs such as tyrosine kinase inhibitors, VEGF inhibitors (except bevacizumab).",69
224,tyrosine,"Prior treatment with Tyrosine kinase inhibitors (TKIs) that do not impact VEGFR -1, -2, or -3, Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Platelet Derived Growth Factor Receptor Beta (-b) of cKIT could be allowed.",21
224,topotecan,This is a 2 arm phase II trial of the combination of topotecan and pazopanib in patients with recurrent GBM or GS.,53
224,pazopanib,This is a 2 arm phase II trial of the combination of topotecan and pazopanib in patients with recurrent GBM or GS.,67
224,bevacizumab,Patients will be enrolled into one of the following groups: (A) Glioblastoma or gliosarcoma with no prior bevacizumab exposure: (B) Glioblastoma or  gliosarcoma with prior bevacizumab exposure.,106
224,bevacizumab,Patients will be enrolled into one of the following groups: (A) Glioblastoma or gliosarcoma with no prior bevacizumab exposure: (B) Glioblastoma or  gliosarcoma with prior bevacizumab exposure.,172
224,topotecan,Topotecan and pazopanib are administered orally daily.,0
224,pazopanib,Topotecan and pazopanib are administered orally daily.,14
224,bevacizumab,The primary efficacy endpoint is progression free survival (PFS) at six months from patient registration for bevacizumab na(SqrRoot) ve patients and progression free survival (PFS) at 3 months for patients with prior bevacizumab treatment.,109
224,bevacizumab,The primary efficacy endpoint is progression free survival (PFS) at six months from patient registration for bevacizumab na(SqrRoot) ve patients and progression free survival (PFS) at 3 months for patients with prior bevacizumab treatment.,217
225,krt-232,PRIMARY OBJECTIVES:  I. Determine the concentration and variability in concentration of MDM2 inhibitor KRT-232 (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM).,103
225,amg232,PRIMARY OBJECTIVES:  I. Determine the concentration and variability in concentration of MDM2 inhibitor KRT-232 (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM).,112
225,krt232,PRIMARY OBJECTIVES:  I. Determine the concentration and variability in concentration of MDM2 inhibitor KRT-232 (AMG 232 [KRT 232]) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM).,121
225,amg232,Determine the maximum tolerated dose (MTD) of AMG 232 (KRT 232) given in combination with standard radiation following surgery for patients with newly diagnosed GBM harboring unmethylated MGMT promoters and wild-type TP53.,46
225,krt232,Determine the maximum tolerated dose (MTD) of AMG 232 (KRT 232) given in combination with standard radiation following surgery for patients with newly diagnosed GBM harboring unmethylated MGMT promoters and wild-type TP53.,55
225,amg232,SECONDARY OBJECTIVES:  I. Determine the safety and toxicity of AMG 232 (KRT 232) in patients with recurrent GBM.,63
225,krt232,SECONDARY OBJECTIVES:  I. Determine the safety and toxicity of AMG 232 (KRT 232) in patients with recurrent GBM.,72
225,amg232,Assess the variability of AMG 232 (KRT 232) concentration in tumor enhancing versus (vs.) infiltrative tissue.,26
225,krt232,Assess the variability of AMG 232 (KRT 232) concentration in tumor enhancing versus (vs.) infiltrative tissue.,35
225,amg232,Assess the pharmacodynamic effect of AMG 232 (KRT 232) on p21 elevation.,37
225,krt232,Assess the pharmacodynamic effect of AMG 232 (KRT 232) on p21 elevation.,46
225,amg232,Determine the safety of AMG 232 (KRT 232) given concurrently with radiation therapy (RT) and adjuvantly as monotherapy for patients with newly diagnosed GBM harboring unmethylated MGMT promoters and wild-type TP53.,24
225,krt232,Determine the safety of AMG 232 (KRT 232) given concurrently with radiation therapy (RT) and adjuvantly as monotherapy for patients with newly diagnosed GBM harboring unmethylated MGMT promoters and wild-type TP53.,33
225,amg232,AMG 232 (KRT 232) exposure and correlations with pharmacodynamic (PD) effect on p21 elevation.,0
225,krt232,AMG 232 (KRT 232) exposure and correlations with pharmacodynamic (PD) effect on p21 elevation.,9
225,krt-232,"This is a phase 0, intratumoral pharmacokinetic (PK)/PD study of MDM2 inhibitor KRT-232 followed by a phase I dose-escalation study.",80
225,amg232,Patients with recurrent glioblastoma receive MDM2 inhibitor AMG 232,60
225,krt-232,(KRT-232) orally (PO) once daily (QD) for 2 days.,1
225,amg232,"Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7.",103
225,krt-232,"Upon recovery (within 45 days), patients with TP53 wild-type tumors continue to receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7.",112
225,amg232,"Patients also receive MDM2 inhibitor AMG 232 (KRT-232) PO 3 times weekly on days 2, 3, and 5 for 6 weeks or 2 times weekly on days 2 and 4 for 6 weeks during radiation therapy.",37
225,krt-232,"Patients also receive MDM2 inhibitor AMG 232 (KRT-232) PO 3 times weekly on days 2, 3, and 5 for 6 weeks or 2 times weekly on days 2 and 4 for 6 weeks during radiation therapy.",46
225,amg232,Patients receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7.,32
225,krt-232/5-ala,Patients receive MDM2 inhibitor AMG 232 (KRT-232) PO QD on days 1-7.,41
227,nivolumab,I. To examine and describe the safety and feasibility of nivolumab plus ipilimumab as neoadjuvant therapy.,57
227,ipilimumab,I. To examine and describe the safety and feasibility of nivolumab plus ipilimumab as neoadjuvant therapy.,72
227,nivolumab,To examine and describe the safety and feasibility of IL13Ralpha2-CAR T cell plus nivolumab as adjuvant therapy.,82
227,nivolumab,Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14.,17
227,ipilimumab,Patients receive nivolumab intravenously (IV) over 60 minutes and ipilimumab IV over 90 minutes on day -14.,66
227,nivolumab,Patients then receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (intracranial intraventricular [ICV]/intracranital intratumoral [ICT]) every week and nivolumab IV over 30 minutes every other week.,177
227,nivolumab,"After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.",70
227,nivolumab,Patients receive IL13Ralpha2 CAR T cells infusion over 5 minutes via Rickham catheter (ICV/ICT) every week and nivolumab IV over 30 minutes every other week.,111
227,nivolumab,"After cycle 4, patients may receive additional CAR T cells weekly and nivolumab IV every other week or monthly at the discretion of the principal investigator and oncologist.",70
228,[18f]fet,"For glioblastoma (GBM) patients it has been proven that a [18F]FET-PET scan is very helpful especially in target volume definition and after the treatment, in turn, the combination of MRI and [18F]FET-PET is diagnostically most useful to distinguish between radiation necrosis and a real progressive disease.  ",58
228,[18f]fet,"For glioblastoma (GBM) patients it has been proven that a [18F]FET-PET scan is very helpful especially in target volume definition and after the treatment, in turn, the combination of MRI and [18F]FET-PET is diagnostically most useful to distinguish between radiation necrosis and a real progressive disease.  ",192
228,[18f]fet,Kinetic and static [18F]FET-PET scans are useful to supplement this modality and its own prognostic value concerning relapsing patients will be examined.  ,19
228,[18f]fet," Secondary methodological issues are dealt with, such as the relationship between contrast uptake, perfusion and [18F]FET uptake.",113
230,aminoacid,"The PET radiotracer FET provides a measure of large, neutral amino acid transport.",61
230,fdg,"FET labels low-grade as well as high-grade gliomas, in contrast to FDG, which almost exclusively labels only high-grade gliomas.",67
230,fdg,"FET imaging may prove to be particularly useful in the setting of infiltrative tumor, which is not contrast-enhancing on MRI and therefore not detectable with FDG.",159
230,steroids,"The former is managed with steroids and the latter is managed with chemotherapy, and anti-angiogenic drugs.",27
233,nivolumab,This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.,42
233,bevacizumab,This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.,77
234,tmz,"HU has been used to treat hematological diseases and solid tumors (such as melanoma, ovarian, squamous cell carcinoma, head and neck carcinoma and brain tumors) in combination with other anti-cancer agents, but never with TMZ.",222
234,tmz,"If found safe, HU+TMZ, is easily translated to the clinic.",18
234,temozolomide,I trial to identify the maximum tolerated dose (MTD) for the combination of dose intense temozolomide (TMZ) and hydroxy-urea (HU) in (maximal) thirty patients with recurrent glioblastoma (rGBM).,89
234,tmz,I trial to identify the maximum tolerated dose (MTD) for the combination of dose intense temozolomide (TMZ) and hydroxy-urea (HU) in (maximal) thirty patients with recurrent glioblastoma (rGBM).,103
234,hydroxy-urea,I trial to identify the maximum tolerated dose (MTD) for the combination of dose intense temozolomide (TMZ) and hydroxy-urea (HU) in (maximal) thirty patients with recurrent glioblastoma (rGBM).,112
234,tmz," Possible results:  Obtaining MTD and safety profile of daily HU+TMZ in patients with rGBM; Preliminary data on the estimation of the median progression-free (PFS) and overall survival (OS), radiographic response proportion in patients with measurable disease, and exploratory correlation of treatment outcomes (PFS and OS) with o6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in archival tumor specimens and further elucidation of underlying mechanism of re-sensitization of TMZ by HU.",65
234,o6-methylguanine," Possible results:  Obtaining MTD and safety profile of daily HU+TMZ in patients with rGBM; Preliminary data on the estimation of the median progression-free (PFS) and overall survival (OS), radiographic response proportion in patients with measurable disease, and exploratory correlation of treatment outcomes (PFS and OS) with o6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in archival tumor specimens and further elucidation of underlying mechanism of re-sensitization of TMZ by HU.",329
234,tmz," Possible results:  Obtaining MTD and safety profile of daily HU+TMZ in patients with rGBM; Preliminary data on the estimation of the median progression-free (PFS) and overall survival (OS), radiographic response proportion in patients with measurable disease, and exploratory correlation of treatment outcomes (PFS and OS) with o6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in archival tumor specimens and further elucidation of underlying mechanism of re-sensitization of TMZ by HU.",502
234,tmz,Exploratory analysis of biomarkers profile of platelets in patients treated with HU+TMZ.,84
236,abemaciclib,"In laboratory studies, abemaciclib was able to enter the brain, stop CDK 4 and CDK 6 from making cells, and slow growth of glioblastoma in mice.",23
236,mk-3475, Pembrolizumab (MK-3475) has been studied in lab experiments and in other types of cancer.,16
236,mk-3475,Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial inrecurrent glioblastoma (GBM).,60
236,mk-3475,Pembrolizumab (MK-3475) is a humanized monoclonal antibody.,15
239,erlotinibhydrochloride,Determine the objective response rate in patients with recurrent epidermal growth factor receptor (EGFR)-positive and PTEN wild-type glioblastoma multiforme or gliosarcoma treated with erlotinib hydrochloride.,185
239,erlotinibhydrochloride,Patients receive oral erlotinib hydrochloride once daily on days 1-28.,22
239,erlotinibhydrochloride,Some patients may receive additional erlotinib hydrochloride after 1 year at their physician's discretion.,37
241,valacyclovir,This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy in recurrent glioblastoma multiforme or anaplastic astrocytoma.,87
242,lapatinib,Determine the maximum tolerated dose and recommended phase II dose of lapatinib in patients with recurrent malignant glioblastoma multiforme who are taking CYP3A4 enzyme-inducing anti-epileptic drugs (EIAEDs).,70
242,lapatinib,Phase I: Patients receive oral lapatinib twice daily on days 1-28.,31
242,lapatinib,Cohorts of 3-6 patients receive escalating doses of lapatinib until the maximum tolerated dose (MTD) is determined.,52
242,lapatinib,Patients receive lapatinib as in phase I at the MTD.,17
243,bevacizumab,To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma,37
243,irinotecan,To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma,54
246,acridinecarboxzmide,OBJECTIVES: I. Determine the efficacy acridine carboxzmide in terms of objective response rate and response duration in patients with glioblastoma multiforme.,38
246,acridinecarboxamide,Patients receive acridine carboxamide IV continuously over days 1-5.,17
248,temozolomide,To define the maximum-tolerated dose of the combination of temozolomide and veliparib in patients with recurrent glioblastoma previously or not treated with temozolomide.,59
248,veliparib,To define the maximum-tolerated dose of the combination of temozolomide and veliparib in patients with recurrent glioblastoma previously or not treated with temozolomide.,76
248,temozolomide,To define the maximum-tolerated dose of the combination of temozolomide and veliparib in patients with recurrent glioblastoma previously or not treated with temozolomide.,157
248,temozolomide,To determine the efficacy of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) as measured by the 6-month progression-free survival rate in patients with recurrent glioblastoma previously treated with temozolomide.,48
248,veliparib,To determine the efficacy of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) as measured by the 6-month progression-free survival rate in patients with recurrent glioblastoma previously treated with temozolomide.,65
248,temozolomide,To determine the efficacy of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) as measured by the 6-month progression-free survival rate in patients with recurrent glioblastoma previously treated with temozolomide.,232
248,temozolomide,To characterize the safety profile of the combination of temozolomide and veliparib.,57
248,veliparib,To characterize the safety profile of the combination of temozolomide and veliparib.,74
248,temozolomide,To determine the adverse event profile and tolerability of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) in patients with recurrent glioblastoma.,78
248,veliparib,To determine the adverse event profile and tolerability of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) in patients with recurrent glioblastoma.,95
248,temozolomide,To determine the efficacy of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) as measured by objective response in patients with measurable disease.,48
248,veliparib,To determine the efficacy of the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule) as measured by objective response in patients with measurable disease.,65
248,temozolomide,To determine the overall survival of patients treated with the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule).,78
248,veliparib,To determine the overall survival of patients treated with the combination of temozolomide and veliparib (using a 5-day vs 21-day schedule).,95
248,bevacizumab,"Patients enrolled in the phase II portion are stratified according to bevacizumab (BEV) status (bevacizumab-naive vs bevacizumab-failure), age (< 50 years vs ≥ 50 years), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs no/biopsy only).",70
248,be,"Patients enrolled in the phase II portion are stratified according to bevacizumab (BEV) status (bevacizumab-naive vs bevacizumab-failure), age (< 50 years vs ≥ 50 years), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs no/biopsy only).",83
248,bevacizumab,"Patients enrolled in the phase II portion are stratified according to bevacizumab (BEV) status (bevacizumab-naive vs bevacizumab-failure), age (< 50 years vs ≥ 50 years), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs no/biopsy only).",96
248,bevacizumab,"Patients enrolled in the phase II portion are stratified according to bevacizumab (BEV) status (bevacizumab-naive vs bevacizumab-failure), age (< 50 years vs ≥ 50 years), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs no/biopsy only).",117
248,temozolomide,Patients receive oral temozolomide once daily and oral veliparib twice daily on days 1-21.,22
248,veliparib,Patients receive oral temozolomide once daily and oral veliparib twice daily on days 1-21.,55
248,temozolomide,Patients receive temozolomide and veliparib as in phase I. Arm II:,17
248,veliparib,Patients receive temozolomide and veliparib as in phase I. Arm II:,34
248,temozolomide,Patients receive oral temozolomide once daily and oral veliparib twice daily on days 1-5.,22
248,veliparib,Patients receive oral temozolomide once daily and oral veliparib twice daily on days 1-5.,55
249,mk-3475,Pembrolizumab (MK-3475) is a humanized monoclonal antibody.,15
249,mk-3475,Pembrolizumab (MK-3475) has been studied in lab experiments and in other types of cancer.,15
249,mk-3475,Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in your type of cancer.,60
249,bevacizumab,"Bevacizumab, also known as Avastin, is approved by the FDA for treating recurrent GBM.",0
249,bevacizumab,"Bevacizumab is an anti-angiogenic medicine, which means it blocks blood vessels from forming that could supply the tumor with nutrients and oxygen.",0
249,oxygen,"Bevacizumab is an anti-angiogenic medicine, which means it blocks blood vessels from forming that could supply the tumor with nutrients and oxygen.",140
249,bevacizumab,There is a safety lead-in to evaluate pembrolizumab in combination of with bevacizumab (cohort A) expected to enroll up to 18 participants.,75
250,dnx2401,DNX2401 will be injected after stereotactic biopsy reveals intraoperative pathology confirming the presence of recurrent glioblastoma.,0
251,vb-111,"In this research study, ofranergene obadenovec (VB-111) is the investigational drug being studied.",48
251,vb-111,"VB-111 has been studied in lab experiments and in other types of cancer, and information from these studies suggest that it may be beneficial for recurrent or progressive glioblastoma.",0
251,vb-111, VB-111 works by targeting and damaging the blood vessels that grow and nourish cancerous tumors leading to tumor starvation.,1
251,vb-111,In group A participants receive VB-111 before and after surgery.,32
251,vb-111,In group B participants receive VB-111 after surgery.,32
251,vb-111,In group C participants won't receive VB-111 but would receive standard of care.,38
251,vb-111,Participants will be given a study medication and it will contain either VB-111 or placebo (IV solution with no medicine).,73
251,vbl, VBL Therapeutics is supporting this research study by providing funding for the research study and the study drug.,1
252,temozolomide,Determine the progression-free survival rate at 6 months in patients with recurrent glioblastoma multiforme or other malignant glioma treated with temozolomide.,147
252,temozolomide,Patients receive oral temozolomide once daily in the absence of disease progression or unacceptable toxicity.,22
254,iodinei131,Determine the maximum tolerated dose of iodine I 131 monoclonal antibody TNT-1/B in patients with progressive or recurrent glioblastoma multiforme.,40
254,iodinei131,"This is an open-label, multicenter, dose-escalation study of therapeutic doses of iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B).",82
255,bevacizumab,"Bevacizumab, an inhibitor of angiogenesis, has been shown to be effective in improving progression-free survival as a single agent.",0
255,bevacizumab,"Thus PSMA ADC, which targets tumor angiogenesis by a mechanism different from that of bevacizumab, may be a novel therapeutic modality for GBM.",86
255,temozolomide,"A phase 2 study of PSMA ADC is proposed for patients with GBM that have progressed after standard treatment that includes radiation, temozolomide and bevacizumab.",133
255,bevacizumab,"A phase 2 study of PSMA ADC is proposed for patients with GBM that have progressed after standard treatment that includes radiation, temozolomide and bevacizumab.",150
255,bevacizumab,Treatment after bevacizumab failure for patients with GBM is a major unmet medical need.,16
256,gadolinium-diethylenetriaminepentaaceticacid,Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (at a starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66 ml over up to 4-6 days at the discretion of the investigator.,138
256,gd-dtpa,Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (at a starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66 ml over up to 4-6 days at the discretion of the investigator.,186
256,gd-dtpa,Gd-DTPA will be co-infused with hrBMP4 to determine the extent of intra-tumour and interstitial drug delivery.,0
257,cc-90010,"CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).",0
257,cc-90010,"CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).",135
258,aflibercept,To define the maximum tolerated dose (MTD) of aflibercept (VEGF Trap) with radiotherapy (RT) and concurrent temozolomide (TMZ) when administered in patients with newly-diagnosed glioblastoma (GBM) or gliosarcoma.,46
258,temozolomide,To define the maximum tolerated dose (MTD) of aflibercept (VEGF Trap) with radiotherapy (RT) and concurrent temozolomide (TMZ) when administered in patients with newly-diagnosed glioblastoma (GBM) or gliosarcoma.,108
258,tmz,To define the maximum tolerated dose (MTD) of aflibercept (VEGF Trap) with radiotherapy (RT) and concurrent temozolomide (TMZ) when administered in patients with newly-diagnosed glioblastoma (GBM) or gliosarcoma.,122
258,aflibercept,To define the MTD of aflibercept with adjuvant TMZ administered at 150mg/m2once daily for 5 days every 28 days in patients with stable or recurrent malignant glioma (MG) after RT.,21
258,tmz,To define the MTD of aflibercept with adjuvant TMZ administered at 150mg/m2once daily for 5 days every 28 days in patients with stable or recurrent malignant glioma (MG) after RT.,47
258,aflibercept,To define the MTD of aflibercept with adjuvant TMZ administered at 100 mg/m2 once daily for 21 days every 28 days in patients with stable or recurrent MG after RT.  IV.,21
258,tmz,To define the MTD of aflibercept with adjuvant TMZ administered at 100 mg/m2 once daily for 21 days every 28 days in patients with stable or recurrent MG after RT.  IV.,47
258,aflibercept,To characterize the safety profile of aflibercept in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.,38
258,tmz,To characterize the safety profile of aflibercept in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.,89
258,aflibercept,To characterize the safety profile of aflibercept in combination with adjuvant TMZ in patients with stable or recurrent MG after RT.,38
258,tmz,To characterize the safety profile of aflibercept in combination with adjuvant TMZ in patients with stable or recurrent MG after RT.,79
258,aflibercept,To characterize the pharmacokinetic profiles of free and bound aflibercept and TMZ in these patients  ,63
258,tmz,To characterize the pharmacokinetic profiles of free and bound aflibercept and TMZ in these patients  ,79
258,aflibercept,"This is a multicenter, dose-escalation study of aflibercept.",48
258,temozolomide,"Group 1 (newly diagnosed glioblastoma multiforme or gliosarcoma): Patients undergo involved field partial brain radiotherapy (RT) once daily, 5 days a week (total of 30 fractions) and receive concurrent oral temozolomide (TMZ) once daily for 6 weeks.",208
258,tmz,"Group 1 (newly diagnosed glioblastoma multiforme or gliosarcoma): Patients undergo involved field partial brain radiotherapy (RT) once daily, 5 days a week (total of 30 fractions) and receive concurrent oral temozolomide (TMZ) once daily for 6 weeks.",222
258,aflibercept,Beginning 2 weeks after the initiation of RT patients also receive aflibercept IV over 1 hour on days 1 and 15 and continue until the end of RT.,67
258,tmz,"Beginning 4 weeks after completion of radiotherapy, patients receive adjuvant oral TMZ once daily on days 1-5.",83
258,tmz,Treatment with adjuvant TMZ repeats every 28 days for up to 12 courses.,24
258,tmz,Patients receive oral TMZ on days 1-5.,22
258,aflibercept,Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day of TMZ treatment.,22
258,tmz,Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day of TMZ treatment.,96
258,tmz,[Note: *The 12 course maximum includes adjuvant TMZ courses administered prior to enrollment.],48
258,tmz,Patients receive oral TMZ on days 1-5.,22
258,aflibercept,Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day of TMZ treatment.,22
258,tmz,Patients also receive aflibercept IV over 1 hour on days 1 and 15 beginning on the first day of TMZ treatment.,96
258,tmz/131i-ipa,[Note: *The 12 course maximum includes adjuvant TMZ courses administered prior to enrollment.]  ,48
259,18f-fet,Gross tumour volume will be determined using contrast-enhanced MRI and amino acid-based PET imaging (18F-FET or 11C-methionine).,101
259,11c-methionine,Gross tumour volume will be determined using contrast-enhanced MRI and amino acid-based PET imaging (18F-FET or 11C-methionine).,112
259,temozolomide,"History of GBM standard therapy (debulking surgery, followed by radio-chemotherapy (50-60 Gy in 2 Gy fractions, temozolomide)",112
259,aminoacid,"Interval since end of 1st line XRT ≥6 months Amino acid-based molecular imaging (preferably 18F-FET- PETor 11C-methionine, as institutionally established) indicating pathologically increased amino acid uptake inside or in the vicinity of the tumour, clearly discernible from background activity.",45
259,18f-fet,"Interval since end of 1st line XRT ≥6 months Amino acid-based molecular imaging (preferably 18F-FET- PETor 11C-methionine, as institutionally established) indicating pathologically increased amino acid uptake inside or in the vicinity of the tumour, clearly discernible from background activity.",92
259,11c-methionine,"Interval since end of 1st line XRT ≥6 months Amino acid-based molecular imaging (preferably 18F-FET- PETor 11C-methionine, as institutionally established) indicating pathologically increased amino acid uptake inside or in the vicinity of the tumour, clearly discernible from background activity.",107
259,aminoacid,"Interval since end of 1st line XRT ≥6 months Amino acid-based molecular imaging (preferably 18F-FET- PETor 11C-methionine, as institutionally established) indicating pathologically increased amino acid uptake inside or in the vicinity of the tumour, clearly discernible from background activity.",191
259,bilirubin,Bilirubin ≤3 times UILN Serum creatinine: within normal limits or <120 μmol/L for patients aged 60 years or older Urine protein dipstick: no protein Female patients surgically sterile or postmenopausal for at least 2 years.,0
259,creatinine,Bilirubin ≤3 times UILN Serum creatinine: within normal limits or <120 μmol/L for patients aged 60 years or older Urine protein dipstick: no protein Female patients surgically sterile or postmenopausal for at least 2 years.,30
259,xr,"A patient will be excluded from participation in the trial if one or more of the following criteria are met:  Primary XRT dose greater than 60 Gy Doses to organs at risk defined by Yasar and Tugrul (2005) exceeded or reached by prior radiation therapy; e.g. cumulative total dose on the optical chiasm greater than 54 Gy for 2 Gy/fraction Multifocal distant recurrence, defined as tumour lesion outside the primary XRT field, as evidenced by amino acid-based PET imaging Prior treatment with brachytherapy Prior treatment with bevacizumab History or evidence of delayed-type hypersensitivity (DTH)-dependent chronic infection (e.g. tuberculosis, systemic fungal or parasitic infection), potentially exacerbating under systemic corticoid therapy Localisation of tumour related to brain stem or axis, unless sufficient reserve capacity (e.g. remnant resection cavity, marked atrophy) to accommodate possible post- procedural tissue reactions, or pre-therapeutic consent for emergency trepanation Haemostaseologic conditions, precluding catheterisation or invasive procedures Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product Known impairment of liver or kidney function or known liver or kidney disease, such as hepatitis, cirrhosis, renal failure Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C Ongoing toxicity > grade 2 NCI-CTC (version 4.03) from previous standard or investigational therapies Administration of another investigational medicinal product within 90 days prior to screening Expected non-compliance with longer-term admission at isolated nuclear medicine ward In pre-menopausal women: Pregnant as evidenced by a positive pregnancy test, or breast-feeding Patients with known phenylketonuria  ",118
259,aminoacid,"A patient will be excluded from participation in the trial if one or more of the following criteria are met:  Primary XRT dose greater than 60 Gy Doses to organs at risk defined by Yasar and Tugrul (2005) exceeded or reached by prior radiation therapy; e.g. cumulative total dose on the optical chiasm greater than 54 Gy for 2 Gy/fraction Multifocal distant recurrence, defined as tumour lesion outside the primary XRT field, as evidenced by amino acid-based PET imaging Prior treatment with brachytherapy Prior treatment with bevacizumab History or evidence of delayed-type hypersensitivity (DTH)-dependent chronic infection (e.g. tuberculosis, systemic fungal or parasitic infection), potentially exacerbating under systemic corticoid therapy Localisation of tumour related to brain stem or axis, unless sufficient reserve capacity (e.g. remnant resection cavity, marked atrophy) to accommodate possible post- procedural tissue reactions, or pre-therapeutic consent for emergency trepanation Haemostaseologic conditions, precluding catheterisation or invasive procedures Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product Known impairment of liver or kidney function or known liver or kidney disease, such as hepatitis, cirrhosis, renal failure Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C Ongoing toxicity > grade 2 NCI-CTC (version 4.03) from previous standard or investigational therapies Administration of another investigational medicinal product within 90 days prior to screening Expected non-compliance with longer-term admission at isolated nuclear medicine ward In pre-menopausal women: Pregnant as evidenced by a positive pregnancy test, or breast-feeding Patients with known phenylketonuria  ",442
259,bevacizumab/131i-ipa/131i-ipa/131i-ipa/131i-ipa/131i-ipa/131i-ipa,"A patient will be excluded from participation in the trial if one or more of the following criteria are met:  Primary XRT dose greater than 60 Gy Doses to organs at risk defined by Yasar and Tugrul (2005) exceeded or reached by prior radiation therapy; e.g. cumulative total dose on the optical chiasm greater than 54 Gy for 2 Gy/fraction Multifocal distant recurrence, defined as tumour lesion outside the primary XRT field, as evidenced by amino acid-based PET imaging Prior treatment with brachytherapy Prior treatment with bevacizumab History or evidence of delayed-type hypersensitivity (DTH)-dependent chronic infection (e.g. tuberculosis, systemic fungal or parasitic infection), potentially exacerbating under systemic corticoid therapy Localisation of tumour related to brain stem or axis, unless sufficient reserve capacity (e.g. remnant resection cavity, marked atrophy) to accommodate possible post- procedural tissue reactions, or pre-therapeutic consent for emergency trepanation Haemostaseologic conditions, precluding catheterisation or invasive procedures Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product Known impairment of liver or kidney function or known liver or kidney disease, such as hepatitis, cirrhosis, renal failure Known human immunodeficiency virus (HIV) positive serology or chronically active hepatitis B or C Ongoing toxicity > grade 2 NCI-CTC (version 4.03) from previous standard or investigational therapies Administration of another investigational medicinal product within 90 days prior to screening Expected non-compliance with longer-term admission at isolated nuclear medicine ward In pre-menopausal women: Pregnant as evidenced by a positive pregnancy test, or breast-feeding Patients with known phenylketonuria  ",527
259,ipa/131i-ipa/131i-ipa-ipa/131-,The remainder of XRT fractions will be given following the 3rd 131I-IPA fraction.,68
259,ipa,"The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.",112
259,ipa/131i-ipa,"The 2nd 131I-IPA fraction will be administered after all 18 XRT fractions have been completed, and the 3rd 131I-IPA fraction will be administered 1 week after the 2nd 131I-IPA fraction.",172
259,xrt,"The 2nd and 3rd 131I-IPA injections should be given on the same day of the week, and some hours after administration of the respective XRT dose of that day.",135
259,ipa,"The three different treatment groups at the first (2.0 GBq) dose level (131I-IPA single dose 1f and 131I-IPA fractionated dose either 3f parallel or 3f sequential) will be recruited in parallel, as appropriate.",77
259,ipa,"The three different treatment groups at the first (2.0 GBq) dose level (131I-IPA single dose 1f and 131I-IPA fractionated dose either 3f parallel or 3f sequential) will be recruited in parallel, as appropriate.",105
259,ipa/131i-ipa,Patients will be allocated to one of the three IPA dosing regimens.,47
259,ipa,"IPA greater than 8 GBq using cohorts of N=3 as follows: 10 GBq, 3f (i.e. 3*3.33 GBq); 12 GBq, 3f (i.e. 3*4 GBq), etc., until MTD is reached or until a satisfactory anti-neoplastic efficacy is observed.",0
259,aminoacid,"For assessment of possible anti-neoplastic effects during dose escalation, only amino acid-based molecular imaging (preferably 18F-FET-PET) will be used, which allows assessment of treatment-induced changes based on a single post-therapeutic imaging study.",80
259,18f-fet,"For assessment of possible anti-neoplastic effects during dose escalation, only amino acid-based molecular imaging (preferably 18F-FET-PET) will be used, which allows assessment of treatment-induced changes based on a single post-therapeutic imaging study.",127
259,ipa,MTD will be determined on day 45 from the first IPA injection.,48
260,mibefradildihydrochloride,"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design.",22
260,mibefradildihydrochloride,Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.,0
260,mibefradildihydrochloride,The primary endpoint of the study is to determine the MTD of mibefradil dihydrochloride when given with concurrent hypofractionated RT.,61
260,mibefradildihydrochloride,"Secondary and tertiary endpoints include evaluating the efficacy of mibefradil dihydrochloride and RT in terms of progression-free survival (PFS) and overall survival (OS), and to perform translational research on resected tumor tissue.",68
261,dnx-2401,"In the initial phase of the study, up to 12 evaluable subjects will be enrolled in 3 dose cohorts to determine the best dose of DNX-2401, as follows:  ",128
261,dnx-2401,"Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W)  ",22
261,dnx-2401,"Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W)  ",157
261,dnx-2401,"Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W) Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed by intravenous pembrolizumab every 3 weeks (Q3W)  ",291
261,dnx-2401,"Following the initial phase, up to 36 additional subjects diagnosed with recurrent glioblastoma or gliosarcoma will be enrolled to receive a single of DNX-2401 determined in the initial phase administered intratumorally followed by intravenous pembrolizumab every 3 weeks.",151
263,nivolumab,To evaluate the efficacy of nivolumab when administered with standard and reduced bevacizumab dosing among recurrent glioblastoma patients as measured by the rate of overall survival at twelve months.,28
263,bevacizumab,To evaluate the efficacy of nivolumab when administered with standard and reduced bevacizumab dosing among recurrent glioblastoma patients as measured by the rate of overall survival at twelve months.,82
263,nivolumab,To evaluate the safety and tolerability of nivolumab in combination with bevacizumab administered according to standard and reduced dosage schedules for recurrent glioblastoma patients.,43
263,bevacizumab,To evaluate the safety and tolerability of nivolumab in combination with bevacizumab administered according to standard and reduced dosage schedules for recurrent glioblastoma patients.,73
263,nivolumab,To compare progression free survival (PFS) at 6 months of nivolumab when administered with standard and reduced bevacizumab dosing for recurrent glioblastoma patients.,58
263,bevacizumab,To compare progression free survival (PFS) at 6 months of nivolumab when administered with standard and reduced bevacizumab dosing for recurrent glioblastoma patients.,112
263,nivolumab,To compare the overall survival rate of nivolumab when administered with standard and reduced bevacizumab dosing for recurrent glioblastoma patients.,40
263,bevacizumab,To compare the overall survival rate of nivolumab when administered with standard and reduced bevacizumab dosing for recurrent glioblastoma patients.,94
263,bevacizumab,To compare progression free survival (PFS) of when administered with standard and reduced bevacizumab dosing for recurrent glioblastoma patients.,90
263,nivolumab,"To compare the objective response rate (ORR) of nivolumab and bevacizumab administered according to standard and reduced dosage schedules for recurrent glioblastoma patients  Exploratory Endpoints (s) To evaluate whether baseline values or subsequent changes in circulating immunologic parameters (including but not limited to the number of T-cells, B-cells and natural killer (NK) cells; the number of T cell subsets; soluble circulating cytokines) are associated with outcome.",48
263,bevacizumab,"To compare the objective response rate (ORR) of nivolumab and bevacizumab administered according to standard and reduced dosage schedules for recurrent glioblastoma patients  Exploratory Endpoints (s) To evaluate whether baseline values or subsequent changes in circulating immunologic parameters (including but not limited to the number of T-cells, B-cells and natural killer (NK) cells; the number of T cell subsets; soluble circulating cytokines) are associated with outcome.",62
263,nivolumab,To assess the perfusion and diffusion base imaging to correlate with changes and response to nivolumab when administered with standard and reduced bevacizumab dosing.,93
263,bevacizumab,To assess the perfusion and diffusion base imaging to correlate with changes and response to nivolumab when administered with standard and reduced bevacizumab dosing.,147
263,nivolumab,"This is a randomized, open-label, phase 2 safety study of nivolumab and bevacizumab administered according to standard and reduced dosage schedules in adult (≥ 18 years) subjects with a first recurrence or second recurrence of glioblastoma (GBM).",58
263,bevacizumab,"This is a randomized, open-label, phase 2 safety study of nivolumab and bevacizumab administered according to standard and reduced dosage schedules in adult (≥ 18 years) subjects with a first recurrence or second recurrence of glioblastoma (GBM).",72
263,nivolumab,Patients will undergo 1:1 randomization to receive treatment with either nivolumab (240 mg flat dosing IV every 2 weeks) and bevacizumab administered according to standard (10 mg/kg IV every 2 weeks; Arm A) and reduced (3 mg/kg IV every 2 weeks; Arm B) dosage schedules for recurrent glioblastoma patients.,73
263,bevacizumab,Patients will undergo 1:1 randomization to receive treatment with either nivolumab (240 mg flat dosing IV every 2 weeks) and bevacizumab administered according to standard (10 mg/kg IV every 2 weeks; Arm A) and reduced (3 mg/kg IV every 2 weeks; Arm B) dosage schedules for recurrent glioblastoma patients.,125
263,decadron,The study will allow patients that require decadron up to 4 mg/ day to participate in the study.,43
264,bevacizumab,"This pilot, non-interventional, observational, Web-based, prospective cohort study is designed to collect self-reported safety and effectiveness and genetic data from subjects with locally recurrent breast cancer (BC) or metastatic breast cancer (MBC), metastatic colorectal cancer (MCRC), metastatic non-squamous non-small cell lung cancer (MNSCLC), recurrent glioblastoma (RGBM), or metastatic renal cell cancer (MRCC) in the United States who have been previously treated with Avastin (bevacizumab).",489
264,bevacizumab/111indium/111in/111/111in/111in/111in,"The cohort will be composed of male and female subjects who have been diagnosed with locally recurrent BC or MBC, MCRC, MNSCLC, RGBM, or MRCC who have received treatment with bevacizumab in combination with chemotherapy, which started prior to or up to 31 December 2012.",175
266,temozolomide,"In a randomized, phase III EORTC-NCIC trial, overall survival in newly diagnosed glioblastoma patients treated with concomitant temozolomide and radiotherapy followed by 6 cycles of temozolomide was 27.2% (95% CI 22.2-32.5) at 2 years, 16.0% (12.0-20.6) at 3 years, 12.1% (8.5-16.4) at 4 years, and 9.8% (6.4-14.0) at 5 years, treatment which is now standard of care.",128
266,temozolomide,"In a randomized, phase III EORTC-NCIC trial, overall survival in newly diagnosed glioblastoma patients treated with concomitant temozolomide and radiotherapy followed by 6 cycles of temozolomide was 27.2% (95% CI 22.2-32.5) at 2 years, 16.0% (12.0-20.6) at 3 years, 12.1% (8.5-16.4) at 4 years, and 9.8% (6.4-14.0) at 5 years, treatment which is now standard of care.",182
266,bevacizumab,"Bevacizumab, a humanized monoclonal antibody against VEGF-A, showed a 28%RR,a 43% 6-month PFS and provided a consistent clinical benefit in terms of both delayed progression and increased median overall survival over historical controls.",0
266,ro5323441,"Humanized monoclonal PlGF antibody RO5323441 was evaluated in phase I trials in healthy volunteers and in cancer patients; no Dose Limiting Toxicity (DLT) was found, thus no Maximum Tolerated Dose (MTD) defined.",35
266,bevacizumab,A phase I/II study of bevacizumab in combination with RO5323441 is currently ongoing in patients with recurrent GBM (NCT01308684).,22
266,ro5323441,A phase I/II study of bevacizumab in combination with RO5323441 is currently ongoing in patients with recurrent GBM (NCT01308684).,54
266,ro5323441,"However, the amount of RO5323441 to reach the recurrent GBM, and how this is affected by bevacizumab treatment, are yet unknown.",23
266,bevacizumab,"However, the amount of RO5323441 to reach the recurrent GBM, and how this is affected by bevacizumab treatment, are yet unknown.",89
266,ro5323441,This can be determined by repetitive measurement of RO5323441 tumor uptake with 89Zr-RO5323441 PET.,52
266,ro5323441,This can be determined by repetitive measurement of RO5323441 tumor uptake with 89Zr-RO5323441 PET.,85
266,ro532441/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441zrro5323441,"Objectives: The objectives of this study are to assess the penetration of RO532441 into recurrent GBM by 89Zr-RO5323441 PET imaging and to quantify its uptake, to visualize and quantify 89Zr-RO5323441 non-tumor organ distribution, and to measure the effect of bevacizumab treatment on 89Zr-RO5323441 uptake in recurrent GBM.",74
266,bevacizumab,"Study design: This is a single center, investigator driven, 89Zr-RO5323441 PET imaging and bio-distribution study in patients with recurrent GBM treated with bevacizumab.",158
266,bevacizumab,Bevacizumab at a dose of 10 mg/kg body weight i.v.,0
266,bevacizumab/89zrro5323441,"The treatment with bevacizumab will continue until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest.",19
266,bevacizumab/89zr-ro5323441zr-ro5323441/89zr-ro5323441,at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment.,72
266,bevacizumab/89zr-ro5323441/89zr-ro5323441,89Zr-RO5323441 uptake values in recurrent GBM lesions at baseline and day 15 will be compared to assess bevacizumab effect on tracer tumor uptake.,104
266,bevacizumab/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441/89zr-ro5323441,"The purpose of the two early brain-only PET scans after each 89Zr-RO5323441 injection is to identify whether changes in 89Zr-RO5323441 uptake in recurrent GBM lesions following treatment with bevacizumab can be solely attributed to an effect on blood volume/ vascular permeability, or rather indicate a possible modulation of placental growth factor (PlGF) level in the tumor tissue.",192
266,bevacizumab/89zrro5323441,"Patients will be assessed for bevacizumab treatment response by brain MRI every 6 weeks (i.e. every cycle) in the first 6 month and every 12 weeks thereafter, until documented progression using the updated RANO criteria.",30
266,bevacizumab,"Nature and extent of the burden and risk associated with participation, benefit and group relatedness: Bevacizumab is registered in The Netherlands for use in metastasized colon and breast cancer, in lung cancer and in advanced renal cell carcinoma and has already been tested in GBM clinical trials.",103
266,bevacizumab,Bevacizumab is expected to have clinical benefit for patients enrolled in this study and similar safety profile compared to the other indications.,0
266,ro5323441,RO5323441 monotherapy was well tolerated in patients with advanced malignant diseases.,0
266,ro5323441,"In this study, one patient will receive a low total protein dose of 10 mg RO5323441 (2X5mg) in the tracer and it is expected that RO5323441 will not enhance bevacizumab related side effects.",74
266,ro5323441/89zr-ro5323441/89zr-ro5323441,"In this study, one patient will receive a low total protein dose of 10 mg RO5323441 (2X5mg) in the tracer and it is expected that RO5323441 will not enhance bevacizumab related side effects.",130
267,enzastaurin,The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.,46
267,bevacizumab,The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.,62
268,disulfiram,"Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism.",0
268,disulfiram,There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent.,77
268,disulfiram,The potency of disulfiram as an anticancer agent seems strengthened by copper.,15
268,copper,The potency of disulfiram as an anticancer agent seems strengthened by copper.,71
268,disulfiram,There is now anecdotal clinical evidence of disulfiram as an anticancer agent.,44
268,disulfiram,The investigators aim to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy.,37
268,copper,The investigators aim to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy.,52
269,temozolomide,"The trial is conducted as a multicenter, open-label, Phase I/II trial to evaluate the efficacy and safety of VXM01 in combination with avelumab in subjects with resectable and non-resectable progressive glioblastoma following tumor resection and radiochemotherapy containing temozolomide.",275
270,bevacizumab,The outcome of subjects treated with the NovoTTF-100A device was compared to those treated with an effective best standard of care chemotherapy (including bevacizumab).,155
270,novo,Similar results showing comparability of NovoTTF-100A to BSC chemotherapy were seen in all secondary endpoints.,41
270,bsc,Similar results showing comparability of NovoTTF-100A to BSC chemotherapy were seen in all secondary endpoints.,57
270,temozolomide,"Patients with GBM whose disease has first recurred despite standard treatment (Surgery, radiation therapy, Temozolomide treatment) and meet all of the requirements for participation in the study will be recruited to one of two groups based on patient preference alone:  ",107
272,amg386,To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1).,41
272,trebananib,To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1).,50
272,bevacizumab,To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1).,98
272,amg386,"To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).",26
272,bevacizumab,"To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).",54
272,bevacizumab,"To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).",101
272,bevacizumab,"To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks compared to bevacizumab monotherapy in bevacizumab-naive patients, as measured by 6-month progression-free survival (PFS6) (Cohort 2).",128
272,amg386,"To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.",25
272,bevacizumab,"To assess feasibility of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1 [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycles.",69
272,bevacizumab,"To determine the radiographic response rate (RR), median progression-free survival (PFS), and overall survival (OS) in bevacizumab-naive patients (Cohort 2).",119
272,amg386,"To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).",26
272,bevacizumab,"To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).",70
272,bevacizumab,"To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by overall survival (OS) (cross-over from placebo arm of Cohort 2).",146
272,bevacizumab,"To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).",76
272,amg386,"To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).",108
272,bevacizumab,"To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of Cohort 2).",136
272,amg386,To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).,43
272,bevacizumab,To determine the serum pharmacokinetics of AMG 386 in patients receiving bevacizumab (Cohort 1 and cross-over from placebo arm of Cohort 2).,73
272,bevacizumab,"Cohort 1: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.",27
272,trebananib,"Cohort 1: Patients receive bevacizumab intravenously (IV) over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.",98
272,bevacizumab,Patients receive bevacizumab and trebananib as in Cohort 1.  ,17
272,trebananib,Patients receive bevacizumab and trebananib as in Cohort 1.  ,33
272,bevacizumab,"Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22.",17
273,bevacizumab,"The investigators have recently demonstrated that bevacizumab (BV), a humanized monoclonal antibody against vascular endothelial growth factor, has significant anti-tumor activity among recurrent glioblastoma multiforme patients.",50
273,vorinostat,Vorinostat has modest anti-tumor activity against malignant glioma and can potentiate the action of both chemotherapy and anti-angiogenics.,0
273,vorinostat,The current study is designed to evaluate the anti-tumor activity of vorinostat when combined with BV among recurrent glioblastoma multiforme patients.,69
274,pvsripo,The catheter will be removed following the post-PVSRIPO infusion MRI.,48
274,lomustine,"All procedures previously described will be followed; however, the addition of a single dose of lomustine 8 weeks after PVSRIPO administration will alter the schedule of events that was previously described.",96
274,steroids,"After 6 patients were treated at dose level 2 in the dose expansion phase, due to continued difficulties tapering patients off steroids, the protocol was amended to further reduce the dose to dose level -1 (5.0 x 10^7 TCID50) with the goal of limiting the occurrence of known possible side effects of prolonged steroid use in patients who otherwise benefit from this investigational therapy.",127
274,steroid,"After 6 patients were treated at dose level 2 in the dose expansion phase, due to continued difficulties tapering patients off steroids, the protocol was amended to further reduce the dose to dose level -1 (5.0 x 10^7 TCID50) with the goal of limiting the occurrence of known possible side effects of prolonged steroid use in patients who otherwise benefit from this investigational therapy.",311
274,steroids,"After the treatment of 24 patients at dose level -1, despite the fact that these patients were able to remain off significant doses of steroids, the patients benefiting the most from PVSRIPO appeared to be those who had experienced minimal or easily controllable inflammation.",135
275,temozolomide,"This is an adaptive, randomized controlled, Phase 3 clinical trial in adult patients with histologically confirmed diagnosis of a recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS), who have been previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now have progressive disease during or after bevacizumab.",293
275,temozolomide,"This is an adaptive, randomized controlled, Phase 3 clinical trial in adult patients with histologically confirmed diagnosis of a recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS), who have been previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now have progressive disease during or after bevacizumab.",320
275,bevacizumab,"This is an adaptive, randomized controlled, Phase 3 clinical trial in adult patients with histologically confirmed diagnosis of a recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS), who have been previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now have progressive disease during or after bevacizumab.",338
275,bevacizumab,"This is an adaptive, randomized controlled, Phase 3 clinical trial in adult patients with histologically confirmed diagnosis of a recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS), who have been previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, +/- adjuvant temozolomide, and bevacizumab and now have progressive disease during or after bevacizumab.",399
275,val-083,"Treatment Groups: Eligible patients will be randomized to receive either the investigational drug (VAL-083) or ""Investigator's choice of salvage therapy"" as a contemporaneous control, in a 2:1 fashion.",99
275,val-083,"Group 1: Up to 120 eligible patients will be randomized to receive VAL-083 at 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation (death, intolerable toxicities, investigator's judgment, or withdrawal of consent).",67
275,val-083,VAL-083 will be administered as an IV infusion over 30-60 minutes.,0
275,temozolomide,"""Investigator's choice of salvage therapy"" will be limited to the following: temozolomide, lomustine, or carboplatin.",77
275,lomustine,"""Investigator's choice of salvage therapy"" will be limited to the following: temozolomide, lomustine, or carboplatin.",91
275,carboplatin,"""Investigator's choice of salvage therapy"" will be limited to the following: temozolomide, lomustine, or carboplatin.",105
275,temozolomide,"The dose level for Investigator's choice salvage therapy (temozolomide, lomustine, or carboplatin), will be in accordance with the product label or institutional guidelines.  ",58
275,lomustine,"The dose level for Investigator's choice salvage therapy (temozolomide, lomustine, or carboplatin), will be in accordance with the product label or institutional guidelines.  ",72
275,carboplatin,"The dose level for Investigator's choice salvage therapy (temozolomide, lomustine, or carboplatin), will be in accordance with the product label or institutional guidelines.  ",86
275,val-083,"For patients randomized to VAL-083, post-baseline tumor assessments are to be performed prior to every other 21-day cycle for VAL-083, i.e., prior to Cycles 3, 5, etc., while the patient is receiving VAL-083 treatment, and then approximately every 42 ± 7 days while remaining on study.",27
275,val-083,"For patients randomized to VAL-083, post-baseline tumor assessments are to be performed prior to every other 21-day cycle for VAL-083, i.e., prior to Cycles 3, 5, etc., while the patient is receiving VAL-083 treatment, and then approximately every 42 ± 7 days while remaining on study.",126
275,val-083,"For patients randomized to VAL-083, post-baseline tumor assessments are to be performed prior to every other 21-day cycle for VAL-083, i.e., prior to Cycles 3, 5, etc., while the patient is receiving VAL-083 treatment, and then approximately every 42 ± 7 days while remaining on study.",200
275,val-083,"In a subgroup of 60 study subjects receiving VAL-083, blood samples will be obtained to determine population pharmacokinetics at pre-dose Cycle 1 Day 1, then at post-infusion on Cycle 1 Day 1, Cycle 1 Day 3, Cycle 2 Day 1 and Cycle 3 (or Cycle 4) Day 1 (or Day 3) in accordance with the study subject's assigned sampling block.",45
275,val-083,"In a separate sub-group of 15 study subjects receiving VAL-083, blood will be drawn from Cycle 1 Day 1 and Cycle 1 Day 3 of dosing for determination of plasma levels of VAL-083 over the first 6 hours after the end of infusion (i.e., 0.25, 0.5, 1, 2, 4 and 6 hr).",55
275,val-083,"In a separate sub-group of 15 study subjects receiving VAL-083, blood will be drawn from Cycle 1 Day 1 and Cycle 1 Day 3 of dosing for determination of plasma levels of VAL-083 over the first 6 hours after the end of infusion (i.e., 0.25, 0.5, 1, 2, 4 and 6 hr).",169
276,niraparib,"The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib).",242
276,18f-fluorthanatrace,The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery.,88
276,18f-ftt,The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery.,109
276,18f-ftt,18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).,0
277,tandutinib,PRIMARY OBJECTIVES:  I. Assess the ability of tandutinib to achieve a target tumor/plasma ratio ≥ 0.33 in patients with recurrent glioblastoma undergoing resection.,46
277,tandutinib,Detect potential biological effects of tandutinib by measuring platelet-derived growth factor receptor phosphorylation status and downstream activation of Akt and Erk.,39
277,tandutinib,Determine the maximum tolerated dose of tandutinib in patients with recurrent or progressive glioblastoma.,40
277,tandutinib,Estimate the frequency of toxicities associated with tandutinib in patients with recurrent or progressive glioblastoma.,53
277,tandutinib,Assess the toxicities associated with tandutinib in these patients.,38
277,tandutinib,Patients receive oral tandutinib twice daily for 7 days.,22
277,tandutinib,"Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28.",62
277,tandutinib,Patients receive oral tandutinib twice daily* on days 1-28.,22
277,tandutinib,Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined.,52
277,tandutinib,"On day 1 of course 1, patients receive only 1 dose of tandutinib.]",54
277,tandutinib,Patients receive tandutinib as in phase I at the MTD determined in phase I.  ,17
277,tandutinib,Patients in the feasibility portion of the study also undergo blood and tissue sample collection for correlative studies by mass spectrometry for tandutinib concentration.,146
277,tandutinib,"Samples are also examined for circulating endothelial cells and plasma proteins (vascular endothelial growth factor [VEGF]-A, -B, -C, and -D, soluble VEGF receptors [sVEGFR's], placental growth factor [P1GF], platelet-derived growth factor [PDGF]-AA, PDGF-AB, PDGF-BB, angiopoietin-1 and -2, tumstatin, thrombospondin-1, and IL-8) as potential markers of the antiangiogenic effect of tandutinib.",384
278,temozolomide,"Temozolomide at a dose of, 150-200 mg/m2, will be administered orally, after fasting for one hour, once a day for 5 consecutive days (days 1 through 5) every 4 weeks (plus up to 3 days).",0
278,sch66336,"SCH66336 will be given orally, with water, in the morning and in the evening for three weeks (Days 8 - 28) every 28 days (plus up to 3 days) 1 hour before or after morning and evening meals.",0
278,temozolomide,Treatment courses may be repeated every 28 days following the first daily dose of Temozolomide for the previous course.,82
280,tpi287,TPI 287 is designed to block a protein that causes cancer cells to resist the effects of chemotherapy.,0
280,bevacizumab," Bevacizumab will be given to patients that are found to have brain damage, as described below.",1
280,tpi287,"On Day 1 of each 21-day study ""cycle,"" you will receive TPI 287 by vein over about 1 hour.",56
280,tpi287,"If you experience intolerable side effects, the dose of TPI 287 may be lowered.",56
280,tpi287,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",40
280,benadryl,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",93
280,diphenhydramine,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",104
280,tpi287,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",179
280,cimetidine,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",187
280,tpi287,"To help prevent an allergic reaction to TPI 287, you will also receive the following drugs:  Benadryl® (diphenhydramine) by vein over 30 minutes, 30-60 minutes before you receive TPI 287 Cimetidine by vein over 30 minutes, 30-60 minutes before you receive TPI 287",256
280,dexamethasone,Either dexamethasone or methylprednisolone (taken by mouth 12 and 6 hours before you receive TPI 287; or by vein over 30 minutes at about 30-60 minutes before you receive TPI 287)  ,7
280,methylprednisolone,Either dexamethasone or methylprednisolone (taken by mouth 12 and 6 hours before you receive TPI 287; or by vein over 30 minutes at about 30-60 minutes before you receive TPI 287)  ,24
280,tpi287,"If you have an MRI scan that shows evidence of brain damage related to the tumor tissue death after you have received TPI 287 for two infusions, you will be eligible to receive bevacizumab.",118
280,bevacizumab,"If you have an MRI scan that shows evidence of brain damage related to the tumor tissue death after you have received TPI 287 for two infusions, you will be eligible to receive bevacizumab.",177
280,bevacizumab,"If you are eligible and you receive it, you may continue to receive bevacizumab for as long as you are benefiting.",68
280,bevacizumab,You will be taken off bevacizumab if the disease gets worse or if you experience intolerable side effects.,22
280,tpi287,TPI 287 is not FDA approved or commercially available.,0
280,bevacizumab,Bevacizumab is FDA approved and commercially available for the treatment of brain tumors.,0
280,bevacizumab,The use of bevacizumab for brain damage related to the tumor tissue death is investigational.,11
281,pamiparib,"An open-label, multiple-dose, dose-escalation study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of Pamiparib in combination with radiation therapy (RT) and/or TMZ.",128
281,tmz,"An open-label, multiple-dose, dose-escalation study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of Pamiparib in combination with radiation therapy (RT) and/or TMZ.",188
281,tmz,"In dose escalation/Phase 1b, Pamiparib will be combined with RT (Arm A) or RT and TMZ (Arm B) in participants with newly diagnosed unmethylated glioblastoma (GBM) and in Arm C of the study Pamiparib will be combined with TMZ in participants with methylated or unmethylated recurrent/refractory GBM.  ",82
281,tmz,"In dose escalation/Phase 1b, Pamiparib will be combined with RT (Arm A) or RT and TMZ (Arm B) in participants with newly diagnosed unmethylated glioblastoma (GBM) and in Arm C of the study Pamiparib will be combined with TMZ in participants with methylated or unmethylated recurrent/refractory GBM.  ",221
281,o-6-methylguanine,"The dose expansion/Phase 2 phase will enroll up to 4 cohorts: participants with newly diagnosed unmethylated GBM in Arms A and B, and 2 cohorts of participants with recurrent/refractory GBM grouped by O-6-methylguanine-DNA methyltransferase (MGMT) status - unmethylated or methylated - in Arm C.  ",201
282,prx321,Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.,47
282,prx321,Primary Objective:  To evaluate the efficacy (expressed as overall survival at 6 months [OS-6]) of intratumoral infusion of PRX321 in subjects with first recurrence or progression of glioblastoma multiforme (GBM).,124
282,prx321, To assess the safety of intratumoral infusion with PRX321 in subjects with recurrent or progressive GBM.  ,52
283,ara-c,We hypothesize that the SVZ is the incubator for future recurrences of GBM and propose targeting SVZ progenitor cells with intraventricular liposomal encapsulated Ara-C (DepoCyt) in combination with systemic metronomic dose temozolomide.,163
283,temozolomide,We hypothesize that the SVZ is the incubator for future recurrences of GBM and propose targeting SVZ progenitor cells with intraventricular liposomal encapsulated Ara-C (DepoCyt) in combination with systemic metronomic dose temozolomide.,224
283,ara-c,Ara-C has been previously demonstrated to inhibit the proliferation and migration of SVZ precursor cells in adult animals.,0
283,cytarabine,"This has also been the basis for successful application and granting of Orphan-Drug designation for cytarabine (Ara-C) liposome injection (trade name: DepoCyt) for the treatment of gliomas (Designation # 06-2348) on January 30, 2007.",100
283,ara-c,"This has also been the basis for successful application and granting of Orphan-Drug designation for cytarabine (Ara-C) liposome injection (trade name: DepoCyt) for the treatment of gliomas (Designation # 06-2348) on January 30, 2007.",112
284,alpha-[11c]methyl-l-tryptophan,Image patients' brain with magnetic resonance imaging (MRI) (performed clinically in 2-month intervals; includes standard structural sequences and perfusion imaging) and alpha-[11C]methyl-L-tryptophan (AMT) positron emission tomography (PET),170
284,amt,Image patients' brain with magnetic resonance imaging (MRI) (performed clinically in 2-month intervals; includes standard structural sequences and perfusion imaging) and alpha-[11C]methyl-L-tryptophan (AMT) positron emission tomography (PET),202
285,pd0332991,A total of 30 patients with recurrent Glioblastoma or Gliosarcoma will be treated with PD 0332991 at a dose of 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days).,87
286,vb-111,"The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.",82
288,cilengitide,PRIMARY OBJECTIVES:  I. Determine the 6-month progression-free survival rate in operative patients with recurrent or progressive glioblastoma multiforme treated with cilengitide.,166
288,cilengitide,"Preoperative Treatment Group I: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1.  ",59
288,cilengitide,"Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1.",26
288,cilengde,"Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks.",96
289,bevacizumab,"PRIMARY OBJECTIVES:  I. Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of 6-month progression-free survival rate, in patients with recurrent or refractory intracranial glioblastoma multiforme or gliosarcoma.",50
289,irinotecanhydrochloride,"PRIMARY OBJECTIVES:  I. Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of 6-month progression-free survival rate, in patients with recurrent or refractory intracranial glioblastoma multiforme or gliosarcoma.",66
289,bevacizumab,Determine the adverse event profile and tolerability of bevacizumab and temozolomide in these patients.,56
289,temozolomide,Determine the adverse event profile and tolerability of bevacizumab and temozolomide in these patients.,72
289,bevacizumab," SECONDARY OBJECTIVES:  I. Determine the efficacy of bevacizumab and temozolomide, in terms of 6-month progression-free survival rate, in patients previously treated with temozolomide.",53
289,temozolomide," SECONDARY OBJECTIVES:  I. Determine the efficacy of bevacizumab and temozolomide, in terms of 6-month progression-free survival rate, in patients previously treated with temozolomide.",69
289,temozolomide," SECONDARY OBJECTIVES:  I. Determine the efficacy of bevacizumab and temozolomide, in terms of 6-month progression-free survival rate, in patients previously treated with temozolomide.",171
289,bevacizumab,"Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of objective response, in patients with measurable disease.",26
289,irinotecanhydrochloride,"Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of objective response, in patients with measurable disease.",42
289,bevacizumab,"Determine the efficacy of bevacizumab and temozolomide, in terms of objective response, in patients with measurable disease who were previously treated with temozolomide.",26
289,temozolomide,"Determine the efficacy of bevacizumab and temozolomide, in terms of objective response, in patients with measurable disease who were previously treated with temozolomide.",42
289,temozolomide,"Determine the efficacy of bevacizumab and temozolomide, in terms of objective response, in patients with measurable disease who were previously treated with temozolomide.",157
289,bevacizumab,Determine the toxicity profile and tolerability of bevacizumab and irinotecan hydrochloride in these patients.,51
289,irinotecanhydrochloride,Determine the toxicity profile and tolerability of bevacizumab and irinotecan hydrochloride in these patients.,67
289,bevacizumab, TERTIARY OBJECTIVES:  I. Assess the potential role of perfusion MRI and magnetic resonance spectroscopy imaging as an early indicator of response to therapy after 2 weeks of treatment with bevacizumab.,190
289,bevacizumab,Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.,17
289,temozolomide,Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.,77
289,bevacizumab,Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.  ,17
289,irinotecanhydrochloride,Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.  ,56
290,dasatinib,"This is a multicenter, phase I, dose-escalation study (Phase I completed) of dasatinib followed by a phase II randomized study.",77
290,bevacizumab,Patients receive bevacizumab IV over 30-90 minutes on day 1.,17
290,dasatinib,Patients also receive oral dasatinib once or twice daily on days 1-14 until the maximum-tolerated dose (MTD) is determined.,27
290,dasatinib,Determine the maximum tolerated dose (MTD) of dasatinib in combination with bevacizumab in high grade glioma patients.,46
290,dasatinib,To assess the safety and adverse events of the dasatinib in combination with bevacizumab in this patient population.,47
290,bevacizumab,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by progression free survival at six months and compare it with the efficacy of bevacizumab alone.,32
290,dasatinib,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by progression free survival at six months and compare it with the efficacy of bevacizumab alone.,61
290,bevacizumab,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by progression free survival at six months and compare it with the efficacy of bevacizumab alone.,199
290,dasatinib, SECONDARY OBJECTIVES:  To describe the overall toxicity associated with the dasatinib/bevacizumab combination.,77
290,bevacizumab, SECONDARY OBJECTIVES:  To describe the overall toxicity associated with the dasatinib/bevacizumab combination.,87
290,bevacizumab,To assess the safety and toxicity of the bevacizumab combination with dasatinib in this patient population.,41
290,dasatinib,To assess the safety and toxicity of the bevacizumab combination with dasatinib in this patient population.,70
290,bevacizumab,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by overall survival time and compare it with the efficacy of bevacizumab alone.,32
290,dasatinib,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by overall survival time and compare it with the efficacy of bevacizumab alone.,61
290,bevacizumab,To estimate the efficacy of the bevacizumab combination with dasatinib in recurrent glioblastoma multiforme as measured by overall survival time and compare it with the efficacy of bevacizumab alone.,181
291,xl184,The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.,115
291,xl184,"XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.",0
292,azd7451,AZD7451 is a first in-class inhibitor of Trk.,0
292,azd7451, OBJECTIVES:  To establish the maximally tolerated dose (MTD) of continuous twice a day AZD7451 dosing in patients with recurrent glioblastoma not on enzyme-inducing anti-epileptic drugs (EIAED).,88
292,azd7451,To generate pharmacokinetic data on continuous twice a day AZD7451 dosing.,59
292,azd7451,Cohorts of 3 to 6 patients will receive continuous AZD7451 twice a day orally for 28 days.,51
292,azd7451,The dose of AZD7451 can be progressively escalated if only 0/3 or 1/6 patients experience a dose limiting toxicity at the prior dose level.,12
292,azd7451,"At the end of Cycle 1, patients may choose to continue to receive AZD7451 until disease progression or until they experience unmanageable drug related toxicity, as long as they are continuing to derive clinical benefit and do not fulfill any of the criteria for removal from protocol therapy.",66
294,bibw2992,Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV).,84
294,tmz,Phase I Part: To determine the maximum tolerated dose (MTD) and pharmacokinetics of BIBW 2992 administered in combination with TMZ in patients with recurrent malignant gliomas (WHO Grade III and IV).,127
294,bibw2992,Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM.,54
294,bibw2992,Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM.,80
294,tmz,Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM.,92
294,tmz,Phase II Part: To estimate the efficacy and safety of BIBW 2992 monotherapy and BIBW 2992 / TMZ combination therapy compared to TMZ monotherapy (three treatment arms) in patients with recurrent GBM.,128
294,bibw2992,To evaluate molecular determinants of response to BIBW 2992.,50
295,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  ,135
295,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  ,284
295,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  ,322
295,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles to the historical Temozolomide data To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  ,418
295,temozolomide,The CAR-T injections occur in between Temozolomide (TMZ) cycles.,38
295,tmz,The CAR-T injections occur in between Temozolomide (TMZ) cycles.,52
295,temozolomide,Temozolomide treatment in the cycle of CAR-T injections will be stopped and resumed next cycle.,0
296,apatinib,The patient was given a daily dose of apatinib 500mg (or based on weight).,38
297,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles vs Temozolomide alone To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  Experimental group:,135
297,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles vs Temozolomide alone To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  Experimental group:,284
297,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles vs Temozolomide alone To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  Experimental group:,307
297,temozolomide,Objectives  To evaluate the safety and tolerability intratumoral/intracerebroventricular injection of B7-H3 CAR-T when used in between Temozolomide cycles To compare the overall survival (OS) and progression-free survival (PFS) of R/R GBM patients treated with B7-H3 CAR-T in between Temozolomide cycles vs Temozolomide alone To access the pharmacokinetics and pharmacodynamics of B7-H3 CAR-T in between Temozolomide cycles  Design  Experimental group:,404
297,temozolomide,The CAR-T injections occur in between Temozolomide (TMZ) cycles.,38
297,tmz,The CAR-T injections occur in between Temozolomide (TMZ) cycles.,52
297,temozolomide,Temozolomide treatment during the cycles of CAR-T injections will be stopped and resumed next cycle.,0
297,temozolomide,Control group: Patients will receive regular cycles of Temozolomide treatment with 5 days of treatment and 23 days of interval.,55
299,verteporfin,To evaluate the safety and tolerability of successively higher doses of verteporfin (Visudyne [liposomal verteporfin]) and determine the maximum tolerated dose (MTD) in study participants with recurrent EGFR positive (+) glioblastoma (GBM).,72
299,visudyne,To evaluate the safety and tolerability of successively higher doses of verteporfin (Visudyne [liposomal verteporfin]) and determine the maximum tolerated dose (MTD) in study participants with recurrent EGFR positive (+) glioblastoma (GBM).,85
299,verteporfin,To evaluate the safety and tolerability of successively higher doses of verteporfin (Visudyne [liposomal verteporfin]) and determine the maximum tolerated dose (MTD) in study participants with recurrent EGFR positive (+) glioblastoma (GBM).,105
299,visudyne,To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS).,39
299,visu,To describe the response rate of EGFR+ GBM in study participants treated with Visudyne.,78
299,visudyne,To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS).,39
299,visu,To describe the response rate of EGFR+ GBM in study participants treated with Visudyne.,78
299,visudyne,To describe pharmacokinetics of Visudyne administered on a weekly schedule.,32
299,visudyne,To evaluate the safety and tolerability of successively higher doses of Visudyne in study participants with recurrent EGFR+ GBM.,72
299,verteporfin,"Patients receive verteporfin intravenously (IV) over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles.",17
300,bevacizumab,Patients who require biopsy only or have previously been treated with bevacizumab will be excluded.,70
300,bevacizumab,Design  Participants will be stratified by NRGS score (NRGS 0 or NRGS 1-2) and randomized to surgery followed by bevacizumab or to bevacizumab alone.,113
300,bevacizumab,Design  Participants will be stratified by NRGS score (NRGS 0 or NRGS 1-2) and randomized to surgery followed by bevacizumab or to bevacizumab alone.,131
300,bevacizumab,Treatment with bevacizumab at a dose of 10 mg/kg every 2 weeks will begin at least 28 days later to allow adequate craniotomy wound healing.,15
300,bevacizumab,Patients assigned to the non-surgical arm will start bevacizumab at a dose of 10 mg/kg every 2 weeks immediately.,53
300,bevacizumab,"MRI evaluations will take place within 72 hours of surgery to assess extent of resection, 28 days postoperatively, 96 hours after starting bevacizumab, and then every 28 days until tumor progression is documented.",139
300,bevacizumab,Follow-up assessments will take place every 28 days while on bevacizumab until tumor progression.,61
300,bevacizumab,The primary outcome measure is median overall survival from the date bevacizumab is started.,69
300,bevacizumab,"Secondary outcome measures include the rate of progression-free survival 6 months after starting bevacizumab, median progression-free survival, overall survival rates at 6 and 12 months after starting bevacizumab, objective response rate, health-related quality of life, change in KPS of 20 points or more, time to need for additional tumor therapy, and use of corticosteroids.",97
300,bevacizumab,"Secondary outcome measures include the rate of progression-free survival 6 months after starting bevacizumab, median progression-free survival, overall survival rates at 6 and 12 months after starting bevacizumab, objective response rate, health-related quality of life, change in KPS of 20 points or more, time to need for additional tumor therapy, and use of corticosteroids.",201
300,corticosteroids,"Secondary outcome measures include the rate of progression-free survival 6 months after starting bevacizumab, median progression-free survival, overall survival rates at 6 and 12 months after starting bevacizumab, objective response rate, health-related quality of life, change in KPS of 20 points or more, time to need for additional tumor therapy, and use of corticosteroids.",361
301,toca511,"This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA.",65
301,lomustine,"This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA.",177
301,temozolomide,"This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA.",190
301,bevacizumab,"This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA.",207
301,toca511,"Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC).",142
302,bev,Stage 1:  Eligible patients will first be administered with BEV 10 mg/kg intravenous (IV) infusion.,60
302,sonovue®,"After 30-60 minutes, patients will receive microbubbles (MB) (SonoVue®)",62
302,bev,"After 4 weeks of treatment with BEV and single unit FUS-MB treatment, if the patient experienced BBB opening using FUS treatment and BEV IV infusion without any serious adverse effects (such as brain significant bleeding), then the patient may proceed to stage 2.  ",32
302,bev,"After 4 weeks of treatment with BEV and single unit FUS-MB treatment, if the patient experienced BBB opening using FUS treatment and BEV IV infusion without any serious adverse effects (such as brain significant bleeding), then the patient may proceed to stage 2.  ",133
302,bev,"Patients who complete stage 1 will enter stage 2 to receive the BEV with MB-mediated multiple units of FUS treatment for up to five minutes (but the maximum exposure time per single unit is two minutes) every 2 weeks for up to 30 weeks or until evidence of progressive disease, unacceptable toxicity, non-compliance with study follow-up, or withdrawal of consent.",64
304,tpi287,"Phase 1 of the trial is a dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation therapy and TMZ.",99
304,bevacizumab,"Phase 1 of the trial is a dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation therapy and TMZ.",127
304,tmz,"Phase 1 of the trial is a dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation therapy and TMZ.",222
304,tpi287,"All subjects will be administered TPI 287 as an intravenous (IV) infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",34
304,bevacizumab,"All subjects will be administered TPI 287 as an intravenous (IV) infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",159
304,tpi287,"The subsequent cycle will start 3 weeks after the last TPI 287 infusion and 2 weeks after the last bevacizumab infusion, maintaining the once every 3 week and once every 2 week schedule, respectively.",55
304,bevacizumab,"The subsequent cycle will start 3 weeks after the last TPI 287 infusion and 2 weeks after the last bevacizumab infusion, maintaining the once every 3 week and once every 2 week schedule, respectively.",99
304,tpi287,"The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg).",12
304,bevacizumab,"The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg).",103
304,tpi,The initial cohort of 3 subjects will be treated at a TPI 287 dose of 140 mg/m2.,54
304,gadolinium,"Efficacy evaluations will include magnetic resonance imaging [MRI, including both pre and post-gadolinium T1-weighted scans and T2/fluid attenuated inversion recovery (FLAIR) images], corticosteroid usage, and neurologic status (as measured by neurologic exam and KPS).",95
304,tpi287, Phase 2 of the trial is a randomized study of the safety and efficacy of the phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects who have GBM that has progressed following prior radiation therapy and TMZ.,93
304,bevacizumab, Phase 2 of the trial is a randomized study of the safety and efficacy of the phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects who have GBM that has progressed following prior radiation therapy and TMZ.,121
304,bevacizumab, Phase 2 of the trial is a randomized study of the safety and efficacy of the phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects who have GBM that has progressed following prior radiation therapy and TMZ.,140
304,tmz, Phase 2 of the trial is a randomized study of the safety and efficacy of the phase 1 MTD of TPI 287 in combination with bevacizumab versus bevacizumab alone in subjects who have GBM that has progressed following prior radiation therapy and TMZ.,241
304,tpi287,Sixty subjects will be randomized 1:1 to receive either TPI 287 in combination with bevacizumab or bevacizumab alone.,56
304,bevacizumab,Sixty subjects will be randomized 1:1 to receive either TPI 287 in combination with bevacizumab or bevacizumab alone.,84
304,bevacizumab,Sixty subjects will be randomized 1:1 to receive either TPI 287 in combination with bevacizumab or bevacizumab alone.,99
304,tpi287,"For the combination arm, the subjects will be administered TPI 287 as an IV infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",59
304,bevacizumab,"For the combination arm, the subjects will be administered TPI 287 as an IV infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",170
304,tpi287,"The dose of TPI 287 will be the MTD determined in phase 1, and the dose of bevacizumab will be the same as phase 1 (10 mg/kg).",12
304,bevacizumab,Subjects randomized to the bevacizumab alone arm will be administered 10 mg/kg bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks,27
304,bevacizumab,Subjects randomized to the bevacizumab alone arm will be administered 10 mg/kg bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks,79
305,cediranib,"This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.",100
305,lomustine,"This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.",130
306,trem,ARM 1: Patients receive tremelimumab intravenously (IV) over 1 hour on day 1.,24
307,thiotepa,"Determine the response rate, disease-free interval, and overall survival of patients with malignant glioma treated with high-dose thiotepa followed by autologous peripheral blood stem cell transplantation.",130
307,cyclophosphamide,"Following a course of induction chemotherapy with cyclophosphamide IV over 4 hours, patients receive filgrastim (G-CSF) daily until the completion of peripheral blood stem cell (PBSC) harvesting.",50
307,thiotepa,Patients receive high-dose thiotepa IV over 5 hours on day -2.,27
308,nivolumab,"This protocol is being performed to 1) characterize the clinical and 2) immunological response of patients with recurrent glioblastoma to treatment with Nivolumab, together with an anti-Lag-3 antibody, BMS-986016, and to evaluate the safety of brain tumor microdialysis in this patient population.",153
308,bms-986016,"This protocol is being performed to 1) characterize the clinical and 2) immunological response of patients with recurrent glioblastoma to treatment with Nivolumab, together with an anti-Lag-3 antibody, BMS-986016, and to evaluate the safety of brain tumor microdialysis in this patient population.",202
308,nivolumab,"After two days (Day 3), the patients will be given one dose of Nivolumab, 240mg IV.",63
308,nivolumab,"Nivolumab, at a dose of 240mg IV over 30 minutes every 2 weeks, will be administered after surgery (starting on Day 17(+/- 2 days), two weeks after the first dose on Day 3) followed by BMS 986016, an anti-Lag-3 antibody at a dose of 80mg IV over 60 minutes, until the study neuroradiologist notes tumor progression on MRI or the patient experiences treatment toxicity.",0
308,bms986016,"Nivolumab, at a dose of 240mg IV over 30 minutes every 2 weeks, will be administered after surgery (starting on Day 17(+/- 2 days), two weeks after the first dose on Day 3) followed by BMS 986016, an anti-Lag-3 antibody at a dose of 80mg IV over 60 minutes, until the study neuroradiologist notes tumor progression on MRI or the patient experiences treatment toxicity.",185
308,nivolumab,"While on therapy with Nivolumab and BMS-986016, patients will be seen and examined every 2 weeks +/- two days for signs of toxicity.",22
308,bms-986016,"While on therapy with Nivolumab and BMS-986016, patients will be seen and examined every 2 weeks +/- two days for signs of toxicity.",36
308,nivolumab,"The primary outcome measures are the proportion of patients who have a measurable increase of interferon gamma levels in the brain tumor tissue after their first dose of Nivolumab as compared to the pre-treatment baseline, the safety of using brain tumor microdialysis to monitor response to immune modulators in patients with recurrent glioblastoma and the safety of the combination of Nivolumab and BMS-986016.",170
308,nivolumab,"The primary outcome measures are the proportion of patients who have a measurable increase of interferon gamma levels in the brain tumor tissue after their first dose of Nivolumab as compared to the pre-treatment baseline, the safety of using brain tumor microdialysis to monitor response to immune modulators in patients with recurrent glioblastoma and the safety of the combination of Nivolumab and BMS-986016.",387
308,bms-986016,"The primary outcome measures are the proportion of patients who have a measurable increase of interferon gamma levels in the brain tumor tissue after their first dose of Nivolumab as compared to the pre-treatment baseline, the safety of using brain tumor microdialysis to monitor response to immune modulators in patients with recurrent glioblastoma and the safety of the combination of Nivolumab and BMS-986016.",401
308,nivolumab,"Exploratory outcome measures include: 1) To determine the change in interferon gamma production within the tumor microenvironment and in the rest of the body from before and after therapy with the immune checkpoint inhibitor, nivolumab; 2) To evaluate the pathological response of the immune microenvironment of brain tumor tissue to the first dose of Nivolumab; 3) To evaluate the clinical response (progression free survival, overall survival) of recurrent glioblastoma patients to this treatment combination; 4) To describe the difference in survival between responders and non-responders on this treatment combination; 5) To examine the differences in the immune cells and secreted factors of the tumor environment as compared to the immune cells and secreted factors of the cerebral spinal fluid, blood and, potentially, bone marrow in response to this treatment.",226
308,nivolumab,"Exploratory outcome measures include: 1) To determine the change in interferon gamma production within the tumor microenvironment and in the rest of the body from before and after therapy with the immune checkpoint inhibitor, nivolumab; 2) To evaluate the pathological response of the immune microenvironment of brain tumor tissue to the first dose of Nivolumab; 3) To evaluate the clinical response (progression free survival, overall survival) of recurrent glioblastoma patients to this treatment combination; 4) To describe the difference in survival between responders and non-responders on this treatment combination; 5) To examine the differences in the immune cells and secreted factors of the tumor environment as compared to the immune cells and secreted factors of the cerebral spinal fluid, blood and, potentially, bone marrow in response to this treatment.",352
309,nivolumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",129
309,ipilimumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",144
309,nivolumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",172
309,ipilimumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",195
309,nivolumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",254
309,ipilimumab,"Participants will receive one of the following study treatments prior to undergoing surgery for tumor removal:  Group A receives nivolumab plus ipilimumab Group B receives nivolumab plus placebo-ipilimumab Group C receives two placebo infusions, placebo-nivolumab plus placebo-ipilimumab  ",277
309,nivolumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",127
309,ipilimumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",142
309,nivolumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",191
309,nivolumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",232
309,nivolumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",276
309,ipilimumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",291
309,nivolumab,"After recovering from surgery, participants will receive doses of study medication based on the study group:  Group A receives nivolumab plus ipilimumab every 3 weeks for 3 doses followed by nivolumab every 4 weeks Group B receives nivolumab every four weeks Group C receives nivolumab plus ipilimumab every 3 weeks for 4 doses followed by nivolumab every 4 weeks  ",340
309,nivolumab,Both nivolumab and ipilimumab are antibodies (types of human protein) that work to stop tumor cells from growing and multiplying by immunotherapy.,5
309,ipilimumab,Both nivolumab and ipilimumab are antibodies (types of human protein) that work to stop tumor cells from growing and multiplying by immunotherapy.,19
309,nivolumab,"Nivolumab and ipilimumab have been used in other research studies, and information from those other research studies suggest these drugs may help to stop glioblastoma cells from growing.",0
310,lde225,The primary purpose of this study is to determine a combination maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LDE225 and BKM120 when co-administered orally in patients with advanced solid tumors.,140
310,bkm120,The primary purpose of this study is to determine a combination maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LDE225 and BKM120 when co-administered orally in patients with advanced solid tumors.,151
310,lde225,"This is a multi-center, open-label, dose finding, phase Ib study to determine the MTD and/or RDE for the combination of LDE225 plus BKM120, followed by an expansion part to further assess safety and preliminary efficacy of the combination in patients with advanced solid tumors that are frequently associated with dysregulated Hh and/or PI3K pathways, specifically triple negative metastatic breast cancer, hormone receptor positive",120
312,temozolomide,To determine the maximum feasible dose (MFD) or maximum tolerated dose (MTD) and safety of cytomegalovirus (CMV)-specific T cells in combination with dose-dense temozolomide in patients with recurrent glioblastoma.,161
312,temozolomide,Safety and tolerability of dose-dense temozolomide in combination with intravenous administered CMV-stimulated adoptive T cells in patients receiving adjuvant therapy after completing external beam radiotherapy with concurrent temozolomide for newly diagnosed glioblastoma.,38
312,temozolomide,Safety and tolerability of dose-dense temozolomide in combination with intravenous administered CMV-stimulated adoptive T cells in patients receiving adjuvant therapy after completing external beam radiotherapy with concurrent temozolomide for newly diagnosed glioblastoma.,227
312,temozolomide,Patients receive temozolomide orally (PO) once a day (QD) on days 1-21 and CMV-specific T cell transfer intravenously (IV) over 1-5 minutes on day 22.,17
312,temozolomide,Patients then receive temozolomide PO QD on days 1-21.,22
312,temozolomide,Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22.,17
312,temozolomide,Patients then receive temozolomide PO QD on days 1-5.,22
314,polyglucin,The preparation is stored in tubes per 4 ml with cryoprotector and 10% polyglucin solution.,71
314,tcs,"Key (3 or 4 proteins with maximal normalized intensity) oncospecific proteins (OSP) are determined according to proteome testing of TCs, while proteome profiling of TSCs and use of databases of protein-protein relations permit detection of intracellular signal transduction pathways (ISTP) unaffected by carcinogenesis and capable of regulation.",132
314,pge2,"The lymphocytes are isolated, cultured with G-CSF and interleukin-2, conditioned by tumor-specific antigens, TNF-α and PGE2 for 48 hours and loaded with recombinant proteins identical to key tumor-specific antigens detected at proteomic testing of TCs.",119
315,tln-4601,The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.,68
316,atengenal,"This is a single arm, open-label study in which adults (≥ 18 years of age) with residual/recurrent/progressed Glioblastoma Multiforme receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached.",208
316,astugenal,"This is a single arm, open-label study in which adults (≥ 18 years of age) with residual/recurrent/progressed Glioblastoma Multiforme receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached.",220
317,sarasar,"To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.",40
317,sch66336,"To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.",49
317,lonafarnib,"To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.",59
317,temodar,"To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.",90
317,temozolomide,"To determine the maximum tolerated dose Sarasar (SCH66336, lonafarnib) when combined with Temodar (temozolomide) in an alternating week schedule.",99
317,sarasar,To describe the toxicities of the Sarasar and Temodar combination treatment using this dosing schedule.,34
317,temodar,To describe the toxicities of the Sarasar and Temodar combination treatment using this dosing schedule.,46
317,lonafarnib,This is a dose-escalation study of lonafarnib.,35
317,temozolomide,Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and lonafarnib PO twice daily (BID) on days 8-14 and 22-28.,17
317,lonafarnib,Patients receive temozolomide orally (PO) once daily (QD) on days 1-7 and 15-21 and lonafarnib PO twice daily (BID) on days 8-14 and 22-28.,84
318,perillylalcohol,Perillyl alcohol has previously been tested in 15 clinical studies in > 600 subjects This includes 13 studies in 255 subjects using oral administration sponsored by the National Cancer Institute and two studies in > 350 subjects using intranasal administration in Brazil.,0
318,perillylalcohol,NEO100 is a highly purified (>99%) form of perillyl alcohol.,43
318,gadolinium,"MRI with gadolinium will be at base line, and at the beginning of even cycles.",9
319,bevacizumab,This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.,70
319,temozolomide,This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.,87
319,bevacizumab,"Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.",64
319,temozolomide,"Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.",81
320,methyl-guaninemethyl,"Correlate clinical and radiological response to known biomarkers of GBM such as Isocitrate Dehydrogenase 1 (IDH-1) mutations, Isocitrate Dehydrogenase 2 (IDH-2) mutations, Methyl-Guanine Methyl Transferase (MGMT) promoter methylation, Phosphatase and tensin homologue (PTEN) loss and KI-67.  ",172
321,oxygen,Anti-angiogenic therapies potentially starve the tumor of necessary oxygen and nutrients.,68
322,temozolomide,"After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%.",6
322,irinotecan,"After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%.",51
322,irinotecan,"After treatment with irinotecan-based chemotherapy regimen, the PFS-6% of recurrent lower-grade gliomas was 40%.",21
322,bevacizumab,"Bevacizumab, a humanized monoclonal antibody directed against VEGF, is the prototypical anti-angiogenic drug and received accelerated approval of the United States Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma.",0
322,bevacizumab,"Bevacizumab inproved the PFS-6% (36%), but had no effect on the overall survival (OS) (9.2 months).",0
322,bevacizumab,"Moreover, the effects of bevacizumab are transient and most patients' tumors progress just after a median time of 3-5 months.",25
322,temozolomide,"In our previous study, we retrospectively analyzed the effect and toxicity of rh-ES when combined with temozolomide and irinotecan on adult recurrent disseminated glioblastoma.",103
322,irinotecan,"In our previous study, we retrospectively analyzed the effect and toxicity of rh-ES when combined with temozolomide and irinotecan on adult recurrent disseminated glioblastoma.",120
322,bevacizumab,"After tumor progression from the combined chemotherapy, bevacizumab usage could help to prolong the survival time (5.1 months versus 2.4 months).",56
322,temozolomide,"On the basis of prior clinical experience, we carry out this prospective trial to confirm the efficacy and safety of the combination of rh-ES, temozolomide and irinotecan in patients with recurrent gliomas.",143
322,irinotecan,"On the basis of prior clinical experience, we carry out this prospective trial to confirm the efficacy and safety of the combination of rh-ES, temozolomide and irinotecan in patients with recurrent gliomas.",160
323,eo2401,"This is a multicenter, Phase 1b/2a, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.",137
323,bevacizumab," EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered alone and in combination with nivolumab, and nivolumab/bevacizumab to generate preliminary safety and efficacy data in patients with progressive glioblastoma.",231
324,temozolomide,"The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal.",147
324,marizomib,Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies.,0
324,marizomib,"In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562).",41
324,marizomib,"Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma.",57
324,tmz,"Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma.",87
324,tmz,"Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma.",97
324,marizomib,"In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.",28
324,tmz,"In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.",94
324,tmz,"In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.",104
325,incmga00012,"In this study, the investigators propose to combine INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM).",52
325,bevacizumab,"In this study, the investigators propose to combine INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM).",96
325,epacadostat,"In this study, the investigators propose to combine INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM).",124
326,nivolumab,Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery.,12
326,nivolumab,Nivolumab will be continued following surgery until toxicity or progression.,0
327,ponatinib,The FDA (the U.S. Food and Drug Administration) has not approved Ponatinib for your specific disease but it has been approved for other uses.,65
327,ponatinib,Ponatinib is a drug that may stop cancer cells from growing by affecting different kinds of proteins in cancer cells.,0
327,ponatinib,Laboratory studies suggest that ponatinib has activity against mutated forms of (KIT) which is important in glioblastoma and therefore suggests that ponatinib may help to control the growth of glioblastoma.,32
327,ponatinib,Laboratory studies suggest that ponatinib has activity against mutated forms of (KIT) which is important in glioblastoma and therefore suggests that ponatinib may help to control the growth of glioblastoma.,149
327,ponatinib,In this research study the study team is looking to see if ponatinib is safe and is able to control the growth of glioblastoma in people who have not responded to treatment with bevacizumab.,59
328,temozolomide,Temozolomide (TMZ) combined with radiotherapy was the first substance to significantly improve the overall survival (to 14.6 months) as compared to surgery and radiotherapy alone and increased the proportion of patients surviving more than 2 years to 26%.,0
328,tmz,Temozolomide (TMZ) combined with radiotherapy was the first substance to significantly improve the overall survival (to 14.6 months) as compared to surgery and radiotherapy alone and increased the proportion of patients surviving more than 2 years to 26%.,14
328,tmz,TMZ showed the best efficacy in patients with a methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter in part by eliminating stem cell-like tumor cells.,0
328,o6-methylguanine,TMZ showed the best efficacy in patients with a methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter in part by eliminating stem cell-like tumor cells.,59
328,doxorubicin,Doxorubicin is one of the most effective substances in vitro against cells derived from glioblastoma.,0
328,doxorubicin,"In a tumor model, tissue and CSF-concentrations of doxorubicin were substantially increased when sterically stabilized liposomes were used resulting in a comparable clinical response using approximately half of the dose of stabilized liposomes compared to conventional doxorubicin.",51
328,doxorubicin,"In a tumor model, tissue and CSF-concentrations of doxorubicin were substantially increased when sterically stabilized liposomes were used resulting in a comparable clinical response using approximately half of the dose of stabilized liposomes compared to conventional doxorubicin.",269
328,peg,A pegylated formulation (PEG-liposomal Doxorubicin) even further improved the penetration of the blood-brain barrier.,25
328,doxorubicin,A pegylated formulation (PEG-liposomal Doxorubicin) even further improved the penetration of the blood-brain barrier.,39
328,peg,Case series and two phase II-studies in patients with recurrent glioblastoma have shown modestly promising results for PEG-Dox.,119
328,dox,Case series and two phase II-studies in patients with recurrent glioblastoma have shown modestly promising results for PEG-Dox.,123
328,peg-,"In this study, the investigators treated patients with recurrent glioblastoma with 20 mg/m2 PEG-Dox on days 1 and 15 of each 28-day cycle.",92
328,dox,"In this study, the investigators treated patients with recurrent glioblastoma with 20 mg/m2 PEG-Dox on days 1 and 15 of each 28-day cycle.",96
328,peg-,"To determine the dose limiting toxicity of PEG-Dox combined with prolonged administration of TMZ, the investigators performed a phase I part ahead of the phase II study.",43
328,dox,"To determine the dose limiting toxicity of PEG-Dox combined with prolonged administration of TMZ, the investigators performed a phase I part ahead of the phase II study.",47
328,tmz,"To determine the dose limiting toxicity of PEG-Dox combined with prolonged administration of TMZ, the investigators performed a phase I part ahead of the phase II study.",93
328,peg-dox,"To investigate, by means of a historical control analysis, if the addition of PEG-Dox to TMZ and radiotherapy improves the survival of patients, the investigators chose similar inclusion criteria and identical TMZ and radiotherapeutic regimes as in the EORTC26981/NCIC-CE.3 study.",78
328,tmz,"To investigate, by means of a historical control analysis, if the addition of PEG-Dox to TMZ and radiotherapy improves the survival of patients, the investigators chose similar inclusion criteria and identical TMZ and radiotherapeutic regimes as in the EORTC26981/NCIC-CE.3 study.",89
328,tmz,"To investigate, by means of a historical control analysis, if the addition of PEG-Dox to TMZ and radiotherapy improves the survival of patients, the investigators chose similar inclusion criteria and identical TMZ and radiotherapeutic regimes as in the EORTC26981/NCIC-CE.3 study.",210
329,bevacizumab,Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.,153
330,mgb453,"To assess the effects of MGB453, spartalizumab and their combination with SRS on immune cells in peripheral blood, including but not limited to the T cell compartments, myeloid cells, and serum proteins (cytokines and other immune modulators).",25
331,bortezomib,"This is an open-label, 2-arm Phase II study assessing safety & efficacy of bortezomib in combination with Avastin for patients with recurrent glioblastoma multiforme (gbm).",75
331,bortezomib,"Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, & 32 of a 42-day cycle.",0
331,bortezomib,The dose of bortezomib was 1.7 mg/m2 for non-EIAED patients & 2.5 mg/m2 for EIAED patients.,12
331,bortezomib,"Bortezomib administration is associated with mild toxicity in most patients, such as fatigue, diarrhea & nausea, constipation & peripheral neuropathy.",0
331,bortezomib,"Less common, bortezomib administration leads to more significant hematologic toxicities & peripheral neuropathies.",13
333,bbi608,"In arm A, patients who are candidates for surgical resection will receive BBI608 as monotherapy prior to resection, followed by post-operative BBI608 administered in combination with temozolomide.",74
333,bbi608,"In arm A, patients who are candidates for surgical resection will receive BBI608 as monotherapy prior to resection, followed by post-operative BBI608 administered in combination with temozolomide.",143
333,temozolomide,"In arm A, patients who are candidates for surgical resection will receive BBI608 as monotherapy prior to resection, followed by post-operative BBI608 administered in combination with temozolomide.",183
333,temozolomide,"In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, in combination with temozolomide.  ",133
335,bevacizumab,"To determine the overall survival of patients with recurrent GBM treated with bevacizumab, irinotecan and radiosurgery  SECONDARY OBJECTIVES:  ",78
335,irinotecan,"To determine the overall survival of patients with recurrent GBM treated with bevacizumab, irinotecan and radiosurgery  SECONDARY OBJECTIVES:  ",91
335,bevacizumab,"To evaluate the toxicities of the combination of bevacizumab, irinotecan and radiosurgery.",49
335,irinotecan,"To evaluate the toxicities of the combination of bevacizumab, irinotecan and radiosurgery.",62
335,bevacizumab,"To evaluate the progression-free survival of patients treated with bevacizumab, irinotecan and radiosurgery.",67
335,irinotecan,"To evaluate the progression-free survival of patients treated with bevacizumab, irinotecan and radiosurgery.",80
335,bevacizumab,Patients receive bevacizumab IV over 30 minutes on days 1 and 15.,17
335,irinotecanhydrochloride,Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2.,22
335,bevacizumab,Patients undergo radiosurgery 10-14 days after beginning bevacizumab.,57
336,erlotinib,The primary objective of this study will be to determine the 6-month progression free survival of patients with recurrent GBM treated with Erlotinib plus Sirolimus.,139
336,sirolimus,The primary objective of this study will be to determine the 6-month progression free survival of patients with recurrent GBM treated with Erlotinib plus Sirolimus.,154
336,erlotinib,"This is an exploratory, single-arm, phase II study designed to assess the anti-tumor activity of a combinatorial regimen consisting of Erlotinib plus Sirolimus among patients with recurrent GBM.",135
336,sirolimus,"This is an exploratory, single-arm, phase II study designed to assess the anti-tumor activity of a combinatorial regimen consisting of Erlotinib plus Sirolimus among patients with recurrent GBM.",150
336,erlotinib,The combinatorial regimen of Erlotinib plus Sirolimus is rationally designed to simultaneously inhibit upstream (EGFR) and downstream (mTOR) mediators of Phosphatidylinositide 3-kinase/Protein Kinase B (PI3/AKT) signaling.,29
336,sirolimus,The combinatorial regimen of Erlotinib plus Sirolimus is rationally designed to simultaneously inhibit upstream (EGFR) and downstream (mTOR) mediators of Phosphatidylinositide 3-kinase/Protein Kinase B (PI3/AKT) signaling.,44
336,gefitinib,"In a recently completed phase I study, we determined that an EGFR inhibitor (Gefitinib) can be safely combined with Sirolimus at dose levels that are routinely used in the monotherapy setting.",77
336,sirolimus,"In a recently completed phase I study, we determined that an EGFR inhibitor (Gefitinib) can be safely combined with Sirolimus at dose levels that are routinely used in the monotherapy setting.",116
336,erlotinib,"Therefore, the primary endpoint of this study is the probability of progression-free survival at 6 months among recurrent GBM patients treated with standard doses of Erlotinib plus Sirolimus.",166
336,sirolimus,"Therefore, the primary endpoint of this study is the probability of progression-free survival at 6 months among recurrent GBM patients treated with standard doses of Erlotinib plus Sirolimus.",181
336,erlotinib,An important secondary objective is to further assess the safety of Erlotinib and Sirolimus for patients with recurrent GBM.,68
336,sirolimus,An important secondary objective is to further assess the safety of Erlotinib and Sirolimus for patients with recurrent GBM.,82
337,amg595,This study of AMG 595 will be conducted in two parts: Part 1 (dose exploration) and Part 2 (dose expansion).,14
337,amg595,The dose of AMG 595 utilized in Part 2 will be dependent upon data obtained in Part 1 of the study.,12
338,losartan,"For this study losartan, an angiotensin-II inhibitor, is defined as the Investigational Medicinal Product (IMP).",15
338,angiotensin-ii,"For this study losartan, an angiotensin-II inhibitor, is defined as the Investigational Medicinal Product (IMP).",28
338,losartan,The focus of the study is to assess the dose-response relationship of losartan on imaging-based measures of tissue perfusion and mechanical forces in patients with brain tumors.,70
338,losartan,"We hypothesize that losartan improves the effect of traditional cancer treatment by alleviating mechanical forces (solid stress) of the tumor microenvironment to improve tissue perfusion, while administration of losartan alone has little effect on cancer patients.",20
338,losartan,"We hypothesize that losartan improves the effect of traditional cancer treatment by alleviating mechanical forces (solid stress) of the tumor microenvironment to improve tissue perfusion, while administration of losartan alone has little effect on cancer patients.",212
338,losartan,The study will assess the safety of losartan treatment and its dose-response relationship on conventional and experimental radiographic characteristics when used alone or as an add-on to standard cancer treatment.,36
339,bevacizumab,OBJECTIVES:  To determine the therapeutic role of bevacizumab as well as the most favorable approach to treatment optimization for sequencing the combination of bevacizumab and lomustine in patients with glioblastoma multiforme in first recurrence.,50
339,bevacizumab,OBJECTIVES:  To determine the therapeutic role of bevacizumab as well as the most favorable approach to treatment optimization for sequencing the combination of bevacizumab and lomustine in patients with glioblastoma multiforme in first recurrence.,161
339,lomustine,OBJECTIVES:  To determine the therapeutic role of bevacizumab as well as the most favorable approach to treatment optimization for sequencing the combination of bevacizumab and lomustine in patients with glioblastoma multiforme in first recurrence.,177
339,steroid,"Patients are stratified according to institution, WHO performance status (0 vs > 0), steroid administration (yes vs no), and largest diameter of tumor (≤ 40 mm vs > 40 mm).",85
339,lomustine,Arm 1: Lomustine 90 mg/m² every 6 weeks (cap.,7
339,bevacizumab,160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion).,10
339,lomustine,In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.,86
339,lomustine,Arm 2 (control arm): Lomustine single agent 110 mg/m² every 6 weeks (cap.,21
339,lomustine,One cycle will be defined arbitrarily (due to the lomustine sequencing) as 6 weeks for all arms.,50
340,ferumoxytol,After undergoing screening assessments and verifying eligibility for study participation subjects will undergo a research ferumoxytol-enhanced MRI of the brain and blood draws for liquid biopsy.,122
341,nivolumab,"To determine safety of each of the following study agents, anti-GITR, IDO1 inhibitor, and ipilimumab, in combination with nivolumab (BMS-936558) flat dose in patients with first recurrence of GBM.",122
341,bms-936558,"To determine safety of each of the following study agents, anti-GITR, IDO1 inhibitor, and ipilimumab, in combination with nivolumab (BMS-936558) flat dose in patients with first recurrence of GBM.",133
341,nivolumab,"To estimate toxicity To estimate progression-free survival To estimate overall survival To evaluate pain for patients undergoing the treatment of anti-GITR, IDO1 inhibitor, and ipilimumab, in combination with nivolumab.",209
342,temozolomide,"For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.",96
342,stuppregimen,"For patients with glioblastoma,postoperative radiotherapy combined with concurrent and adjuvant temozolomide (Stupp regimen) has long been considered a standard treatment approach.",110
342,tyrosine,"As a novel small molecule multi-target tyrosine kinase inhibitor, anlotinib hydrochloride has been found to be able to inhibit both tumor angiogenesis and cell growth.",39
342,anlotinibhydrochloride,"As a novel small molecule multi-target tyrosine kinase inhibitor, anlotinib hydrochloride has been found to be able to inhibit both tumor angiogenesis and cell growth.",66
342,anlotinibhydrochloride,The current study is designed to evaluate the efficacy and feasibility of the additional anlotinib hydrochloride to the Stupp regimen for newly diagnosed glioblastoma.,89
342,stupp,The current study is designed to evaluate the efficacy and feasibility of the additional anlotinib hydrochloride to the Stupp regimen for newly diagnosed glioblastoma.,120
343,kb004,This is a study of drug KB004 in patients with recurrent glioblastoma (GBM).,24
343,zirconium,Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM and normal tissues.,86
343,kb004/89zrkb004,Eligible patients with measurable tumours will receive an initial trace (5mg) dose of zirconium labelled KB004 (89ZrKB004) on day 1 followed by sequential Positron emission tomography (PET) imaging over 1 week to determine its biodistribution into GBM and normal tissues.,105
343,kb004/89z004,"On Day 8, patients commence weekly KB004 infusions over 2 hours with standard premedications.",35
343,kb004,"On day 36, patients receive both 89ZrKB004 and KB004, allowing assessment of receptor occupancy to guide recommended phase two dose (RPTD) determination.",47
343,kb004,Response rate (RANO) and survival data will be collected and patients benefiting may continue KB004 treatment until disease progression.,94
343,kb004/89zrkb004/89zrkb004,Primary objective: to determine the toxicity and recommended phase two dose (RPTD) of KB004 in patients with advanced Glioblastoma (GBM).,86
343,kb004," Secondary objectives: to determine the biodistribution and pharmacokinetics of 89ZrKB004; to determine frequency of EphA3 (ephrin receptor A3) positive glioblastoma in archival specimens and by 89ZrKB004 scans, and correlate with known biomarkers; to describe response rates per RANO criteria (Response Assessment in Neuro-Oncology Criteria) and pharmacodynamics following KB004 infusion; Exploratory objectives: to perform exploratory analysis between clinical outcomes and biodistribution/Pharmacokinetics (PK)/pharmacodynamics (PD) data, including from matched biopsies.",374
344,chlorotoxin,PRIMARY OBJECTIVES:  I. Assess the feasibility and safety of dual delivery of chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs (chlorotoxin [CLTX]-CAR T cells) for participants with MMP2+ recurrent or progressive glioblastoma.,78
344,chlorotoxin,PRIMARY OBJECTIVES:  I. Assess the feasibility and safety of dual delivery of chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs (chlorotoxin [CLTX]-CAR T cells) for participants with MMP2+ recurrent or progressive glioblastoma.,152
344,cl,PRIMARY OBJECTIVES:  I. Assess the feasibility and safety of dual delivery of chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs (chlorotoxin [CLTX]-CAR T cells) for participants with MMP2+ recurrent or progressive glioblastoma.,165
344,chlorotoxin,Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via dual delivery starting on day 0 for 3 weekly cycles over 28 days.,17
345,plerixafor,Plerixafor is given as subcutaneous injection (under the skin).,0
345,plerixafor,The research doctor will specify which days participants should take plerixafor.,69
345,ple,"In general, plerixafor will be given once daily during the first three weeks of every cycle (during part 3, patients will receive plerixafor the last week of each cycle, as well).",12
345,ple,"In general, plerixafor will be given once daily during the first three weeks of every cycle (during part 3, patients will receive plerixafor the last week of each cycle, as well).",130
345,bevacizumab,Bevacizumab (10 mg/kg) will be given as an infusion on Days 1 and 15 of each cycle.,0
345,plerixafor,"During Part 2, before patient begins their post-surgical cycles of treatment, plerixafor will be administered daily for 5-9 days at the MTD established in Part 1 of the study; patient will continue to surgery; and once recovered from surgery, patient will begin post-surgical cycles of treatment (plerixafor and bevacizumab) at the MTD/regimen established in Part 1 of the study.",78
345,plerixafor,"During Part 2, before patient begins their post-surgical cycles of treatment, plerixafor will be administered daily for 5-9 days at the MTD established in Part 1 of the study; patient will continue to surgery; and once recovered from surgery, patient will begin post-surgical cycles of treatment (plerixafor and bevacizumab) at the MTD/regimen established in Part 1 of the study.",297
346,bevacizumab,A team recently showed that baseline plasma levels of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were correlated to bevacizumab activity in patients with recurrent glioblastoma.,145
346,temozolomide,"Methods: Plasmatic levels of MMP2, MMP9, vascular endothelial growth factor-A (VEGFA), vascular endothelial growth factor-R2 (VEGFR2), stromal cell-derived factor 1 (SDF1) and chemokine receptor-4 (CXCR4) will be analyzed by enzyme-linked immunosorbent assay (ELISA) in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma.",336
346,temozolomide,"Tumor volume, infiltration and perfusion degrees will be analyzed on Magnetic Resonance Imaging (MRI) performed before and after surgery and before adjuvant temozolomide.",157
348,mannitol,The experimental aspects of this treatment plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 25%; 10 mL over 2 minutes) in order to disrupt the blood brain barrier.,99
348,mannitol,The experimental aspects of this treatment plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 25%; 10 mL over 2 minutes) in order to disrupt the blood brain barrier.,140
348,bevacizumab,To treat patients <22 years of age with recurring or relapsing glioma with a single intraarterial delivery (SIACI) of Cetuximab and Bevacizumab.,132
349,irinotecan,This is a phase II study of the combination of panitumumab with irinotecan in malignant glioma patients.,64
349,irinotecan,The primary objective of the study is to determine the activity of the combination of panitumumab with irinotecan as measured by 6-month progression-free survival.,103
349,irinotecan,"Secondary objectives include the following- to determine the safety of panitumumab in combination with irinotecan in patients with malignant glioma; to determine the effect of panitumumab in combination with irinotecan on corticosteroid dose for each patient; to explore any relationship between epidermal growth factor receptor (EGF-R) mutational analysis and efficacy or toxicity; and, to determine the response rate and overall survival of recurrent glioblastoma (GBM) patients treated with panitumumab in combination with irinotecan.",103
349,irinotecan,"Secondary objectives include the following- to determine the safety of panitumumab in combination with irinotecan in patients with malignant glioma; to determine the effect of panitumumab in combination with irinotecan on corticosteroid dose for each patient; to explore any relationship between epidermal growth factor receptor (EGF-R) mutational analysis and efficacy or toxicity; and, to determine the response rate and overall survival of recurrent glioblastoma (GBM) patients treated with panitumumab in combination with irinotecan.",208
349,irinotecan,"Secondary objectives include the following- to determine the safety of panitumumab in combination with irinotecan in patients with malignant glioma; to determine the effect of panitumumab in combination with irinotecan on corticosteroid dose for each patient; to explore any relationship between epidermal growth factor receptor (EGF-R) mutational analysis and efficacy or toxicity; and, to determine the response rate and overall survival of recurrent glioblastoma (GBM) patients treated with panitumumab in combination with irinotecan.",526
349,irinotecan,"The most common side effects associated with irinotecan have been decreased blood counts of platelets (increased risk of bleeding), white blood cells (increased risk of infection), red blood cells (anemia); diarrhea, constipation, nausea, vomiting, tiredness, fever, mouth sores, dehydration (excessive loss of body fluids), rash, itching, changes in skin color, swelling, numbness, tingling, dizziness, confusion, low blood pressure, sweating, hot flashes, hair loss, inflammation of the liver, flu-like symptoms,",45
350,bevacizumab,PRIMARY OBJECTIVES:  Anti-angiogenic Therapy Naive Patients: To determine 6 month progression-free survival (PFS6) in anti-angiogenic therapy (including anti-vascular endothelial growth factor (VEGF) therapy or bevacizumab) naive patients with recurrent glioblastoma (GBM) in patients treated with dovitinib  ,211
350,dovitinib,PRIMARY OBJECTIVES:  Anti-angiogenic Therapy Naive Patients: To determine 6 month progression-free survival (PFS6) in anti-angiogenic therapy (including anti-vascular endothelial growth factor (VEGF) therapy or bevacizumab) naive patients with recurrent glioblastoma (GBM) in patients treated with dovitinib  ,298
350,dovitinib, SECONDARY OBJECTIVES:  To evaluate the side effect profile of dovitinib in both patient populations.,63
350,dovitinib,To evaluate the efficacy of dovitinib as measured by objective response rate (ORR) in both patient populations.,28
350,bevacizumab,To estimate time to progression in anti-angiogenic therapy (including anti-VEGF therapy or bevacizumab),91
350,dovitinib,naiVe patients with recurrent glioblastoma (GBM) in patients treated with dovitinib.,74
350,dovitinib,Patients receive dovitinib orally (PO) 5 days a week.,17
351,talazoparib,D1-4: Oral talazoparib 0.75mg daily; D1: Carboplatin (AUC 1.5).,11
351,carboplatin,D1-4: Oral talazoparib 0.75mg daily; D1: Carboplatin (AUC 1.5).,41
353,tryptophan,"Once we receive the results of the PET scan, these will be compared to the MRI in order to help us analyze the tryptophan uptake in your brain.",111
353,amt,The PET scan will be used to measure the accumulation of the injected radioactive tracer AMT in your brain.,89
353,am,"For the PET scan, an intravenous catheter (a small tube placed in your vein) will be inserted for the injection of the AMT for this PET scan.",119
353,tryptophan,The goal of these tests is to identify various clinical problems that can be associated with brain tumors and affected by abnormal tryptophan metabolism that we measure with the PET scan.,131
354,bpm31510,"Primary Objective:  Assess the safety and tolerability of BPM31510 plus vitamin K in subjects with high-grade glioma(HGG), defined as anaplastic astrocytoma (AA) or glioblastoma (GB) that has recurred on a BEV containing regimen.",58
354,vitamink,"Primary Objective:  Assess the safety and tolerability of BPM31510 plus vitamin K in subjects with high-grade glioma(HGG), defined as anaplastic astrocytoma (AA) or glioblastoma (GB) that has recurred on a BEV containing regimen.",72
354,bev,"Primary Objective:  Assess the safety and tolerability of BPM31510 plus vitamin K in subjects with high-grade glioma(HGG), defined as anaplastic astrocytoma (AA) or glioblastoma (GB) that has recurred on a BEV containing regimen.",206
354,bpm31510, To evaluate plasma pharmacokinetics (PK) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,47
354,vitamink, To evaluate plasma pharmacokinetics (PK) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,61
354,bev, To evaluate plasma pharmacokinetics (PK) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,116
354,bev,Estimate the overall survival in subjects with HGG recurrent on a BEV containing regimen from the 1st day of infusion of BPM31510 plus vitamin K to death.,66
354,bpm31510,Estimate the overall survival in subjects with HGG recurrent on a BEV containing regimen from the 1st day of infusion of BPM31510 plus vitamin K to death.,121
354,vitamink,Estimate the overall survival in subjects with HGG recurrent on a BEV containing regimen from the 1st day of infusion of BPM31510 plus vitamin K to death.,135
354,bpm31510,To evaluate the effects of BPM31510 plus vitamin K on shifting HGG metabolism to aerobic respiration by PET imaging.,27
354,vitamink,To evaluate the effects of BPM31510 plus vitamin K on shifting HGG metabolism to aerobic respiration by PET imaging.,41
354,bpm1510,To evaluate the effects of BPM1510 plus vitamin K on MRI imaging by Response Assessment in Neuro Oncology (RANO) criteria [specifically progression free survival (PFS) and response rate (RR)].,27
354,vitamink,To evaluate the effects of BPM1510 plus vitamin K on MRI imaging by Response Assessment in Neuro Oncology (RANO) criteria [specifically progression free survival (PFS) and response rate (RR)].,40
354,bpm31510,To evaluate plasma pharmacodynamics (PD) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,46
354,vitamink,To evaluate plasma pharmacodynamics (PD) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,60
354,bev,To evaluate plasma pharmacodynamics (PD) when BPM31510 plus vitamin K is given to subjects with HGG recurrent on a BEV containing regimen.,115
355,azd1390,"This first time-in patients (FTIP), open-label, multicentre study of AZD1390 will be conducted in the United States and in the United Kingdom, and it consists of three treatment arms:",69
355,azd1390,This Phase 1 study will assess safety and tolerability of AZD1390 in combination with radiation therapy (RT) in brain malignancies.,58
355,azd1390,The combination cohorts have been designed to assess escalating cumulative doses of AZD1390 in settings with 3 different radiation treatment regimens:  ,84
356,bevacizumab,This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab.,108
356,bevacizumab,Bevacizumab is a drug that your doctor believes is the best treatment option available to subjects at this time for this type of tumor.,0
356,bevacizumab,"Bevacizumab affects the growth of blood vessels by tumors such as glioblastoma, thus effectively starving the tumor of oxygen and food.  ",0
356,oxygen,"Bevacizumab affects the growth of blood vessels by tumors such as glioblastoma, thus effectively starving the tumor of oxygen and food.  ",119
356,bevacizumab,This project will allow us to compare the images of vessel and tumor structure to the effectiveness of Bevacizumab as a treatment option.,103
356,bevacizumab,With this project the investigators will hopefully develop an accurate way to predict whether or not Bevacizumab will be an effective treatment option for patients.,101
357,mk-3475,This study will identify the effectiveness of oral inhibitors of PI3K / Akt pathway in comparison with MK-3475 (pembrolizumab).,103
358,mk-2206,"Participants will have the following tests and procedures within 2 days before the first dose of MK-2206: medical history, physical examination, blood tests, urine tests and EKG.",97
358,fdg,Participants in Part 2 of this research study may also have optional FDG-PET imaging done.,69
358,mk-2206,Participants in Part 1 will take MK-2206 orally prior to surgery on days 1-8 (with surgery after the MK-2206 dose on day 8).,33
358,mk-2206,Participants in Part 1 will take MK-2206 orally prior to surgery on days 1-8 (with surgery after the MK-2206 dose on day 8).,101
358,mk-2206,"They will have an EKG within 4-8 hours after their first dose of MK-2206, and again on Day 8.",65
358,mk-2206,The tumor tissue will be analyzed to measure the level of MK-2206 in the tumor and to study the effect of the drug on the tumor.,58
358,mk-2206,You will also have 3 teaspoons of blood drawn to measure the level of MK-2206 in the blood.,70
358,mk-2206,"One to 4 weeks after surgery (within 14 days of the last MRI/CT scan), MK-2206 treatment will restart at the same schedule as before surgery (weekly dosing).",71
358,mk-2206,"Within 2 days prior to restarting MK-2206 the following tests and procedures must be completed: medical history, physical examination, blood tests, urine test and EKG.",34
358,mk-2206,"Participants in both groups will receive MK-2206 by mouth once a week (Days 1, 8, 15, and 22).",41
358,mk-2206,"Participants will receive an EKG within 4-8 hours after their first dose of MK-2206 (for Part 1 participants, this is day 1 pre-surgery; for Part 2 participants, this is day 1 of the first cycle of treatment).",76
358,mk-2206,Participants will receive an EKG weekly during their first cycle of treatment with MK-2206.,83
358,mk-2206,"The following tests and procedures are required within 2 days before the start of each subsequent 4-week cycle of MK-2206 treatment: medical history, physical examination, blood tests, urine test, and EKG.",114
360,bevacizumab,"One arm (the ""bevacizumab naïve"" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the ""post-bevacizumab"" arm) will enroll patients who have experienced progression on bevacizumab.",14
360,bevacizumab,"One arm (the ""bevacizumab naïve"" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the ""post-bevacizumab"" arm) will enroll patients who have experienced progression on bevacizumab.",87
360,bevacizumab,"One arm (the ""bevacizumab naïve"" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the ""post-bevacizumab"" arm) will enroll patients who have experienced progression on bevacizumab.",137
360,bevacizumab,"One arm (the ""bevacizumab naïve"" arm) will enroll patients who have not received prior bevacizumab therapy, and the other arm (the ""post-bevacizumab"" arm) will enroll patients who have experienced progression on bevacizumab.",212
360,bibf1120,"All subjects will receive BIBF 1120 at 200mg orally, twice daily in cycles of 28 days.",26
360,gadolinium,"Subjects will have gadolinium-enhanced brain MRI scans performed with tumor measurements at screening, at the start of even-numbered cycles, and at the end of active study treatment(unless already obtained within 4 weeks of completing study treatment).",19
361,bevacizumab,Arm number one will receive Bevacizumab every 2 weeks in combination with TVB-2640 from day 1 until day 28 of the first cycle.,28
361,tvb-2640,Arm number one will receive Bevacizumab every 2 weeks in combination with TVB-2640 from day 1 until day 28 of the first cycle.,74
361,bevacizumab,"Arm number two will receive Bevacizumab alone every 2 weeks, from on days 1 and 15 of the first until day 28 of the first cycle.",28
361,bevacizumab,"Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to receive bevacizumab every 2 weeks in combination with TVB-2640.",99
361,tvb-2640,"Starting on cycle 2 day 1, all patients will converge to a single arm and will continue to receive bevacizumab every 2 weeks in combination with TVB-2640.",145
362,bgb-290,"PRIMARY OBJECTIVES:  (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",109
362,bgb-290,"PRIMARY OBJECTIVES:  (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",118
362,temozolomide,"PRIMARY OBJECTIVES:  (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",131
362,tmz,"PRIMARY OBJECTIVES:  (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",145
362,bgb-290,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,39
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,52
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,129
362,bgb-290,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant glioma that have failed one alkylator with >= 12 months since last treatment (Arm B) in the Phase II portion.,39
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant glioma that have failed one alkylator with >= 12 months since last treatment (Arm B) in the Phase II portion.,52
362,bgb-290," PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",100
362,bgb-290," PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",109
362,temozolomide," PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",122
362,tmz," PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion.",136
362,bgb-290,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,39
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,52
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant gliomas that have progressed on TMZ and another alkylator (Arm A) in the Phase II portion.,129
362,bgb-290,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant glioma that have failed one alkylator with >= 12 months since last treatment (Arm B) in the Phase II portion.,39
362,tmz,Determine the overall response rate of BGB-290 with TMZ in patients with recurrent IDH1/2-mutant glioma that have failed one alkylator with >= 12 months since last treatment (Arm B) in the Phase II portion.,52
362,bgb-290, I. Determine the progression-free survival (PFS) and overall survival (OS) after treatment with BGB-290 and TMZ in recurrent IDH1/2-mutant gliomas in Arms A and B.  II.,97
362,tmz, I. Determine the progression-free survival (PFS) and overall survival (OS) after treatment with BGB-290 and TMZ in recurrent IDH1/2-mutant gliomas in Arms A and B.  II.,109
362,bgb-290,Confirm the safety and tolerability of BGB-290 in combination with TMZ.,39
362,tmz,Confirm the safety and tolerability of BGB-290 in combination with TMZ.,67
362,bgb-290," EXPLORATORY OBJECTIVES:  I. Assess tumor response rates, PFS, and OS in patients with World Health Organization (WHO) grade IV glioblastoma (GBM) treated with BGB-290 and TMZ.",160
362,tmz/2-hydroxyglutarate," EXPLORATORY OBJECTIVES:  I. Assess tumor response rates, PFS, and OS in patients with World Health Organization (WHO) grade IV glioblastoma (GBM) treated with BGB-290 and TMZ.",172
362,2hg,V. Quantify 2-hydroxyglutarate (2HG) in archival formalin-fixed paraffin-embedded (FFPE) specimens via liquid chromatography mass spectrometry (LC-MS) detection and correlate with treatment response.,32
362,formalin,V. Quantify 2-hydroxyglutarate (2HG) in archival formalin-fixed paraffin-embedded (FFPE) specimens via liquid chromatography mass spectrometry (LC-MS) detection and correlate with treatment response.,49
362,bgb-290,"Assess tumor tissue BGB-290 levels, 2HG, and PolyADP-ribosylation (PARylation) in a patient subset treated with drug prior to re-resection.",20
362,temozolomide,"This is a phase I, dose de-escalation study of temozolomide followed by a phase II study.",47
362,bgb-290,"Patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO once daily (QD) on days 1-28, 1-21, 1-14, or 1-7.",32
362,temozolomide,"Patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO once daily (QD) on days 1-28, 1-21, 1-14, or 1-7.",87
362,bgb-290, SURGICAL PORTION: 10 patients eligible for re-resection at the time of recurrence receive PARP inhibitor BGB-290 PO BID on days 1-6 and QD on day 7 (the morning of surgery).,106
362,bgb-290,"Within 45 days after surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide on the schedule established in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",62
362,temozolomide,"Within 45 days after surgery, patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide on the schedule established in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.",94
362,bgb-290,Patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO QD on the schedule established in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.,32
362,temozolomide,Patients receive PARP inhibitor BGB-290 PO BID on days 1-28 and temozolomide PO QD on the schedule established in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.,64
363,f-18fluoroethyltyrosine,To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1.  II.,16
363,fet,To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1.  II.,42
363,f-18fluoroethyltyrosine,Participants receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute and undergo PET over 40 minutes.,21
364,dnx-2401,"To determine at the molecular and cellular level the capacity of allogeneic BM-hMSCs-DNX2401 administered intra-arterially to home to and deliver DNX-2401 to recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma by analyzing post-treatment surgical brain tumor specimens for the expression and distribution of adenoviral proteins.",146
365,wp1066,"PRIMARY OBJECTIVES; I. Identify the maximum tolerated dose (MTD) of STAT3 inhibitor WP1066 (WP1066) in patients with recurrent malignant glioma (glioblastoma, anaplastic glioma), and melanoma patients with progressive brain metastasis.",84
365,wp1066,"PRIMARY OBJECTIVES; I. Identify the maximum tolerated dose (MTD) of STAT3 inhibitor WP1066 (WP1066) in patients with recurrent malignant glioma (glioblastoma, anaplastic glioma), and melanoma patients with progressive brain metastasis.",92
365,wp1066,Assess the safety and tolerability of WP1066 in patients with recurrent malignant glioma and melanoma patients with progressive brain metastasis using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) with special attention directed at determining whether any induced autoimmune reactions occur.,38
365,wp1066, SECONDARY OBJECTIVES:  I. Pharmacokinetic analysis of the in vivo bioavailability of WP1066.,86
365,wp1066,Assess time to radiographically assessed progression and/or response in patients treated with WP1066.,94
365,wp1066, V. Assess progression-free survival (PFS) and overall survival (OS) in patients treated with WP1066.  VI.,94
365,wp1066,"Estimate the proportion of patients treated with WP1066 who develop additional melanoma metastatic lesions, including those in the central nervous system (CNS).",49
365,wp1066,"Patients receive STAT3 inhibitor WP1066 orally (PO) twice daily (BID) on Monday, Wednesday, and Friday of weeks 1 and 2.",33
366,fimepinostat,"I. To confirm penetration of fimepinostat across the blood brain barrier (BBB) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG), recurrent medulloblastoma, or recurrent high-grade glioma (HGG) by measuring concentration of fimepinostat and metabolite in primary tumor tissue.",29
366,fimepinostat,"I. To confirm penetration of fimepinostat across the blood brain barrier (BBB) in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG), recurrent medulloblastoma, or recurrent high-grade glioma (HGG) by measuring concentration of fimepinostat and metabolite in primary tumor tissue.",264
366,fimepinostat,"To assess pharmacokinetics (PK) of fimepinostat in plasma and tumor tissue of children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.",35
366,fimepinostat,"To assess pharmacodynamics (PD) of fimepinostat in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG as measured by phosphorylation and acetylation in tumor tissue.",35
366,fimepinostat,"To assess the safety and tolerability of fimepinostat in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.",41
366,fimepinostat,"To assess preliminary efficacy of fimepinostat given as monotherapy after surgery in children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG, as based on progression-free survival (PFS) and objective response rate (ORR) as appropriate.",34
366,fimepinostat,Patients receive fimepinostat orally (PO) once daily (QD) on days -2 to 0.,17
366,fimepinostat,"Within 2 hours of receiving fimepinostat on day 0, patients undergo tumor resection.",28
366,fimepinostat,"Patients receive fimepinostat by mouth, once daily for days 1-5 each week.",17
368,temozolomide,"While a standard of care is established for the initial treatment of GBM - radiation with concurrent and adjuvant temozolomide chemotherapy - management of recurrent disease (NCCN, 2014) remains suboptimal.",114
368,temozolomide,Epigenetic silencing of MGMT by promoter methylation is an important factor in predicting outcome for patients with GBM treated with temozolomide.,133
368,temozolomide,"Approximately 66% of GBM tumors are MGMT unmethylated (high expression of MGMT), which through a MGMT repair mechanism, confers resistance to temozolomide, the standard chemotherapy treatment of GBM.",142
368,val-083," VAL-083, Dianhydrogalactitol (DAG), unlike temozolomide, is demonstrated to be active independent of MGMT resistance mechanisms, in vitro.",1
368,dianhydrogalactitol," VAL-083, Dianhydrogalactitol (DAG), unlike temozolomide, is demonstrated to be active independent of MGMT resistance mechanisms, in vitro.",10
368,dag," VAL-083, Dianhydrogalactitol (DAG), unlike temozolomide, is demonstrated to be active independent of MGMT resistance mechanisms, in vitro.",31
368,temozolomide," VAL-083, Dianhydrogalactitol (DAG), unlike temozolomide, is demonstrated to be active independent of MGMT resistance mechanisms, in vitro.",44
368,temozolomide,"Thus, it may provide a treatment option for those patients that are considered likely to be poor responders to temozolomide.",111
368,val-083,"This is a non-comparative, two arm, biomarker-driven study with VAL-083 in GBM patients with either recurrent disease (Group 1) or newly diagnosed GBM patients requiring maintenance therapy after chemoradiation with temozolomide (Group 2).",64
368,temozolomide,"This is a non-comparative, two arm, biomarker-driven study with VAL-083 in GBM patients with either recurrent disease (Group 1) or newly diagnosed GBM patients requiring maintenance therapy after chemoradiation with temozolomide (Group 2).",216
368,temozolomide,Group 2: Up to an additional 36 newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide will be enrolled.,110
368,temozolomide,Group 2: Up to an additional 36 newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide will be enrolled.,162
368,val-083,"Eligible patients will receive VAL-083 IV on days 1, 2, and 3, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation (disease progression, death, intolerable toxicities, investigator's judgment, or withdrawal of consent).",31
368,val-083,"Disease status will be evaluated with clinical and MRI evaluation every other 21-day cycle, while the patient is receiving VAL-083 treatment, and then approximately every 42 ± 7 days while remaining on study.",123
368,val-083,"Blood samples will be taken at Cycle 1 Day 1 pre-dose, 15 ± 5 min, 30 ± 5 min, 60 ± 10 min, 120 ± 10 min, 240 ± 15 min, and 360 ± 15 min after the end of the of iv infusion with VAL-083 to determine the PK profile and dose-exposure relationship of VAL-083.",178
368,val-083,"Blood samples will be taken at Cycle 1 Day 1 pre-dose, 15 ± 5 min, 30 ± 5 min, 60 ± 10 min, 120 ± 10 min, 240 ± 15 min, and 360 ± 15 min after the end of the of iv infusion with VAL-083 to determine the PK profile and dose-exposure relationship of VAL-083.",248
369,temozolomide,"This is a nonrandomized, open label, single institution phase II trial with a safety run-in to evaluate the safety and efficacy of LDFRT plus temozolomide in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) previously treated with surgical resection followed by adjuvant radiation therapy plus temozolomide.",142
369,temozolomide,"This is a nonrandomized, open label, single institution phase II trial with a safety run-in to evaluate the safety and efficacy of LDFRT plus temozolomide in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) previously treated with surgical resection followed by adjuvant radiation therapy plus temozolomide.",345
369,temozolomide,The primary objective of the phase II study is to estimate response rate in patients treated with twice daily fractions of low dose radiation plus temozolomide chemotherapy.,147
370,im,"The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.",167
372,nivolumab,"To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab and placebo, ipilimumab and placebo, and nivolumab and ipilimumab in children and young adults with recurrent or progressive high grade glioma (HGG) when compared to a cohort of archived non-treated recurrent pediatric HGG samples.",137
372,nivolumab,"To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab and placebo, ipilimumab and placebo, and nivolumab and ipilimumab in children and young adults with recurrent or progressive high grade glioma (HGG) when compared to a cohort of archived non-treated recurrent pediatric HGG samples.",188
372,nivolumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",59
372,ipilimumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",94
372,ipilimumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",134
372,nivolumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",149
372,ipilimumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",180
372,nivolumab,"To characterize the safety and tolerability of neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, and neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab in children and young adults with recurrent or progressive HGG.",195
372,nivolumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",148
372,ipilimumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",171
372,nivolumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",198
372,ipilimumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",212
372,nivolumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",244
372,ipilimumab,"To determine the 6 month and 12 month overall survival (OS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",258
372,nivolumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",158
372,ipilimumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",181
372,nivolumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",208
372,ipilimumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",222
372,nivolumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",254
372,ipilimumab,"To determine the 6 month and 12 month progression-free survival (PFS) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab followed by adjuvant nivolumab and ipilimumab.",268
372,nivolumab,"To measure relative changes in interferon gamma associated genetic signature within the tumor microenvironment post administration of neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG compared to archived non-treated recurrent pediatric HGG samples.",146
372,nivolumab,"To measure relative changes in interferon gamma associated genetic signature within the tumor microenvironment post administration of neoadjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG compared to archived non-treated recurrent pediatric HGG samples.",196
372,nivolumab,"To measure TIL density post administration of neoadjuvant nivolumab and placebo compared to neo-adjuvant ipilimumab and placebo, and neoadjuvant nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.",58
372,ipilimumab,"To measure TIL density post administration of neoadjuvant nivolumab and placebo compared to neo-adjuvant ipilimumab and placebo, and neoadjuvant nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.",105
372,nivolumab,"To measure TIL density post administration of neoadjuvant nivolumab and placebo compared to neo-adjuvant ipilimumab and placebo, and neoadjuvant nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.",145
372,ipilimumab,"To measure TIL density post administration of neoadjuvant nivolumab and placebo compared to neo-adjuvant ipilimumab and placebo, and neoadjuvant nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.",159
372,nivolumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",134
372,ipilimumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",169
372,ipilimumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",208
372,nivolumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",223
372,ipilimumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",254
372,nivolumab,"To estimate the objective response rate (ORR) in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",269
372,amine,"To evaluate the association between advanced magnetic resonance imaging (MRI) parameters (apparent diffusion coefficient (ADC) on diffusion weighted imaging (DWI), relative cerebral blood volume (rCBV) on dynamic susceptibility contrast (DSC) perfusion MRI, pre-contrast T1 shortening on T1-weighed images, and/or magnetization transfer ratio with asymmetric analysis (MTRasym) on pH-weighted amine chemical exchange saturation transfer (CEST)-echo planar imaging (EPI)) and tumor and peripheral blood immune responses.",393
372,nivolumab,"To measure relative change in peripheral T-cell response and post administration of neo-adjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.  VII.",97
372,nivolumab,"To measure relative change in peripheral T-cell response and post administration of neo-adjuvant nivolumab and placebo, ipilimumab and placebo, or nivolumab and ipilimumab in children and young adults with recurrent or progressive HGG.  VII.",147
372,nivolumab,"To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab, and evaluate the differences between the three arms as well as between each group and archived non-treated recurrent pediatric HGG samples.",142
372,ipilimumab,"To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab, and evaluate the differences between the three arms as well as between each group and archived non-treated recurrent pediatric HGG samples.",177
372,ipilimumab,"To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab, and evaluate the differences between the three arms as well as between each group and archived non-treated recurrent pediatric HGG samples.",216
372,nivolumab,"To measure PD-1 and PDL-1 expression by immunohistochemistry for children and young adults with recurrent or progressive HGG post neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab, and evaluate the differences between the three arms as well as between each group and archived non-treated recurrent pediatric HGG samples.",231
372,nivolumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",164
372,ipilimumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",199
372,ipilimumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",238
372,nivolumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",253
372,ipilimumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",284
372,nivolumab,"To explore the correlation of tumor mutational load with clinical response for children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",299
372,nivolumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",143
372,ipilimumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",178
372,ipilimumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",217
372,nivolumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",232
372,ipilimumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",263
372,nivolumab,"To assess quality of life (QOL) and cognitive measures in children and young adults with recurrent or progressive HGG treated with neoadjuvant nivolumab and placebo, neoadjuvant ipilimumab and placebo, or neoadjuvant ipilimumab and nivolumab followed by adjuvant ipilimumab and nivolumab.",278
372,nivolumab,Patients receive nivolumab intravenously (IV) over 30 minutes and placebo IV over 30 minutes 14 days before undergoing standard of care surgical resection.,17
372,nivolumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",80
372,ipilimumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",113
372,nivolumab,"ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15.",81
372,nivolumab,Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes 14 days before undergoing standard of care surgical resection.,17
372,nivolumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",80
372,ipilimumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",113
372,nivolumab,"ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15.",81
372,nivolumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",80
372,ipilimumab,"After recovery from surgery (no more than 35 days afterwards), patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1.",113
372,nivolumab,"ADJUVANT MAINTENANCE: After completion of combination infusion, patients receive nivolumab IV over 30 minutes on days 1 and 15.",81
373,os2966,"This study is an open-label, ascending-dose, 2-part study designed to determine the safety and tolerability of OS2966, as well as the optimal infusion parameters when administering OS2966 directly to the tumor and the surrounding tumor-infiltrated brain by CED in participants with recurrent/progressive HGG undergoing a surgical resection.",111
373,os2966,"This study is an open-label, ascending-dose, 2-part study designed to determine the safety and tolerability of OS2966, as well as the optimal infusion parameters when administering OS2966 directly to the tumor and the surrounding tumor-infiltrated brain by CED in participants with recurrent/progressive HGG undergoing a surgical resection.",181
373,os2966, OS2966 is an anti-CD29 (Beta1 Integrin) monoclonal antibody (mAb) that has demonstrated preclinical efficacy in resistant/recurrent glioblastoma animal models.,1
373,os2966, OS2966 will be delivered by CED using the Infuseon Cleveland Multiport Catheter (ICMC) in both parts of the study.,1
373,os,"In Study Part 1, participants will receive a single intratumoral infusion of OS2966 directly to the contrast-enhancing bulk tumor by CED using one ICMC over 4 hours or until maximal tumor coverage is obtained.",77
373,os2966,"Immediately following surgical resection, 2 ICMCs will be placed directly into the surrounding tumor-infiltrated brain, and OS2966 will be infused over a 4 hour period and then the catheters removed.",124
373,os2966,"To confirm the quality of OS2966 delivery, a gadolinium contrast agent will be added to OS2966 before each infusion in order to monitor the infusion via magnetic resonance imaging.",26
373,gadolinium,"To confirm the quality of OS2966 delivery, a gadolinium contrast agent will be added to OS2966 before each infusion in order to monitor the infusion via magnetic resonance imaging.",45
373,os2966,"To confirm the quality of OS2966 delivery, a gadolinium contrast agent will be added to OS2966 before each infusion in order to monitor the infusion via magnetic resonance imaging.",88
373,os2966,"All participants will be closely monitored clinically, and through the use of imaging assessments to determine how effective OS2966 is at preventing further disease progression.",125
373,os2966,Tumor tissue will be collected in both study parts to evaluate how well OS2966 binds to its intended target and to confirm mechanism of action.,72
374,bevacizumab,Bevacizumab is used for treatment of recurrent disease; however patients who fail bevacizumab do not have many treatment options.,0
374,bevacizumab,Bevacizumab is used for treatment of recurrent disease; however patients who fail bevacizumab do not have many treatment options.,82
374,dianhydrogalactitol,Dianhydrogalactitol (DAG) rapidly penetrates both the cerebrospinal fluid (CSF) and the blood-brain barrier and accumulates in brain tissue.,0
374,dag,Dianhydrogalactitol (DAG) rapidly penetrates both the cerebrospinal fluid (CSF) and the blood-brain barrier and accumulates in brain tissue.,21
374,dag[eq]bbze[eq]bbze[eq]bbze[eq]bbze[eq]bbzeta,Clinical study of DAG in patients with GBM or with progressive secondary brain tumors is warranted.,18
377,poly(adp-ribose),"PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.",84
377,bgb-290,"PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.",130
377,bgb-290,"PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.",139
377,temozolomide,"PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.",152
377,tmz,"PRIMARY OBJECTIVES:  I. Determine the safety and tolerability of the combination of Poly (ADP-Ribose) polymerase (PARP) inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in adolescent and young adult (AYA) subjects with IDH1/2-mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in both, newly diagnosed and recurrent treatment arms.",166
377,bgb-290," I. Evaluate the preliminary efficacy of BGB-290 and temozolomide in terms of progression free survival (PFS) and overall survival (OS) in Arm A and B stratified by tumor diagnosis, calculated using the Kaplan-Meier method with a goal of improving the historical high grade glioma progression free survival of 10% and overall survival of 20% at 2 years.",41
377,temozolomide," I. Evaluate the preliminary efficacy of BGB-290 and temozolomide in terms of progression free survival (PFS) and overall survival (OS) in Arm A and B stratified by tumor diagnosis, calculated using the Kaplan-Meier method with a goal of improving the historical high grade glioma progression free survival of 10% and overall survival of 20% at 2 years.",53
377,bgb-290,Arm A: Newly diagnosed IDH1/2-mutant high-grade glioma patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.,87
377,temozolomide,Arm A: Newly diagnosed IDH1/2-mutant high-grade glioma patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.,142
377,bgb-290,Arm B: Recurrent IDH1/2-mutant low-grade or high-grade glioma patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.,94
377,temozolomide,Arm B: Recurrent IDH1/2-mutant low-grade or high-grade glioma patients receive PARP inhibitor BGB-290 orally (PO) twice daily (BID) on days 1-28 and temozolomide PO daily on days 1-21.,149
377,bgb-290,Recurrent IDH1/2-mutant low-grade or high-grade glioma patients receive PARP inhibitor BGB-290 PO for 7 days pre-surgery at the MTD determined in the Phase,87
378,bevacizumab,Group 1 are patients who have never been treated with bevacizumab.,54
378,bevacizumab,Group 2 and Group 2C patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab).,62
378,bevacizumab,Group 2 and Group 2C patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab).,138
378,bevacizumab,Group 2 and Group 2C patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab).,186
378,rindopepimut,These patients will all receive rindopepimut/GM-CSF along with bevacizumab.,32
378,bevacizumab,These patients will all receive rindopepimut/GM-CSF along with bevacizumab.,63
379,irinotecan,To define the recommended phase II doses (RP2D) of intracranially administered carboxylesterase-expressing allogeneic neural stem cells (hCE1m6-NSCs) in combination with intravenous irinotecan in patients with recurrent high grade glioma.,182
379,sn-38,To describe the relationship between hCE1m6-NSC dose and liposomal SN-38 (SN-38) concentrations in brain interstitium.,67
379,sn-38,To describe the relationship between hCE1m6-NSC dose and liposomal SN-38 (SN-38) concentrations in brain interstitium.,74
379,irinotecan,To characterize the relationship between intracerebral and systemic concentrations of irinotecan (irinotecan hydrochloride) and SN-38.,86
379,irinotecanhydrochloride,To characterize the relationship between intracerebral and systemic concentrations of irinotecan (irinotecan hydrochloride) and SN-38.,98
379,sn-38,To characterize the relationship between intracerebral and systemic concentrations of irinotecan (irinotecan hydrochloride) and SN-38.,128
379,sn-38,To investigate the biologic activity of hCE1m6 NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan versus irinotecan alone.,65
379,irinotecan,To investigate the biologic activity of hCE1m6 NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan versus irinotecan alone.,136
379,irinotecan,To investigate the biologic activity of hCE1m6 NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan versus irinotecan alone.,154
379,irinotecan,"V. To describe the clinical benefit (defined as stable disease, partial response, or complete response) in patients who receive treatment with repeat cycles of NSCs and irinotecan.",169
379,irinotecanhydrochloride,Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride intravenously (IV) over 90 minutes on days 3 and 17.,171
380,lapatinib,To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5 uM in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib.,27
380,lapatinibditosylate,To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5 uM in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib.,38
380,lapatinib,To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5 uM in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib.,162
380,lapatinib,To determine the pharmacodynamic (PD) effect of pulsatile lapatinib (at pulsatile maximum tolerated dose [MTD]) on epidermal growth factor receptor (EGFR) phosphorylation (using Mesoscale Discovery enzyme-linked immunosorbent assay [ELISA] assay for total and phospho-EGFR).,58
380,phospho,To determine the pharmacodynamic (PD) effect of pulsatile lapatinib (at pulsatile maximum tolerated dose [MTD]) on epidermal growth factor receptor (EGFR) phosphorylation (using Mesoscale Discovery enzyme-linked immunosorbent assay [ELISA] assay for total and phospho-EGFR).,260
380,lapatinib,To evaluate the safety profile of pulsatile lapatinib in pre-operative patients with EGFR amplified recurrent high-grade glioma.,44
380,lapatinib,To evaluate acute and late toxicities associated with pulsatile lapatinib.,64
380,lapatinib,To determine the effect of lapatinib on tumor cell proliferation (marker of proliferation Ki-67,27
380,lapatinib,To determine the ex-vivo sensitivity of tumor sphere cultures to lapatinib.,65
380,lapatinibditosylate,Patients receive lapatinib ditosylate orally (PO) twice daily (BID) on days -2 to 0.,17
380,lapatinibditosylate,"Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0.",36
380,lapatinibdito,"Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days.",64
380,lapatinibdito,"Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days.",64
381,temozolomide,This is a phase II trial of the combination of Avastin and metronomic temozolomide in recurrent WHO grade IV malignant glioma patients.,70
381,temozolomide,Patients will receive up to 12 cycles of Avastin and temozolomide and cycles are continuous 28 days.,53
381,temozolomide,Patients will receive daily temozolomide at a dose of 50mg/m2 and will receive Avastin every other week at a dose of 10mg/kg.,28
381,temozolomide,"Given the activity of metronomic temozolomide and the safety and activity of Avastin against malignant glioma, it is reasonable to study the combination in recurrent malignant glioma patients.",33
382,imatinibmesylate,"This is an open-label, single stage, uncontrolled, non-randomized Phase II study of continuous, daily doses of imatinib mesylate & hydroxyurea in adult patients with progressive/recurrent Grade II low-grade glioma (LGG).",111
382,hydroxyurea,"This is an open-label, single stage, uncontrolled, non-randomized Phase II study of continuous, daily doses of imatinib mesylate & hydroxyurea in adult patients with progressive/recurrent Grade II low-grade glioma (LGG).",131
382,imatinibmesylate,The treatment cycle is defined as imatinib mesylate & hydroxyurea administered daily for 28 days for purpose of scheduling evaluations.,34
382,hydroxyurea,The treatment cycle is defined as imatinib mesylate & hydroxyurea administered daily for 28 days for purpose of scheduling evaluations.,54
382,imatinibmesylate,"All patients who receive 1 or more doses of either imatinib mesylate or hydroxyurea will be evaluable for toxicity, whereas all patients who receive a minimum of 14 consecutive days of study regimen will be evaluable for response.",51
382,hydroxyurea,"All patients who receive 1 or more doses of either imatinib mesylate or hydroxyurea will be evaluable for toxicity, whereas all patients who receive a minimum of 14 consecutive days of study regimen will be evaluable for response.",72
383,gadolinium,The 'border zone' of the tumor will be targeted for SRS (defined as a combination of the MRI volume of gadolinium enhancement plus up to 2 cm of the surrounding T2 volume).,103
383,bevacizumab,"Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), has been used with safety and clinical success with concomitant chemotherapy in solid tumors, including GBM.  ",0
383,bevacizumab,The investigators further hypothesize that a combined approach of SRS with this VEGF inhibitor will be an effective strategy for GBM because bevacizumab will maximize the effects of radiation in the treated volume and potentially reduce radiation toxicity in the adjacent brain.,141
384,toca511,This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of their tumor.,70
384,toca511,"Patients meeting all of the inclusion and none of the exclusion criteria will receive an initial dose of Toca 511 administered as an intravenous, bolus injection, followed approximately 11 days later by an additional dose injected into the walls of the resection cavity at the time of planned tumor resection.",105
385,toca511,"This is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to patients with recurrent high grade glioma (rHGG) who have undergone surgery followed by adjuvant radiation therapy and chemotherapy.",110
385,toca511,"Patients will receive Toca 511 either via stereotactic, transcranial injection into their tumor or as an intravenous injection given daily for 3 & 5 days, depending on cohort.",22
386,mk-8669,This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752.,37
386,ridaforolimus,This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752.,46
386,mk-2206,This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752.,72
386,mk-0752,This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752.,83
386,mk-0752,As of 19 July 2012 the MK-0752 arms of the study were fully enrolled and closed to further recruitment.,23
387,toca511,"This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have elected to undergo surgical removal of their tumor.",90
387,toca511,"Approximately 6 weeks after injection of Toca 511, patients will begin an oral courses of Toca FC, an antifungal agent.",41
387,tocafc,"Approximately 6 weeks after injection of Toca 511, patients will begin an oral courses of Toca FC, an antifungal agent.",90
387,toca511,Two separate cohorts of patients treated with Toca 511 and Toca FC will also be evaluated with either of the following standard treatments for glioma: lomustine or bevacizumab.,46
387,toc,Two separate cohorts of patients treated with Toca 511 and Toca FC will also be evaluated with either of the following standard treatments for glioma: lomustine or bevacizumab.,59
387,lomustine,Two separate cohorts of patients treated with Toca 511 and Toca FC will also be evaluated with either of the following standard treatments for glioma: lomustine or bevacizumab.,151
387,bevacizumab,Two separate cohorts of patients treated with Toca 511 and Toca FC will also be evaluated with either of the following standard treatments for glioma: lomustine or bevacizumab.,164
391,toca511,"This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations.",101
391,tocafc,"This is a multicenter, open-label, continuation study to allow subjects who have previously received Toca 511 to continue to receive Toca FC and to allow for extended safety observations.",133
391,gadolinium,Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scans will be performed as per standard of care.,0
391,gd,Gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scans will be performed as per standard of care.,12
391,toca511,"If the subject has recurred/progressed, repeat intracranial injection of Toca 511 followed by Toca FC treatment may be offered to consenting patients.",73
392,carboxyamidotriazoleorotate,"The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.",128
392,cto,"The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.",158
392,temodar®,"The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.",260
392,temr®,"The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.",365
393,crenolan,"This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification.",60
393,temozolomide,"Eligible patients include those with recurrent/refractory glioblastoma after prior therapy including surgery, radiation, and temozolomide.",125
393,creno,The trial is designed to assess the anti-tumor activity of crenolanib in recurrent/refractory glioblastoma with PDGFRA gene amplification based on the estimation of progression-free survival (PFS) at 6 months.,59
393,crenolanib, Crenolanib will be administered orally continuously at 100 mg TID on a 28-day cycle basis .,1
393,crenolanib,Patients are allowed to receive crenolanib for a maximum of 26 cycles if clinical benefit has been observed.,32
394,abi-009,"A phase 2, open-label study of ABI-009 (nab-Rapamycin) in patients with recurrent high grade glioma following prior therapy and subjects with newly diagnosed glioblastoma.",31
394,nab,"A phase 2, open-label study of ABI-009 (nab-Rapamycin) in patients with recurrent high grade glioma following prior therapy and subjects with newly diagnosed glioblastoma.",40
394,rapamycin,"A phase 2, open-label study of ABI-009 (nab-Rapamycin) in patients with recurrent high grade glioma following prior therapy and subjects with newly diagnosed glioblastoma.",44
394,abi-009,ABI-009 will be tested as single agent or in combination with standard therapies.,0
395,dsp-7888,"This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.",100
395,bevacizumab,"This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.",130
395,bevacizumab,"This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.",149
396,veledimex,"On the day of surgery, patients will receive one dose of veledimex before the resection procedure.",57
396,veledimex,Patients will continue on oral veledimex for 14 days.,31
396,veledimex,"Following veledimex, patients will receive cemiplimab-rwlc via infusion every three weeks.",10
397,cediranibmaleate,"OBJECTIVES:  To compare progression-free survival, overall survival, radiological response, and safety and tolerability of cediranib maleate in combination with gefitinib versus cediranib maleate in combination with a placebo in patients with recurrent or progressive glioblastoma following standard front-line treatment.",123
397,gefitinib,"OBJECTIVES:  To compare progression-free survival, overall survival, radiological response, and safety and tolerability of cediranib maleate in combination with gefitinib versus cediranib maleate in combination with a placebo in patients with recurrent or progressive glioblastoma following standard front-line treatment.",161
397,cediranibmaleate,"OBJECTIVES:  To compare progression-free survival, overall survival, radiological response, and safety and tolerability of cediranib maleate in combination with gefitinib versus cediranib maleate in combination with a placebo in patients with recurrent or progressive glioblastoma following standard front-line treatment.",178
397,cediranibmaleate,Patients receive cediranib maleate and gefitinib or cediranib maleate and a placebo once daily on days 1-42.,17
397,gefitinib,Patients receive cediranib maleate and gefitinib or cediranib maleate and a placebo once daily on days 1-42.,39
397,cediranibmaleate,Patients receive cediranib maleate and gefitinib or cediranib maleate and a placebo once daily on days 1-42.,52
398,erc1671,"This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with relapsed, bevacizumab naive glioblastoma.",36
398,bevacizumab,"This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with relapsed, bevacizumab naive glioblastoma.",64
398,bevacizumab,"This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with relapsed, bevacizumab naive glioblastoma.",103
398,erc1671,"The patients who will be randomized (in a 1:1 ratio) to receive either ERC 1671 in combination with GM-CSF and cyclophosphamide or a placebo control, in combination with bevacizumab.",71
398,cyclophosphamide,"The patients who will be randomized (in a 1:1 ratio) to receive either ERC 1671 in combination with GM-CSF and cyclophosphamide or a placebo control, in combination with bevacizumab.",111
398,bevacizumab,"The patients who will be randomized (in a 1:1 ratio) to receive either ERC 1671 in combination with GM-CSF and cyclophosphamide or a placebo control, in combination with bevacizumab.",170
398,erc1671," ERC1671/GM-CSF will be intradermally administered, while cyclophosphamide is orally administered.",1
398,cyclophosphamide," ERC1671/GM-CSF will be intradermally administered, while cyclophosphamide is orally administered.",58
398,cyclophosphamide,GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day.,37
398,bevacizumab,Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.,0
398,bevacizumab,Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.,24
399,tyrosine,"At present, targeted therapies with small molecule inhibitors directed against receptor tyrosine kinases (RTKs) or downstream signaling pathways seem to be the most promising therapeutic approaches by directly influencing oncogenetically altered signaling pathways4.",88
399,imatinibmesylate,"Imatinib Mesylate (STI571, Gleevec) is a potent inhibitor of the Bcr-Abl, PDGFR-α/ß, c-Fms and c-KIT tyrosine kinases.",0
399,sti571,"Imatinib Mesylate (STI571, Gleevec) is a potent inhibitor of the Bcr-Abl, PDGFR-α/ß, c-Fms and c-KIT tyrosine kinases.",19
399,tyrosine,"Imatinib Mesylate (STI571, Gleevec) is a potent inhibitor of the Bcr-Abl, PDGFR-α/ß, c-Fms and c-KIT tyrosine kinases.",101
399,imatinib,"Its ability to inhibit PDGFR signaling suggested therapeutic potential in malignant gliomas, but single-agent imatinib showed only minimal therapeutic activity5.",110
399,erlotinib,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",0
399,osi-774,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",11
399,tarceva,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",20
399,gefitinib,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",33
399,zd1839,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",44
399,iressa,"Erlotinib (OSI-774, Tarceva) and Gefitinib (ZD1839, Iressa) are potent inhibitors of the Epidermal-Growth-Factor-Receptor (EGFR).",52
399,tipifarnib,"Tipifarnib (R115777, Zarnestra) is a potent and selective inhibitor of the farnesyl-transferase and influences the Ras oncogene pathway.",0
399,r115777,"Tipifarnib (R115777, Zarnestra) is a potent and selective inhibitor of the farnesyl-transferase and influences the Ras oncogene pathway.",12
399,zarnestra,"Tipifarnib (R115777, Zarnestra) is a potent and selective inhibitor of the farnesyl-transferase and influences the Ras oncogene pathway.",21
399,sutent,"SUTENT (SUNITINIB, SU11248) is a potent multi-target inhibitor of VEGFR1-3, PDGFR-α/β, FLT3, c-KIT, RET and CSF-1R. This drug has shown good solubility, bioavailability and protein-binding characteristics9 and was highly effective in metastatic clear-cell renal cell carcinoma (MRCC)10-12 and gastrointestinal stromal tumor (GIST)13,14.",0
399,sunitinib,"SUTENT (SUNITINIB, SU11248) is a potent multi-target inhibitor of VEGFR1-3, PDGFR-α/β, FLT3, c-KIT, RET and CSF-1R. This drug has shown good solubility, bioavailability and protein-binding characteristics9 and was highly effective in metastatic clear-cell renal cell carcinoma (MRCC)10-12 and gastrointestinal stromal tumor (GIST)13,14.",8
399,su11248,"SUTENT (SUNITINIB, SU11248) is a potent multi-target inhibitor of VEGFR1-3, PDGFR-α/β, FLT3, c-KIT, RET and CSF-1R. This drug has shown good solubility, bioavailability and protein-binding characteristics9 and was highly effective in metastatic clear-cell renal cell carcinoma (MRCC)10-12 and gastrointestinal stromal tumor (GIST)13,14.",19
399,sutent,"The target molecules of SUTENT (i.e. VEGFR, PDGFR, FLT-3, c-KIT, RET) are strongly expressed in GBM tissue and have a crucial role in tumor progression and tumor neovascularization The vascular density in GBMs is among the highest of all human neoplasm Clinical studies with SUTENT demonstrated a radiological response and a significant improvement in progression free survival due to SUTENT treatment in MRCC and Imatinib-resistant GIST In clinical trials using SUTENT the incidence and severity of adverse events and laboratory abnormalities was relatively low (MRCC and GIST patients)",24
399,sutent,"The target molecules of SUTENT (i.e. VEGFR, PDGFR, FLT-3, c-KIT, RET) are strongly expressed in GBM tissue and have a crucial role in tumor progression and tumor neovascularization The vascular density in GBMs is among the highest of all human neoplasm Clinical studies with SUTENT demonstrated a radiological response and a significant improvement in progression free survival due to SUTENT treatment in MRCC and Imatinib-resistant GIST In clinical trials using SUTENT the incidence and severity of adverse events and laboratory abnormalities was relatively low (MRCC and GIST patients)",275
399,sutent,"The target molecules of SUTENT (i.e. VEGFR, PDGFR, FLT-3, c-KIT, RET) are strongly expressed in GBM tissue and have a crucial role in tumor progression and tumor neovascularization The vascular density in GBMs is among the highest of all human neoplasm Clinical studies with SUTENT demonstrated a radiological response and a significant improvement in progression free survival due to SUTENT treatment in MRCC and Imatinib-resistant GIST In clinical trials using SUTENT the incidence and severity of adverse events and laboratory abnormalities was relatively low (MRCC and GIST patients)",385
399,imatinib,"The target molecules of SUTENT (i.e. VEGFR, PDGFR, FLT-3, c-KIT, RET) are strongly expressed in GBM tissue and have a crucial role in tumor progression and tumor neovascularization The vascular density in GBMs is among the highest of all human neoplasm Clinical studies with SUTENT demonstrated a radiological response and a significant improvement in progression free survival due to SUTENT treatment in MRCC and Imatinib-resistant GIST In clinical trials using SUTENT the incidence and severity of adverse events and laboratory abnormalities was relatively low (MRCC and GIST patients)",414
399,sutent,"The target molecules of SUTENT (i.e. VEGFR, PDGFR, FLT-3, c-KIT, RET) are strongly expressed in GBM tissue and have a crucial role in tumor progression and tumor neovascularization The vascular density in GBMs is among the highest of all human neoplasm Clinical studies with SUTENT demonstrated a radiological response and a significant improvement in progression free survival due to SUTENT treatment in MRCC and Imatinib-resistant GIST In clinical trials using SUTENT the incidence and severity of adverse events and laboratory abnormalities was relatively low (MRCC and GIST patients)",463
400,temozolomide,Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or placebo for the patients with recurrent or refractory Glioblastoma.,61
400,metformin,Studies will investigate the efficacy and safety of low dose Temozolomide with Metformin or placebo for the patients with recurrent or refractory Glioblastoma.,79
400,metformin,The dosage of the Metformin will follow the domestically permitted dose to minimize side effects.,18
401,veledimex,Patients who are scheduled for craniotomy and tumor resection will receive one dose of veledimex before the resection procedure.,87
401,veledimex,Patients will continue on oral veledimex for 14 days.,31
402,mpc-6827,Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.,21
402,carboplatin,Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.,56
402,mpc-6827,"Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.",153
402,carboplatin,"Study endpoints will include determination of the maximum tolerated dose, dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with carboplatin.",178
403,temozolomide,Standard of care for newly-diagnosed GBM is a combination of surgical debulking followed by concurrent radiotherapy and chemotherapy with temozolomide.,138
403,g-202,G-202 (mipsagargin) is an example of prodrug chemotherapy.,0
403,g-202,It is believed that activation of the prodrug G-202 will allow the drug to kill cancer cells.,46
403,g-202,"This study will evaluate the activity, safety and CNS exposure of G-202 in patients with recurrent or progressive GMB receiving G-202 by intravenous infusion on three consecutive days of a 28-day cycle.",66
403,g-202,"This study will evaluate the activity, safety and CNS exposure of G-202 in patients with recurrent or progressive GMB receiving G-202 by intravenous infusion on three consecutive days of a 28-day cycle.",128
404,ro4929097,Efficiency of neurosphere generation after pretreatment with RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097).,61
404,ro4929097,Efficiency of neurosphere generation after pretreatment with RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097).,123
404,ro4929097,"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 orally (PO) once daily (QD) on days 1-3, 8-10, 15-17, and 22-24.",68
404,ro4929097, GROUP B (surgical resection indicated): Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1.,109
404,ro4929097,"Within 30 days after surgical resection, patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 as in Group A.  After completion of study treatment, patients are followed up every 2 months.",109
405,aee788,"AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases.",0
405,tyrosine,"AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases.",165
405,aee788,"This study will assess the safety, pharmacokinetic/pharmacodynamic (PK/PD) profiles and clinical activity of AEE788 in a recurrent GBM population.",109
406,ap12009,"The purpose of this study is to compare the safety and efficacy of the 10 µM concentration of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma (GBM, WHO grade IV).",94
406,temozolomide,"The purpose of this study is to compare the safety and efficacy of the 10 µM concentration of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma (GBM, WHO grade IV).",130
406,bcnu,"The purpose of this study is to compare the safety and efficacy of the 10 µM concentration of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma (GBM, WHO grade IV).",144
406,ccnu,"The purpose of this study is to compare the safety and efficacy of the 10 µM concentration of AP 12009 and standard chemotherapy (temozolomide, BCNU, CCNU) in adult patients with recurrent or refractory anaplastic astrocytoma (AA, WHO grade III) or secondary glioblastoma (GBM, WHO grade IV).",150
406,ap12009,"AP 12009 (trabedersen) is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2 (TGF-beta-2), which is applied intratumorally.",0
407,erlotinib,Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib.,107
407,erlotinib,Patients receive oral erlotinib daily.,22
408,sunitinib,"Trial patients received sunitinib 50 mg daily for 4 weeks without regard to meals, followed by a 2-week rest period.",24
408,creatinine," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",397
408,blood," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",409
408,ureanitrogen," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",415
408,bun," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",430
408,alanine," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",436
408,aspartate," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",468
408,lactate," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",502
408,bilirubin," SCHEDULE OF EVENTS - PROTOCOL ACTIVITIES  <14 Days Prior to Initial Study Treatment:  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status Quality of Life (QOL) FACT-L Laboratory Studies; complete blood count (CBC), Differential, Platelets, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio (INR), Serum Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), Total Bilirubin, alkaline phosphatase (AlkPHs), Pregnancy Test, electrocardiogram (EKG) Cranial MRI or CT with and without contrast Multiple uptake gated acquisition (MUGA)",537
408,creatinine,"Every Cycle, Days 42-45 (within 3 days of next scheduled Sutent treatment):  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status QOL FACT-L Laboratory Studies; Serum Creatinine, BUN, ALT, AST, LDH, Total Bilirubin, AlkPHs Cranial MRI or CT with and without contrast Survival  ",223
408,bilirubin,"Every Cycle, Days 42-45 (within 3 days of next scheduled Sutent treatment):  Neurological/Oncological History Neurological Examination Height/Weight/Body Surface Area Performance Status QOL FACT-L Laboratory Studies; Serum Creatinine, BUN, ALT, AST, LDH, Total Bilirubin, AlkPHs Cranial MRI or CT with and without contrast Survival  ",261
409,dichloroacetate,"Importantly, recurrent malignant brain tumor's shared characteristics may be usefully exploited by an emerging class of biologic agents called metabolic modulators of which Dichloroacetate (DCA) is the drug in the class most thoroughly investigated clinically.",173
409,dca,"Importantly, recurrent malignant brain tumor's shared characteristics may be usefully exploited by an emerging class of biologic agents called metabolic modulators of which Dichloroacetate (DCA) is the drug in the class most thoroughly investigated clinically.",190
409,dca,DCA's mechanism of action and tolerability have been extensively demonstrated in the treatment of chronic metabolic disorders.,0
409,dca,"Furthermore, the preciseness of DCA's mechanism of action appears to target abnormal tumor cell metabolism.",32
410,irinotecanhydrochloride,"CM-BC2, an irinotecan hydrochloride drug-eluting bead, is an investigational medicinal product intended for direction injection into the tumor resection margin.",11
410,irinotecanhydrochloride,The objective of this trial is demonstration of safety and feasibility of this intraparenchymal injection of irinotecan hydrochloride drug-eluting beads in the treatment of recurrent Glioblastoma multiforme.,109
411,aee788,Determine the maximum tolerated dose and dose-limiting toxicity of AEE788 when administered in combination with 1 of 2 different doses of everolimus in patients with recurrent or relapsed glioblastoma multiforme.,67
411,everolimus,Determine the maximum tolerated dose and dose-limiting toxicity of AEE788 when administered in combination with 1 of 2 different doses of everolimus in patients with recurrent or relapsed glioblastoma multiforme.,138
411,aee788,"This is an open-label, multicenter, dose-escalation study of AEE788.",61
411,aee788, Group 1: Patients receive oral AEE788 once daily and oral everolimus once daily on days 1-28.,32
411,everolimus, Group 1: Patients receive oral AEE788 once daily and oral everolimus once daily on days 1-28.,59
411,aee788,"Group 2: Beginning at the first occurrence of dose-limiting toxicity in group 1, patients receive AEE788 as in group 1 and a higher-dose of oral everolimus once daily on days 1-28.",98
411,everolimus,"Group 2: Beginning at the first occurrence of dose-limiting toxicity in group 1, patients receive AEE788 as in group 1 and a higher-dose of oral everolimus once daily on days 1-28.",145
411,aee788,Cohorts of 3-6 patients per group receive escalating doses of AEE788 until the maximum tolerated dose is determined.,62
411,aee788,"Group 1 (eligible for tumor biopsy, surgical resection, or tumor debulking): Patients receive oral AEE788 once daily at the MTD and oral everolimus once daily for 5-9 days.",99
411,everolimus,"Group 1 (eligible for tumor biopsy, surgical resection, or tumor debulking): Patients receive oral AEE788 once daily at the MTD and oral everolimus once daily for 5-9 days.",137
411,aee788,"Beginning 15-21 days after surgery, patients receive oral AEE788 and oral everolimus once daily on days 1-28.",58
411,everolimus,"Beginning 15-21 days after surgery, patients receive oral AEE788 and oral everolimus once daily on days 1-28.",74
411,aee788,Group 2 (ineligible for surgery): Patients receive oral AEE788 once daily at the MTD and oral everolimus once daily on days 1-28.  ,56
411,everolimus,Group 2 (ineligible for surgery): Patients receive oral AEE788 once daily at the MTD and oral everolimus once daily on days 1-28.  ,94
411,aee788,"In both phases, if treatment with AEE788 or everolimus is stopped due to toxicity, patients may continue to receive AEE788 or everolimus alone once daily.",34
411,everolimus,"In both phases, if treatment with AEE788 or everolimus is stopped due to toxicity, patients may continue to receive AEE788 or everolimus alone once daily.",44
411,aee788,"In both phases, if treatment with AEE788 or everolimus is stopped due to toxicity, patients may continue to receive AEE788 or everolimus alone once daily.",116
411,everolimus,"In both phases, if treatment with AEE788 or everolimus is stopped due to toxicity, patients may continue to receive AEE788 or everolimus alone once daily.",126
412,zotiraciclib,"Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3).",0
412,tg02,"Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3).",14
412,pyrimidine,"Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3).",25
412,tyrosine,"Zotiraciclib (TG02) is a pyrimidine-based multi-kinase inhibitor that has been shown to have inhibitory effects on CDKs, Janus Kinase 2 (JAK2) and Fm-like tyrosine kinase 3 (Flt3).",155
412,zotiraciclib,There is clinical experience in using Zotiraciclib (TG02) as both a single agent and in combination with other chemotherapy agents for cancer treatment.,38
412,tg02,There is clinical experience in using Zotiraciclib (TG02) as both a single agent and in combination with other chemotherapy agents for cancer treatment.,52
412,temozolomide,Temozolomide (TMZ) is an oral alkylating agent that has proven efficacy in anaplastic glioma and glioblastoma.,0
412,tmz,Temozolomide (TMZ) is an oral alkylating agent that has proven efficacy in anaplastic glioma and glioblastoma.,14
412,zotiraciclib,"Our preclinical data have demonstrated that Zotiraciclib (TG02) down-regulates CDK9 activity and its target proteins, such as anti-apoptotic protein Mcl-1, XIAP and survivin.",44
412,tg02,"Our preclinical data have demonstrated that Zotiraciclib (TG02) down-regulates CDK9 activity and its target proteins, such as anti-apoptotic protein Mcl-1, XIAP and survivin.",58
412,zotiraciclib,A treatment with Zotiraciclib (TG02) and TMZ has synergistic anti-glioma effects in a variety of glioma models with different genetic background.,17
412,tg02,A treatment with Zotiraciclib (TG02) and TMZ has synergistic anti-glioma effects in a variety of glioma models with different genetic background.,31
412,tmz,A treatment with Zotiraciclib (TG02) and TMZ has synergistic anti-glioma effects in a variety of glioma models with different genetic background.,41
412,zotiraciclib,Phase I:  -To determine the maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.,60
412,tg02,Phase I:  -To determine the maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.,74
412,tmz,Phase I:  -To determine the maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.,85
412,tmz,Phase I:  -To determine the maximum tolerated dose (MTD) of Zotiraciclib (TG02) plus TMZ using both the dd and mn TMZ schedules in adult patients with recurrent anaplastic astrocytoma or glioblastoma/gliosarcoma.,114
412,zotiraciclib,Phase II:  -To determine the efficacy of Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma as determined by progression free survival.,41
412,tg02,Phase II:  -To determine the efficacy of Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma as determined by progression free survival.,55
412,tmz,Phase II:  -To determine the efficacy of Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma as determined by progression free survival.,66
412,tmz,Phase II:  -To determine the efficacy of Zotiraciclib (TG02) plus TMZ versus TMZ alone in patients with recurrent WHO grade III or IV astrocytoma as determined by progression free survival.,77
412,bevacizumab,No prior use of bevacizumab as a treatment for brain tumor.,16
412,tmz,"In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered.",25
412,zotiraciclib,"In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered.",90
412,tg02,"In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered.",104
412,tmz,"Patients will be randomized between two competing treatment arms: (""winner"" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.",89
412,zotiraciclib,"Patients will be randomized between two competing treatment arms: (""winner"" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.",95
412,tg02,"Patients will be randomized between two competing treatment arms: (""winner"" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.",109
412,tmz,"Patients will be randomized between two competing treatment arms: (""winner"" of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design.",128
412,temozolomide,"At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).",56
412,tmz,"At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).",70
412,tmz,"At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).",126
412,zotiraciclib,"At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).",160
412,tg02,"At progression, patients randomized to the control arm (Temozolomide [TMZ] alone) will be offered the opportunity to continue TMZ and additional treatment with Zotiraciclib (TG02).",174
413,temozolomide,"Currently,6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and Temozolomide chemotherapy(STUPP regimen)for newly diagnosed postoperative GBM can increase the 2-year and 5-year overall survival rates of patients to 26.5% and 9.8%, respectively.",22
413,temozolomidep,"Currently,6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and Temozolomide chemotherapy(STUPP regimen)for newly diagnosed postoperative GBM can increase the 2-year and 5-year overall survival rates of patients to 26.5% and 9.8%, respectively.",91
413,anlotinib,"Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs, FGFRs, PDGFRs.",0
413,tyrosine,"Anlotinib is an efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration and proliferation of endothelial cells and reduce tumor microvascular density by targeting VEGFRs, FGFRs, PDGFRs.",39
413,anthracycline,"It has been proved to be safe and effective in advanced lung cancer(including NSCLC,SCLC)after second-line standard chemotherapy failure,and advanced soft tissue sarcoma after anthracycline-containing chemotherapy failure.",176
413,temozolomide,"Here, we prepared to evaluate whether the combination of dose-dense Temozolomide and Anlotinib can preferably improved survival of the first recurrent or progressive GBM after STUPP regimen.",68
413,anlotinib,"Here, we prepared to evaluate whether the combination of dose-dense Temozolomide and Anlotinib can preferably improved survival of the first recurrent or progressive GBM after STUPP regimen.",85
413,stupp,"Here, we prepared to evaluate whether the combination of dose-dense Temozolomide and Anlotinib can preferably improved survival of the first recurrent or progressive GBM after STUPP regimen.",176
414,cobalt60,"In another report from University of Nebraska Medical Center, 49 patients with glioblastoma multiforme were treated with interstitial Cobalt 60 high dose-rate irradiation to a dose of 20 Gy to the tumor with a 1-cm margin.",134
414,cobalt60,The Cobalt 60 probe was guided into the tumor using CT scans and a stereotactic frame.,4
414,prs,"For use of the PRS as an adjuvant treatment, treatment applicators made from a rigid biocompatible plastic (ULTEM 1000) with known x-ray transmission characteristics are used.",15
414,cobalt60,These doses are also lower than the 20-40 Gy doses utilized for intraoperative irradiation of adult brain tumors with electrons and Cobalt 60 sources.,132
415,mdx447,Assess the safety and tolerability of bispecific antibody MDX447 and activated monocytes in patients with recurrent or refractory glioblastoma multiforme.,58
415,mdx,Cohorts of 1 or 3 patients receive escalating doses of bispecific antibody MDX447 and activated monocytes until the maximum tolerated dose (MTD) is determined.,75
416,methionine,Methionine is an essential amino acid.,0
416,aminoacid,Methionine is an essential amino acid.,27
416,methionine,Many solid tumors depend on the methionine that is taken in through the diet.,32
416,methionine,The tumors need methionine to grow.,16
416,methionine,A methionine free (or reduced) diet may help to shrink or slow the growth of some tumors.,2
416,temozolomide,Temozolomide is a drug that is commonly used in the treatment of glioma.,0
416,methionine,A methionine free (or reduced) diet may increase the effectiveness of temozolomide in the treatment of glioma.,2
416,temozolomide,A methionine free (or reduced) diet may increase the effectiveness of temozolomide in the treatment of glioma.,70
416,methionine,The instructions and food plan will help you maintain a methionine-free (or reduced) diet during the study.,56
416,temozolomide,"During the study, all participants will receive standard chemotherapy with temozolomide by mouth once a day at bedtime for 7 days on Days 8 through 14 and 22 through 28, every 28 days, 4 weeks This 4-week period is called a cycle of chemotherapy.",75
416,methionine,"During treatment, you will be asked to maintain a methionine free diet during Days 1 - 7 and Days 15 - 21.",50
416,methionine,"During the periods of methionine free diet, you will consume only ""shakes"" containing Hominex-2®.",22
416,hominex-2,"During the periods of methionine free diet, you will consume only ""shakes"" containing Hominex-2®.",86
416,hominex-2,The Hominex-2® shakes are nutritionally complete and easy to prepare.,4
416,methionine,You will be given instructions on how to maintain this methionine-free diet.  ,55
416,methionine,"All participants enrolled in the study will consume a methionine free diet for 1 week, alternating with temozolomide chemotherapy for 1 week.",54
416,temozolomide,"All participants enrolled in the study will consume a methionine free diet for 1 week, alternating with temozolomide chemotherapy for 1 week.",104
416,methionine,"The participants will then be switched to a methionine ""replete"" diet for 1 week while taking chemotherapy.",44
416,methionine,This replete diet contains methionine.,27
416,methionine,The dietician will record what you eat to make sure you are eating the right amount of methionine during this period.,87
416,methionine,Methionine restriction diet (Hominex®-2,0
416,aminoacid,Amino Acid-Modified Medical Food) has been approved by the FDA for nutrition support of children and adults with vitamin B6-nonresponsive homocystinuria.,0
416,vitaminb6,Amino Acid-Modified Medical Food) has been approved by the FDA for nutrition support of children and adults with vitamin B6-nonresponsive homocystinuria.,113
416,temozolomide,Temozolomide has been approved by the FDA for the treatment of brain tumors and is commercially available.,0
417,mk-3475,Pembrolizumab (MK-3475) is a humanized monoclonal antibody.,15
419,temozolomide,Temozolomide works by killing cancer cells.,0
419,r115777,R115777 is a new drug that may slow down the growth of cancer cells.,0
419,temozolomide,Temozolomide and R115777 will both be taken by mouth.,0
419,r115777,Temozolomide and R115777 will both be taken by mouth.,17
419,temozolomide,Participants in this study will take temozolomide once a day for 7 days every other week (Days 1-7 and 15-21).,37
419,r115777,"During the alternate weeks (Days 8-14 and 22-28), participants will take R115777 tablets by mouth in the morning and evening with food.",73
419,r115777,"At the beginning of the study, groups of 3 participants each will take increasing doses of both R115777 and temozolomide until the highest safe dose of each drug, when given in combination, is found.",96
419,temozolomide,"At the beginning of the study, groups of 3 participants each will take increasing doses of both R115777 and temozolomide until the highest safe dose of each drug, when given in combination, is found.",108
419,temozolomide,"If tumors do not grow and serious side effects do not occur, participants may keep on taking temozolomide and R115777 for up to 2 year.",93
419,r115777,"If tumors do not grow and serious side effects do not occur, participants may keep on taking temozolomide and R115777 for up to 2 year.",110
419,r115777,"If your physician thinks it is advisable, treatment may continue with R115777 alone after that time.",70
419,temozolomide,Temozolomide is approved by the FDA for the treatment of some brain tumors and is commercially available.,0
419,r115777,R115777 is approved for research use only in the treatment of brain tumors.,0
420,temozolomide,Newly diagnosed patients will undergo standard radiation therapy (RT) with or without temozolomide after leukapheresis.,86
420,temozolomide,"Bridge therapy is approved or standard therapy for the tumor intended to bridge the time without the study drugs, dose-intensified temozolomide (DI-TMZ) or CMV-DC vaccine.",131
420,di-tmz,"Bridge therapy is approved or standard therapy for the tumor intended to bridge the time without the study drugs, dose-intensified temozolomide (DI-TMZ) or CMV-DC vaccine.",145
420,temozolomide,"All participants will undergo a cycle of ""dose-intensified"" temozolomide.",60
420,tmz,Progression-free survival is defined as the time between starting DI TMZ and disease progression.,69
421,vorinostat,To evaluate the strength of the association between magnetic resonance spectroscopy (MRS) imaging measurable biomarkers and response to vorinostat plus temozolomide.,136
421,temozolomide,To evaluate the strength of the association between magnetic resonance spectroscopy (MRS) imaging measurable biomarkers and response to vorinostat plus temozolomide.,152
421,inositol,I. To evaluate MRS-detected inositol and N-acetylaspartate (NAA) levels (at 3 tesla) as indicators of mood alterations as measured by a self-report depression survey (IDS-SR).,28
421,n-acetylaspartate,I. To evaluate MRS-detected inositol and N-acetylaspartate (NAA) levels (at 3 tesla) as indicators of mood alterations as measured by a self-report depression survey (IDS-SR).,41
421,naa,I. To evaluate MRS-detected inositol and N-acetylaspartate (NAA) levels (at 3 tesla) as indicators of mood alterations as measured by a self-report depression survey (IDS-SR).,60
421,vorinostat,Patients receive vorinostat orally (PO) once daily (QD) on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide PO QD on days 1-5.,17
421,temozolomide,Patients receive vorinostat orally (PO) once daily (QD) on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide PO QD on days 1-5.,117
421,temozolomide,Patients previously treated with standard radiotherapy and temozolomide receive maintenance temozolomide PO on days 1-5.  ,59
421,temozolomide,Patients previously treated with standard radiotherapy and temozolomide receive maintenance temozolomide PO on days 1-5.  ,92
422,gsk3326595,"The study drug, GSK3326595, is an inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models.",16
422,arginine,"The study drug, GSK3326595, is an inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor growth in vitro and in vivo in animal models.",55
422,gsk3326595,"This first time in human (FTIH), open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent solid tumors, as well as clinical activity in participants with a subset of solid tumors and NHL.",174
422,gsk3326595,"This is an open-label, repeat-dose, multicenter, three-part study to establish the maximally tolerated dose (MTD)/ recommended phase 2 dose (RP2D) based on safety and tolerability and preliminary clinical efficacy of orally-administered GSK3326595.",237
422,gsk3326595,"Part 1 is a dose-escalation phase to identify the MTD/RP2D based on the safety, PK, and PD profiles observed after oral administration of GSK3326595 and to preliminarily identify whether or not there is an effect of fed versus fasted state and of tablet versus capsule formulation on the PK of GSK3326595.",138
422,gsk3326595,"Part 1 is a dose-escalation phase to identify the MTD/RP2D based on the safety, PK, and PD profiles observed after oral administration of GSK3326595 and to preliminarily identify whether or not there is an effect of fed versus fasted state and of tablet versus capsule formulation on the PK of GSK3326595.",294
422,gsk3326595,Disease-specific expansion cohorts (Part 2) are planned to further explore clinical activity of GSK3326595 in participants with selected solid tumors and NHL.,96
422,gsk3326595,"Part 3 will be a dose determination study to evaluate the safety, PK/PD profile, and clinical activity of orally-administered GSK3326595 in combination with intravenous pembrolizumab.",126
423,nivolumab,"Eligible patients will receive one dose of nivolumab, via infusion, one week prior to standard of care craniotomy and tumor resection (subtotal or total).",43
423,veledimex,"On the day of surgery, patients will receive one dose of veledimex before the resection procedure.",57
423,veledimex,Patients will continue on oral veledimex for 14 days.,31
423,veledimex,"Following veledimex, patients will receive nivolumab via infusion every two weeks.",10
423,nivolumab,"Following veledimex, patients will receive nivolumab via infusion every two weeks.",43
424,nk-92,The main objective of this clinical study is to evaluate the safety and tolerability of NK-92/5.28.z and to determine the maximum tolerated dose or maximum feasible dose (MFD).,88
425,temoda,1 primary objective is to determine maximum tolerated dose of Temodar in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM.,62
425,o6-benzylguanine,1 primary objective is to determine maximum tolerated dose of Temodar in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM.,81
425,temozolomide,Another primary objective is to characterize toxicity associated w Temozolomide in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM.,67
425,bg,Another primary objective is to characterize toxicity associated w Temozolomide in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM.,94
425,temozolomide,3rd primary objective is to determine Neulasta-supported MTD defined as MTD of Temozolomide in combo w O6-BG administered for 5 days while receiving Neulasta once per treatment cycle between days 7 & 14 in pts w progressive/recurrent GBM.,79
425,temoda,Secondary objective is to obtain preliminary response rates of Temodar in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM.,63
425,bg,Secondary objective is to obtain preliminary response rates of Temodar in combo w O6-BG administered for 5 consecutive days in pts w progressive/recurrent GBM.,85
425,o6-bg,O6-BG Administration: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30mg/m2/day for 5 consecutive days.,0
425,o6-bg,O6-BG Administration: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30mg/m2/day for 5 consecutive days.,22
425,o6-bg,O6-BG Administration: O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30mg/m2/day for 5 consecutive days.,109
425,temodar,"Temodar Administration: Temodar administered orally, in fasting state within 60 mins of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG.",0
425,temodar,"Temodar Administration: Temodar administered orally, in fasting state within 60 mins of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG.",24
425,o6-bg,"Temodar Administration: Temodar administered orally, in fasting state within 60 mins of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG.",116
425,o6-bg,"Temodar Administration: Temodar administered orally, in fasting state within 60 mins of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG.",172
425,temozolomide,Temozolomide administered on day 1 of treatment cycle and every 24 hrs thereafter for 5 days w treatment cycles repeated every 28 days.,0
425,temozolomide,Body surface area calculated at beginning of each cycle will be used to calculate daily dose of Temozolomide administered for that cycle.,96
425,neu, Neulasta Administration.,1
425,neulas,Neulasta should not be administered in period between 14 days before & 24hrs after administration of cytotoxic chemo including Temozolomide.,0
425,temozolomide,Neulasta should not be administered in period between 14 days before & 24hrs after administration of cytotoxic chemo including Temozolomide.,127
426,oxygen,"The activated photosensitizer reacts with endogenous oxygen to yield highly reactive species of oxygen that cause destruction of cellular structures such as mitochondria, lysosomes and cell walls leading to irreversible cell damage and tissue death.",53
426,oxygen,"The activated photosensitizer reacts with endogenous oxygen to yield highly reactive species of oxygen that cause destruction of cellular structures such as mitochondria, lysosomes and cell walls leading to irreversible cell damage and tissue death.",96
426,ls11,"Either twenty-four or twelve hours prior to surgery, the patient will receive an intravenous dose of 1 mg/kg of LS11, given IV by slow push over 3-5 minutes.",112
427,veledimex,Patients who are scheduled for a standard of care craniotomy and tumor resection will receive one dose of veledimex before the resection procedure.,106
427,veledimex,Patients will continue on oral veledimex for 14 days.  ,31
427,veledimex,Patients not scheduled for tumor resection will receive Ad-RTS-hIL-12 by stereotactic injection and then will continue on oral veledimex for 14 days.  ,127
428,capecitabine,Capecitabine is a drug that damages the DNA (deoxyribonucleic acid) of tumor cells and blocks the function of DNA and RNA (ribonucleic acid) of tumor cells.,0
428,celecoxib,Celecoxib is a drug that may help to prevent the development of some types of cancer by blocking a type of enzyme (COX-2) that is found in tumor cells.,0
428,temozolomide,Temozolomide and CCNU are the current standard treatment for malignant brain tumors.,0
428,ccnu/6-thioguanine,Temozolomide and CCNU are the current standard treatment for malignant brain tumors.,17
428,temozolomide, 6-Thioguanine is a drug that helps to increase the effects of Temozolomide and CCNU on tumor cells.,63
428,ccnu, 6-Thioguanine is a drug that helps to increase the effects of Temozolomide and CCNU on tumor cells.,80
428,temozolomide,"If you have not received temozolomide before, you will be treated on Arm 1.",25
428,temozolomide,"If you have received temozolomide before but only during radiation therapy and not as chemotherapy afterwards and the treatment was over 6 months ago, you will be treated with temozolomide according to Arm 1.",21
428,temozolomide,"If you have received temozolomide before but only during radiation therapy and not as chemotherapy afterwards and the treatment was over 6 months ago, you will be treated with temozolomide according to Arm 1.",176
428,lomustine,"If you have not received lomustine or carmustine, you will be treated on Arm 2.",25
428,carmustine,"If you have not received lomustine or carmustine, you will be treated on Arm 2.",38
428,lomustine,"If you have received Gliadel wafers at surgery greater than 6 months ago and have not been treated with lomustine or carmustine, you will be treated with CCNU according to Arm 2.",104
428,carmustine,"If you have received Gliadel wafers at surgery greater than 6 months ago and have not been treated with lomustine or carmustine, you will be treated with CCNU according to Arm 2.",117
428,ccnu,"If you have received Gliadel wafers at surgery greater than 6 months ago and have not been treated with lomustine or carmustine, you will be treated with CCNU according to Arm 2.",154
428,temozolomide,Arm 3 will include glioblastoma multiforme patients who may be treated with either temozolomide or lomustine according to the above guidelines and regimens described in Arms 1 and 2.  ,83
428,lomustine/6-thioguanine,Arm 3 will include glioblastoma multiforme patients who may be treated with either temozolomide or lomustine according to the above guidelines and regimens described in Arms 1 and 2.  ,99
428,temozolomide,This will be followed by temozolomide taken by mouth at bedtime for 5 days in a row (Days 4-8).,25
428,capecitabine,"After a rest period of 6 days, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 14-27).",31
428,celecoxib/6-thioguanine,"After a rest period of 6 days, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 14-27).",48
428,lomustine,This will be followed by lomustine taken by mouth at bedtime for 1 day (Day 4).,25
428,capecitabine,"After a rest period of 1 week, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 11-24).",31
428,celecoxib,"After a rest period of 1 week, capecitabine and celecoxib will be taken by mouth twice a day (12 hours apart) for 14 days (Days 11-24).",48
428,ccnu,"The neurological exam, anticonvulsant level blood tests and the stool test for blood, will be repeated before every cycle on Arms 2 and 3 (CCNU) and before every 2 cycles on Arms 1 and 3 (temozolomide).",139
428,temozolomide,"The neurological exam, anticonvulsant level blood tests and the stool test for blood, will be repeated before every cycle on Arms 2 and 3 (CCNU) and before every 2 cycles on Arms 1 and 3 (temozolomide).",188
428,coumadin,"Patients taking anticoagulants (coumadin, warfarin) will have procedures to test the clotting ability of the blood before each cycle or more frequently if the doctor feels it is necessary.",32
428,warfarin,"Patients taking anticoagulants (coumadin, warfarin) will have procedures to test the clotting ability of the blood before each cycle or more frequently if the doctor feels it is necessary.",42
429,bendamustine,To determine the safety of single agent bendamustine (Treanda) (bendamustine hydrochloride) the treatment of malignant gliomas.,40
429,treanda,To determine the safety of single agent bendamustine (Treanda) (bendamustine hydrochloride) the treatment of malignant gliomas.,54
429,bendamustinehydrochloride,To determine the safety of single agent bendamustine (Treanda) (bendamustine hydrochloride) the treatment of malignant gliomas.,64
429,bendamustine,To determine the efficacy of bendamustine (Treanda) as a single agent as assessed by progression-free survival (PFS) at 6 months.,29
429,treanda,To determine the efficacy of bendamustine (Treanda) as a single agent as assessed by progression-free survival (PFS) at 6 months.,43
429,bendamustinehydrochloride,Patients receive bendamustine hydrochloride intravenously (IV) over 30-90 minutes on days 1-2.,17
430,everolimus,"Determine the maximum tolerated dose(s) and the recommended phase II dose(s) of everolimus when administered with standard-dose temozolomide in patients with newly diagnosed, recurrent, or progressive glioblastoma multiforme.",80
430,temozolomide,"Determine the maximum tolerated dose(s) and the recommended phase II dose(s) of everolimus when administered with standard-dose temozolomide in patients with newly diagnosed, recurrent, or progressive glioblastoma multiforme.",128
430,everolimus,"This is a nonrandomized, nonblinded, parallel-group, multicenter, dose-escalation study of everolimus.",91
430,temozolomide,Patients receive oral temozolomide once daily on days 2-5 in course 1 and on days 1-5 in all subsequent courses.,22
430,everolimus,Patients also receive oral everolimus once daily on days 1-28.,27
430,everolimus,Cohorts of 3-6 patients per stratum receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined.,64
430,rapamycin,Patients' archival diagnostic tumor tissue is evaluated during study for correlative molecular studies (by immunohistochemical staining) of mammalian target of rapamycin inhibition status (mTOR activity) and pretreatment molecular markers.,160
431,tr05,"TRC105 is an antibody to CD105, an important non-VEGF angiogenic target on proliferating endothelial cells.",0
431,trc105,"TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models.",0
431,trc105,TRC105 has been well tolerated in patients with glioblastoma (GBM) as a single agent.,0
431,trc105,The combination of TRC105 in combination with bevacizumab has demonstrated activity in bevacizumab refractory cancer patients.,19
431,bevacizumab,The combination of TRC105 in combination with bevacizumab has demonstrated activity in bevacizumab refractory cancer patients.,46
431,bevacizumab,The combination of TRC105 in combination with bevacizumab has demonstrated activity in bevacizumab refractory cancer patients.,87
431,trc105,We hypothesize that TRC105 when administered with bevacizumab will have activity in GBM patients who progress on bevacizumab.,20
431,bevacizumab,We hypothesize that TRC105 when administered with bevacizumab will have activity in GBM patients who progress on bevacizumab.,50
431,bevacizumab,We hypothesize that TRC105 when administered with bevacizumab will have activity in GBM patients who progress on bevacizumab.,113
431,trc105,"By targeting a non-VEGF pathway, TRC105 has the potential to complement VEGF inhibition by bevacizumab, which could represent a major advance in GBM therapy.",33
431,bevacizumab,"By targeting a non-VEGF pathway, TRC105 has the potential to complement VEGF inhibition by bevacizumab, which could represent a major advance in GBM therapy.",91
432,sorafenib,Sorafenib is an oral multi-kinase inhibitor with effects on tumor proliferation and tumor angiogenesis.,0
432,everolimus,Everolimus (everolimus; Novartis) is a novel oral derivative of rapamycin.,0
432,everolimus,Everolimus (everolimus; Novartis) is a novel oral derivative of rapamycin.,12
432,rapamycin,Everolimus (everolimus; Novartis) is a novel oral derivative of rapamycin.,64
432,everolimus,"Combining everolimus and sorafenib allows targeting of both the PI3K pathway and the RAF-MAPK pathway and in addition targets VEGF and PDGF, other active targets in malignant glioma.",10
432,sorafenib,"Combining everolimus and sorafenib allows targeting of both the PI3K pathway and the RAF-MAPK pathway and in addition targets VEGF and PDGF, other active targets in malignant glioma.",25
432,everolimus,Objectives  Phase 1  -To determine the maximum tolerated dose and safety of everolimus in combination with  sorafenib for patients with recurrent malignant gliomas.,76
432,sorafenib,Objectives  Phase 1  -To determine the maximum tolerated dose and safety of everolimus in combination with  sorafenib for patients with recurrent malignant gliomas.,108
432,bevacizumab,Phase 2  6 month progression free survival rate for glioblastoma patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,88
432,everolimus,Phase 2  6 month progression free survival rate for glioblastoma patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,122
432,sorafenib,Phase 2  6 month progression free survival rate for glioblastoma patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,137
432,bevacizumab,3 month progression free survival rate for glioblastoma patients with prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,76
432,everolimus,3 month progression free survival rate for glioblastoma patients with prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,110
432,sorafenib,3 month progression free survival rate for glioblastoma patients with prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,125
432,bevacizumab,6 month progression free survival rate for AG patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,69
432,everolimus,6 month progression free survival rate for AG patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,103
432,sorafenib,6 month progression free survival rate for AG patients with no prior bevacizumab exposure treated with everolimus and sorafenib at the maximum tolerated dose as determined in the phase I study.,118
432,bevacizumab,Prior bevacizumab therapy is allowed.,6
432,everolimus,This is a phase 1 /2 study of everolimus and sorafenib in patients with recurrent highgrade gliomas.,30
432,sorafenib,This is a phase 1 /2 study of everolimus and sorafenib in patients with recurrent highgrade gliomas.,45
432,everolimus,Phase 1: Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib.,45
432,sorafenib,Phase 1: Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib.,88
432,sorafenib,Phase 2: Patients will be treated with the combination of sorafenib and everolimus.,58
432,everolimus,Phase 2: Patients will be treated with the combination of sorafenib and everolimus.,72
432,sorafenib,"Sorafenib will be taken daily for 7 days on, then 7 days off.",0
432,everolimus,Everolimus will be taken daily.,0
432,bevacizumab,"There will be a total accrual of approximately 82 eligible patients to the Phase II study (34 recurrent GBM with no prior exposure to bevacizumab, 16 recurrent Anaplastic Glioma with no prior exposure to bevacizumab, and 32 glioblastoma with prior exposure to bevacizumab).",134
432,bevacizumab,"There will be a total accrual of approximately 82 eligible patients to the Phase II study (34 recurrent GBM with no prior exposure to bevacizumab, 16 recurrent Anaplastic Glioma with no prior exposure to bevacizumab, and 32 glioblastoma with prior exposure to bevacizumab).",204
432,bevacizumab,"There will be a total accrual of approximately 82 eligible patients to the Phase II study (34 recurrent GBM with no prior exposure to bevacizumab, 16 recurrent Anaplastic Glioma with no prior exposure to bevacizumab, and 32 glioblastoma with prior exposure to bevacizumab).",260
433,vbi-1901,"This is a two-part, dose-escalation study to define the safety, tolerability, and optimal dose level of candidate GBM vaccine VBI-1901 with subsequent extension of optimal dose level in recurrent GBM subjects.",126
434,gw572106,"The studies outlined in this proposal are designed to determine which glioblastoma patients are most likely to benefit from GW572106, and may provide a blueprint for analyzing promising new pathway inhibitors in the future.",124
434,gw572016,"Thus, the overall goal is to evaluate the efficacy of GW572016 in the treatment of recurrent malignant gliomas in patients who are candidates for re-resection.",54
434,gw572016,Determine the 6-month progression-free survival rate for patients with recurrent or progressive glioblastoma treated with GW572016.,122
434,gw572016,"Determine whether GW572016 inhibits the phosphorylation of its cellular targets EGFR and HER2, and the downstream PI3K-AKT and RAS-ERK signaling pathways in glioblastoma patients in vivo.",18
434,gw572016,Determine tumor concentrations of GW572016.,34
434,gw2016,(10ml) will be obtained in all patients for genotyping Pre- Operative: GW572016 will be administered at a starting dose of 750 mg orally BID daily on an outpatient basis for 7-10 days.,71
434,gw572016,GW572016 will be continued up to and including the evening before surgery.,0
434,edta,At the time of surgery 10ml of blood will be collected in EDTA containing tubes for pharmacodynamic analysis Treatment may be instituted postoperatively as soon as patients have recovered from effects of surgery and demonstrated wound healing.,58
434,gw572016,Treatment with GW572016 post-operatively should start no later than 28 days after surgery.,15
434,gw572016,GW572016 will be administered at a starting dose of 750 mg orally BID daily on an outpatient basis.,0
434,gw572016,"GW572016 will be administered continuously; however, for the purposes of protocol evaluations, a cycle will be defined as 28 days.",0
435,tarceva,Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs & 450 mg/day for pts on EIAEDs.,0
435,dasatinib,Starting dose level of dasatinib will be 100 mg once day via continuous oral daily dosing.,23
435,dasatinib,Dasatinib will be increased in successive cohorts of enrolled pts.,0
436,temozolomide,Standard of care for newly-diagnosed GBM is a combination of surgical debulking followed by concurrent radiotherapy and chemotherapy with temozolomide.,138
436,g-202,G-202 (mipsagargin) is an example of prodrug chemotherapy.,0
436,g-202,It is believed that activation of the prodrug G-202 will allow the drug to kill cancer cells.,46
437,erlotinib,"In August 2003, the U.S. Food and Drug Administration (FDA) granted orphan drug status for Erlotinib in patients with malignant glioma.",91
437,erlotinib,"Erlotinib (OSI-774) has been shown to be active in a range of tumors including GBM, AA and non small cell lung cancer.",0
437,osi-774,"Erlotinib (OSI-774) has been shown to be active in a range of tumors including GBM, AA and non small cell lung cancer.",11
437,erlotinib,"Because of the promising results in preliminary studies of Erlotinib and because of significant experience with the safety of the dosages proposed in this study, this study will offer a safe adjuvant treatment for patients with relapsing recurring glioblastoma or anaplastic astrocytoma.",59
437,erlotinib,"Therefore, this phase I/II clinical research trial will test the hypothesis that Erlotinib can be safely used up to a dose of 150 mg bid for 12 cycles to ultimately enhance survival of patients with relapsed/refractory GBM/AA with particular genetic alterations including EGFRvIII amplification and PTEN loss.",81
438,bal101553,This is the first study of the oral formulation of BAL101553.,51
438,bal101553,"BAL101553 will be administered once daily during each day of a 28-day treatment cycle in capsule form to adults with advanced or recurrent solid tumors or recurrent or progressive glioblastoma or high-grade glioma who have failed standard therapy, or for whom no effective standard therapy is available.  ",0
438,bal101553,"In Phase 1, the highest dose of BAL101553 was determined that can safely be given to adults with advanced or recurrent solid tumors, recurrent or progressive glioblastoma or high-grade glioma who have failed standard therapy, or for whom no effective standard therapy is available.  ",32
438,bal101553,"In Phase 2a, the tolerability and potential anticancer activity of oral BAL101553 will be assessed in patients with recurrent glioblastoma whose tumor tissue tests positive for end-binding protein 1 (EB1).",72
440,amg102,The primary purpose of the study is to assess the response rate of AMG 102 and Avastin treatment in subjects with advanced malignant glioma.,67
440,amg102,Subjects will receive Avastin and AMG 102 every two weeks.,34
440,amg,Avastin will be administered prior to AMG 102.,38
440,amg102,The most common side effect for AMG 102 have been nausea and fatigue.,32
441,nitrosurea,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",172
441,platinum,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",185
441,temozolomide,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",205
441,procarbazine,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",219
441,procarbazine,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",240
441,lomustine,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",254
441,ccnu,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",265
441,vincristine,"Study Design:  Multicenter, open label, randomized study comparing TransMID with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosureas, platinum compounds, temozolomide, procarbazine or PCV (procarbazine, lomustine (CCNU) & vincristine).",273
442,temozolomide,OBJECTIVES: I. Determine the efficacy of temozolomide and thalidomide in patients with recurrent or progressive supratentorial glioblastoma multiforme or gliosarcoma.,41
442,thalidomide,OBJECTIVES: I. Determine the efficacy of temozolomide and thalidomide in patients with recurrent or progressive supratentorial glioblastoma multiforme or gliosarcoma.,58
442,temozolomide,Patients receive oral temozolomide once daily on days 1-5 and oral thalidomide daily on days 1-28.,22
442,thalidomide,Patients receive oral temozolomide once daily on days 1-5 and oral thalidomide daily on days 1-28.,67
443,etoposide,"Exploratory, single-arm, ph II study designed to assess anti-tumor activity of combinatorial regimen consisting of Etoposide + Bevacizumab among patients with RMG.",115
443,bevacizumab,"Exploratory, single-arm, ph II study designed to assess anti-tumor activity of combinatorial regimen consisting of Etoposide + Bevacizumab among patients with RMG.",127
443,etoposide,Important secondary objective is to further assess safety of Etoposide & Bevacizumab for patients with recurrent malignant glioma.,61
443,bevacizumab,Important secondary objective is to further assess safety of Etoposide & Bevacizumab for patients with recurrent malignant glioma.,73
443,etoposide,"If study demonstrates that combinatorial regimen of Etoposide + Bevacizumab is associated with encouraging anti-tumor activity among patients with RMG, further assessment of regimen in additional phase II & possibly phase III studies, will be considered.",52
443,bevacizumab,"If study demonstrates that combinatorial regimen of Etoposide + Bevacizumab is associated with encouraging anti-tumor activity among patients with RMG, further assessment of regimen in additional phase II & possibly phase III studies, will be considered.",64
444,vorinostat,Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day),30
444,temozolomide,Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day),93
444,temozolomide,Temozolomide will be taken orally once every day.,0
444,vorinostat,Vorinostat will be taken orally on days 1-7 and 15-21 of each 28-day cycle.,0
444,vorinostat,"In the phase I portion of this study, the dose of Vorinostat will be escalated in successive cohorts of patients to determine the maximum tolerated dose (MTD) based on dose-limiting toxicities (DLTs).",50
444,vorinostat,"In the phase II portion of this study, the dose of Vorinostat will be the MTD determined in the phase I portion.",51
445,13cpyruvate,"The new metabolic imaging will use hyperpolarized 13C pyruvate, which allows for pictures of the brain that we won't be able to get with standard imaging.",50
445,13cpyruvate,Hyperpolarized 13C pyruvate has not been approved for use by the Food and Drug Administration (FDA) and is available for research only.,15
445,carbon,This investigational agent is a non-radioactive isotope of carbon.,59
445,13cpyruvate,Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as standard MR.,42
445,13cpyruvate, Subjects in Group 2 will have one MR examination time point with hyperpolarized 13C pyruvate injection for research and standard MR.,81
445,13cpyruvate,Each time point includes a hyperpolarized 13C pyruvate injection for research imaging as well as standard MR.,42
447,bms-986016,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",123
447,bms-986016,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",167
447,bms-663513,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",237
447,ureluma,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",251
447,nivolumab,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",346
447,bms-936558,"To determine a maximum tolerated dose or maximum administrated dose of anti-lymphocyte activation gene-3 (LAG-3) antibody (BMS-986016) (anti-LAG-3 monoclonal antibody BMS-986016) and anti-cluster of differentiation 137 (CD137) antibody (BMS- 663513) (urelumab) given independently and in combination with anti-programmed death-1 (PD-1) antibody (nivolumab, BMS-936558) safely in patients with recurrent glioblastoma multiforme (GBM).",357
447,bms-986016,"To assess the pharmacodynamic effects of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS- 663513), and/or anti-PD-1 antibody (BMS-936558) on biomarkers in peripheral blood, including the T cell compartments, and serum proteins (cytokines and other immune modulators).",62
447,bms-663513,"To assess the pharmacodynamic effects of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS- 663513), and/or anti-PD-1 antibody (BMS-936558) on biomarkers in peripheral blood, including the T cell compartments, and serum proteins (cytokines and other immune modulators).",96
447,bms-936558,"To assess the pharmacodynamic effects of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS- 663513), and/or anti-PD-1 antibody (BMS-936558) on biomarkers in peripheral blood, including the T cell compartments, and serum proteins (cytokines and other immune modulators).",137
447,bms-986016,"To further characterize the occupancy and immune cell function at multiple dose levels of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS-663513), and/or anti-PD-1 antibody (BMS-936558).",111
447,bms-663513,"To further characterize the occupancy and immune cell function at multiple dose levels of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS-663513), and/or anti-PD-1 antibody (BMS-936558).",145
447,bms-936558,"To further characterize the occupancy and immune cell function at multiple dose levels of anti-LAG-3 antibody (BMS-986016), anti-CD137 antibody (BMS-663513), and/or anti-PD-1 antibody (BMS-936558).",185
447,bms-986016,"To explore characteristics of tumor immune microenvironment changes after the treatment of anti-LAG-3, anti-CD137, and its combination treatment with anti- PD-1 in surgically indicated patients undergoing tumor resection  OUTLINE:  PART A: This is a dose-escalation study of the monotherapy of Anti-LAG-3 monoclonal antibody BMS-986016 and Anti-CD137 (urelumab).",325
447,bms-986016,Patients receive anti-LAG-3 monoclonal antibody BMS-986016 intravenously (IV) on days 1 and 15.,48
447,bms-986016,This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1(nivolumab) and Anti-CD137 (urelumab) plus Anti-PD-1 (nivolumab).,96
447,nivolumab,This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1(nivolumab) and Anti-CD137 (urelumab) plus Anti-PD-1 (nivolumab).,122
447,urelu,This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1(nivolumab) and Anti-CD137 (urelumab) plus Anti-PD-1 (nivolumab).,149
447,nivolumab,This is the dose-escalation combination therapy portion study of Anti-LAG-3 monoclonal antibody BMS-986016 plus Anti-PD-1(nivolumab) and Anti-CD137 (urelumab) plus Anti-PD-1 (nivolumab).,175
447,nivolumab,Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody,28
447,bms-986016,BMS-986016 IV on days 1 and 15.,0
447,nivolumab,Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and urelumab IV on day 1.,28
447,bms-663513, (2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,48
447,bms, (2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,95
447,bms, (2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,129
447,bms-986016,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",121
447,urelumab,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",152
447,nivolumab,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",188
447,bms-986016,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",233
447,nivolumab,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",267
447,urelumab,"Patients enrolled on the Intratumoral Studies surgical arm pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",281
447,bms-986016,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",110
447,urelu,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",141
447,nivolumab,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",177
447,bms-986016,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",222
447,nivolumab,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",256
447,urelumab,"Within 45 days of surgical resection, patients post-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 as in Part A Arm I, urelumab as in as in Part A Arm II, nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B Arm I, or nivolumab and urelumab as in Part B Arm II.",270
447,bms-663513, (3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,48
447,bms, (3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,95
447,bms, (3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program.,129
448,bevacizumab,There are still no effective markers to predict the response rate to bevacizumab.,69
448,bevacizumab,So the investigators initiate a single-arm Phase II study to evaluate the efficacy and tolerability of bevacizumab and nimustine regimen and to explore the predictive markers in patients with recurrent high-grade glioma.,103
448,nimustine,So the investigators initiate a single-arm Phase II study to evaluate the efficacy and tolerability of bevacizumab and nimustine regimen and to explore the predictive markers in patients with recurrent high-grade glioma.,119
450,cpt-11,Patients with recurrent malignant glioma will receive Nanoliposomal CPT-11 at the time of relapse.,68
451,zactima,"Regimen of Zactima + imatinib mesylate represents novel anti-glioma strategy because it targets 3 key mediators of dysregulated cell signalling involving VEGF & PI3K-AKT pathways including VEGFR, epidermal growth factor receptor (EGFR) & platelet derived growth factor(PDGFR).",11
451,imatinibmesylate,"Regimen of Zactima + imatinib mesylate represents novel anti-glioma strategy because it targets 3 key mediators of dysregulated cell signalling involving VEGF & PI3K-AKT pathways including VEGFR, epidermal growth factor receptor (EGFR) & platelet derived growth factor(PDGFR).",21
451,zactima,Furthermore by combining Zactima,25
451,imatinibmesylate,"w imatinib mesylate, VEGF & PI3-k/AKT pathways can potentially inhibit multiple mediators of each of these pathways.",2
451,zact,"1st, Zactima can directly inhibit VEGFR activation.",5
451,zactima,"2nd, both Zactima & imatinib mesylate can indirectly decrease activity of VEGF pathway by diminishing positive input from activated PI3-K/AKT signalling.",10
451,imatinibmesylate,"2nd, both Zactima & imatinib mesylate can indirectly decrease activity of VEGF pathway by diminishing positive input from activated PI3-K/AKT signalling.",20
451,imatinibmesylate,"3rd, imatinib mesylate may inhibit PDGF-regulated pericyte maturation of tumor blood vessels.",5
451,imatinibmesylate,We have previously demonstrated that regimen of imatinib mesylate + hydroxyurea is active regimen among recurrent glioblastoma multiforme (GBM) pts.,48
451,hydroxyurea,We have previously demonstrated that regimen of imatinib mesylate + hydroxyurea is active regimen among recurrent glioblastoma multiforme (GBM) pts.,68
451,imatinibmesylate,Furthermore this activity appears substantially better than that reported for imatinib mesylate alone.,78
451,imatinibmesylate,"Although mechanism of enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than imatinib mesylate alone.",44
451,hydroxyurea,"Although mechanism of enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than imatinib mesylate alone.",75
451,imatinibmesylate,"Although mechanism of enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than imatinib mesylate alone.",136
451,hydroxyurea,"Although mechanism of enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than imatinib mesylate alone.",156
451,imatinibmesylate,"Although mechanism of enhanced activity for imatinib mesylate when combo w hydroxyurea is unclear, it is logical to build upon combo of imatinib mesylate + hydroxyurea in subsequent studies rather than imatinib mesylate alone.",202
451,zact,Current study will therefore determine MTD of Zactima when combo w standard doses of imatinib mesylate & hydroxyurea among RMG pts.,46
451,imatinibmesylate,Current study will therefore determine MTD of Zactima when combo w standard doses of imatinib mesylate & hydroxyurea among RMG pts.,85
451,hydroxyurea,Current study will therefore determine MTD of Zactima when combo w standard doses of imatinib mesylate & hydroxyurea among RMG pts.,105
451,zactima,"Ph II study will then be performed, incorporating maximum tolerated dose (MTD) of Zactima + imatinib mesylate in order to evaluate anti-glioma potential of regimen.",82
451,imatinibmesylate,"Ph II study will then be performed, incorporating maximum tolerated dose (MTD) of Zactima + imatinib mesylate in order to evaluate anti-glioma potential of regimen.",92
452,cc-8490,Phase I trial of CC-8490 for the treatment of subjects with recurrent/refractory high-grade gliomas,17
453,imatinibmesylate,"This is open-label, single center, 1-arm ph I dose-escalation study of continuous, daily doses of imatinib mesylate & RAD001 administered orally in combination w fixed doses of hydroxyurea in adult pts w recurrent or relapsing glioblastoma multiforme.",98
453,rad001,"This is open-label, single center, 1-arm ph I dose-escalation study of continuous, daily doses of imatinib mesylate & RAD001 administered orally in combination w fixed doses of hydroxyurea in adult pts w recurrent or relapsing glioblastoma multiforme.",118
453,hydroxyurea,"This is open-label, single center, 1-arm ph I dose-escalation study of continuous, daily doses of imatinib mesylate & RAD001 administered orally in combination w fixed doses of hydroxyurea in adult pts w recurrent or relapsing glioblastoma multiforme.",177
453,imatinibmesylate,"Study format includes classical ""3+3"" dose escalation design to determine MTD & DLT of imatinib mesylate + RAD001 when combined w hydroxyurea among GBM pts.",87
453,rad001,"Study format includes classical ""3+3"" dose escalation design to determine MTD & DLT of imatinib mesylate + RAD001 when combined w hydroxyurea among GBM pts.",107
453,hydroxyurea,"Study format includes classical ""3+3"" dose escalation design to determine MTD & DLT of imatinib mesylate + RAD001 when combined w hydroxyurea among GBM pts.",130
454,gdc-0084,"This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma.",155
454,gdc-0084,"Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.",31
455,erlotinib,"Exploratory, Phase II study designed to assess anti-tumor activity of combinatorial regimen consisting of erlotinib + bevacizumab among pts w recurrent malignant glioma.",106
455,bevacizumab,"Exploratory, Phase II study designed to assess anti-tumor activity of combinatorial regimen consisting of erlotinib + bevacizumab among pts w recurrent malignant glioma.",118
455,erlotinib,"Signal transduction inhibitors, such as erlotinib, as well as anti-angiogenic agents, such as bevacizumab, are expected to exert a cytostatic anti-tumor effect.",40
455,erlotinib,An important secondary objective is to further assess the safety of erlotinib + bevacizumab for pts w RMG.,68
455,bevacizumab,An important secondary objective is to further assess the safety of erlotinib + bevacizumab for pts w RMG.,80
455,erlotinib,Pharmacokinetic studies included in protocol will evaluate impact of enzyme-inducing anti-epileptic drugs (EIAEDs) on metabolism of erlotinib.,132
455,erlotinib,"If study demonstrates that combo regimen of erlotinib + bevacizumab is associated w encouraging anti-tumor activity among pts w recurrent malignant glioma (RMG), further assessment of regimen in additional ph II & possibly ph III studies, will be considered.",44
456,thalidomide,Thalidomide is a drug that interferes with the growth of blood vessels.,0
456,thalidomide,Thalidomide may help to decrease the blood supply in the tumor and make it unable to grow.,0
456,cpt-11,CPT-11 is a drug that was designed to stop cancer cells from dividing.,0
456,thalidomide,All participants will take thalidomide capsules by mouth every evening at bedtime.,27
456,thalidomide,"In addition to thalidomide, you will receive treatment with CPT-11 through a continuous injection into a vein over 90 minutes once a week for 4 weeks followed by 2 weeks of rest from the drug.",15
456,cpt-11,"In addition to thalidomide, you will receive treatment with CPT-11 through a continuous injection into a vein over 90 minutes once a week for 4 weeks followed by 2 weeks of rest from the drug.",60
456,thalidomide,Thalidomide and CPT-11 are FDA approved for the treatment of some cancers.,0
456,cpt-11,Thalidomide and CPT-11 are FDA approved for the treatment of some cancers.,16
457,selinexor,"After screening and registration/randomization in the study, patients enrolling in Arm A or randomized to Arm C will receive 60 mg selinexor orally twice weekly.",131
458,ap12009,"The purpose of this study is to compare the safety and efficacy of two doses of AP 12009 and standard chemotherapy in adult patients with recurrent high-grade glioma (anaplastic astrocytoma [AA], WHO grade III; or glioblastoma [GBM], WHO grade IV).",80
458,ap12009,AP 12009 is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor-beta2 (TGF-beta2).,0
459,paclitaxel,OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent glioblastoma multiforme or anaplastic astrocytoma treated with paclitaxel (TAX) and topotecan (TOPO) with granulocyte colony-stimulating factor (G-CSF) support.,147
459,tax,OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent glioblastoma multiforme or anaplastic astrocytoma treated with paclitaxel (TAX) and topotecan (TOPO) with granulocyte colony-stimulating factor (G-CSF) support.,159
459,topotecan,OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent glioblastoma multiforme or anaplastic astrocytoma treated with paclitaxel (TAX) and topotecan (TOPO) with granulocyte colony-stimulating factor (G-CSF) support.,168
459,topo,OBJECTIVES: I. Determine the response rate in patients with refractory or recurrent glioblastoma multiforme or anaplastic astrocytoma treated with paclitaxel (TAX) and topotecan (TOPO) with granulocyte colony-stimulating factor (G-CSF) support.,179
459,tax,Describe the toxicity of TAX/TOPO/G-CSF.,25
459,topo,Describe the toxicity of TAX/TOPO/G-CSF.,29
459,paclitaxel,"OUTLINE: All patients receive paclitaxel, topotecan, and G-CSF every 3 weeks for at least 2 courses and until 2 courses beyond maximum response.",30
459,topotecan,"OUTLINE: All patients receive paclitaxel, topotecan, and G-CSF every 3 weeks for at least 2 courses and until 2 courses beyond maximum response.",42
460,gefitinib,Determine the maximum tolerated dose of gefitinib in patients with recurrent or progressive supratentorial malignant gliomas or brain or spinal meningiomas receiving enzyme-inducing antiepileptic drugs (EIAEDs).,40
460,gefitinib,Patients receive oral gefitinib once daily on days 1-28.,22
460,gefitinib,Cohorts of 3-6 patients (who are receiving EIAEDs) receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined.,79
461,ribociclib,"In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor.",53
461,everolimus,"In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor.",64
461,ribociclib,"In the lead-in dose escalation study, the first six subjects (lead-in) will receive ribociclib 400 mg and everolimus 2.5 mg orally-administered in 5 daily doses with the last dose.",84
461,everolimus,"In the lead-in dose escalation study, the first six subjects (lead-in) will receive ribociclib 400 mg and everolimus 2.5 mg orally-administered in 5 daily doses with the last dose.",106
461,ribociclib,"If one or less patient experiences DLT among the 6 patients, this regimen with ribociclib 400 mg and everolimus 2.5mg will be considered safe and we will continue with the dose escalation phase of the study up to Level 3.",79
461,everolimus,"If one or less patient experiences DLT among the 6 patients, this regimen with ribociclib 400 mg and everolimus 2.5mg will be considered safe and we will continue with the dose escalation phase of the study up to Level 3.",101
461,ribociclib,Four dose escalation levels:  Level 0: ribociclib 400mg and everolimus 2.5  Level 1: ribociclib 600mg and everolimus 2.5mg  ,39
461,everolimus,Four dose escalation levels:  Level 0: ribociclib 400mg and everolimus 2.5  Level 1: ribociclib 600mg and everolimus 2.5mg  ,60
461,ribociclib,Four dose escalation levels:  Level 0: ribociclib 400mg and everolimus 2.5  Level 1: ribociclib 600mg and everolimus 2.5mg  ,85
461,everolimus,Four dose escalation levels:  Level 0: ribociclib 400mg and everolimus 2.5  Level 1: ribociclib 600mg and everolimus 2.5mg  ,106
461,ribociclib,Level 2: ribociclib 600mg and everolimus 5mg  ,9
461,everolimus,Level 2: ribociclib 600mg and everolimus 5mg  ,30
461,ribociclib,Level 3: ribociclib 600mg and everolimus 10mg,9
461,everolimus,Level 3: ribociclib 600mg and everolimus 10mg,30
462,paclitaxel,"Paclitaxel has demonstrated activity against 9L glioma tumor lines, but has poor central nervous system penetration after intravenous administration.",0
462,paclitaxel,"OncoGel is a new formulation of paclitaxel in a bioerodible gel that can be administered directly to the brain, thereby bypassing the blood-brain barrier.",32
463,temozolomide,"To determine the overall survival (OS) for patients with recurrent high grade malignant gliomas treated with concurrent radiation, temozolomide, and bevacizumab followed by adjuvant temozolomide and bevacizumab.",131
463,bevacizumab,"To determine the overall survival (OS) for patients with recurrent high grade malignant gliomas treated with concurrent radiation, temozolomide, and bevacizumab followed by adjuvant temozolomide and bevacizumab.",149
463,temozolomide,"To determine the overall survival (OS) for patients with recurrent high grade malignant gliomas treated with concurrent radiation, temozolomide, and bevacizumab followed by adjuvant temozolomide and bevacizumab.",182
463,bevacizumab,"To determine the overall survival (OS) for patients with recurrent high grade malignant gliomas treated with concurrent radiation, temozolomide, and bevacizumab followed by adjuvant temozolomide and bevacizumab.",199
463,bevacizumab,Determine the progression free survival (PFS) at 6 and 12 months (all patients) as well as at 3 months (bevacizumab-exposed patients only).,104
463,temozolomide,Patients also receive temozolomide orally (PO) once daily (QD) and bevacizumab intravenously (IV) over 30-90 minutes once every 2 weeks beginning on days -3 to 0.,22
463,bevacizumab,Patients also receive temozolomide orally (PO) once daily (QD) and bevacizumab intravenously (IV) over 30-90 minutes once every 2 weeks beginning on days -3 to 0.,67
463,temozolomide,"ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks.",92
463,bevacizumab,"ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks.",127
464,imatinibmesylate,"Evaluate the activity of imatinib mesylate and hydroxyurea, as measured by 6-month progression-free survival, in patients with recurrent or progressive meningioma.",25
464,hydroxyurea,"Evaluate the activity of imatinib mesylate and hydroxyurea, as measured by 6-month progression-free survival, in patients with recurrent or progressive meningioma.",47
464,imatinibmesylate,Patients receive oral imatinib mesylate once or twice daily and oral hydroxyurea twice daily on days 1-28.,22
464,hydroxyurea,Patients receive oral imatinib mesylate once or twice daily and oral hydroxyurea twice daily on days 1-28.,69
465,tmz,"In correspondence to the third vaccine injection (week 7), 6 cycles of maintenance TMZ (mTMZ) will start.",83
465,mt,"In correspondence to the third vaccine injection (week 7), 6 cycles of maintenance TMZ (mTMZ) will start.",88
466,tpi287,"This multi-center trial is a phase 2, dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation and TMZ therapy and that has progressed following prior bevacizumab therapy.",111
466,bevacizumab,"This multi-center trial is a phase 2, dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation and TMZ therapy and that has progressed following prior bevacizumab therapy.",139
466,tmz,"This multi-center trial is a phase 2, dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation and TMZ therapy and that has progressed following prior bevacizumab therapy.",226
466,bevacizumab,"This multi-center trial is a phase 2, dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that has progressed following prior radiation and TMZ therapy and that has progressed following prior bevacizumab therapy.",278
466,tpi287,"All subjects will be administered TPI 287 as an intravenous (IV) infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",34
466,bevacizumab,"All subjects will be administered TPI 287 as an intravenous (IV) infusion (target duration of 1 hour) once every 3 weeks (Days 1 and 22 of a 42-day cycle) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of the 42-day cycle).",159
466,tpi287,"The subsequent cycle will start 3 weeks after the last TPI 287 infusion and 2 weeks after the last bevacizumab infusion, maintaining the once every 3 week and once every 2 week schedule, respectively.",55
466,bevacizumab,"The subsequent cycle will start 3 weeks after the last TPI 287 infusion and 2 weeks after the last bevacizumab infusion, maintaining the once every 3 week and once every 2 week schedule, respectively.",99
466,tpi287,"The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg).",12
466,bevacizumab,"The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg).",103
466,tpi,The initial cohort of 3 subjects will be treated at a TPI 287 dose of 140 mg/m2 (dose level 0).,54
466,gadolinium,"Efficacy evaluations will include magnetic resonance imaging [MRI, including both pre and post-gadolinium T1-weighted scans and T2/fluid attenuated inversion recovery (FLAIR) images], corticosteroid usage, and neurologic status (as measured by neurologic exam and KPS).",95
467,temsirolimus,PRIMARY OBJECTIVES:  I. Define the maximum tolerated dose (MTD) of temsirolimus in combination with perifosine in patients with recurrent or progressive malignant glioma who are not taking enzyme-inducing anti-epileptic drugs (EIAEDs).,67
467,perifosine,PRIMARY OBJECTIVES:  I. Define the maximum tolerated dose (MTD) of temsirolimus in combination with perifosine in patients with recurrent or progressive malignant glioma who are not taking enzyme-inducing anti-epileptic drugs (EIAEDs).,100
467,temsirolimus,Determine the efficacy of temsirolimus in combination with perifosine in patients with recurrent/progressive glioblastomas (GBMs) not taking EIAEDs as measured by 6 month progression-free survival (6mPFS) and radiographic response rates.,26
467,perifosine,Determine the efficacy of temsirolimus in combination with perifosine in patients with recurrent/progressive glioblastomas (GBMs) not taking EIAEDs as measured by 6 month progression-free survival (6mPFS) and radiographic response rates.,59
467,perifosine, I. Characterize the safety profile of perifosine and temsirolimus.,39
467,temsirolimus, I. Characterize the safety profile of perifosine and temsirolimus.,54
467,phosphatidylinositol,"Explore molecular effects during treatment including phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (S6K) and rat sarcoma (RAS)/mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (ERK) signaling, proliferation, and apoptosis.",53
467,rapamycin,"Explore molecular effects during treatment including phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (S6K) and rat sarcoma (RAS)/mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (ERK) signaling, proliferation, and apoptosis.",133
467,temsirolimus,"This is a phase I dose-escalation study of temsirolimus, followed by a phase II study.",43
467,temsirolimus,"Patients receive temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22 and perifosine orally (PO) once daily (QD) on days 1-28.",17
467,perifosine,"Patients receive temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22 and perifosine orally (PO) once daily (QD) on days 1-28.",94
467,temsirolimus,Patients receive temsirolimus and perifosine as in phase I.,17
467,perifosine,Patients receive temsirolimus and perifosine as in phase I.,34
468,nitrosoureas,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",168
468,platinum,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",182
468,temozolomide,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",202
468,procarbazine,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",216
468,pcv,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",230
468,procarbazine,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",236
468,lomustine,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",250
468,ccnu,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",261
468,vincristine,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",269
468,cpt-11,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",283
468,etoposide,"This is a Multicenter, open label, randomized study comparing TransMID™ with a chemotherapeutic regimen considered to be best standard of care and consisting of either nitrosoureas, platinum compounds, temozolomide, procarbazine, PCV, (procarbazine, lomustine (CCNU) & vincristine), CPT-11, or Etoposide.",294
469,ascorbicacid,To evaluate the toxicities and determine the recommended dose of intravenous ascorbic acid given three times weekly in combination with intravenous bevacizumab every two weeks in patients with recurrent high grade glioma.,77
469,bevacizumab,To evaluate the toxicities and determine the recommended dose of intravenous ascorbic acid given three times weekly in combination with intravenous bevacizumab every two weeks in patients with recurrent high grade glioma.,148
469,ascorbicacid,To evaluate changes in the levels of serum ascorbic acid (using high performance liquid chromatography [HPLC] with coulometric electrochemical detection) during therapy with ascorbic acid and bevacizumab.,43
469,ascorbicacid,To evaluate changes in the levels of serum ascorbic acid (using high performance liquid chromatography [HPLC] with coulometric electrochemical detection) during therapy with ascorbic acid and bevacizumab.,174
469,bevacizumab,To evaluate changes in the levels of serum ascorbic acid (using high performance liquid chromatography [HPLC] with coulometric electrochemical detection) during therapy with ascorbic acid and bevacizumab.,192
469,ascorbicacid,Radiographic assessment of disease status after 2 cycles of therapy with ascorbic acid and bevacizumab.,73
469,bevacizumab,Radiographic assessment of disease status after 2 cycles of therapy with ascorbic acid and bevacizumab.,91
469,ascorbicacid,To evaluate progression-free and overall survival of patients with recurrent high grade glioma treated with therapy with ascorbic acid and bevacizumab.,121
469,bevacizumab,To evaluate progression-free and overall survival of patients with recurrent high grade glioma treated with therapy with ascorbic acid and bevacizumab.,139
469,ascorbicacid,Patients with stable or responsive disease after every 2 cycles will continue on therapy with ascorbic acid and bevacizumab until intolerance or progressive disease.,94
469,bevacizumab,Patients with stable or responsive disease after every 2 cycles will continue on therapy with ascorbic acid and bevacizumab until intolerance or progressive disease.,112
469,ascorbicacid,This is a dose-escalation study of ascorbic acid.,35
469,ascorbicacid,Patients receive ascorbic acid intravenously (IV) over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15.,17
469,bevacizumab,Patients receive ascorbic acid intravenously (IV) over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15.,121
470,axl1717,"AXL1717, as a ready-to-use suspension of picropodophyllin for oral administration, will be distributed in bottles for single use at a concentration of 25 mg/mL. Fixed doses will be used, i.e. there are no adjustments for weight or body surface.",0
470,picropodophyllin,"AXL1717, as a ready-to-use suspension of picropodophyllin for oral administration, will be distributed in bottles for single use at a concentration of 25 mg/mL. Fixed doses will be used, i.e. there are no adjustments for weight or body surface.",41
470,axl1717,"In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days.",87
470,axl1717,The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 in patients with recurrent or progressive glioblastoma and to assess the safety and toxicity of AXL1717 in this patient population.,95
470,axl1717,The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 in patients with recurrent or progressive glioblastoma and to assess the safety and toxicity of AXL1717 in this patient population.,199
470,axl1717,The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles.,76
470,axl1717,"If two or three of the first 3 patients on a specific dose level experience a DLT during the first 28 days of treatment with AXL1717, the following patients will be treated with a lower dose level.",125
470,rptd,The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RPTD.,91
470,axl7,"In the second phase, 12 patients will be enrolled and treated with the identified RP2D of AXL1717 for 28 days repeated in five cycles.",90
470,axl1717,"The primary endpoints of phase II is to assess the proportion of patients who are progression-free at 24 weeks and to assess safety, tolerability, and adverse event profile of AXL1717.",176
471,gcv,"This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.",206
472,carboplatin," Laboratory studies demonstrate that glioma tumour cells are sensitive to a number of different chemotherapies, including carboplatin.",122
472,carboplatin,"When given intravenously however, carboplatin does not reach a sufficient concentration in the tumour to have a beneficial effect.",34
472,carboplatin,"However, studies have shown that carboplatin can be infused directly into the brain at a concentration that is highly toxic to tumour cells, but not to normal brain tissue.",33
472,carboplatin,"Using very small tubes implanted around the tumour, the investigators are able to infuse carboplatin reliably and repeatedly into the area where tumours typical recur.",89
472,carboplatin,"In this study, the investigators intend to evaluate the safety of this approach and determine the optimal dose of carboplatin to administer.",114
473,bevacizumab,"In vivo experiments have documented the ability of anti-vascular endothelial growth factor (VEGF) antibodies like bevacizumab to inhibit tumor growth in various preclinical tumor models, including gliomas.",114
473,bevacizumab,"Given the pronounced neovasculature associated with over-expression of VEGF in malignant gliomas, and abundant published data demonstrating the dependence of glioma growth on the maintenance and proliferation of this neovasculature, bevacizumab represents a potentially promising new therapeutic approach to these otherwise refractory tumors.",233
473,bevacizumab,To establish data regarding the anti-tumor activity of bevacizumab in patients with recurrent high-grade gliomas as determined by progression-free-survival.,55
473,bevacizumab,To obtain information regarding the safety of bevacizumab administered to patients with recurrent high-grade gliomas.,46
473,bevacizumab,Patients must have progressed after radiation therapy and must have an interval of greater than or equal to 4 weeks from the completion of radiation therapy to study entry  Design  Patients will be treated with bevacizumab by intravenous injection at a dose of 10mg/,211
473,bevacizumab,"Prior to the first dose of bevacizumab and at the completion of the first 4-weeks of treatment, patients will undergo a fludeoxyglucose 18F -positron emission tomography (FDG-PET) scan",27
473,fludeoxyglucose,"Prior to the first dose of bevacizumab and at the completion of the first 4-weeks of treatment, patients will undergo a fludeoxyglucose 18F -positron emission tomography (FDG-PET) scan",120
473,18f,"Prior to the first dose of bevacizumab and at the completion of the first 4-weeks of treatment, patients will undergo a fludeoxyglucose 18F -positron emission tomography (FDG-PET) scan",136
473,fdg,"Prior to the first dose of bevacizumab and at the completion of the first 4-weeks of treatment, patients will undergo a fludeoxyglucose 18F -positron emission tomography (FDG-PET) scan",171
473,bevacizumab,"Additionally, patients will undergo a MRI perfusion scan within 48-96 hours of their first dose of bevacizumab (in cycle one only).",99
473,bevacizumab,"For patients who are clinically/neurologically stable and with stable or responding radiographic disease at the end of each treatment cycle, treatment will continue with bevacizumab every 2 weeks, repeating MRI-perfusion scans at the conclusion (e.g. prior to another administration of bevacizumab) of each 4 week cycle.",170
473,bevacizumab,"For patients who are clinically/neurologically stable and with stable or responding radiographic disease at the end of each treatment cycle, treatment will continue with bevacizumab every 2 weeks, repeating MRI-perfusion scans at the conclusion (e.g. prior to another administration of bevacizumab) of each 4 week cycle.",286
474,sunitinib,"Sunitinib, through its multiple tyrosine kinase receptor targets, represents an attempt to capitalize on the concept of targeting multiple mechanisms responsible for glioma-associated angiogenesis.",0
474,tyrosine,"Sunitinib, through its multiple tyrosine kinase receptor targets, represents an attempt to capitalize on the concept of targeting multiple mechanisms responsible for glioma-associated angiogenesis.",32
474,sunitinib,Sunitinib inhibits platelet derived growth factor receptor (PDGFR) and c-kit (stem cell factor (SCF) receptor) at nanomolar concentrations.,0
474,sunitinib,"Based on this scientific rationale, the promising anti-glioma activity of sunitinib in preclinical models, and the promising clinical data in patients with gliomas treated with other VEGF inhibitors, we are now proposing a phase II trial of sunitinib in patients with recurrent malignant gliomas.",74
474,sunitinib,"Based on this scientific rationale, the promising anti-glioma activity of sunitinib in preclinical models, and the promising clinical data in patients with gliomas treated with other VEGF inhibitors, we are now proposing a phase II trial of sunitinib in patients with recurrent malignant gliomas.",241
474,sunitinib, Objectives:  To evaluate the anti-glioma activity of sunitinib in patients with recurrent malignant gliomas who are either naive or resistant to prior bevacizumab therapy.,54
474,bevacizumab, Objectives:  To evaluate the anti-glioma activity of sunitinib in patients with recurrent malignant gliomas who are either naive or resistant to prior bevacizumab therapy.,152
474,bevacizumab,"This is a phase II study with a target enrollment of 64 (32 with glioblastoma multiforme (GBM) and 32 with anaplastic glioma (AG)) patients who have not progressed on prior treatment with anti-VEGF therapy, and 64 (32 with GBM and 32 with AG)patients who have progressed on prior bevacizumab therapy.",280
474,sunitinib,"Sunitinib will be self-administered orally at 37.5 mg daily, with dose adjustments allowed for toxicity and concomitant drug interactions.",0
474,bev,"Now, we have observed one out 10 Bev-naïve who haven't progressed by 6 months.",33
474,bev,"For Bev-resistant patients,",4
475,phosphorusp32,OBJECTIVES:  Determine the dosimetry toxicity of interstitial colloidal phosphorus P32 (C P32) in patients with recurrent or poor prognosis grade 4 astrocytoma.,72
475,cp32,OBJECTIVES:  Determine the dosimetry toxicity of interstitial colloidal phosphorus P32 (C P32) in patients with recurrent or poor prognosis grade 4 astrocytoma.,88
475,cp32,Determine the maximum tolerated dose of C P32 administered directly into the tumor of these patients.,40
475,phosphorusp32,Patients receive interstitial colloidal phosphorus P32 (C P32) on day 0.,40
476,infigratinib,Participants will be administered infigratinib prior to surgical resection of their tumor.,34
477,azd1775,Patients will be administered one dose of AZD1775 prior to surgical resection of their tumor.,42
479,ap23573,"The primary objective of the study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously once daily for five days repeated every two weeks to patients with progressive or recurrent gliomas who have failed standard therapy and who are or are not receiving enzyme-inducing anticonvulsant (EIAC) medications.",113
479,ap23573,"The secondary objectives are to: characterize the pharmacokinetic profile of AP23573 when administered daily for five days repeated every two weeks at the indicated dosage levels in patients receiving and not receiving EIAC; describe the progression-free survival at six months; describe changes in proteins affected by mTOR inhibition; describe single timepoint status of proteins affected by mTOR inhibition in tumor tissue surgical specimens after AP23573 dosing; describe the status of key proteins in the mTOR signaling pathway in archival tumor samples, if available; describe health-related quality of life at the start of the trial and prior to study drug infusion and at various timepoints throughout the trial.",77
479,ap23573,"The secondary objectives are to: characterize the pharmacokinetic profile of AP23573 when administered daily for five days repeated every two weeks at the indicated dosage levels in patients receiving and not receiving EIAC; describe the progression-free survival at six months; describe changes in proteins affected by mTOR inhibition; describe single timepoint status of proteins affected by mTOR inhibition in tumor tissue surgical specimens after AP23573 dosing; describe the status of key proteins in the mTOR signaling pathway in archival tumor samples, if available; describe health-related quality of life at the start of the trial and prior to study drug infusion and at various timepoints throughout the trial.",451
479,ap23573,"This is a Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety, tolerability, and MTD of AP23573 when administered intravenously as a 30-minute infusion, once daily for five days, repeated every two weeks, to patients with progressive or recurrent malignant glioma.",127
480,thalidomide,Thalidomide and Peg-Intron (IFN - Interferon) are attractive drugs to use in combination to test the hypothesis of combination anti-angiogenesis therapy inhibition given their proven activity as single agents in patients with malignant gliomas and their spectrum of largely non-overlapping toxicities.,0
480,peg-intron,Thalidomide and Peg-Intron (IFN - Interferon) are attractive drugs to use in combination to test the hypothesis of combination anti-angiogenesis therapy inhibition given their proven activity as single agents in patients with malignant gliomas and their spectrum of largely non-overlapping toxicities.,16
480,thalidomide,"Given recent preclinical data describing more potent antiangiogenic and anti-tumor effects of low dose, continuous IFN administration, we are interested in evaluating the use of pegylated IFN in combination with thalidomide.",212
480,thalidomide,"Thus, we are proposing a phase II trial of pegylated IFN with thalidomide in patients with recurrent gliomas.",62
480,peg-intron, Objectives:  To obtain preliminary evidence of anti-tumor efficacy of PEG-Intron in combination with thalidomide in patients with recurrent high grade gliomas as assessed by prolongation of progression-free survival compared to historical controls.,71
480,thalidomide, Objectives:  To obtain preliminary evidence of anti-tumor efficacy of PEG-Intron in combination with thalidomide in patients with recurrent high grade gliomas as assessed by prolongation of progression-free survival compared to historical controls.,102
480,peg-intron,A secondary endpoint in this trial is to determine the response rate associated with the combination therapy in each of the two strata and to evaluate and document all toxicities from PEG-Intron in combination with thalidomide at the doses prescribed in this protocol in this patient population.,184
480,thalidomide,A secondary endpoint in this trial is to determine the response rate associated with the combination therapy in each of the two strata and to evaluate and document all toxicities from PEG-Intron in combination with thalidomide at the doses prescribed in this protocol in this patient population.,215
480,peg-intron,Patients must not have received prior therapy with Peg-Intron or Thalidomide.,51
480,thalidomide,Patients must not have received prior therapy with Peg-Intron or Thalidomide.,65
480,peg-intron,Patients will be treated with weekly PEG-Intron plus daily oral thalidomide.,37
480,thalidomide,Patients will be treated with weekly PEG-Intron plus daily oral thalidomide.,64
482,rqnestin34.5v.2,The FDA (the U.S. Food and Drug Administration) has not approved rQNestin34.5v.2 as a treatment for any disease.,65
482,rq,This is the first time that rQnestin34.5v.2 will be given to humans.,28
482,rq,"The research drug, rQNestin34.5v.2, is an oncolytic viral vector made from the herpes simplex virus type 1 (HSV1).",19
482,rq,"If it is effective, the rQNestin34.5v.2 drug will spread to a glioma cell, kill it, and then make a copy of itself and spread again.",24
482,rqtin34,"The purpose of this research study is to test if rQnestin34.5v.2 is safe to use in humans, and if it is effective in treating malignant glioma.",49
482,rqnestin34.5v.2,This study is also looking for the highest dose of rQNestin34.5v.2 that can be given safely to people with malignant brain tumors.,51
483,fr901228,PRIMARY OBJECTIVES:  I. Determine the maximum tolerated dose (MTD) of FR901228 (depsipeptide) in patients with recurrent malignant gliomas who are taking enzyme-inducing antiepileptic drugs (EIAEDs).,70
483,fr901228," Phase I (group B only): Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15.",42
483,fr901228,Cohorts of 3-6 patients receive escalating doses of FR901228 until the maximum tolerated dose (MTD) is determined.,52
483,fr901228,(groups A and B):  Group A (phase II): Patients receive FR901228 as in phase I at dose level 1.,56
483,fr901228,Group B (phase II): Patients receive FR901228 as in phase I at the MTD.,37
484,cpt-11,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,60
484,temodar,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,95
484,o6-benzylguanine,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,105
484,o6-bg,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,123
484,cpt-11,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,182
484,temodar,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,191
484,o6-bg,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,201
484,cpt-11,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,279
484,temodar,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,288
484,o6-bg,Objectives of study: to determine maximum tolerated dose of CPT-11 when administered following Temodar + O6-benzylguanine (O6-BG); to characterize any toxicity associated w combo of CPT-11 + Temodar + O6-BG; to observe pts for clinical antitumor response when treated w combo of CPT-11 + Temodar plus O6-BG.,301
484,dilantin,"2 separate strata accrued independently of each other: Stratum 1-pts receiving Dilantin, Tegretol/phenobarbital.",79
484,tegretol,"2 separate strata accrued independently of each other: Stratum 1-pts receiving Dilantin, Tegretol/phenobarbital.",89
484,phenobarbital,"2 separate strata accrued independently of each other: Stratum 1-pts receiving Dilantin, Tegretol/phenobarbital.",98
484,dilantin,"Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants.",45
484,tegretol,"Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants.",55
484,phenobarbital,"Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants.",64
484,pts,"Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants.",78
484,o6-bg,"Pre-chemo, O6-BG administered intravenously at 120 mg/m2, over 1hr, prior to administration of Temodar on day 1 of 21-day cycle.",11
484,temodar,"Pre-chemo, O6-BG administered intravenously at 120 mg/m2, over 1hr, prior to administration of Temodar on day 1 of 21-day cycle.",95
484,o6-bg,"Post-chemo, O6-BG administered intravenously at 30 mg/m2/day, over 48hrs, immediately after completion of the CPT-11 infusion on day 1 of 21-day cycle.",12
484,cpt-11,"Post-chemo, O6-BG administered intravenously at 30 mg/m2/day, over 48hrs, immediately after completion of the CPT-11 infusion on day 1 of 21-day cycle.",110
484,temodar,"Temodar administered orally at 355 mg/m2, in fasting state, within 60 minutes of the end of 1hr O6-BG infusion.",0
484,o6-bg,"Temodar administered orally at 355 mg/m2, in fasting state, within 60 minutes of the end of 1hr O6-BG infusion.",96
484,temozolomide,Treatment cycles may be repeated every 3 weeks following dose of Temozolomide from previous cycle.,65
484,cpt-11,CPT-11 will be administered intravenously in fasting state over 90min.,0
484,cpt-11,CPT-11 infusion will begin 1hr after Temozolomide administration.,0
484,temozolomide,CPT-11 infusion will begin 1hr after Temozolomide administration.,37
484,cpt-11,Treatment cycles may be repeated every 3 wks following dose of CPT-11 from previous cycle.,63
484,cpt-11,Major toxicities associated w CPT- 11 are myelosuppression & diarrhea.,30
484,temozolomide,Temozolomide has been well tolerated by both adults & children w most common toxicity being mild myelosuppression.,0
484,temozolomide,Hypersensitivity reactions have not yet been noted w Temozolomide.,53
484,temozolomide,"As is case w many anti-cancer drugs, Temozolomide may be carcinogenic.",37
484,o6-bg,O6-BG toxicities include transient lymphopenia has been seen w O6-BG as single agent.,0
484,wo6-bg,O6-BG toxicities include transient lymphopenia has been seen w O6-BG as single agent.,61
484,o6-bg,"O6-BG in combo w other agents could cause exacerbation of any adverse event currently known to be caused by other agent,/ combo may result in events never previously associated w either agent.",0
486,rta744,RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin.,0
486,doxorubicin,RTA 744 is a close chemical analogue of the well characterized anti-cancer agent doxorubicin.,81
486,doxorubicin,"Unlike doxorubicin, RTA 744 has shown ability to cross the blood brain barrier and to achieve high concentration in CNS tumor tissue in animal models.",7
486,rta744,"Unlike doxorubicin, RTA 744 has shown ability to cross the blood brain barrier and to achieve high concentration in CNS tumor tissue in animal models.",20
487,iodinei131,"Determine the median time to disease progression in patients with newly diagnosed unresectable glioblastoma multiforme (GBM), recurrent GBM, or recurrent anaplastic astrocytoma treated with interstitial iodine I 131 monoclonal antibody TNT-1/B. Determine the median survival time of these patients treated with this regimen.",203
487,gadolinium,Assess the response of these patients in terms of MRI measured gadolinium enhanced tumor volume and gadolinium enhanced tumor area at 8 and 12 weeks following the last dose of study drug.,63
487,gadolinium,Assess the response of these patients in terms of MRI measured gadolinium enhanced tumor volume and gadolinium enhanced tumor area at 8 and 12 weeks following the last dose of study drug.,100
487,iodinei131,"One day later, patients receive iodine I 131 monoclonal antibody TNT-1/B interstitially over approximately 24 hours.",32
487,gadolinium,A gadolinium enhanced MRI is performed during week 8.,2
489,tamoxifen,"Background:  Tamoxifen (TAM), a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER) expressing breast cancer.",13
489,tam,"Background:  Tamoxifen (TAM), a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER) expressing breast cancer.",24
489,estrogen,"Background:  Tamoxifen (TAM), a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER) expressing breast cancer.",56
489,estrogen,"Background:  Tamoxifen (TAM), a member of the selective estrogen receptor modulator (SERM) family, is widely used in the treatment of estrogen receptor (ER) expressing breast cancer.",134
489,tam,"It has previously been shown that high-dose TAM has cytotoxic activity against glioma cells, but whether this effect is drug-specific or represents a general property of SERMs was unknown.",44
489,bortezomib,"Bortezomib is a potent inhibitor of the 26S proteosome and causes significant anti-proliferative and cytotoxic effects in a number of cell lines through its protean effects on a variety of cellular signaling pathways, including its ability to potently inhibit the NF-kB pathway.",0
489,bortezomib,We have recently demonstrated that bortezomib has significant anti-glioma activity in vitro and a ongoing clinical trial has demonstrated some possible activity in patients with recurrent gliomas.,35
489,bortezomib,We have now also generated preclinical data demonstrating that bortezomib in combination with Tamoxifen has synergistic cytotoxic effects on glioma cells.,63
489,tamoxifen,We have now also generated preclinical data demonstrating that bortezomib in combination with Tamoxifen has synergistic cytotoxic effects on glioma cells.,94
489,bortezomib,"Thus, given the minimal to modest activity of both drugs in patients with recurrent gliomas, given their spectrum of non-overlapping toxicities, and given the marked synergistic glioma cell killing of the combination of drugs in our preclinical screens, we are now proposing a phase II trial of bortezomib in combination with Tamoxifen in patients with recurrent gliomas not taking enzyme inducing anti-epileptic drugs (EIAEDs).",295
489,tamoxifen,"Thus, given the minimal to modest activity of both drugs in patients with recurrent gliomas, given their spectrum of non-overlapping toxicities, and given the marked synergistic glioma cell killing of the combination of drugs in our preclinical screens, we are now proposing a phase II trial of bortezomib in combination with Tamoxifen in patients with recurrent gliomas not taking enzyme inducing anti-epileptic drugs (EIAEDs).",326
490,bevacizumab,"Background  Bevacizumab is a monoclonal antibody directed against vascular- endothelial growth factor (VEGF), the major angiogenesis factor involved in high-grade glioma-mediated angiogenesis.",12
490,bevacizumab,Preclinical studies in our laboratory and others have shown potent antiglioma activity in vivo and early clinical trials of bevacizumab in combination with irinotecan and alone (National Institutes of Health (NIH) study) have demonstrated significant anti-vascular permeability and anti-glioma effects in patients with recurrent gliomas.,124
490,irinotecan,Preclinical studies in our laboratory and others have shown potent antiglioma activity in vivo and early clinical trials of bevacizumab in combination with irinotecan and alone (National Institutes of Health (NIH) study) have demonstrated significant anti-vascular permeability and anti-glioma effects in patients with recurrent gliomas.,156
490,tandutinib,Tandutinib (MLN518) along with bevacizumab represents an attempt to further capitalize on the concept of targeting the tumor vasculature.,0
490,mln518,Tandutinib (MLN518) along with bevacizumab represents an attempt to further capitalize on the concept of targeting the tumor vasculature.,12
490,tandutinib,"Tandutinib is a small molecule inhibitor of fms-like tyrosine kinase receptor-3 (FLT3), platelet derived growth factor receptor (PDGFR), and cKIT (type III receptor tyrosine kinases).",0
490,tyrosine,"Tandutinib is a small molecule inhibitor of fms-like tyrosine kinase receptor-3 (FLT3), platelet derived growth factor receptor (PDGFR), and cKIT (type III receptor tyrosine kinases).",53
490,tyrosine,"Tandutinib is a small molecule inhibitor of fms-like tyrosine kinase receptor-3 (FLT3), platelet derived growth factor receptor (PDGFR), and cKIT (type III receptor tyrosine kinases).",165
490,tandutinib,"However, in this study tandutinib is being added to bevacizumab primarily for its activity against the PDGFR and cKIT.",23
490,bevacizumab,"Objectives  To establish data regarding the anti-tumor activity of the combination of bevacizumab and tandutinib in patients with recurrent high-grade gliomas, as determined by progression-free-survival.",86
490,tandutinib,"Objectives  To establish data regarding the anti-tumor activity of the combination of bevacizumab and tandutinib in patients with recurrent high-grade gliomas, as determined by progression-free-survival.",102
490,tandutinib,Patients will receive tandutinib as a single agent at a daily dose of 500 mg PO bid for the first 14 days of treatment.,22
490,tandutinib,Prior to the first dose of tandutinib patients will undergo an MRI-perfusion scan and an FDG-PET scan.,27
490,tandutinib,An MRI-perfusion scan will then be repeated between days 12-14 of the first 14 days of tandutinib monotherapy.,87
490,bevacizumab,"On day 15, treatment with bevacizumab will be added to the ongoing treatment with tandutinib.",26
490,tandutinib,"On day 15, treatment with bevacizumab will be added to the ongoing treatment with tandutinib.",82
490,bevacizumab,"Bevacizumab will be given intravenously in a dose of 10 mg/kg, repeated once every 2 weeks.",0
490,tandutinib,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,50
490,bevacizumab,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,65
490,tandutinib,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,126
490,fludeoxyglucose,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,199
490,18f,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,215
490,fdg,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,249
490,bevacizumab,After completion of the first 4 weeks of combined tandutinib and bevacizumab therapy (6 weeks after initiating treatment with tandutinib) considered the first cycle of therapy) the MRI-perfusion and fludeoxyglucose 18F-positron emission tomography (FDG-PET) scans will be repeated before the next dose of bevacizumab is given.,305
490,tandutinib,"Patients who are clinically/neurologically stable, and who have radiographically stable or responding disease at the end of that first cycle and every cycle thereafter (every 4 weeks), will continue treatment with tandutinib and bevacizumab.",214
490,bevacizumab,"Patients who are clinically/neurologically stable, and who have radiographically stable or responding disease at the end of that first cycle and every cycle thereafter (every 4 weeks), will continue treatment with tandutinib and bevacizumab.",229
491,icapamespib,"This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions.",128
491,icapamespib,"Part 1: Up to 30 patients with 1st, 2nd or 3rd recurrence of IDH wild type glioblastoma multiforme (GBM) or grade 3 or 4, Isocitrate dehydrogenase (IDH) mutant astrocytoma will be enrolled to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and MTD of single agent oral icapamespib administered daily.",283
491,icapamespib,Icapamespib will be administered orally once daily for each 28-day cycle.,0
492,cyanocobalamin,Arm I (intervention): Patients receive oral Boswellia serrata herbal extract 4 times a day and oral cyanocobalamin (vitamin B-12) once a day for 6 months in the absence of unacceptable toxicity.,100
492,vitaminb-12,Arm I (intervention): Patients receive oral Boswellia serrata herbal extract 4 times a day and oral cyanocobalamin (vitamin B-12) once a day for 6 months in the absence of unacceptable toxicity.,116
492,vitaminb-12,Arm II (control): Patients receive oral vitamin B-12 once a day for 6 months.,40
493,lomustine,"Generally worldwide, lomustine is the most commonly used agent at first progression despite moderate efficacy and high rates of serious toxicities.",21
493,lomustine,"Therefore, there is a need for alternative chemotherapeutic agents that are superior or have at least equivalent efficacy as lomustine but less toxicity.",125
493,tamoxifen,"In a retrospective review of our centre using tamoxifen in recurrent glioma, the use of tamoxifen as a single agent in 167 patients, typically as third line treatment or beyond, resulted in at least stable disease for approximately 20% of patients with a median survival of >20 months for recurrent non-GBM and >10 months for recurrent GBM.",46
493,tamoxifen,"In a retrospective review of our centre using tamoxifen in recurrent glioma, the use of tamoxifen as a single agent in 167 patients, typically as third line treatment or beyond, resulted in at least stable disease for approximately 20% of patients with a median survival of >20 months for recurrent non-GBM and >10 months for recurrent GBM.",88
493,tamoxifen,Tamoxifen was well tolerated with no toxicities reported.,0
493,tamoxifen,"Tamoxifen may be a better alternative to lomustine where only 20% of patients treated are alive in six months, typically with high rates of toxicity.",0
493,lomustine,"Tamoxifen may be a better alternative to lomustine where only 20% of patients treated are alive in six months, typically with high rates of toxicity.",41
493,lomustine,Primary Objective  ● To compare one-year progression-free survival rate of lomustine and tamoxifen treatment in patients with first recurrence of GBM.,75
493,tamoxifen,Primary Objective  ● To compare one-year progression-free survival rate of lomustine and tamoxifen treatment in patients with first recurrence of GBM.,89
493,lomustine,"Arm 1: Lomustine 110 mg/m2 as a single dose at bedtime on day 1 only every 42 days cycle Arm 2: Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID, continuously",7
493,tamoxifen,"Arm 1: Lomustine 110 mg/m2 as a single dose at bedtime on day 1 only every 42 days cycle Arm 2: Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID, continuously",96
494,dichloroacetate,"We recently showed that Dichloroacetate (DCA, an inhibitor of the mitochondrial pyruvate dehydrogenase kinase) was able to depolarize cancer (but not normal) mitochondria and induce apoptosis in cancer but not normal tissues.",24
494,dca,"We recently showed that Dichloroacetate (DCA, an inhibitor of the mitochondrial pyruvate dehydrogenase kinase) was able to depolarize cancer (but not normal) mitochondria and induce apoptosis in cancer but not normal tissues.",41
494,pyruvate,"We recently showed that Dichloroacetate (DCA, an inhibitor of the mitochondrial pyruvate dehydrogenase kinase) was able to depolarize cancer (but not normal) mitochondria and induce apoptosis in cancer but not normal tissues.",80
494,dca,We believe that altering the metabolism of cancers like glioblastoma (DCA switches metabolism from the cytoplasmic glycolysis to the mitochondrial glucose oxidation) we inhibit the resistance to apoptosis that characterizes cancer.,70
494,glucose,We believe that altering the metabolism of cancers like glioblastoma (DCA switches metabolism from the cytoplasmic glycolysis to the mitochondrial glucose oxidation) we inhibit the resistance to apoptosis that characterizes cancer.,147
494,dca,"Because metabolism (i.e. glycolysis) is the end result of many and diverse molecular pathways, the effects of DCA might be positive in cancers with diverse molecular backgrounds.",110
494,dca,DCA is also a very small molecule that readily crosses the blood brain barrier.,0
494,dca,Therefore we hypothesize that DCA will be an effective and relative non-toxic potential therapy for malignant gliomas.,30
494,dca,DCA will be given orally and patients will be followed for a minimum of 6 months.,0
494,glucose,The tumor size will be followed by standard MRI or CT criteria and glucose uptake (a direct effect of DCA on the tumor) will be measured by FDG-PET imaging.,67
494,dca,The tumor size will be followed by standard MRI or CT criteria and glucose uptake (a direct effect of DCA on the tumor) will be measured by FDG-PET imaging.,102
494,fdg,The tumor size will be followed by standard MRI or CT criteria and glucose uptake (a direct effect of DCA on the tumor) will be measured by FDG-PET imaging.,140
494,dca,"In addition, escape protocols for the application of standard therapy (when appropriate) are in place in patients with no evidence of response to DCA.",146
497,thymidine,"The earliest studies used an HSV that was genetically engineered so that the gene for an important enzyme, thymidine kinase (tk) was deleted.",107
497,acyclovir,"These viruses retained the viral tk gene, and so are susceptible to the antiviral drug acyclovir which is routinely used to treat HSV Infection, making them even more safe .  ",87
498,irofulven,"Determine the maximum tolerated dose (MTD) of irofulven alone or combined with anticonvulsants known to be metabolized by cytochrome P450 in patients with progressive or recurrent high-grade anaplastic astrocytoma, anaplastic oligodendroglioma, or glioblastoma multiforme.",46
498,irofulven,Patients receive irofulven IV over 30 minutes on days 1-4 or 1-5 (depending on dose-escalation level).,17
498,irofulven,Cohorts of 3-6 patients (per stratum) receive escalating doses of irofulven until the maximum tolerated dose (MTD) is determined.,66
498,irofulven,"Once the MTD is determined, additional patients are accrued to receive treatment with irofulven at the recommended phase II dose.",86
499,procarbazine,Determine the maximum tolerated dose of oral procarbazine when administered to patients with recurrent glioma receiving or not receiving anticonvulsants metabolized by the P450 hepatic enzyme complex.,45
499,procarbazine,"Determine the pharmacokinetics of oral procarbazine, including any effects of hepatic enzyme inducing drugs, in these patients.",39
499,procarbazine,Assess the response rate to procarbazine in these patients.,28
499,procarbazine,Phase I: Patients receive oral procarbazine once daily for 5 days.,31
499,procarbazine,Cohorts of 6 patients receive escalating doses of oral procarbazine until the maximum tolerated dose (MTD) is determined.,55
499,procarbazine,"Once the MTD is determined, patients receive procarbazine as in Phase I.  ",45
500,sch-58500,"Patients receive SCH-58500 via stereotactic injection into the tumor, followed 24-72 hours later by craniotomy.",17
500,sch-58500,"Patients undergo tumor resection, followed by injection of SCH-58500 into the tumor bed during craniotomy.",59
500,sch-58500,Cohorts of 3-6 patients receive escalating doses of SCH-58500 until the maximum tolerated dose (MTD) is determined.,52
501,oxygen,"The principle behind photodynamic therapy is light-mediated activation of a photosensitizer that is selectively accumulated in the target tissue, causing tumor cell destruction through singlet oxygen production.",193
501,photofrin,The investigators will be testing the hypothesis that pediatric subjects with progressive/recurrent malignant brain tumors undergoing PDT with increased doses of Photofrin® and light energy than were used in our previous clinical study will show better progression free survival (PFS) and overall survival (OS) outcomes.,162
501,photofrin,The specific aims include determining the maximum tolerable dose (MTD) of Photofrin in children and looking for preliminary effectiveness trends.,74
502,enzastaurin,This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).,40
502,lomustine,This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).,56
503,bcnu,PRIMARY OBJECTIVES:  I. Establish the safety of NovoTTF-100A in combination with bevacizumab and BCNU (carmustine) in glioblastoma multiforme (GBM) patients who have relapsed after chemoradiation therapy (first relapse).,97
503,carmustine,PRIMARY OBJECTIVES:  I. Establish the safety of NovoTTF-100A in combination with bevacizumab and BCNU (carmustine) in glioblastoma multiforme (GBM) patients who have relapsed after chemoradiation therapy (first relapse).,103
503,bevacizumab,Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses.,17
503,carmustine,Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses.,124
503,carmustine,Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.,111
504,sorafenib,"The combination of sorafenib, valproic acid, and sildenafil may have therapeutic potential for the treatment of recurrent high-grade glioma in the clinic.",19
504,valproicacid,"The combination of sorafenib, valproic acid, and sildenafil may have therapeutic potential for the treatment of recurrent high-grade glioma in the clinic.",30
504,sildenafil,"The combination of sorafenib, valproic acid, and sildenafil may have therapeutic potential for the treatment of recurrent high-grade glioma in the clinic.",49
504,sorafenib,The combination of sorafenib and valproic acid is predicated on the basis that sorafenib activity is enhanced by HDAC inhibition.,19
504,valproicacid,The combination of sorafenib and valproic acid is predicated on the basis that sorafenib activity is enhanced by HDAC inhibition.,33
504,sorafenib,The combination of sorafenib and valproic acid is predicated on the basis that sorafenib activity is enhanced by HDAC inhibition.,79
504,sildenafil,The addition of sildenafil is based on its ability to block ABCB1 and ABCG2 drug efflux pumps.,16
504,sorafenib,"As the ABCG2 transporter is the primary transporter involved in the efflux of sorafenib at the BBB, blocking its action is predicted to increase the concentration of sorafenib in the brain.",78
504,sorafenib,"As the ABCG2 transporter is the primary transporter involved in the efflux of sorafenib at the BBB, blocking its action is predicted to increase the concentration of sorafenib in the brain.",166
505,encorafenib,"Primary Objective Estimate the efficacy of combination treatment with encorafenib and binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF V600E/K-mutated malignant glioma (MG) and anaplastic pleomorphic xanthoastrocytoma (PXAs).",70
505,binimetinib,"Primary Objective Estimate the efficacy of combination treatment with encorafenib and binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF V600E/K-mutated malignant glioma (MG) and anaplastic pleomorphic xanthoastrocytoma (PXAs).",86
505,encorafenib,Characterize the toxicity profile of the combination of encorafenib and binimetinib in this patient population.,56
505,binimetinib,Characterize the toxicity profile of the combination of encorafenib and binimetinib in this patient population.,72
505,encorafenib,"Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity.",44
505,binimetinib,"Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity.",60
505,encorafenib,"Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity.",110
505,binimetinib,"Following enrollment, patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours, continuously in 28-day cycles until progression or unacceptable toxicity.",171
505,encorafenib,Surgical: These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery.,35
505,binimetinib,Surgical: These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery.,51
505,encorafenib,"After surgery, the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam, physical exam, and performance status, at 2-6 weeks post-operatively.",50
505,binimetinib,"After surgery, the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam, physical exam, and performance status, at 2-6 weeks post-operatively.",65
508,nivolumab,"This two-arm randomized trial will evaluate the safety of nivolumab in combination with DC vaccinations for the treatment of bevacizumab-naïve subjects with first or second recurrent, resectable World Health Organization (WHO) Grade III and IV malignant gliomas (MGs).",58
508,bevacizumab,"This two-arm randomized trial will evaluate the safety of nivolumab in combination with DC vaccinations for the treatment of bevacizumab-naïve subjects with first or second recurrent, resectable World Health Organization (WHO) Grade III and IV malignant gliomas (MGs).",125
508,nivolumab,Up to 66 patients will be enrolled and treated with the goal of accruing 30 patients (15 per arm) that will receive nivolumab and at least 3 vaccines.,116
508,tetanusanddiphtheriatoxoids,All subjects will undergo standard of care tetanus booster vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen.,90
508,nivolumab,Subjects will initially return every 2 weeks and receive approximately 3 infusions of nivolumab 3 mg/kg IV while the DC vaccines are being prepared from the initial leukapheresis and will then be randomized 1:1 to one of 2 arms (Group I: nivolumab only pre-surgery; Group II: nivolumab with DC vaccines pre-surgery).,86
508,nivolumab,Subjects will initially return every 2 weeks and receive approximately 3 infusions of nivolumab 3 mg/kg IV while the DC vaccines are being prepared from the initial leukapheresis and will then be randomized 1:1 to one of 2 arms (Group I: nivolumab only pre-surgery; Group II: nivolumab with DC vaccines pre-surgery).,238
508,nivolumab,Subjects will initially return every 2 weeks and receive approximately 3 infusions of nivolumab 3 mg/kg IV while the DC vaccines are being prepared from the initial leukapheresis and will then be randomized 1:1 to one of 2 arms (Group I: nivolumab only pre-surgery; Group II: nivolumab with DC vaccines pre-surgery).,276
508,nivolumab,Patients who are unable to tolerate nivolumab will be withdrawn from the study and replaced.,36
508,nivolumab,Patients whose DCs or Peripheral Blood Lymphocytes (PBLs) fail to meet release criteria will continue to receive nivolumab only and will not undergo repeat leukapheresis.,113
508,nivolumab,Peripheral blood will be drawn for immune monitoring prior to treatment with the 4th cycle of nivolumab (first post-randomization infusion of nivolumab).,94
508,nivolumab,Peripheral blood will be drawn for immune monitoring prior to treatment with the 4th cycle of nivolumab (first post-randomization infusion of nivolumab).,142
508,nivolumab, Group I Treatment Plan (Nivolumab Only Pre-Surgery),25
508,nivolumab,"After randomization, patients in Group I will receive nivolumab 3 mg/kg IV every 2 weeks x approximately 8 weeks.",54
508,nivolumab,"Approximately 1 day to 2 weeks after leukapheresis, the subject will resume nivolumab 3mg/kg IV every two weeks with DC vaccine administration intradermally (i.d.) for a total of 3 vaccines.",76
508,nivolumab,Nivolumab will continue until progression.,0
508,nivolumab,"At the clinic visit following the last vaccine (#8), subjects will have peripheral blood drawn for immune monitoring prior to infusion of nivolumab.",138
508,nivolumab, Group II Treatment Plan (Nivolumab with DC Vaccines Pre-Surgery),26
508,nivolumab,"After randomization, patients in Group II will receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV along with DC vaccines intradermally every 2 weeks x approximately 6 weeks for a total of 3 vaccines.",75
508,nivolumab,"After randomization, patients in Group II will receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV along with DC vaccines intradermally every 2 weeks x approximately 6 weeks for a total of 3 vaccines.",98
508,nivolumab,"Approximately 1 day to 2 weeks after leukapheresis, the subject will resume nivolumab",76
508,nivolumab,Nivolumab will continue until progression.,0
508,nivolumab,"At the clinic visit following the last vaccine (#8), subjects will have peripheral blood drawn for immune monitoring prior to infusion of nivolumab.",138
509,bms-247550,"To determine the maximum tolerated dose of BMS-247550 when administered to adults with recurrent malignant gliomas, receiving (Group A) or not receiving (Group B) anticonvulsants known to be metabolized by the P450 hepatic enzyme complex.",43
509,bms-247550,"To describe the pharmacokinetics of this route of administration, measuring BMS-247550, and determine the effects of hepatic enzyme inducing drugs, such as anticonvulsants, on the pharmacokinetics.",76
509,bms-247550,To determine the response rate of adult patients with recurrent glioma to BMS-247550 administered at the MTD.,74
509,ixabepilone,Patients receive ixabepilone IV over 1 hour on days 1-5.,17
509,ixabepilone,Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined.,50
509,ixabepilone,"Phase II: Once the MTD is determined, additional patients receive ixabepilone as above at the MTD.",66
510,cabazitaxel,"If you are in Part 1, you will be assigned to a dose level of cabazitaxel based on when you join this study.",62
510,cabazitaxel,Up to 5 dose levels of cabazitaxel will be tested.,23
510,cabazitaxel,"Each new group will receive a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.",51
510,cabazitaxel,"If you are in Part 2, you will receive cabazitaxel at the highest dose that was tolerated in Part 1.  ",39
510,cabazitaxel,"On Day 1 of every 21-day study cycle, you will receive cabazitaxel by vein over either 30 or 60 minutes.",55
510,cabazitaxel,Cabazitaxel is FDA approved and commercially available for the treatment of prostate cancer.,0
512,bevacizumab,This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.,56
513,ateng,"This is a single arm, open-label study in which children with recurrent/progressive high grade gliomas receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached.",177
514,aminoacid/18-fluoro-ethyltyrosine,"Positron emission tomography (PET) using an amino acid tracer, 18-fluoro-ethyltyrosine (18F-FET), is used for target delineation.",44
514,18f-fet,"Positron emission tomography (PET) using an amino acid tracer, 18-fluoro-ethyltyrosine (18F-FET), is used for target delineation.",88
515,talampanel,"To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.",29
518,imatinibmesylate,Determine the maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea in patients with recurrent or relapsed grade 3 or 4 malignant glioma.,67
518,vatalanib,Determine the maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea in patients with recurrent or relapsed grade 3 or 4 malignant glioma.,89
518,hydroxyurea,Determine the maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea in patients with recurrent or relapsed grade 3 or 4 malignant glioma.,122
518,imatinibmesylate,Determine the single-dose and repeated-dose pharmacokinetic profiles of imatinib mesylate (in serum) and vatalanib in these patients.,72
518,vatalanib,Determine the single-dose and repeated-dose pharmacokinetic profiles of imatinib mesylate (in serum) and vatalanib in these patients.,105
518,imatinibmesylate,"This is an open-label, dose-escalation study of imatinib mesylate and vatalanib.",48
518,vatalanib,"This is an open-label, dose-escalation study of imatinib mesylate and vatalanib.",70
518,vatalanib,"Patients receive oral vatalanib once daily, oral imatinib mesylate once daily, and oral hydroxyurea twice daily on days 1-28*.",22
518,imatinibmesylate,"Patients receive oral vatalanib once daily, oral imatinib mesylate once daily, and oral hydroxyurea twice daily on days 1-28*.",49
518,hydroxyurea,"Patients receive oral vatalanib once daily, oral imatinib mesylate once daily, and oral hydroxyurea twice daily on days 1-28*.",88
518,vatalanib,"*Patients receive vatalanib alone daily on days 1-7 followed by vatalanib, imatinib mesylate, and hydroxyurea on days 8-35 in course 1 only.  ",18
518,vatalanib,"*Patients receive vatalanib alone daily on days 1-7 followed by vatalanib, imatinib mesylate, and hydroxyurea on days 8-35 in course 1 only.  ",64
518,imatinibmesylate,"*Patients receive vatalanib alone daily on days 1-7 followed by vatalanib, imatinib mesylate, and hydroxyurea on days 8-35 in course 1 only.  ",75
518,hydroxyurea,"*Patients receive vatalanib alone daily on days 1-7 followed by vatalanib, imatinib mesylate, and hydroxyurea on days 8-35 in course 1 only.  ",98
518,imatinibmesylate,Cohorts of 3-6 patients receive escalating doses of imatinib mesylate and vatalanib until the maximum tolerated dose (MTD) is determined.,52
518,vatalanib,Cohorts of 3-6 patients receive escalating doses of imatinib mesylate and vatalanib until the maximum tolerated dose (MTD) is determined.,74
519,ribociclib, STRATUM A:  Combination Treatment: ribociclib and gemcitabine.,36
519,gemcitabine, STRATUM A:  Combination Treatment: ribociclib and gemcitabine.,51
519,ribociclib, STRATUM B:  Combination Treatment: ribociclib and trametinib.,36
519,trametinib, STRATUM B:  Combination Treatment: ribociclib and trametinib.,51
519,ribociclib, STRATUM C:  Combination Treatment: ribociclib and sonidegib.,36
519,sonidegib, STRATUM C:  Combination Treatment: ribociclib and sonidegib.,51
520,ptk,"Since we are looking for the highest dose of PTK that can be administered safely without severe or unmanageable side effects, not everyone who participates will get the same dose of PTK.",45
520,ptk,"Since we are looking for the highest dose of PTK that can be administered safely without severe or unmanageable side effects, not everyone who participates will get the same dose of PTK.",182
520,temozolomide,Participants will receive PTK twice daily along with temozolomide daily during each treatment cycle.,53
520,ptk,PTK will start on Day 0 of the first cycle and will be given twice daily for the 7 weeks the participant receives radiation therapy.,0
520,temozolomide,Daily doses of temozolomide will begin on Day of the first cycle and continue until the last dose of radiation therapy in cycle 1.,15
520,temozolomide,"When radiation stops, temozolomide and PTK will be given for a maximum of 6 post-radiation cycles of study treatment.",22
520,ptk,"When radiation stops, temozolomide and PTK will be given for a maximum of 6 post-radiation cycles of study treatment.",39
520,ptk,"During these cycles, PTK and temozolomide will be given for 5 consecutive days followed by 23 days of no drugs.",21
520,temozolomide,"During these cycles, PTK and temozolomide will be given for 5 consecutive days followed by 23 days of no drugs.",29
522,azd8055,"AZD8055 is a first in-class inhibitor of the kinase activity of mTOR, specifically inhibiting both mTORC1 and mTORC2 complexes.",0
522,azd8055,Preclinical data generated in the Neuro-Oncology Branch Laboratory of Dr. Howard Fine demonstrated that AZD8055 has significant anti-glioma activity in vivo and in vitro.,104
522,azd8055,Objectives:  To establish the maximally tolerated dose (MTD) of continuous once daily AZD8055 in patients with recurrent malignant gliomas not on enzyme-inducing anti-epileptic drugs (EIAED).,86
522,azd8055,To generate pharmacokinetic data on continuous once daily AZD8055 dosing.,58
522,azd8055,Cohorts of 3 or 6 patients will receive continuous AZD8055 once daily orally for 42 days.,51
522,azd8055,The dose of AZD8055 can be progressively escalated if only 0/3 or 1/6 patients experience a dose limiting toxicity at the prior dose level.,12
522,azd8055,A subset of patients in whom tumor re-resection is considered standard of care will receive 1-week treatment with AZD8055 and then undergo resection.,114
522,azd8055,"Once patients recover from surgery, they will restart treatment with AZD8055 and stay on treatment as long as there is no tumor progression or protocol-mandated removal criteria.",69
522,azd8055,"the end of Cycle 1, patients in both treatment arms (surgical and non-surgical) may choose to continue to receive AZD8055 until disease progression or until they experience unmanageable drug related toxicity, as long as they are continuing to derive clinical benefit and do not fulfill any of the criteria for removal from protocol therapy.",114
524,tm-601,"This Phase I study will evaluate the safety of TM-601 in patients with recurrent malignant glioma who have failed first-line, standard therapy.",47
524,tm-601,"Patients will be administered an imaging dose of 131I-TM-601, intravenously, to demonstrate tumor-specific localization prior to study treatment with non-labeled TM-601.",54
524,tm-601,"Patients will be administered an imaging dose of 131I-TM-601, intravenously, to demonstrate tumor-specific localization prior to study treatment with non-labeled TM-601.",162
524,tm-601,"Eligible patients demonstrating tumor-specific imaging will be assigned to a treatment cohort and will received non-labeled TM-601 once a week for 3 weeks, followed by clinical follow-up visits and MR imaging.",124
524,tm-601,Data from this study will help determine the IV dose of TM-601 required to produce MR perfusion changes (as well as other biomarker changes) in patients with recurrent malignant glioma.,56
524,tm-601,"It is not known whether participation in this trial will provide patients with benefit in terms of improved tumor control, although pre-clinical evidence and evidence from other clinical trials with 131I TM-601 suggest that TM-601 is an active agent in malignant glioma.",204
524,tm-601,"It is not known whether participation in this trial will provide patients with benefit in terms of improved tumor control, although pre-clinical evidence and evidence from other clinical trials with 131I TM-601 suggest that TM-601 is an active agent in malignant glioma.",224
525,temozolomide,"In the last 20 years, only temozolomide has obtained indication for the treatment of High-grade glioma (HGG).",27
525,temozolomide,Temozolomide during and later radiation therapy has doubled one year survival and is the standard treatment for glioblastoma.,0
525,temozolomide,An effective pre-radiation treatment should improve their prognosis and allow them to complete concomitant radiotherapy and temozolomide treatment.,124
525,bevacizumab,Bevacizumab in recurrent HGG displays 63% of objective responses when combined with irinotecan.,0
525,irinotecan,Bevacizumab in recurrent HGG displays 63% of objective responses when combined with irinotecan.,84
525,irinotecan,But irinotecan is not the most active treatment in this disease.,4
525,temozolomide,"We propose a phase II, two arms, open label, randomized, multicentric study with 2 cycles of temozolomide before radiation therapy and concomitant temozolomide, in patients with glioblastoma and 'biopsy-only'.",93
525,temozolomide,"We propose a phase II, two arms, open label, randomized, multicentric study with 2 cycles of temozolomide before radiation therapy and concomitant temozolomide, in patients with glioblastoma and 'biopsy-only'.",147
525,bevacizumab,Bevacizumab will be added to one arm.,0
526,amg596,"This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).",102
526,amg404,"This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).",145
527,carmustine,"The product in this study, Carmustine Sustained Release Implant (CASANT), is similar to that of Gliadel wafer as for the API(Active Pharmaceutical Ingredient), but different as for drug delivering system.",27
527,bcnu,"Based on the results of phase I/II , 8-10 wafers containing given dose of BCNU will be administered intracranially in this phase III to the tumor resected cavity to investigate the safety and efficacy in the treatment of recurrent malignant glioma in 212 patients.",74
528,cabozantinib,This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory high grade glioma for which there are no curative options.,72
529,carbon, Carbon ions offer physical and biological characteristics.,1
529,carbon,"Moreover, in comparison to photons, carbon ions offer an increase relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the Glioblastoma (GBM) cell line as well as the endpoint analyzed.",36
529,carbon,First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of primary high-grade gliomas showed promising results in a small and heterogeneous patient collective.,41
529,carbon,In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in patients with recurrent gliomas.,64
529,carbon,"Within the Phase I Part of the trial, the Recommended Dose (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme.",67
530,tomozolomide,"This is a multicentre, prospective longitudinal observational cohort study in patients with high grade glioma, who have surgery planned to remove >90% of the tumour, and subsequent radical radiotherapy with concomitant tomozolomide.",219
531,boron,"This is a prospective, single arm, open label phase I/II trial with boron neutron capture (BNCT) therapy for patients with previously irradiated and locally recurrent head and neck cancer.",68
531,18f-fluoro-l-bpa,"Once entering this study, patients will receive angiographies to evaluate bloody supply of the tumor and PET scan with 18F-fluoro-L-BPA as the tracer.",119
531,boron,Boron concentration of normal tissues is derived from measurement of BPA concentration in the blood.,0
531,bpa,Boron concentration of normal tissues is derived from measurement of BPA concentration in the blood.,69
531,l-bpa-fructose,"After treatment plan approved and on the day of treatment, intravenous or intra-arterial L-BPA- Fructose complex 500 mg/kg was administered at a constant rate over about 3 hours before and during neutron irradiation.",89
532,tmz,"Four to six weeks after finishing chemoradiation, patients will start monthly cycles of adjuvant TMZ.",97
532,tmz,A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given.,52
532,tmz,Treatment with Optune will start at approximately the same time as the first cycle of adjuvant TMZ and continue until second disease progression or a maximum of 2 years.,95
532,tmz,"Within one week after starting Cycle 2 of adjuvant TMZ and Optune therapy, patients will begin open-label treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.",51
532,tmz,"All patients will be seen before Cycle 1 of TMZ, before cycle 2 of TMZ, before starting the second dose of pembrolizumab, and every 3 weeks before each subsequent pembrolizumab dose at an outpatient clinic until they complete all 12 cycles of adjuvant TMZ or discontinue TMZ due to toxicity or first progression.",44
532,tmz,"All patients will be seen before Cycle 1 of TMZ, before cycle 2 of TMZ, before starting the second dose of pembrolizumab, and every 3 weeks before each subsequent pembrolizumab dose at an outpatient clinic until they complete all 12 cycles of adjuvant TMZ or discontinue TMZ due to toxicity or first progression.",67
532,tmz,"All patients will be seen before Cycle 1 of TMZ, before cycle 2 of TMZ, before starting the second dose of pembrolizumab, and every 3 weeks before each subsequent pembrolizumab dose at an outpatient clinic until they complete all 12 cycles of adjuvant TMZ or discontinue TMZ due to toxicity or first progression.",252
532,tmz,"All patients will be seen before Cycle 1 of TMZ, before cycle 2 of TMZ, before starting the second dose of pembrolizumab, and every 3 weeks before each subsequent pembrolizumab dose at an outpatient clinic until they complete all 12 cycles of adjuvant TMZ or discontinue TMZ due to toxicity or first progression.",271
533,dasatinib,"This is an open-label, single center, one-arm phase I dose-escalation study of dasatinib plus protracted , daily TMZ administered orally on a continuous daily dosing schedule among adult patients with recurrent or relapsing malignant glioma.",79
533,tmz,"This is an open-label, single center, one-arm phase I dose-escalation study of dasatinib plus protracted , daily TMZ administered orally on a continuous daily dosing schedule among adult patients with recurrent or relapsing malignant glioma.",113
533,dasatinib,"The study format includes a classical ""3+3"" dose escalation design to determine the MTD and DLT of dasatinib plus protracted, daily TMZ among recurrent malignant glioma patients.",99
533,tmz,"The study format includes a classical ""3+3"" dose escalation design to determine the MTD and DLT of dasatinib plus protracted, daily TMZ among recurrent malignant glioma patients.",132
533,dasatinib,"Additionally, the study will characterize the safety, tolerability, biologic activity, and pharmacokinetic profile of dasatinib when used in combination with protracted, daily TMZ.",118
533,tmz,"Additionally, the study will characterize the safety, tolerability, biologic activity, and pharmacokinetic profile of dasatinib when used in combination with protracted, daily TMZ.",176
533,dasatinib,Patients will start treatment on day 1 of cycle 1 with dasatinib.,55
533,dasatinib,"For patients undergoing dasatinib pharmacokinetic (PK) analysis, dasatinib will be administered alone until initial PK assessments are collected.",24
533,dasatinib,"For patients undergoing dasatinib pharmacokinetic (PK) analysis, dasatinib will be administered alone until initial PK assessments are collected.",65
533,tmz,Protracted TMZ will be initiated after initial dasatinib PK assessments are collected and will continue to be administered with dasatinib on a continuous daily dosing schedule.,11
533,dasatinib,Protracted TMZ will be initiated after initial dasatinib PK assessments are collected and will continue to be administered with dasatinib on a continuous daily dosing schedule.,47
533,dasatinib,Protracted TMZ will be initiated after initial dasatinib PK assessments are collected and will continue to be administered with dasatinib on a continuous daily dosing schedule.,128
533,dasatinib,The initial dasatinib PK assessments will be collected over 24 hours between days 3-7 of cycle 1.,12
533,dasatinib,"Patients not undergoing dasatinib PK collections will begin both dasatinib and protracted, daily TMZ together on day 1, cycle 1.  ",24
533,dasatinib,"Patients not undergoing dasatinib PK collections will begin both dasatinib and protracted, daily TMZ together on day 1, cycle 1.  ",65
533,tmz,"Patients not undergoing dasatinib PK collections will begin both dasatinib and protracted, daily TMZ together on day 1, cycle 1.  ",97
533,tmz,"The protracted, daily TMZ dose will be 50 mg/m² daily for all patients.",22
533,dasatinib,The dose level of dasatinib will be increased in successive cohorts.,18
533,calcium,"The most common side effects include vomiting, diarrhea, anorexia (loss of appetite), fluid retention, fatigue, headache, rash, hypocalcemia (low calcium level), and decreases in blood counts.",146
533,temodar,Temodar has been well tolerated by both adults and children with the most common toxicity being mild myelosuppression.,0
533,temodar,"As in the case with many anti-cancer drugs, Temodar may be carcinogenic.",44
533,temodar,Rats given Temodar have developed breast cancer.,11
534,cortisol,Whether stress-induced disruption of diurnal cortisol rhythmicity as measured by the salivary cortisol slope is an independent prognostic factor for (progression-free) survival in patients with newly diagnosed GBM undergoing standard multimodal treatment.,45
534,cortisol,Whether stress-induced disruption of diurnal cortisol rhythmicity as measured by the salivary cortisol slope is an independent prognostic factor for (progression-free) survival in patients with newly diagnosed GBM undergoing standard multimodal treatment.,94
534,cortisol,Whether high levels of stress in the patients' partner (baseline diurnal cortisol slope) are correlated with high levels of stress in the patient (i.e. stress-modulating factor) and shorter (progression-free) survival  ,73
534,dexamethasone,Perioperative dexamethasone treatment is not an exclusion criterion as short time treatment does not clearly affect the HPA axis and synthetic corticosteroids can be discriminated in salivary cortisol measurements.,14
534,cortisol,Perioperative dexamethasone treatment is not an exclusion criterion as short time treatment does not clearly affect the HPA axis and synthetic corticosteroids can be discriminated in salivary cortisol measurements.,192
534,temozolomide,"Secondary endpoints include overall survival and measures of treatment tolerance:  Number of patients, who stopped treatment for reasons other than progressive disease Percentage of planned temozolomide doses received  Study Flow and Assessments  ",190
534,cortisol,Salivary cortisol samples will be performed at days -2 and -1 before start of radiochemotherapy.,9
534,cortisol,"Neuroendocrine stress evaluations using standard laboratory essays (salivary diurnal cortisol slope, cortisol awakening response (CAR), short adrenocorticotropic hormone (ACTH)-test as well as ii)",85
534,cortisol,"Neuroendocrine stress evaluations using standard laboratory essays (salivary diurnal cortisol slope, cortisol awakening response (CAR), short adrenocorticotropic hormone (ACTH)-test as well as ii)",101
534,cortisol, Diurnal Cortisol Slope:,9
534,cortisol,Salivary cortisol levels peak 30-60 minutes after awakening and then drop to a nadir during sleep.,9
534,cortisol,This diurnal rhythm is disrupted in chronically stressed patients: leading to a flattening of the slope (beta) of the curve that connects salivary cortisol concentrations over time (from awakening to bedtime).,147
534,cortisol,"Salivary cortisol will be measured on two consecutive days (patients will receive a kit with ""salivettes"" containers to use at home and store in the refrigerator until next day hospital visit).",9
534,cortisol,"Cortisol level analyses will be done by the immunoassay ECLIA (E170 Roche, Switzerland) at the reference hospital (University Hospital Basel).",0
534,cortisol,"The cortisol awakening response (CAR) describes the increase of about 50% in saliva cortisol levels, which occurs 20-30 minutes after waking up in the morning.",4
534,cortisol,"The cortisol awakening response (CAR) describes the increase of about 50% in saliva cortisol levels, which occurs 20-30 minutes after waking up in the morning.",84
534,dexamethasone,"As perioperative dexamethasone is usually given in these patients, a short or ""low-dose"" ACTH test (Synacthen test) will be performed, to rule out relative adrenal insufficiency.",17
534,cortisol,A baseline sampling of Cortisol is performed before 1 ug Synacthen is applied by intravenous route.,23
534,cortisol,Stimulated Cortisol serum level is measured exactly 30min after Synacthen application.,11
534,cortisol,"Cortisol level analyses will be done by the immunoassay ECLIA (E170 Roche, Switzerland).",0
534,argininevasopressin,"Aim III: Copeptin Arginine Vasopressin (AVP) is a hypothalamic stress hormone, which is produced in the hypothalamus and released from the posterior pituitary.",18
534,avp,"Aim III: Copeptin Arginine Vasopressin (AVP) is a hypothalamic stress hormone, which is produced in the hypothalamus and released from the posterior pituitary.",40
534,cortisol,"Together with corticotropin-releasing hormone, it leads to secretion of ACTH and cortisol.",81
534,c,"With the recent development of a novel sandwich immunoassay for copeptin (the C-terminal glycoprotein of the pre-provasopressin), a stable and easy to measure surrogate of AVP secretion has become available.",78
534,avp,"With the recent development of a novel sandwich immunoassay for copeptin (the C-terminal glycoprotein of the pre-provasopressin), a stable and easy to measure surrogate of AVP secretion has become available.",172
534,avp,"(Direct AVP measurement is hampered by technical, pre-analytical difficulties).",8
534,cortisol,As a stress hormone copeptin mirrors individual stress levels even more subtly than cortisol.,84
535,bevacizumab,The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%.,74
535,bevacizumab,We have recently completed a Phase I clinical trial that has shown that SIACI of Bevacizumab is safe and effective up to a dose of 15mg/kg in patients with recurrent malignant glioma.,81
535,bevacizumab,Is it necessary to combine this IA regimen of treatment with biweekly IV Bevacizumab in order to improve progression free survival (PFS) and overall survival (OS)?,73
535,bevacizumab,"Intravenous Bevacizumab (10mg/kg) Day 14, 28 (and every two weeks thereafter): Intravenous Bevacizumab  ",12
535,bevacizumab,"Intravenous Bevacizumab (10mg/kg) Day 14, 28 (and every two weeks thereafter): Intravenous Bevacizumab  ",91
535,mannitol,Therefore the experimental aspects of this treatment plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 20%; 12.5 mL/s over 2 minutes) in order to disrupt the blood brain barrier.,109
535,mannitol,Therefore the experimental aspects of this treatment plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 20%; 12.5 mL/s over 2 minutes) in order to disrupt the blood brain barrier.,150
535,bevacizumab,To treat patients with one of two arms with repeated intraarterial delivery (SIACI) of Bevacizumab for patients with recurring or relapsing high grade glioma.,87
535,bevacizumab,Each arm gets IA delivery with one arm getting IV Bevacizumab biweekly as well and the other arm not getting intervening IV therapy.,50
537,bevacizumab,The investigators have shown in a previous phase I trial that a single Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (up to 15mg/kg) is safe and effective in the treatment of recurrent GBM.,129
537,bevacizumab,"Therefore, this phase I/II clinical research trial is an extension of that trial in that the investigators seek to test the hypothesis that repeated dosing of intra-arterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma.",174
537,carboplatin,Additionally the investigators will analyze if a combination with IA Carboplatin will further improve the treatment response.,69
537,bevacizumab,By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.,93
537,carboplatin,By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.,113
537,bevacizumab,By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.,182
537,carboplatin,By achieving the aims of this study the investigators will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.,199
537,bevacizumab,"The investigators expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for malignant glioma, and may alter the way these drugs are delivered to the investigators patients in the near future.",118
538,temozolomide,"Standard initial treatment for newly diagnosed GBM consists of maximal surgical resection followed by radiotherapy to the tumor bed and chemotherapy with an oral DNA alkylator, temozolomide.",177
539,irinotecan,Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab.,178
539,cpt-11,Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab.,190
539,bevacizumab,Significant activity (radiographic response rates of approximately 60%) has recently been demonstrated in phase II studies in patients with relapsed GBM from the combined use of Irinotecan (CPT-11) and bevacizumab.,202
539,temozolomide,"The current first line therapy of GBM patients following initial surgical resection/debulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy.",184
539,temozolomide,"The current first line therapy of GBM patients following initial surgical resection/debulking is the concomitant use of cerebral radiotherapy and the orally available alkylating agent temozolomide, followed by temozolomide for 6 months post-radiotherapy.",210
539,bevacizumab,"Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.",59
539,irinotecan,"Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.",73
539,temozolomide,"Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.",148
539,bevacizumab,"Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.",208
539,temozolomide,"Considering the significant activity of the combination of Bevacizumab + irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab + Temozolomide may also be an active regimen.",222
539,bevacizumab,Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational.,0
539,temozolomide,Bevacizumab + Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational.,14
539,bevacizumab,This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.,40
539,irinitecan,This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.,56
539,bevacizumab,This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.,70
539,temozolomide,This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.,86
539,temozolomide,This study will try to identity whether Bevacizumab and Irinitecan or Bevacizumab and Temozolomide should be the experimental arm in future phase III comparison with standard care with concomitant Temozolomide and radiotherapy.,197
540,dabrafenib,The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection.,65
540,trametinib,The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection.,80
540,dabrafenib,People (adults or children) with brain tumors who are already taking dabrafenib and / or trametinib and are in need of a surgical resection are potentially eligible.,69
540,trametinib,People (adults or children) with brain tumors who are already taking dabrafenib and / or trametinib and are in need of a surgical resection are potentially eligible.,89
541,bkm120,In the phase I part of the study the optimal dose of BKM120 when combined with bevacizumab was determined.,53
541,bevacizumab,In the phase I part of the study the optimal dose of BKM120 when combined with bevacizumab was determined.,79
541,bkm120,"In the Phase II part of this study, patients with relapsed/refractory GBM following first line therapy are being treated with the BKM120/bevacizumab combination.",130
541,bevacizumab,"In the Phase II part of this study, patients with relapsed/refractory GBM following first line therapy are being treated with the BKM120/bevacizumab combination.",137
541,bkm120,Limited BKM120 pharmacokinetic evaluation will be performed on all patients treated during this part of the study.,8
541,bevacizumab,Two populations of patients with relapsed/refractory GBM will be treated in the Phase II trial: 1) patients with no previous exposure to bevacizumab (N= 55) and 2) patients who received bevacizumab as part of first-line combined modality treatment (N= 20).,137
541,bevacizumab,Two populations of patients with relapsed/refractory GBM will be treated in the Phase II trial: 1) patients with no previous exposure to bevacizumab (N= 55) and 2) patients who received bevacizumab as part of first-line combined modality treatment (N= 20).,186
542,g2,"The first cohort will receive G207 alone, and the next cohorts will receive G207 at one of three doses followed by a 5 Gy dose of radiation to active areas of tumor.",30
542,g2,"The first cohort will receive G207 alone, and the next cohorts will receive G207 at one of three doses followed by a 5 Gy dose of radiation to active areas of tumor.",76
543,vandetanib,In vivo experiments have documented the ability of vandetanib (ZD6474) to inhibit tumor growth in various preclinical tumor models.,51
543,zd6474,In vivo experiments have documented the ability of vandetanib (ZD6474) to inhibit tumor growth in various preclinical tumor models.,63
543,vandetanib,"Given the pronounced neovasculature associated with malignant gliomas, and abundant published data demonstrating the dependence of glioma growth on the maintenance and proliferation of this neovasculature, vandetanib represents a potentially promising new therapeutic approach to these otherwise refractory tumors.",206
543,vandetanib,Phase II data of vandetanib for recurrent glioblastomas conducted at the National Institutes of Health showed promising activity but responses were usually short-lasting.  ,17
543,carboplatin,Carboplatin has shown activity as monotherapy in the treatment of recurrent malignant gliomas in adults and preclinical data generated at Dr. Fines' laboratory demonstrate additive anti-glioma activity with vandetanib.,0
543,vandetanib,Carboplatin has shown activity as monotherapy in the treatment of recurrent malignant gliomas in adults and preclinical data generated at Dr. Fines' laboratory demonstrate additive anti-glioma activity with vandetanib.,207
543,carboplatin,The safety profile of carboplatin and the preclinical and clinical data supports its use in combination with vandetanib in patients with malignant gliomas.,22
543,vandetanib,The safety profile of carboplatin and the preclinical and clinical data supports its use in combination with vandetanib in patients with malignant gliomas.,109
543,vandetanib,Vandetanib is also an epidermal growth factor receptor (EGFR) inhibitor and it has been demonstrated that the presence of the EGFRvIII mutant and/or the presence of an intact phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and non-phosphorylated protein kinase B (AKT) predict for a higher likelihood of response to the EGFR inhibitors Tarceva and Iressa.,0
543,vandetanib,Objectives:  To establish data regarding the anti-tumor activity of vandetanib in combination with carboplatin and single agent carboplatin and to collect information regarding the spectrum of toxicities.,68
543,carboplatin,Objectives:  To establish data regarding the anti-tumor activity of vandetanib in combination with carboplatin and single agent carboplatin and to collect information regarding the spectrum of toxicities.,99
543,carboplatin,Objectives:  To establish data regarding the anti-tumor activity of vandetanib in combination with carboplatin and single agent carboplatin and to collect information regarding the spectrum of toxicities.,128
543,vandetanib,To determine if the presence of the EGFRvIII mutant and/or the presence of an intact PTEN and non-phosphorylated AKT predict for a higher likelihood of response to vandetanib.,164
543,vandetanib,"Patients in group one will be treated with vandetanib (300 mg daily for patients not on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg daily for patients on EIAEDs) and with carboplatin (area under the concentration-time curve at steady-state [area under curve (AUC)], 6mg/mL x min) once every 4-week cycle (combination group).",43
543,carboplatin,"Patients in group one will be treated with vandetanib (300 mg daily for patients not on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg daily for patients on EIAEDs) and with carboplatin (area under the concentration-time curve at steady-state [area under curve (AUC)], 6mg/mL x min) once every 4-week cycle (combination group).",184
543,carboplatin,Patients in group two will receive carboplatin alone (AUC 6mg/mL x min) once every 4-week cycle.,35
543,carboplatin,Patients who develop tumor progression or unacceptable toxicity on carboplatin alone (group 2) can then receive single agent vandetanib (300 mg daily for patients not on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg daily for patients on EIAEDs) in 4-week cycles (sequential group).,67
543,vandetanib,Patients who develop tumor progression or unacceptable toxicity on carboplatin alone (group 2) can then receive single agent vandetanib (300 mg daily for patients not on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg daily for patients on EIAEDs) in 4-week cycles (sequential group).,125
544,temozolomide,"60 Gy of radiotherapy together with chemotherapy using temozolomide (TMZ), followed by 6 cycles of maintenance chemotherapy.",55
544,tmz,"60 Gy of radiotherapy together with chemotherapy using temozolomide (TMZ), followed by 6 cycles of maintenance chemotherapy.",69
546,mk-3475,Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.,29
546,mla,Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.,41
546,mla,Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.,131
546,mk-3475,Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.,199
547,ritonavir,I. To evaluate the 6-month progression-free survival in patients with recurrent or progressive high grade gliomas treated with ritonavir and lopinavir.,127
547,lopinavir,I. To evaluate the 6-month progression-free survival in patients with recurrent or progressive high grade gliomas treated with ritonavir and lopinavir.,141
547,ritonavir,I. To evaluate the toxicity of ritonavir and lopinavir in this patient population.,31
547,lopinavir,I. To evaluate the toxicity of ritonavir and lopinavir in this patient population.,45
547,ritonavir,Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.,22
547,lopinavir,Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.,36
551,temozolomide,New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.,163
551,tmz,New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.,177
551,bevacizumab,"Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB.",0
551,bev,"Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB.",13
551,tmz,The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy.,86
551,bev,The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy.,94
551,tmz,The investigators retrospectively analyzed tumor and target volumes and clinical neurological status in 39 patients with bulky GB and/or with severe neurological impairment after an induction treatment combining TMZ and BEV.,212
551,bev,The investigators retrospectively analyzed tumor and target volumes and clinical neurological status in 39 patients with bulky GB and/or with severe neurological impairment after an induction treatment combining TMZ and BEV.,220
552,irinotecan,Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies.,0
552,irinotecan,"Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.",26
552,bevacizumab,"Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.",41
552,bevacizumab,"Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.",198
552,irinotecan,"Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant gliomas, one would expect synergy between bevacizumab and irinotecan against gliomas.",214
552,irinotecan,"By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone.",27
552,bevacizumab,"By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone.",42
552,irinotecan,"By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone.",95
552,bevacizumab,"By combing cetuximab, with irinotecan and bevacizumab, one would expect further response, than irinotecan and bevacizumab alone.",110
553,aminoacid," Amino acid PET-CT (Positon Emission Tomography with Computed Tomography) could be an interesting alternative to tumor delineation because its results, do not depend on the rupture of the blood-brain barrier.",1
553,aminoacid,"Several studies have used amino acid PET in the planning of radiotherapy treatment for high-grade gliomas, but without a well-conducted prospective study.",26
553,18f-dopa/6-fluoro-[18f]-l-dihydroxyphenylalanine,"In the recurrent high-grade glioma population, no studies have been performed with 18F-DOPA.",83
553,18f-dopa,"The question therefore relates to the interest of cerebral 18F-DOPA PET-CT to improve the delineation of the volumes to be re-irradiated, during the recurrence of high-grade gliomas, and on the optimal methodology for determining GTV- PET.",59
553,18f-dopa,"Thus, within the rGTV relapse volume, it's important to know whether VSC of 18F-DOPA PET-CT is significant compared to that of MRI and would thus allow better definition of the volumes to be irradiated.",76
554,valacyclovir,"Patients will receive an injection of AdV-tk into the tumor or tumor bed during the surgical procedure followed by 14 days of anti-herpetic prodrug, valacyclovir, starting 1-3 days after vector injection.",149
554,valacyclovir,Standard chemotherapy may begin after completion of valacyclovir at the discretion of the treating physician and family.,52
554,adv,Two dose levels of AdV-tk will be evaluated with a fixed dose of valacyclovir.,19
554,valacyclovir,Two dose levels of AdV-tk will be evaluated with a fixed dose of valacyclovir.,65
555,bay43-9006,"To determine the maximum tolerated dose (MTD) of BAY 43-9006 when administered to adults with recurrent malignant glioma, receiving (Group A) or not receiving (Group B) anticonvulsants known to be metabolized by the P450 hepatic enzyme complex.",49
555,bay43-9006,"To describe the pharmacokinetics of this route of administration, measuring BAY 43-9006, and to assess the pharmacokinetic difference between patients taking enzyme-inducing agents and those who are not.  ",76
555,sorafenib,Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only).,22
555,sorafenib,Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined.,64
556,tmz,"Recently, it was shown that TMZ could be an alternative to RT.",28
556,tmz,"In elderly patients with poor functional status at symptom onset (KPS < 70), RT does not appear to be a satisfactory option in this frail population; however, investigators previously found that TMZ alone was associated with improvements in functional status in 1/3 of cases and appeared to increase survival compared with supportive care alone, especially in methylated MGMT promoter patients.",195
556,bevacizumab,"Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting VEGF (vascular endothelial growth factor) that is currently used in recurrent GBM, particularly in combination with alkylating agents.",0
556,bev,"Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting VEGF (vascular endothelial growth factor) that is currently used in recurrent GBM, particularly in combination with alkylating agents.",13
556,alkylatingagents,"Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting VEGF (vascular endothelial growth factor) that is currently used in recurrent GBM, particularly in combination with alkylating agents.",185
556,tmz,Its effect as first line treatment in combination with TMZ and RT is controversial.,55
556,tmz,"In this study, investigators evaluated the efficacy and safety of the upfront combination of TMZ + Bev as an initial treatment for elderly patients with GBM and impaired functional status (KPS <70).",93
556,bev,"In this study, investigators evaluated the efficacy and safety of the upfront combination of TMZ + Bev as an initial treatment for elderly patients with GBM and impaired functional status (KPS <70).",99
557,su011248,"Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan.",31
557,irinotecan,"Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan.",42
557,bevacizumab,"Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan.",206
557,irinotecan,"Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan.",235
557,su011248,SU011248 is being evaluated in current regimen because it may exert more potent anti-angiogenic effect than bev among MG pts due to its ability to inhibit PDGFR-mediated pericyte stabilization in tumor neovasculature.,0
557,bev,SU011248 is being evaluated in current regimen because it may exert more potent anti-angiogenic effect than bev among MG pts due to its ability to inhibit PDGFR-mediated pericyte stabilization in tumor neovasculature.,108
557,su011248,Current proposed ph I study is designed to determine MTD & DLT of SU011248 when combo w irinotecan for pts w RMG.,66
557,irinotecan,Current proposed ph I study is designed to determine MTD & DLT of SU011248 when combo w irinotecan for pts w RMG.,88
557,su01148,Both SU01148 & irinotecan are known to be metabolized by CYP3A4 cytochrome system.,5
557,irinotecan,Both SU01148 & irinotecan are known to be metabolized by CYP3A4 cytochrome system.,15
558,mebendazole,The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing tolerance in a dose expansion cohort.,95
558,mebendazole,The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing tolerance in a dose expansion cohort.,217
558,mebendazole,"Secondary Objectives of the study include to determine the safety, tolerability and toxicity of mebendazole in this patient population, determine the plasma levels of mebendazole in this patient population and Determine progression-free and overall survival of mebendazole in an extended cohort of patients with treatment refractory pediatric brain cancer.",96
558,mebendazole,"Secondary Objectives of the study include to determine the safety, tolerability and toxicity of mebendazole in this patient population, determine the plasma levels of mebendazole in this patient population and Determine progression-free and overall survival of mebendazole in an extended cohort of patients with treatment refractory pediatric brain cancer.",167
558,mebendazole,"Secondary Objectives of the study include to determine the safety, tolerability and toxicity of mebendazole in this patient population, determine the plasma levels of mebendazole in this patient population and Determine progression-free and overall survival of mebendazole in an extended cohort of patients with treatment refractory pediatric brain cancer.",261
558,mebendazole,"Mebendazole (MBZ) is a drug developed to treat human helminthic disease and is FDA-approved for the treatment of roundworm, common hookworm, American hookworm, pinworm and whipworm.",0
558,mbz,"Mebendazole (MBZ) is a drug developed to treat human helminthic disease and is FDA-approved for the treatment of roundworm, common hookworm, American hookworm, pinworm and whipworm.",13
558,mbz,MBZ use is well documented and frequently used in tropical countries at higher doses for the rarer parasitic infections of the brain.,0
558,mebendazole,Mebendazole therapy demonstrated safety in a phase I clinical trial for adults with high grade gliomas such as glioblastoma.,0
558,mebendazole,"This trial completed the maximum approved enrollment of 24 patients treated with mebendazole, with high doses consistent with dosing published for severe parasitic infections.",81
558,mebendazole, Laboratory studies indicate that mebendazole enters the brain and brain tumors at concentrations that may be effective for a combination of anti-cancer mechanisms.,34
558,mebendazole,"In animal models of brain cancer evidence suggest that mebendazole can prevent cell proliferation by interfering with tubulin formation, and it may prevent the formation of new abnormal blood vessels that feed tumor growth.  ",55
558,mebendazole," Mebendazole is provided at no cost in the form of a chewable 500 mg tablets, recommended to be taken three times daily with meals or food.",1
558,mebendazole,"Patients can continue to receive the drug as long as in the attending physicians opinion the therapy is not causing any severe side effects, and there is no clear indication that the patient will not respond to mebendazole therapy.",211
559,temozolomide,"The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m^2).",187
559,temozolomide,"The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m^2).",435
561,bortezomib,OBJECTIVES:  I. Determine the maximum tolerated dose of bortezomib with or without anticonvulsant drugs known to be metabolized by the P450 hepatic enzyme complex in patients with recurrent glioma.,56
561,phenytoin,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",73
561,carbamazepine,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",84
561,phenobarbital,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",99
561,primidone,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",114
561,felbamate,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",128
561,gabapentin,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",141
561,lamotrigine,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",153
561,valproicacid,"Patients are stratified according to concurrent anticonvulsant drug use (phenytoin, carbamazepine, phenobarbital, primidone, or felbamate vs gabapentin, lamotrigine, valproic acid, or no anticonvulsant drugs).",166
561,bortezomib,Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks.,17
561,bortezomib,Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined.,52
561,bortezomib,"Once the MTD is determined, 10 additional patients are treated with bortezomib at the MTD.",68
562,ribociclib,"Additionally, blood samples will be obtained at 0.5, 1, 2, 4, 6, 8, and 24 hours after the final ribociclib dose is administered.  ",97
562,ribociclib,"Preliminary rates of progression-free survival in patients with high-grade gliomas and high-grade meningiomas treated with ribociclib will be measured through radiographic and clinical response metrics, specifically Response Assessment in Neuro-Oncology (RANO) criteria and investigator discretion.",123
562,ribociib,Overall survival in patients with high-grade gliomas and high-grade meningiomas treated with ribociclib will be assessed by medical record review and survival follow up.,93
563,irinotecan,To define the recommend phase II doses of intracranially administered active modified human form of carboxylesterase (hCE1m6)- neuronal stem cells (NSCs) (carboxylesterase-expressing allogeneic neural stem cells) in combination with intravenous irinotecan (irinotecan hydrochloride).,245
563,irinotecanhydrochloride,To define the recommend phase II doses of intracranially administered active modified human form of carboxylesterase (hCE1m6)- neuronal stem cells (NSCs) (carboxylesterase-expressing allogeneic neural stem cells) in combination with intravenous irinotecan (irinotecan hydrochloride).,257
563,sn-38,To determine the biologic activity of the hCE1m6-NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan compared to irinotecan alone.,67
563,irinotecan,To determine the biologic activity of the hCE1m6-NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan compared to irinotecan alone.,138
563,irinotecan,To determine the biologic activity of the hCE1m6-NSCs by comparing SN-38 concentrations in the brain after treatment with hCE1m6-NSCs and irinotecan compared to irinotecan alone.,161
563,sn-38,I. To investigate the relationship between hCE1m6-NSC dose and SN-38 concentrations in brain interstitium.,63
563,irinotecan,To characterize the relationship between intracerebral and systemic concentrations of irinotecan and SN-38.,86
563,sn-38,To characterize the relationship between intracerebral and systemic concentrations of irinotecan and SN-38.,101
563,iron,To evaluate the intracerebral distribution of NSCs by using iron-labeling as a cellular tracker.,60
563,irinotecan,"To describe the clinical benefit (defined as stable disease, partial response, or complete response) in patients who receive treatment with repeat cycles of NSCs and irinotecan.",166
563,irinotecanhydrochloride,"Patients also receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4.",22
564,bxq-350,"This is a first in man study of BXQ-350, a novel anti-neoplastic therapeutic agent composed of two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.",32
564,dioleoylphosphatidyl-serine,"This is a first in man study of BXQ-350, a novel anti-neoplastic therapeutic agent composed of two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.",190
564,dops,"This is a first in man study of BXQ-350, a novel anti-neoplastic therapeutic agent composed of two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.",219
564,sapcdops,"When both the components are assembled together forming stable SapC-DOPS nanovesicles (clinical formulation BXQ-350), the agent exhibits the propensity to enter the body and brain, target cells in the tumor mass, and induce cell death.",63
564,bxq-350,"When both the components are assembled together forming stable SapC-DOPS nanovesicles (clinical formulation BXQ-350), the agent exhibits the propensity to enter the body and brain, target cells in the tumor mass, and induce cell death.",108
564,bx,"Dose Escalation Scheme Sequential cohorts of adult patients with advanced solid tumors and recurrent high-grade gliomas will be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL.",161
564,bx,"During Part 2, patients with advanced solid tumors and recurrent high-grade gliomas will be enrolled and administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL, if the MAD is not reached.",118
564,bx,"During Part 3, patients with either ependymoma, GI tumors , or advanced solid tumors other than HGG, will be enrolled and administered BXQ-350 at the 2.4 mg/kg dose level.",135
565,incb7839, Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high- grade glioma growth and improves overall survival.,25
565,incb7839, Pre-clinical studies of INCB7839 in patient-derived pediatric high-grade gliomas (GBM and DIPG) revealed that INCB7839 inhibits pediatric high- grade glioma growth and improves overall survival.,111
565,incb7839,In vivo testing also demonstrated that INCB7839 penetrates brain tissue sufficient to achieve its pharmacodynamic effect of ADAM10 inhibition.,39
565,calcium,"Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.",154
565,cholesterol,"Further pre-clinical studies in other animals revealed minimal toxicity, including non-adverse to mild increases in serum hepatobiliary enzymes, protein, calcium, cholesterol values, along with minimal decreases in RBC mass parameters; all parameters recovered.",163
565,incb7839, INCB7839 has been evaluated in Phase I and Phase II clinical trials for previously treated solid tumors and breast cancer.,1
565,incb7839,The dose-limiting toxicity for monotherapy with INCB7839 in Phase I clinical trials was declared to be deep venous thrombosis (DVT).,48
565,incb7839/123,"Overall, INCB7839 does exhibit a pro-coagulant effect in some adult patients, resulting in an increased incidence of DVT, whether used alone or in combination.",9
568,mannitol,"The experimental aspects of this experimental plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 20%; delivered IA, 12.5 mL over 2 minutes) in order to disrupt the blood brain barrier.",102
568,mannitol,"The experimental aspects of this experimental plan will include:  Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol 20%; delivered IA, 12.5 mL over 2 minutes) in order to disrupt the blood brain barrier.",143
568,bevacizumab,Subjects will then be treated with repeated intraarterial delivery (SIACI) of Bevacizumab.,78
568,bevacizumab,"Each subject will receive one dose of IA Bevacizumab on day 30, followed by chemoradiation.",41
568,bevacizumab,SIACI of Bevacizumab will be repeated every three months for a total of 3 infusions.,9
569,hec,The second is defined using safety and tolerability of study drug administered after tumor resection at doses up to the HEC.,120
569,hec,Stopping criteria for dose escalation of the pre-surgery infusion are determination of the HEC or the maximum tolerated dose (MTD).,91
570,mercaptopurine,"Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5.",17
570,carmustine,"Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5.",48
570,streptozocin,"Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5.",99
571,tipifarnib,Determine the maximum tolerated dose of tipifarnib in patients with recurrent or progressive malignant glioma receiving enzyme-inducing antiepileptic drugs.,40
571,steroids,Patients are stratified according to their pretreatment medications (not receiving enzyme-inducing antiepileptic drugs [EIAEDs] vs receiving EIAEDs with or without steroids).,164
571,tipifarnib,Patients receive oral tipifarnib twice daily on days 1-21.,22
571,tip,Cohorts of 3-6 patients from stratum II receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is determined.,68
571,tip,"Phase II (open only to patients requiring resection and who provide surgical tissue samples [effective 3/13/2003]): Once the MTD is determined, additional patients with glioblastoma multiforme from stratum II are accrued to receive treatment with tipifarnib at the recommended phase II dose.",247
573,temozolomide,"60 Gy of radiotherapy together with chemotherapy using temozolomide (TMZ), followed by maintenance TMZ for 6 months.",55
573,tmz,"60 Gy of radiotherapy together with chemotherapy using temozolomide (TMZ), followed by maintenance TMZ for 6 months.",69
573,tmz,"60 Gy of radiotherapy together with chemotherapy using temozolomide (TMZ), followed by maintenance TMZ for 6 months.",99
573,tmz,"In the Phase 3 trial in newly diagnosed GBM (trial EF-14) the results demonstrated that the addition of TTFields to maintenance TMZ significantly extends both, median and long term survival, as well as progression free survival of patients with newly diagnosed GBM.",128
573,tmz,"The magnitude of survival benefit seen is even better to that seen for addition of TMZ to radiation, which established TMZ as the standard of care for 1st line GBM treatment in 2005.",83
573,tmz,"The magnitude of survival benefit seen is even better to that seen for addition of TMZ to radiation, which established TMZ as the standard of care for 1st line GBM treatment in 2005.",119
573,tmz,Quality of life (QoL) was maintained with the use of TTFields + TMZ in patients for whom 12 months of QoL data were available.,64
573,tmz,The addition of TTFields to TMZ therapy in patients with newly diagnosed glioblastoma was not associated with any significant increase in systemic toxic effects compared with TMZ therapy alone.,28
573,tmz,The addition of TTFields to TMZ therapy in patients with newly diagnosed glioblastoma was not associated with any significant increase in systemic toxic effects compared with TMZ therapy alone.,175
574,r04929097,Primary Objective:  To assess the safety profile of R04929097 in combination with bevacizumab and to determine a recommended Phase II dose of R04929097 in combination with bevacizumab in patients with recurrent malignant glioma  ,52
574,bevacizumab,Primary Objective:  To assess the safety profile of R04929097 in combination with bevacizumab and to determine a recommended Phase II dose of R04929097 in combination with bevacizumab in patients with recurrent malignant glioma  ,82
574,r04929097,Primary Objective:  To assess the safety profile of R04929097 in combination with bevacizumab and to determine a recommended Phase II dose of R04929097 in combination with bevacizumab in patients with recurrent malignant glioma  ,142
574,bevacizumab,Primary Objective:  To assess the safety profile of R04929097 in combination with bevacizumab and to determine a recommended Phase II dose of R04929097 in combination with bevacizumab in patients with recurrent malignant glioma  ,172
574,r04929097,Secondary Objectives:  To describe the toxicity associated with this combination regimen To assess pharmacokinetics of R04929097 in combination with bevacizumab  Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent malignant glioma.,119
574,bevacizumab,Secondary Objectives:  To describe the toxicity associated with this combination regimen To assess pharmacokinetics of R04929097 in combination with bevacizumab  Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent malignant glioma.,149
574,ro4929097,Secondary Objectives:  To describe the toxicity associated with this combination regimen To assess pharmacokinetics of R04929097 in combination with bevacizumab  Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent malignant glioma.,263
574,ro4929097,Secondary Objectives:  To describe the toxicity associated with this combination regimen To assess pharmacokinetics of R04929097 in combination with bevacizumab  Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent malignant glioma.,274
574,bevacizumab,Secondary Objectives:  To describe the toxicity associated with this combination regimen To assess pharmacokinetics of R04929097 in combination with bevacizumab  Phase II I. Assess the safety profile and the recommended phase II dose of gamma-secretase inhibitor RO4929097 (RO4929097) in combination with bevacizumab in patients with recurrent malignant glioma.,305
574,ro4929097,Compare the overall survival of patients with recurrent glioblastoma treated with RO4929097 and bevacizumab versus bevacizumab alone.,82
574,bevacizumab,Compare the overall survival of patients with recurrent glioblastoma treated with RO4929097 and bevacizumab versus bevacizumab alone.,96
574,bevacizumab,Compare the overall survival of patients with recurrent glioblastoma treated with RO4929097 and bevacizumab versus bevacizumab alone.,115
574,ro4929097,Estimate the proportion of patients alive and progression-free survival at 6 months in patients treated with RO4929097 and bevacizumab versus bevacizumab alone.,109
574,bevacizumab,Estimate the proportion of patients alive and progression-free survival at 6 months in patients treated with RO4929097 and bevacizumab versus bevacizumab alone.,123
574,bevacizumab,Estimate the proportion of patients alive and progression-free survival at 6 months in patients treated with RO4929097 and bevacizumab versus bevacizumab alone.,142
574,ro4929097,"This is a multicenter, phase I, dose-escalation study of gamma-secretase inhibitor RO4929097 (RO4929097) followed by a randomized phase II study.",83
574,ro4929097,"This is a multicenter, phase I, dose-escalation study of gamma-secretase inhibitor RO4929097 (RO4929097) followed by a randomized phase II study.",94
574,ro4929097,"Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15 (days 2 or 3 and 15 of course 1 only).",22
574,bevacizumab,"Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15 (days 2 or 3 and 15 of course 1 only).",73
574,ro4929097,"Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.",22
574,bevacizumab,"Patients receive oral RO4929097 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.",73
574,bevacizumab,Patients receive bevacizumab as in arm I.  ,17
575,cilengitide,To determine the objective response rate to cilengitide in younger patients with recurrent or progressive high-grade glioma that is refractory to standard therapy.,44
575,cilengitide,To evaluate the pharmacokinetics of cilengitide in plasma using a limited sampling strategy.,36
575,cilengitide,"To evaluate the pharmacogenetic polymorphisms in drug transporters (eg, breast cancer resistance protein [BCRP], P-glycoprotein [P-gp]) and relate to cilengitide disposition.",150
575,cilengitide,"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25.",17
576,ctx,The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects.,56
577,valproicacid,"Patients with progressive or recurrent pediatric brain tumors are administered valproic acid, an HDAC inhibitor, along with standard of care therapy (radiation and temozolomide) for induction therapy.",79
577,temozolomide,"Patients with progressive or recurrent pediatric brain tumors are administered valproic acid, an HDAC inhibitor, along with standard of care therapy (radiation and temozolomide) for induction therapy.",164
577,valproicacid,"Thereafter, patients will be able to continue on valproic acid and temozolomide therapy as long as the combination is well tolerated and the tumor is not progressing.",49
577,temozolomide/9-(4-fluoro-3-hydroxy-methyl-butyl)guanine,"Thereafter, patients will be able to continue on valproic acid and temozolomide therapy as long as the combination is well tolerated and the tumor is not progressing.",67
578,18fhbg,I. To investigate the ability of 9-(4-fluoro-3-hydroxy-methyl-butyl) guanine (18FHBG) positron emission tomography PET to image GRm13Z40-2 CTL's in research participants.,78
578,dexamethasone,To study the impact of concurrent dexamethasone administration on the tempo and magnitude of T cell allograft rejection responses in treated research participants by tracking the frequency of anti-GRm13Z40-2 immune responses in serially acquired peripheral blood samples.,34
578,ganciclovir,To evaluate ganciclovir administration for ablating transferred GRm13Z40-2 in vivo should significant graft-mediated toxicities be encountered.,12
579,erlotinib,the maximum tolerated dose of erlotinib in patients with recurrent malignant glioma or recurrent or progressive meningioma.,30
579,erlotinib,Phase 2 - Secondary Recurrent Malignant Glioma I. Objective Tumor Response rate associated with erlotinib therapy in recurrent or progressive malignant glioma.,96
579,steroids,"Patients are stratified according to study phase (I vs II), concurrent enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no), histology (recurrent GBM vs recurrent anaplastic glioma vs recurrent meningioma vs stable GBM), preoperative candidacy (yes vs no), and concurrent steroids (yes vs no).",276
579,erlotinib,Patients concurrently receiving EIAEDs receive oral erlotinib once daily.,52
579,erlotinib,Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined.,52
579,erlotinib,"Phase II: Once the MTD is determined, additional patients concurrently receiving EIAEDs are treated with erlotinib as above at the phase II dose.",105
579,erlotinib,Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose.,60
580,temozolomide,"The vaccine is given after the radiation and chemotherapy portion of the treatment, in the maintenance phase of temozolomide in conjunction with the TTFields.",112
581,disulfiram,"The proposed phase I/II study of disulfiram (DSF) for patients with presumed glioblastoma multiforme (GBM) based on magnetic resonance imaging (MRI) or biopsy, including administration before surgery and during adjuvant chemoradiotherapy.",33
581,dsf,"The proposed phase I/II study of disulfiram (DSF) for patients with presumed glioblastoma multiforme (GBM) based on magnetic resonance imaging (MRI) or biopsy, including administration before surgery and during adjuvant chemoradiotherapy.",45
581,copper,"Patients will be treated with 3 days of preoperative DSF/copper (Cu) prior to their surgery (or biopsy), which will be followed by collection of blood and tumor samples during surgery for analysis of drug uptake.",57
581,cu,"Patients will be treated with 3 days of preoperative DSF/copper (Cu) prior to their surgery (or biopsy), which will be followed by collection of blood and tumor samples during surgery for analysis of drug uptake.",65
581,temozolomide,"After the surgery, patients will receive standard radiation therapy (RT) and temozolomide (TMZ) with the addition of concurrent DSF/Cu.",77
581,tmz,"After the surgery, patients will receive standard radiation therapy (RT) and temozolomide (TMZ) with the addition of concurrent DSF/Cu.",91
581,cu,"After the surgery, patients will receive standard radiation therapy (RT) and temozolomide (TMZ) with the addition of concurrent DSF/Cu.",132
582,temozolomide,PRIMARY OBJECTIVES:  I. Determine the therapeutic efficacy of VEGF Trap in patients with temozolomide-resistant malignant gliomas at first recurrence as measured by 6-month progression-free survival (PFS).,89
583,18fdg,OUTLINE:  Subjects receive 18FDG (first scan) and (18)F-FDOPA (2-14 days from the first scan) intravenously (IV) slowly over a period of 15-20 seconds and then undergo dynamic PET scans over a period of 60-90 minutes.,27
583,(18)f-fdopa,OUTLINE:  Subjects receive 18FDG (first scan) and (18)F-FDOPA (2-14 days from the first scan) intravenously (IV) slowly over a period of 15-20 seconds and then undergo dynamic PET scans over a period of 60-90 minutes.,50
583,fdopa,"Subjects also undergo MRI brain examinations just prior to the FDOPA scan over a period of 1 hour, which includes T1 weighed, T1 weighted contrast enhanced, T2 weighted, Diffusion tensor imaging, MR spectroscopy, and Dynamic susceptibility contrast perfusion weighted (DSC-PWI) imaging.",63
584,indoximod,"The aim of this study is to identify the safety profile and the recommended dose for phase 2 study of the combination of indoximod (portion 1, phase 1b study).",121
584,indoximod,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,157
584,temozolomide,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,171
584,bevacizumab,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,185
584,indoximod,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,228
584,temozolomide,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,242
584,bevacizumab,Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:  Combination of indoximod and temozolomide (bevacizumab-naive patients) Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.,317
584,indoximod,Combination of indoximod and temozolomide with stereotactic radiation.,15
584,temozolomide,Combination of indoximod and temozolomide with stereotactic radiation.,29
586,cytosine/5-fluorocytosine,To define the phase II recommended dose of intracerebrally administered cytosine deaminase (CD)-expressing neural stem cells (NSCs) in combination with oral 5-fluorocytosine (FC) (flucytosine) and leucovorin.,72
586,flucytosine,To define the phase II recommended dose of intracerebrally administered cytosine deaminase (CD)-expressing neural stem cells (NSCs) in combination with oral 5-fluorocytosine (FC) (flucytosine) and leucovorin.,180
586,leucovorin/5-fc,To define the phase II recommended dose of intracerebrally administered cytosine deaminase (CD)-expressing neural stem cells (NSCs) in combination with oral 5-fluorocytosine (FC) (flucytosine) and leucovorin.,197
586,leucovorin/5-fc/5-fu,To determine the feasibility of treating study patients with more than 1 dose of NSCs followed by 7-day courses of 5-FC and leucovorin.,124
586,flucytosine,This is dose-escalation study of CD-expressing genetically modified neural stem cells and flucytosine.,90
586,flucytosine,Patients receive CD-expressing neural stem cells intracranially (IC) on days 1 and 15 and flucytosine orally (PO) every 6 hours on days 4-10 and 18-24.,90
586,leucovorin,"Depending on when a subject enters the study, s/he may also be given leucovorin orally every 6 hours on days 4-10 and 18-24.",69
